Document:

License, Development, Supply & Distribution Agreement

 Exhibit 10.44 
 ** Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under Rule 24b-2 of the General Rules and Regulations under
the Securities Exchange Act of 1934. 
 LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT 
 This LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2006
(“Effective Date”) by and between IMMUNICON CORPORATION, a Delaware corporation, having its principal office at 3401 Masons Mill Road, Suite 100, Huntingdon Valley, PA 19006 and its subsidiaries (collectively, “Immunicon”), and
DIAGNOSTIC HYBRIDS, INC., an Ohio corporation, having its principal office at 350 West State St., Athens, OH 45701 (“DHI”). 
  

	1.	BACKGROUND 

 1.0 Immunicon has expertise and certain
proprietary technology relating to cell enrichment, isolation and analysis systems, including fluorescence assay instrumentation, reagents and assays for the isolation and detection and diagnosis of certain disease states of mammalian and other
cells or cellular components in tissue, blood or other body fluids, and Immunicon has intellectual property including certain patents and know-how pertaining to such proprietary technology. 
 1.1 DHI has expertise in the development, marketing, distribution, and sales of products used in the detection of certain pathogens in mammalian cells and for the
diagnosis of certain disease states relating thereto, has certain proprietary technology, including reagents, useful in such products, and has experience in regulatory matters relating to such products, and further DHI desires to obtain a license
from Immunicon under Immunicon’s aforementioned patents and know-how in order to allow DHI to develop, market, distribute and sell new products, and to sell instrumentation supplied by Immunicon, based upon or utilizing Immunicon’s
proprietary technologies. 
 1.2 Immunicon and DHI desire to collaborate in the development of products in the aforementioned areas utilizing their
respective technologies and expertise, with the intent that such new products shall be developed and manufactured, in part by Immunicon and in part by DHI, and marketed and sold for in vitro diagnostic applications exclusively by DHI in the
United States and Canada and their respective territories and possessions. In addition, the parties will use their respective best efforts to negotiate commercially reasonable terms and conditions, to be set forth in a separate written agreement,
with respect to marketing and sale of such products in all other countries in the manner, and subject to the provisions, of Section 7.2.3 below. 
  

 1 

	2.	DEFINITIONS 

 As used herein, the following terms shall have
the respective meanings set forth below: 
 “Affiliate” of a party means any entity that directly or indirectly controls, is
controlled by or is under common control with such party. “Control” (and, with correlative meanings, the terms “controlled by” and “under common control with”) means, in the case of a corporation, the ownership of fifty
percent (50%) or more of the outstanding voting securities thereof or, in the case of any other type of entity, an interest that results in the ability to direct or cause the direction of the management and policies of such party or the power
to appoint fifty percent (50%) or more of the members of the governing body of the party, or if not meeting the preceding requirement, any company owned or controlled by or owning or controlling a party at the maximum control or ownership right
permitted in the country where such party exists. 
 “Bulk Reagents” means quantities of Capture Reagents supplied by Immunicon to
DHI under this Agreement, including all cartridges and other consumable accessories. 
 “Bulk Reagent Cost” means Immunicon’s
fully loaded cost of Bulk Reagents manufactured by Immunicon, determined in accordance with GAAP. 
 “Calendar Year” means each
twelve-month period commencing with January 1 and ending with December 31. 
 “Capture Reagent” means [************]
having a [*******] and other [*******] capable of acting as a [************] for a Target Entity, such [*******] including, but not limited to, [*******], [******], [*****], [*******], or combinations thereof, and provided to DHI by Immunicon under
this Agreement. 
 “Clinical Trial(s)” means human clinical testing as determined by the Management Board meeting regulatory
requirements and ethical guidelines as may be specified in individual countries where clinical trials of Products will be conducted or where such trials will be used to seek approval under Regulatory Authority requirements to market, use and sell
Products in such country. 
 “Clinical Trial Plan” means the pre-investigational device exemption (IDE) submitted to the FDA for
approval prior to commencing a Clinical Trial for a Product. 
 “Commercial Period” means the period commencing upon the first date
of receipt from the FDA of a pre-marketing clearance or approval for a Product. 
 “Commercialization Plan” means a plan which
includes the identification of target markets, market sizes, sales and marketing strategies and tactics to achieve Forecasts for Products and Instrument Systems under this Agreement. 
 “Confidential Information” means (i) any proprietary or confidential information or other material in a tangible form that is marked as
“confidential” at the time it is delivered to the receiving party thereof, or (ii) proprietary or confidential information disclosed orally that is identified as confidential or proprietary when disclosed and such disclosure is
confirmed in writing to the receiving party as confidential or proprietary by the disclosing party within thirty (30) days following disclosure. 
  

 2 

 “Detection Reagent” means [*******] or [*********] conjugated with [*******], [******],
[*********] or other labels capable of providing a detectable response to the presence of a Target Entity captured by a Capture Reagent and detected using an Instrument System. 
 “DHI [******] and [*************]” means all [*******] owned by or licensed [******] which Immunicon [*********] are [**********] in order for
it to make [********] for use in accordance with this Agreement, which [*********] will be provided by DHI to Immunicon in accordance with this Agreement. 
 “FDA” means the United States Food and Drug Administration, or any successor body. 
 “Field” means the in vitro application of Instrument Systems for the diagnosis or monitoring of Target Entities for the Infectious Diseases identified in Exhibit A in humans solely by detection of [*******] or [*********]
and/or [*********] ([*************]) utilizing Products. For the resolution of doubt but not in limitation, the Field shall not include [********], [*******] or [**********] or [********] conditions; applications or analysis involving [********]
circulating in blood, [*********], [*********], or [********]; [************], [*******] or [********]; [************], [********] or [******]; [**********] for [*******]; analysis of [****] taken by [*********]; [************], [*******] or
[*******]; [***********]; [*********] or [**********] for assessing [**********]; applications involving [************] or other [**************] techniques; or applications involving [*************] techniques. 
 “GAAP” means U.S. generally accepted accounting principles consistently applied. 
 “Infectious Disease” means a disease state characterized by the presence of one or more viruses or bacteria in, on or from the body of a human
being. 
 “Initial Feasibility” means demonstrating proof of principle with respect to the Initial Product(s) in accordance with a
feasibility plan approved by the Management Board (“Feasibility Plan”), using prototype reagents and existing laboratory tools, including but not limited to the Immunicon CellTracks® Analyzer II. It is anticipated that the Management Board, in determining whether
Initial Feasibility has been achieved with respect to a Product, will consider such factors as sensitivity, specificity, agreement to predicate device methods, and other key performance characteristics defined as Marketing Essential Characteristics,
as indicative of potential success in the relevant marketplace for Products. 
 “Initial Feasibility Period” means the period prior
to Product Development for conducting targeted research and demonstrating Initial Feasibility. 
 “Instrument System” or
“Instrument Systems” means a cell counting device, with non-consumable ancillary accessories and related components and software, that is capable of presenting, characterizing, and counting cells, and providing processed
diagnostic information sufficient for detecting the [****************] through the use of [*******]. By way of example but not limitation, an Instrument System contemplated at the Effective Date of this Agreement includes the Immunicon
EasyCountTM System together with related components and software, as 

  

 3 

 
the same may be improved, modified, updated or superceded from time to time. In addition, if Immunicon has another instrument platform in addition to
the Easy Count System that may be suitable for use as an Instrument System in the Field utilizing Products, it shall bring the same to the attention of the Management Board, and the Management Board shall determine the suitability of such other
platform for use as an Instrument System in the Field utilizing Products. If a decision is taken by the Management Board to undertake a Project Plan for the use of such other platform for such purpose, DHI and Immunicon shall negotiate in good faith
commercially reasonable terms and conditions, to be set forth in a separate written agreement, for the sharing of costs associated with such Project Plan. Immunicon at its sole discretion shall determine the suitability of the Immunicon
CellTracks® Analyzer II System for use as an
Instrument System in the Field utilizing Products, and if a decision is taken to undertake a Project Plan for the use of the CellTracks® Analyzer II System for such purpose, DHI and Immunicon shall negotiate in good faith commercially reasonable terms and conditions, to be set forth in a
separate written agreement, for the sharing of costs associated with such Project Plan. The Instrument System does not include Bulk Reagents. 
 “Instrument System Cost” means Immunicon’s standard cost of manufacturing an Instrument System, as determined in accordance with GAAP. 
 “Internal End User” means any Affiliate of DHI that is not in the business of reselling Products and whose use of such Products normally results in such Products’ consumption. 
 “Inventions” means the Patents and all inventions (patentable or otherwise), developments, designs, applications, improvements, formulae,
concepts, ideas, Know-How, methods or processes, discoveries and techniques necessary or desirable for the development, manufacture, sale or distribution of or otherwise relating to Products, Bulk Reagents, Detection Reagents or Instrument Systems,
whether owned as of the date hereof or hereafter acquired or licensed. 
 “In vitro diagnostic” or “IVD” means
reagents and/or kits registered for ASR sale, cleared or approved by FDA via 510(K) or PMA process or an equivalent international regulatory process. 
 “Know-How” means any proprietary information including, without limitation, any trade secret, that is useful in any aspect of the development, use, manufacture or sale of Products or Instrument System and is
not publicly known, disclosed or published, including, without limitation, all pre-clinical, clinical, chemical, biochemical, toxicological, analytical, manufacturing, process, formulation and scientific research information, whether or not capable
of precise separate description but that alone or when accumulated give to the one acquiring it an ability to study, test, produce, formulate or market Products or Instrument Systems which one otherwise would not have known to study, test, produce,
formulate or market in the same way. 
 “Management Board” means the body comprised of management representatives of Immunicon and
DHI as described in Section 3 hereof. The responsibilities of the Management Board are set forth in Section 3.2. 
 “Marketing
Essential Characteristics” means the set of properties, characteristics, and functional requirements that must be incorporated in or displayed by Products and Instrument Systems when combined to make them commercially acceptable in the market
in which they are intended to be sold, consistent with the competitive positioning and proposed pricing of the Products and the Instrument Systems. 
  

 4 

 “Material Breach” means a failure of a party to perform an express covenant or obligation under
this Agreement or a breach of a representation or warranty of a party which failure or breach has had or would reasonably be expected to have a material adverse financial consequence to the non-failing or non-breaching party. 
 “Patents” means (i) all U.S. and foreign patent applications and patents owned or licensed by Immunicon or any of its Affiliates or DHI or
any of its Affiliates that have application in the Field; (ii) all U.S. and foreign patent applications and patents owned by Immunicon or DHI, or owned jointly by Immunicon and DHI, that claim inventions that have application in the Field and
which are conceived or reduced to practice as part of a Project Plan; and (iii) all divisions, continuations, continuations-in-part, and substitutions thereof; and all extensions, reissues and re-examinations of any of the foregoing; in each
case, wherein such patents or applications contain claims that would, but for the respective ownership of, or license to, Immunicon or DHI under clause (i), (ii) or (iii) above or licenses granted under this Agreement, be infringed by
Immunicon’s or DHI’s respective activities under this Agreement. A list of the current Patents of Immunicon is attached to this Agreement as Schedule 2. 
 “Product(s)” means a kit consisting of one or more Detection Reagents, Bulk Reagents, consumable cartridges and other disposable items utilizing an Instrument System for the purpose of magnetic separation or
another separation method for capture of Target Entities for the detection of a viral or bacterial microorganism in a Specimen that causes one or more of the Infectious Diseases identified as such in Exhibit A hereto and which performs to the
specifications set forth in the Marketing Essential Characteristics therefor as determined by the Management Board, but which in any event shall demonstrate [************] to [************] for such Target Entities commercially available as of the
Effective Date if such [***********] exist as of the Effective Date. The term “Initial Products” refers to the Products identified in Exhibit A hereto as Initial Products. 
 “Product Development” means activities conducted as described generally in Section 3 of this Agreement during the period following the
Initial Feasibility Period, including advancing prototypes and design, transfer to manufacturing and preparing for commercialization of Initial Products and Instrument Systems for the clinical infectious disease market, under Project Plans as
determined by the Management Board. Product Development activities shall include but not be limited to developing specific and sensitive capture and detection antibodies and/or other reagents for Target Entities for the Infectious Diseases
identified in Exhibit A hereto, and preparing and submitting Clinical Trial Plans to the FDA for Products that meet the related Marketing Essential Characteristics. 
 “Project Plan” means the written summary, to be developed jointly by Immunicon and DHI, including the Initial Feasibility, Product Development and Product commercialization activities that are to be
conducted by the parties as described in Section 3 of this Agreement, in order to develop and commercialize Products and Instrument Systems under this Agreement. A Project Plan shall be developed for each proposed Product and/or Family of
Products hereunder. A Project Plan shall satisfy the process design control elements of DHI’s and Immunicon’s quality management systems. A Project Plan may be modified only in writing by the Management Board. 
  

 5 

 “RAP” means a reagent agreement, reagent rental or similar plan or arrangement wherein Products
sold by DHI or an Affiliate are increased in price to include an amount to cover the amortized cost of an Instrument System, including maintenance costs, or other equipment (amortized over the useful life thereof) supplied to a customer of DHI or an
Affiliate under an agreement with the customer to purchase the Product(s) at such increased price in order that the customer may have the use of such Instrument System and/or other equipment. 
 “Revenue” or “Revenues” means all of the income received by DHI or any of its Affiliates (other than Internal End Users) during a
given period from the sale of Products to Third Parties, and income received by DHI from use of Products by Internal End Users, whether or not such income is recognized by DHI as revenue in accordance with standard DHI accounting procedures, less
the following amounts: (i) discounts, including cash discounts, or rebates actually allowed or granted, (ii) credits or allowances actually granted upon claims or returns regardless of the party requesting the return, (iii) taxes or
other governmental charges levied on or measured by the invoiced amount whether absorbed by the billing or the billed party. In the event that any Product is sold as a combination containing one or more other products, Revenue for such combination
will be calculated by multiplying actual Revenue by the fraction A/(A+B) where A is the invoice price of the Product if sold separately, and B is the total invoice price of any other product or products in the combination if sold separately by DHI
or any of its Affiliates (or if such other product or products are not sold separately then the standard costs of the Products and such other product or products shall be used); provided, however, that in no event shall such fraction be less than
0.85. In the event that any Products are sold to Third Parties pursuant to a RAP, DHI shall reasonably determine that portion of the amount charged under the RAP that is attributable to Products in accordance with standard DHI accounting procedures
reasonably acceptable to Immunicon, and consistent with GAAP. Revenues shall not include income received by DHI or any of its Affiliates from the sale of Specimen Collection devices or the Specimen Transport medium or Revenues received as a
commission on the sale of a service or maintenance plan or contract to a customer of an Instrument System. 
 “Regulatory
Authority” means all governmental entities, including but not limited to the US Food and Drug Administration (“FDA”), regulating the development, manufacture, sale, shipping or distribution of Products or Instrument Systems in any
country or groups of countries. 
 “Regulatory Approval” means any authorization received from a Regulatory Authority to commence
commercial marketing, sale and distribution of a Product or Instrument System in any country and any other approvals, clearances, registrations, or permits that may be required to manufacture, market, sell and distribute Products, Instrument
Systems, or any related components of such Products or Instrument Systems. 
 “Research Use Only” or “RUO” as applied to
Products or Instrument Systems, means that such Products or Instrument Systems are suitable for use without a Regulatory Approval by an end-user solely for the limited purpose of the end user’s internal research. An ASR-designated reagent shall
not be considered a RUO reagent. 
  

 6 

 “Specimen” means, but is not limited to, a [*********] such as [*****], [********], [*******],
[*****], [********], [******] or [******] which is subjected to analysis for one or more Target Entities using a Product. 
 “Specimen
Collection” and “Specimen Transport” means the collection device and transport medium provided by DHI solely at DHI’s responsibility for processing Specimens prior to analysis by use of Product(s). 
 “Third Party” means any person or entity other than Immunicon, DHI or their respective Affiliates. 
 “Transfer Price” means the price charged to DHI by Immunicon for an Instrument System or Bulk Reagents supplied to DHI under this Agreement.

 “Target Entity(ies)” means any aspect or component of a biological sample that upon appropriate analysis with Product(s) and
Instrument Systems, would provide diagnostically relevant information in assessing an Infectious Disease condition. A Target Entity may include, without limitation, cells, cell components, an infectious agent, or combinations thereof and
specifically includes the Target Entities listed in Exhibit A. 
  

	3.	PRODUCT DEVELOPMENT 

 3.1 Project Plans. Immunicon and
DHI shall conduct Product Development under Project Plans with the goal of developing Products and Instrument Systems for commercial sale by DHI in accordance with this Agreement. Immunicon and DHI shall each use its reasonable efforts to conduct
the activities for which it is responsible with respect to Product Development, in accordance with Project Plans and the provisions of this Agreement, in each case within the time schedule set forth therein and herein. Immunicon and DHI will conduct
such activities in a prudent and skillful manner and in accordance in all material respects with the Project Plan then in effect, and further in accordance with all applicable Federal, state and local laws, rules, regulations and other requirements
(including, without limitation, Good Laboratory Practices, cGMP, QSR, ISO and the regulations of other non-US Regulatory Authorities). 
 3.2 Management
Board. The Management Board shall provide oversight and advice for the conduct of Product Development as follows: 
 3.2.1 The
Management Board shall be composed of four (4) management representatives of each of Immunicon and DHI, including the Chief Executive Officer of each, and senior sales and marketing, research and development and finance executives. Each party
may substitute one or more of its representatives, from time to time in its sole discretion, effective upon notice to the other party of such change. Immunicon shall appoint the chairperson of the Management Board (who shall in any event be the
Chief Executive Officer of Immunicon or DHI until after the one year anniversary date of the commencement of the Commercial Period) and so inform DHI, including any changes to the designated chairperson.  
  

 7 

 3.2.2 The activities of the Management Board with respect to developing, managing and overseeing
execution of the Project Plan(s) from feasibility through commercialization shall include: 
  

	 	(a)	Initial Feasibility Period. Provide oversight and guidance during the Initial Feasibility Period, including developing feasibility plans and establishing Marketing Essential
Characteristics for Products. 

  

	 	(b)	Product Development Period. Provide oversight and guidance during Product Development, including: 

 (i) developing the Project Plan for each Product and the Instrument System, including the Product Development Plan, the Clinical Trial Plan and the
Commercialization Plan, 
 (ii) reviewing and approving activities and progress under each Project Plan and approving any modifications to
Project Plans, 
 (iii) approving all Clinical Trial Plans and any modifications to Clinical Trial Plans. 
 (iv) reviewing progress of all Clinical Trials, and reviewing and evaluating data and conclusions developed from Clinical Trials, 
 (v) reviewing the process for seeking Regulatory Approvals of Products and Instrument Systems, and 
 (vi) reviewing and authorizing submissions for Regulatory Approval. 
  

	 	(c)	Commercialization Period. 

 (i) review and approve
Commercialization Plans including Firm Forecasts, and 
 (ii) consider and adopt any modifications to the Commercialization Plans.

  

	 	(d)	Additional Responsibilities. Carry out such other activities as the parties may from time to time agree. 

 3.2.3 Unless otherwise agreed, the Management Board shall meet no less frequently than quarterly. Each party shall be responsible for its own costs
incurred in connection with such meetings. The site of the meetings shall alternate between a site chosen by Immunicon and a site chosen by DHI. 
  

 8 

 3.2.4 The representatives of DHI to the Management Board, voting together, shall have one vote, and the
representatives of Immunicon, voting together, shall have one vote. Any approval, determination, decision or other action by the Management Board shall require the approval of the DHI representatives and the Immunicon representatives.
Notwithstanding the foregoing and except as otherwise provided in Section 6.8.2(d), in the event the DHI representatives to the Management Board and the Immunicon representatives to the Management Board are unable to reach agreement on a Firm
Forecast (as defined in Section 6.8.1), other than the Firm Forecasts for the first and second forecast years, the Immunicon representatives to the Management Board shall cast the deciding vote on such Firm Forecast. 
 3.2.5 The chairperson of the Management Board or his/her designee shall prepare and deliver to the members of the Management Board within thirty
(30) days after the date of a Management Board meeting minutes of such meeting summarizing the matters reviewed and any actions taken and decisions made at such meetings in form and content reasonably acceptable to the parties. 
 3.3 Project Representative. DHI and Immunicon each shall appoint a person (a “Project Representative”) to oversee the progress of each Project Plan. The
Project Representative of each party shall be the primary contact between the parties for day-to-day collaboration pursuant to this Agreement. Each party shall notify the other within thirty (30) days after the commencement of each Project Plan
hereunder of the appointment of its Project Representative and shall notify the other party as soon as practicable upon changing this appointment. 
 3.4
Development Responsibilities of Immunicon and DHI. 
 3.4.1 Immunicon shall develop the Instrument System(s) and Bulk Reagents, and
DHI shall develop the Detection Reagents and conduct the pre-Clinical Trial and Clinical Trial evaluations of Products, as described more fully in one or more Project Plans. Notwithstanding the foregoing, the parties acknowledge that in order to
assure optimization of Bulk Reagents and Detection Reagents and integration thereof into Products, the parties must collaborate in certain of their respective development activities with respect thereto, and accordingly each party hereby agrees to
cooperate and collaborate with the other party to provide such scientific, technical and other resources as it in good faith deems to be necessary to assist the other party in its development responsibilities hereunder. Immunicon shall be allowed to
utilize its judgment and expertise in such development of Instrument Systems and Bulk Reagents but recognizes that DHI wishes to be informed of all key decisions in advance of their execution and be afforded the opportunity to influence the same.
DHI shall be allowed to utilize its judgment and expertise in such development of Detection Reagents but recognizes that Immunicon wishes to be informed of all key decisions in advance of their execution and be afforded the opportunity to influence
the same. 
 3.4.2 DHI, in consultation with Immunicon and as directed by the Management Board, shall conduct evaluations of Bulk Reagents
and Detection Reagents for use in Products and evaluate the utilization of same on Instrument Systems, develop Marketing Essential Characteristics and Commercialization Plans, and manage, coordinate, implement and administer Clinical Trials in

  

 9 

 
accordance with one or more Project Plans subject to the approval of the Management Board. All Clinical Trials of Products and Instrument Systems shall be
conducted in accordance with all applicable legal and regulatory requirements and under the direction of the Management Board. DHI shall not depart in any material manner from the Clinical Trial Plan for a Clinical Trial that is established by the
Management Board, without the prior approval of the Management Board. 
 3.4.3 Immunicon will provide assistance, consultation and advice as
appropriate and as determined necessary by the Management Board in connection with Clinical Trials for the filing of submissions with Regulatory Authorities by DHI, and with respect to all other aspects of Regulatory Approval processes. To the
extent that the FDA or any other Regulatory Authority requests information with respect to Immunicon in connection with any regulatory filing, Immunicon shall provide such information promptly at no cost to DHI. Immunicon shall use all reasonable
efforts to cooperate fully with DHI to comply with and obtain appropriate Regulatory Approvals from Regulatory Authorities necessary for DHI to market, sell and distribute Products and Instrument Systems in accordance with this Agreement. Immunicon
agrees to provide DHI (and any appropriate Regulatory Authority) reasonable access to its data, records, facilities, employees and consultants in order to assist in the Regulatory Approval process, subject to appropriate protections for
Immunicon’s Confidential Information. 
 3.5 Funding/Sharing of Revenue. 
 3.5.1 In consideration of the license granted to DHI by Immunicon hereunder and for Immunicon’s agreement to the terms and conditions hereof, DHI
shall pay to Immunicon a non-refundable, non-creditable license fee of $1,500,000 to be paid in the following manner; 
 (a) an initial
payment of $500,000 shall be due and payable upon the Effective Date; 
 (b) provided that this Agreement has not terminated earlier pursuant
to its terms, a second payment of $1,000,000 shall be due and payable immediately upon the approval by the FDA of a Clinical Trial Plan for the first Initial Product. 
 3.5.2 In consideration for the performance of Immunicon’s obligations under Section 3.4 hereof, DHI shall pay to Immunicon Two Hundred Thousand Dollars ($200,000) per calendar quarter for the first six
(6) calendar quarters following the Effective Date, such payment to be due and payable at the commencement of each calendar quarter. Immunicon agrees that it will use its reasonable judgment in accordance with accepted commercial practices in
the industry to engage individuals of appropriate experience and product development expertise on development of the Initial Products and Instrument System. Product and Instrument System development payments for Products that are not Initial
Products which are developed under this Agreement after the commencement of the Commercial Period shall be subject to mutual agreement of, and negotiated in good faith by, Immunicon and DHI and set forth in written amendments to this Agreement.

 3.5.3 Except as otherwise set forth herein, Immunicon and DHI shall each be responsible for the funding of its own activities and
responsibilities under this Agreement. 
  

 10 

 3.5.4 DHI may purchase from Immunicon up to twenty (20) Instrument Systems prior to the commencement
of the Commercial Period at a Transfer Price to DHI for each such Instrument System to be determined in good faith by Immunicon, but which shall not be [******] Immunicon’s [*************] of such Instrument System plus [*********]. 

3.5.5 DHI may purchase from Immunicon up to two (2) CellTracks® Analyzer II Systems prior to the commencement of the Commercial Period at a Transfer Price for each such
CellTracks® Analyzer II System to DHI to be
determined in good faith by Immunicon, but which shall not be [*******] Immunicon’s [***********] of a comparable CellTracks® Analyzer II System. 
 3.5.6 Following
commencement of the Commercial Period, Immunicon and DHI shall share all Revenue from Products as follows: 
 Within thirty (30) days
after the end of each calendar quarter during the Commercial Period, DHI shall remit to Immunicon (in order to compensate Immunicon for Bulk Reagents supplied to DHI and a royalty under Immunicon Patents and Know-How) an amount equal to
(a) forty-one percent (41%) of Revenues during such calendar quarter less (b) the total Bulk Reagent Cost during such quarter for that amount of Bulk Reagents that was incorporated in and/or used to make the Products that generated
such Revenues. Notwithstanding the foregoing, DHI’s share of Revenues as provided for in the preceding sentence shall be appropriately increased by the parties in the event that, with respect to any Product, technical modifications requiring
the use of [************] are necessary for meeting the Marketing Essential Characteristics for such Product and such technical modifications have the effect of increasing the projected cost to DHI of producing such Product by more than [****] above
DHI’s initial projection of such cost. The parties will negotiate and determine in good faith the terms of any such modification of the revenue sharing arrangement. 
 3.6 Reports and Exchange of Information. 
 3.6.1 Reports. (a) Immunicon and DHI shall
report to each other the status of their activities under this Agreement including all relevant findings and all results from the performance of Project Plans in a manner and at such intervals as the parties shall reasonably agree, but no less
frequently than in a written report every calendar quarter, and provide such report to members of the Management Board no less than one week prior to their scheduled meetings. Each such quarterly written report shall summarize the progress and
results during the previous quarter in implementing Project Plans and achieving the goals thereof, and shall provide such other related information as Immunicon or DHI shall reasonably request. 
 (b) DHI shall report the status of efforts to commercialize and commercialization of the Products and Instrument System before and after commencement of
the Commercial Period, in a manner and at such intervals as the parties shall reasonably agree but no less frequently than in a written report every calendar quarter, and provide such report to members of the Management Board no less than one week
prior to their scheduled meetings. Each such quarterly written report shall summarize the progress of DHI’s commercialization efforts during the previous quarter toward achieving commercialization goals established in the Project Plans. DHI
also shall provide such other related information as Immunicon shall reasonably request. 
  

 11 

 3.6.2 Access to Facilities. Each party agrees to permit personnel of the other party to visit the
facilities that are utilized in connection with the production, quality assurance, research and development of Products and Instrument Systems, at mutually agreed upon times, during normal business hours to observe the activities being conducted.

 3.6.3 Audit Rights. Each party shall have the right, upon reasonable notice to the other party and during regular business hours,
to inspect and audit the books and records of such other party to assure compliance with the provisions of this Agreement including, without limitation, compliance with Sections 3.5.4, 3.5.5, 3.5.6, and 6.2. The parties acknowledge that the
provisions of this section granting certain audit rights shall in no way relieve either party of any of its obligations under this Agreement, nor shall such provisions require either party to conduct any such audits. 
  

	4.	PRE-COMMERCIALIZATION ACTIVITIES  

 4.1 Marketing
Essential Characteristics. DHI shall, in consultation with Immunicon, define the Marketing Essential Characteristics for Products, Instrument Systems, and related components and materials and shall apprise Immunicon of any changes therein. In
the event of disagreement regarding Marketing Essential Characteristic definitions, the Management Board shall decide the matter and such decision shall be final. 
 4.2 Regulatory Approval Submissions. DHI shall, with the consultation of Immunicon and at DHI’s sole expense, have the responsibility for submissions in connection with Regulatory Approvals for any Product or Instrument System
and determine when any regulatory filing for such Products and Instrument System should be submitted to a Regulatory Authority. Prior to any submission to any Regulatory Authority, DHI shall consult with, and provide a final draft copy of the
proposed submission to Immunicon, which shall, within thirty (30) days after receipt of the draft, provide any written comments to DHI. DHI shall consider in good faith and consult with Immunicon regarding any such comments, but DHI shall have
final decision making authority with respect to all regulatory filings. Necessary filings required for Regulatory Approvals shall be filed within sixty (60) days after completion of the relevant Clinical Trials. 
 4.3 Supplemental Submissions. DHI shall consult with Immunicon concerning all supplemental or additional regulatory and other governmental submissions related to
Products and Instrument Systems, and all components and materials related thereto, and provide Immunicon with access to such submissions prior to filing the same. 
 4.4 Ownership of Regulatory Approvals. All documents filed with Regulatory Authorities shall be prepared and submitted by and in the name of DHI or one of its Affiliates, and DHI shall own all such Regulatory Approvals unless
otherwise required by applicable law. 
 4.5 Filling and Packaging. At DHI’s own cost and expense, including, without limitation, the cost and
expense of validation, DHI shall make ready a facility (either owned by DHI or an Affiliate 

  

 12 

 
thereof or by a Third Party) for producing and packaging Products consistent with the Firm Forecast as approved by the Management Board. 
  

	5.	COMMERCIAL ACTIVITIES 

 5.1 Manufacturing and Supply
Arrangement. Except as expressly provided elsewhere in this Agreement, Immunicon shall manufacture (or cause to be manufactured) and supply DHI with DHI’s requirements of Bulk Reagents, Instrument Systems and components and materials
related thereto, and DHI shall source such requirements exclusively from Immunicon, as follows: 
 5.1.1 (a) Prior to the commencement
of the Commercial Period and if approved by the Management Board in a Project Plan, Immunicon will manufacture and supply DHI with DHI’s requirements for Bulk Reagents for DHI to create finished Products, in amounts reasonably requested by DHI
from time to time in connection with DHI’s validation of finishing and packaging facilities, and marketing activities, as well as the performance by DHI of its obligations hereunder with respect to making appropriate regulatory filings under
Article 4. The Bulk Reagents shall meet the specifications as set forth in Schedule 5.1.1 hereto, as may be amended from time to time by mutual agreement of the parties (the “Reagent Specifications”). 
 (b) From and after the commencement of the Commercial Period, Immunicon shall manufacture and supply DHI with DHI’s requirements for Bulk Reagents
for DHI to produce finished Products, as ordered by DHI and meeting the Reagent Specifications, and for Instrument Systems in accordance with the terms and conditions of the Distribution Agreement, attached hereto as Exhibit B and incorporated
herein by reference (the “Distribution Agreement”). The Distribution Agreement shall be entered into between DHI and Immunicon immediately upon commencement of the Commercial Period. 
 (c) Prior to the commencement of the Commercial Period, DHI shall manufacture and supply all of its requirements for Detection Reagents in order for DHI
to create finished Products as required for validation of finishing and packaging facilities, for marketing activities and the performance by DHI of its obligations with respect to making appropriate regulatory filings under Article 4. The Detection
Reagents shall meet the appropriate specifications as set forth in the Reagent Specifications. 
 (d) From and after the commencement of the
Commercial Period, DHI shall manufacture and supply Detection Reagents meeting the Reagent Specifications to satisfy its entire requirements to produce finished Products. 
 5.1.2 Transfer Pricing for Bulk Reagents. DHI shall pay to Immunicon an amount equal to the Bulk Reagent Cost for that amount of Bulk Reagent shipped to DHI that meets the Reagent Specifications within thirty
(30) days after receipt by DHI of the invoice therefor, except that prior to the commencement of the Commercial Period Immunicon will ship to DHI reasonable amounts as determined solely by Immunicon (not to exceed, in the aggregate, $[*******]
worth of Bulk Reagent at Bulk Reagent Cost) of Bulk Reagent [*******] in order for DHI to make ready and validate its facility for producing and packaging Products pursuant to Section 4.5. 
  

 13 

	6.	DISTRIBUTION OF INSTRUMENT SYSTEMS 

 From and after the
commencement of the Commercial Period and until this Agreement expires or is terminated as provided herein, DHI shall act as Immunicon’s distributor for Instrument Systems, pursuant to the terms and conditions of this Agreement and as set forth
in the Distribution Agreement. To the extent any of the terms and conditions of the Distribution Agreement may be inconsistent, or are in conflict with, the terms and conditions of the body of this Agreement, the latter shall govern and prevail.

 6.1 Sales and Training Costs. DHI shall be responsible for all expenses which it may incur in carrying out sales and training with respect to
Products and Instrument Systems hereunder including, without limitation, all travel expenses (including meals and lodging) and those expenses associated with the training of its employees and officers at the facilities of DHI and elsewhere related
to the Instrument Systems. Immunicon shall be responsible for providing appropriate training to DHI, as determined by Immunicon, to enable DHI to train customers in use of Products and Instrument Systems. 
 6.2 Promotional Efforts; Materials. DHI shall be responsible for all expenses which it may incur in marketing, selling and promoting Instrument Systems, to
include but not limited to, (i) selling aids, (ii) promotional materials and (iii) distribution related items. In any event, Immunicon shall have the right to review materials relating to DHI’s promotional efforts with respect to
Instrument Systems. 
 6.3 Instrument System Specifications; Validation. The Instrument Systems supplied to DHI shall meet applicable specifications
for such Instrument Systems as agreed to by the Management Board and as may be amended from time to time by the Management Board. References in this Agreement to the applicable specifications for the Instrument Systems shall refer to such
specifications as agreed to by the Management Board, as amended from time to time. Immunicon shall perform all software development and validation of Instrument Systems and all testing and quality assurance release functions for Instrument Systems
generally as well as the software contained therein; provided that the quality assurance release criteria shall be subject to approval by the Management Board and the application thereof shall be subject to the audit and inspection rights of DHI.

 6.4 Pricing to Customers. DHI shall set the pricing for sales to its customers of Instrument Systems supplied to DHI by Immunicon pursuant to the
Distribution Agreement. 
 6.5 Customer Support; Warranty and Service; Service Contracts.  
 6.5.1 Immunicon shall provide to those customers of DHI who purchase, lease or otherwise acquire an Instrument System in the ordinary course of business
from DHI and which has been supplied by Immunicon under the Distribution Agreement of Exhibit B, with a warranty covering parts and labor for, or replacement of, the Instrument System, which warranty shall run for a period of twelve (12) months
after the date such system is installed at an end user site (such period, the “Initial Warranty Period”), which means that in the event that such system fails to 

  

 14 

 
operate in accordance with the applicable specifications for the Instrument System during the Initial Warranty Period Immunicon shall be responsible for
paying cost of repairs and/or replacement of parts or the entirety of the Instrument System. In the event that during the Initial Warranty Period for any Instrument System a customer utilizing such system reports a problem with such system to DHI,
DHI shall use its best reasonable efforts to notify Immunicon of such problem within two business days of its receipt of the report of such problem. 
 6.5.2 (a) Immunicon shall have sole responsibility for repair or replacement of any Instrument System within the Initial Warranty Period or thereafter. Immunicon shall receive all revenue from servicing or repair of
Instrument Systems, whether or not such repair or service is performed under warranty or under a service contract, or similar service or maintenance plan. All revenue received by DHI from sale of service contracts or similar service or maintenance
plans on Instrument Systems shall be remitted to Immunicon within thirty (30) days of the receipt of such revenue by DHI, [**********************]. [*************************]. In the event DHI includes a service contract or similar service or
maintenance plan as a component of a transaction involving an Instrument System that is placed under a RAP or similar arrangement, [*****************] or similar [******************] shall [******************] for [****************] and shall be
[***********] in full as provided above, provided that DHI shall be [******************] of such [*************] or similar arrangement that is attributable to the service contract or similar service or maintenance plan. 
 (b) The service contracts to be offered by Immunicon to DHI’s Instrument System customers will be for a term of [********]. After the
Initial Warranty Period the price of such service contracts will be [**********] for the [******] and [********]. After DHI has completed its first [********] of Instrument Sales, Immunicon and DHI will evaluate whether the price of the service
contracts is commercially reasonable in light of the historical and estimated future cost to Immunicon of providing service under such contracts, and will adjust the price if and to the extent appropriate based on such evaluation. 
 (c) In order to minimize downtime during operation of Instrument Systems by customers, DHI shall use its best commercially reasonable
efforts to encourage at least [*************] of its purchasers of Instrument Systems and customers of Instrument Systems placed under a RAP or similar arrangement to purchase service contracts or substantially equivalent service or maintenance
plans covering such Instrument Systems or to include the price of such service contracts or substantially equivalent service or maintenance plans in the RAP or similar arrangement. If fewer than [***********] of DHI’s purchasers of Instrument
Systems and customers of Instrument Systems placed under a RAP or similar arrangement over any twenty-four month period purchase service contracts or substantially equivalent service or maintenance plans or include service contracts or substantially
equivalent service or maintenance plans in their RAP or similar arrangement covering their Instrument Systems, then Immunicon will thereafter have the right to [**********************], and DHI shall no longer [***********************]. In the event
the circumstances of the immediately preceding sentence are triggered, DHI shall provide to Immunicon within [********] following the closing of each transaction with customers of Instrument Systems the [*******************] to enable Immunicon to
[*************] regarding such service contract or substantially equivalent service or maintenance plan. 
  

 15 

 6.6 Forecasting; Supply Process. In order to expedite the supply process, DHI will be responsible for forecasting
Instrument System requirements on which Immunicon’s manufacturing plans will be based in accordance with the provisions set forth in Section 6.8. 
 6.7 Limitation of Use of Instrument Systems. DHI acknowledges and agrees that Instrument Systems shall be limited to accepting and utilizing Products (as such term is defined in this Agreement). DHI acknowledges that Immunicon has a
legitimate interest in protecting its intellectual property rights related to, and the quality and integrity of, Instrument Systems, and in furtherance thereof DHI shall not, and shall not authorize or permit any Third Party, including but not
limited to any customer of DHI or any other acquirer of an Instrument System from DHI, to utilize any reagents, assays, or similar products other than Products in connection with an Instrument System, or to modify any aspect of an Instrument System
to accept or utilize any reagents, assays, or similar products other than Products. 
 6.8 Sales Forecasts 
 6.8.1 Strategic Forecast. Prior to commencement of the Commercial Period, DHI shall develop and submit to the Management Board for its review and
approval an initial three (3) year strategic forecast (the “Strategic Forecast”) and a twelve-month forecast for sales of Products and Instrument Systems (each, a Twelve-Month Forecast”). The first Twelve-Month Forecast will
cover a twelve-month period commencing as of the first day of the first full month following the commencement of the Commercial Period. Upon approval by the Management Board (with such modifications as may be agreed to by the Management Board), the
Twelve-Month Forecast for the first forecast year will be deemed to be a Firm Forecast for purposes of Section 6.8.2 below. The Strategic Forecast will be updated annually with the next succeeding year (each such year, a “Forecast
Year”) being deemed a Firm Forecast for purposes of Section 6.8.2. DHI will develop and submit to the Management Board for its review and approval a revised Strategic Forecast and an updated Twelve-Month Forecast at least ninety
(90) days prior to the commencement of each Forecast Year. Forecasted Revenues for new Products will be reflected in the Twelve-Month Forecast and will then be rolled into the three year Strategic Forecast; provided, however, that the parties
recognize that such new Products may be subject to delays with respect to their anticipated commercial launch due to factors that were unanticipated by the parties when the Firm Forecast containing such new Products was created, which factors may
include but not limited to unanticipated Product development delays and delays in obtaining Regulatory Approvals. Accordingly, the parties agree that they will make reasonable adjustments to any Firm Forecast which may be subject to such
unanticipated new Product delays as provided in the immediately preceding sentence. Each Twelve-Month Forecast shall reflect a good faith effort to forecast reasonably anticipated sales for the relevant time period or periods, taking into account
all relevant factors including, without limitation, actual sales in prior periods, performance of the Products and the Instrument Systems, competition, and pricing. 
  

 16 

 6.8.2 Failure of DHI to Achieve Revenue Forecasts. (a) If Revenue does not equal or exceed
Minimum Performance (as defined below) in the third, fourth or fifth Forecast Years, DHI will owe to Immunicon, in addition to Immunicon’s share of Revenue calculated in accordance with Section 3.5.6, the amount set forth in the following
table: 
  

					
	 Forecast Year
	 	 Minimum Performance by DHI
	 	 Additional Amount Owing to
 Immunicon by DHI

			
	[***]	 	[***] of forecasted Revenue in Firm Forecast	 	[***] percent of the forecasted Revenue in the Firm Forecast for each [***] percent below [***]% of such forecasted Revenue up to a maximum additional amount of [***] percent of the
forecasted Revenue in the Firm Forecast.
			
	[***]	 	 [***] of forecasted Revenue in
 Firm
Forecast
	 	[***] percent of the forecasted Revenue in the Firm Forecast for each [***] percent below [***]% of such forecasted Revenue up to a maximum additional amount of [***] percent of the
forecasted Revenue in the Firm Forecast.
			
	[***]	 	[***] of forecasted Revenue in Firm Forecast	 	[***] percent of the forecasted Revenue in the Firm Forecast for each [***] percent below [***]% of such forecasted Revenue up to a maximum additional amount of [***] percent of the
forecasted Revenue in the Firm Forecast.

 (b) In the event this Agreement terminates prior to the end of the [***] Forecast
Year, no additional amount shall be owing by DHI to Immunicon pursuant to Section 6.8.2 for the Forecast Year in which this Agreement terminates or for any future Forecast Year. If this Agreement extends beyond the [***] Forecast Year and
Revenue for the [***] Forecast Year or any Forecast Year thereafter does not equal or exceed [***]% of forecasted Revenue for such Forecast Year as established by the applicable Firm Forecast, then DHI will owe to Immunicon, in addition to its share
of Revenue calculated in accordance with Section 3.5.6, an amount equal to [***] percent ([***]%) of the difference between [***]% of such forecasted Revenue and actual Revenue for such Forecast Year. Any such additional amount will be due and
payable thirty (30) days after the final determination of Revenue for such Forecast Year. 
 (c) Any additional amount
owing by DHI to Immunicon pursuant to this Section 6.8.2 shall be due and payable thirty (30) days after the final determination of Revenue for the Forecast Year for which such payment is owing. When calculating the difference between
Minimum Performance for a Forecast Year and DHI actual Revenue for such Forecast Year, DHI shall be given credit for any Revenue that DHI can reasonably establish was not recognized in such Forecast 

  

 17 

 
Year because of the failure of Immunicon to meet and fill orders for Bulk Reagents or Instrument Systems or to deliver such items to DHI or its Affiliates in
accordance with this Agreement. Any Revenue that DHI is given credit for pursuant to the preceding sentence shall not be recognized again by DHI in any subsequent Forecast Year for purposes of Section 6.8.2. 
 (d) Any other provision of Section 6.8.2 to the contrary notwithstanding, if Revenue payable to Immunicon under Section 3.5.6
and this Section 6.8.2 for any Forecast Year equals or exceed $[*****] DHI shall have no obligation to make any payment to Immunicon under this Section 6.8.2 for any subsequent Forecast Year and the representatives of Immunicon to the
Management Board will no longer have the right to cast the deciding vote on the Firm Forecast for any such subsequent Forecast Year; provided, however, that if Revenue payable to Immunicon in any Forecast Year thereafter is less than $[*********],
DHI’s obligation to make payment to Immunicon under this Section 6.8.2 shall be reinstated for such Forecast Year and for any subsequent Forecast Year in which the Revenue payable to Immunicon is less than $[**********], and the
representatives of Immunicon to the Management Board will again have the right to cast the deciding vote on the Firm Forecast for the subsequent Forecast Year and thereafter for as long as the Revenue payable to Immunicon remains less than
$[*********] in any Forecast Year. 
 6.9 Orders and Order Forecasts 
 6.9.1 Forecasts. At least thirty (30) days prior to the beginning of each and every three-month period (a “Quarter”), commencing with the first three-month period that is included in the first
Firm Forecast, DHI shall provide Immunicon with a written forecast (the “Quarterly Forecast”) of DHI’s expected requirements for Bulk Reagents and Instrument Systems for each of the next four Quarters, the first Quarter of which shall
be approved by the Management Board and shall be binding upon both parties with respect to Bulk Reagents only and the remaining three Quarters shall be provided for planning purposes only and shall not be binding upon either party. 
 6.9.2 Limits on Product Orders. Immunicon shall use commercially reasonable efforts but shall otherwise not be required to fill any orders of DHI
for Bulk Reagents or Instrument Systems for any Quarter to the extent the amount of Bulk Reagents or Instrument Systems ordered for such Quarter exceeds [***]% of the amount of Bulk Reagents or Instrument Systems ordered by DHI during the
immediately preceding Quarter to the extent Immunicon was required to fill the products so ordered by DHI during such preceding Quarter. 
 6.9.3 Orders. DHI shall place any binding orders for quantities of Bulk Reagents, by written or electronic purchase order (or by any other means agreed to by the parties) to Immunicon, which shall be placed at least thirty
(30) days prior to the desired date of delivery. Immunicon shall not be obligated to accept and fill orders that exceed (but only to the extent of such excess) the Quarterly Forecast by over [***]%. 
 6.9.4 Conflicts. To the extent of any conflict or inconsistency between this Agreement and any purchase order, purchase order release,
confirmation, acceptance or any similar document, including the Distribution Agreement, the terms of this Agreement shall govern and control. 
  

 18 

 6.9.5 Country Forecast. During the Commercial Period, DHI shall develop and provide to Immunicon
an annual forecast (the “Country Forecast”), for each country where Products and Instrument Systems are anticipated to be sold, ninety (90) days prior to the commencement of the each Calendar Year (commencing with the first full
Calendar Year during which Products and Instrument Systems are approved for sale in such country) which forecast will also set forth the number of units and sales of each Product and of Instrument Systems that are forecasted to be sold during such
Calendar Year. 
 6.10 Delivery and Inventory 
 6.10.1 Delivery. All charges for packing, hauling, storage, bar coding, and transportation to point of delivery are included in the Transfer Prices unless otherwise agreed to by the parties. All shipments must be accompanied by a
packing slip that describes the articles, states the purchase order number and shows the shipment’s destination. Immunicon agrees to promptly forward the original bill of lading or other shipping receipt for each shipment in accordance with
DHI’s instructions. Immunicon further agrees to promptly render, after delivery of goods or performance of services, correct and complete invoices to DHI, and to accept payment by check or at DHI’s discretion, other cash equivalent
(including electronic transfer of funds). 
 6.10.2 Shipment. The risk of loss with respect to Bulk Reagents and Instrument Systems
shall transfer to DHI upon leaving Immunicon’s facilities, or upon leaving the facilities of any contract manufacturer of Bulk Reagents or Instrument Systems for Immunicon, as the case may be. Immunicon will pack all Bulk Reagents and
Instrument Systems ordered hereunder in a manner suitable for shipment and sufficient to withstand the effects of shipping, including handling during loading and unloading. 
 6.11 Improvements and Changes to Bulk Reagents, Instrument Systems and Detection Reagents 
 Immunicon
will notify the Management Board and consult with DHI regarding any significant changes or modifications to the method or process of manufacture or production of any Bulk Reagents or Instrument Systems. In the event of any such changes or
modifications, DHI shall establish an appropriate qualification protocol, and DHI and Immunicon shall determine an appropriate inventory level for all pre-change Bulk Reagents or Instrument Systems, as the case may be, in order to cover on-going
requirements during the qualification process. DHI will notify the Management Board and consult with Immunicon regarding any significant changes or modifications to the method or process of manufacture or production of any Detection Reagents. In the
event of any such changes or modifications, Immunicon shall establish an appropriate qualification protocol, and DHI and Immunicon shall determine an appropriate inventory level for all pre-change Detection Reagents, in order to cover on-going
requirements during the qualification process. 
 6.12 Quality Inspections/Testing 
 6.12.1 Inspections. (a) DHI shall have the right, upon reasonable notice to Immunicon and during regular business hours, to inspect and audit
the facilities being used by Immunicon (or any 

  

 19 

 
third party) for production and storage of Bulk Reagents or Instrument Systems to assure compliance by Immunicon (and its suppliers) with GMP and applicable
FDA and other rules and regulations and with other provisions of this Agreement. Immunicon shall within thirty (30) days remedy or cause the remedy of any deficiencies which may be noted in any such audit or, if any such deficiencies can not
reasonably be remedied within such thirty (30) day period, present to DHI a written plan to remedy such deficiencies as soon as possible; and the failure by Immunicon to remedy or cause the remedy of any such deficiencies within such thirty day
period or to present such a plan within such thirty (30) day period and then use its commercially reasonable efforts to remedy or cause the remedy of such deficiencies in accordance with such written plan, as the case may be, shall be deemed a
Material Breach of this Agreement. Immunicon acknowledges that the provisions of this Section granting DHI certain audit rights shall in no way relieve Immunicon of any of its obligations under this Agreement, nor shall such provisions require DHI
to conduct any such audits. 
 (b) Immunicon shall have the right, upon reasonable notice to DHI and during regular business hours, to
inspect and audit the facilities being used by DHI for finishing and filling the Products and the storage of such Products, and the production and storage of Detection Reagents, to assure compliance by DHI with GMP and applicable FDA and other rules
and regulations and with other provisions of this Agreement. DHI shall within thirty (30) days remedy or cause the remedy of any deficiencies which may be noted in any such audit or, if any such deficiencies can not reasonably be remedied
within such thirty (30) day period, present to Immunicon a written plan to remedy such deficiencies as soon as possible; and the failure by DHI to remedy or cause the remedy of any such deficiencies within such thirty (30) day period or to
present such a plan within such thirty (30) day period and then use its commercially reasonable efforts to remedy or cause the remedy of such deficiencies in accordance with such written plan, as the case may be, shall be deemed a Material
Breach of this Agreement. DHI acknowledges that the provisions of this section granting Immunicon certain audit rights shall in no way relieve DHI of any of its obligations under this Agreement, nor shall such provisions require Immunicon to conduct
any such audits. 
 6.12.2 Bulk Reagent and Instrument System Quality. Immunicon represents that any Bulk Reagents or Instrument
Systems provided to DHI hereunder shall conform in all respects to applicable specifications and shall be free from defects in design, material and workmanship. Immunicon shall replace at its own cost and expense, including reimbursement of freight
and disposition costs incurred by DHI or any DHI customer of Instrument Systems, any Bulk Reagents or Instrument Systems that fail to conform with applicable specifications or has any such defects. DHI shall notify Immunicon of the existence and
nature of any non-conformance or defect and Immunicon shall have a reasonable opportunity, not to exceed ten (10) days from receipt of notification, to inspect such defective Bulk Reagents or Instrument Systems, as the case may be, and provide
DHI or the Instrument System customer with detailed written instructions to return or dispose of such defective Bulk Reagents or Instrument Systems, as the case may be. DHI shall have no obligation to pay for any Bulk Reagents or Instrument Systems,
as the case may be, that is subject to such a claim of non-conformance or defect. If Immunicon fails to so inspect and instruct DHI as to the disposition of such defective Bulk Reagents or Instrument Systems, as the case may be, DHI may dispose of
such defective Bulk Reagents or Instrument Systems as it sees fit and Immunicon shall promptly (1) reimburse DHI for all direct, out-of-pocket costs incurred by DHI in such disposition, and (2) replace such defective Bulk Reagents or
Instrument Systems at its own cost and expense. 
  

 20 

 6.12.3 Independent Testing of Bulk Reagents and Instrument Systems. If, after Immunicon’s
inspections of such Bulk Reagents or Instrument Systems, as the case may be, the parties disagree as to whether the Bulk Reagents or Instrument Systems conform to applicable specifications or whether the Bulk Reagents or Instrument Systems have a
defect, either party may deliver the item to a validated, independent third-party laboratory, mutually and reasonably acceptable to both parties, for analytical testing to confirm such item’s conformance to the applicable specifications or the
presence or absence of defects. All costs associated with such third-party testing shall be at DHI’s expense unless the tested item is deemed by such third-party to be defective or not in conformance with the applicable specifications, in which
case all such costs, including reimbursement of freight and disposition costs, shall be promptly paid by Immunicon. No inspection or testing of or payment for Bulk Reagents or Instrument Systems, as the case may be, by DHI or any third-party agent
of DHI shall constitute acceptance by DHI thereof, nor shall any such inspection or testing be in lieu or substitution of any obligation of Immunicon for testing, inspection and quality control as provided in the applicable specifications or under
applicable local, state, or federal laws, rules, regulations, standards, codes or statutes. 
 6.12.4 Detection Reagents and Product
Quality. DHI represents that any Detection Reagents or Products manufactured hereunder shall conform in all respects to applicable specifications and shall be free from defects in design, material and workmanship. DHI shall replace at its own
cost and expense, including reimbursement of freight and disposition costs incurred by Immunicon or any customer of Products, any Detection Reagent or Product that fails to conform to applicable specifications or has any such defects. Immunicon
shall notify DHI of the existence and nature of any non-conformance or defect of which Immunicon becomes aware, and DHI shall have a reasonable opportunity, not to exceed ten (10) days from receipt of notification, to inspect such defective
Detection Reagents or Products, as the case may be, and provide Immunicon or such customer with detailed written instructions to return or dispose of such defective Detection Reagents or Products, as the case may be. DHI may dispose of such
defective Detection Reagents or Products as it sees fit at its own cost and expense and, if Immunicon has incurred any direct, out-of-pocket expenses in connection therewith, shall promptly reimburse Immunicon for all direct, out-of-pocket costs
incurred by Immunicon with respect to any such defective Detection Reagents or Products in such disposition. 
 6.12.5 Independent Testing
of Detection Reagents and Products. If, after DHI’s inspection of such Detection Reagents or Products, as the case may be, the parties disagree as to whether any Detection Reagents or Products conform to the applicable specifications or
whether such Detection Reagents or Products have a defect, either party may deliver the item to a validated, independent third-party laboratory, mutually and reasonably acceptable to both parties, for analytical testing to confirm such item’s
conformance to the applicable specifications or the presence or absence of defects. All costs associated with such third-party testing shall be at Immunicon’s expense unless the tested item is deemed by such third-party to be defective or not
in compliance with the applicable specifications, in which case all such costs, including reimbursement of freight and disposition costs, shall be promptly paid by DHI. No inspection or testing of or payment for Detection Reagents or Products, as
the case may be, by Immunicon or any third-party agent of 

  

 21 

 
Immunicon shall constitute acceptance by Immunicon thereof, nor shall any such inspection or testing be in lieu or substitution of any obligation of DHI for
testing, inspection and quality control as provided in the applicable specifications or under applicable local, state, or federal laws, rules, regulations, standards, codes or statutes. 
 6.12.6 Corrective Action. In the event any governmental agency having jurisdiction shall request or order, or if DHI shall determine to undertake
such request or order, any corrective action with respect to any Product or Instrument System, as the case may be, including any recall, corrective action or market action, and the cause or basis of such recall or action is attributable to any
cause, fact or condition other than a breach by DHI of any of its warranties, guarantees, representations, obligations or covenants contained herein, then Immunicon shall be liable, and shall reimburse DHI for the reasonable costs of such action
including the cost of any Product or Instrument System, as the case may be, that is so recalled whether or not any specific unit of Bulk Reagents or Instrument Systems shall be established to be in breach of any warranty by Immunicon hereunder. If
any such corrective action is taken as result of a breach by DHI of any of its warranties, guarantees, representations, obligations or covenants contained herein, DHI shall reimburse Immunicon for its costs. 
 6.13 Supply Assurances; Failure To Supply; Force Majeure 
 6.13.1 Supply Assurances; Failure to Supply. The parties recognize that the availability of adequate quantities of Bulk Reagents, Detection Reagents, Instrument Systems and Products, consistent with the forecasts as required under
Sections 6.8.1 and 6.9.1 of this Agreement, is essential for the commercial success of Products. The parties therefore agree as follows: 
 (a) Immunicon shall maintain an inventory of Bulk Reagents and Instrument Systems sufficient to satisfy the Quarterly Forecasts for such items, as approved by the Management Board, for at least [*********]. DHI shall
maintain an inventory of Detection Reagents and Products to satisfy the next succeeding [*********] period in each Firm Forecast, as approved by the Management Board. 
 (b) Immunicon shall use its best reasonable commercial efforts to supply adequate quantities of Bulk Reagents and Instrument Systems to
meet market demand for Products and Instrument Systems, pursuant to its rights and obligations hereunder. If Immunicon, for more than [*********] consecutive days during the term of this Agreement, for reason other than Material Breach of this
Agreement by DHI or the inability or failure of DHI to supply sufficient DHI [******] and [******] [********], is unable to meet at least [********] ([***]%) of the applicable Firm Forecast with respect to Bulk Reagents or Instrument Systems,
applicable to such [********] day period, then upon [********] days written notice from DHI, DHI shall be free to make or have made Bulk Reagents or Instrument Systems, unless Immunicon thereafter is able to fully resume its supply obligations
hereunder, whereupon DHI shall be required to source its requirements of Bulk Reagents for Products and Instrument Systems exclusively from Immunicon commencing with the [***********] date of such resumption. In furtherance of the foregoing, if this
paragraph becomes operable and only during such time (but in no event for a period surviving the termination or expiration of this Agreement), Immunicon shall use its best efforts to give DHI access to any [*****************************] that,
absent which, Bulk Reagents, Products or 

  

 22 

 
Instrument Systems, as the case may be, would [*************] or any other [************************], as well as to provide all technical and proprietary
materials, information, know-how and techniques necessary or helpful for DHI to produce or arrange an alternative supplier of Bulk Reagents and Instrument Systems, and provide advice and consultation in connection therewith. The percentage of
Revenue due to DHI under Section 3.5.6 during any such shortfall period shall be increased by [****]%. 
 (c) DHI shall
use its best reasonable commercial efforts to supply adequate quantities of Products and to distribute sufficient Instrument Systems to meet market demand for same, pursuant to its rights and obligations hereunder. If DHI, for more than [******]
([***]) consecutive days during the term of this Agreement, for reason other than Material Breach of this Agreement by Immunicon or the inability or failure of Immunicon to supply sufficient Bulk Reagents or Instrument Systems, is unable to meet at
least [**************] ([***]%) of the applicable Firm Forecast with respect to Products, applicable to such [*****] ([***]) day period, then upon [*******] ([***]) days written notice from Immunicon, if such failure to supply market demand involves
Products, Immunicon shall be free to make or have made Detection Reagents and Products, or utilize an alternative supplier to make or have made Detection Reagent and Products, in order to meet the shortfall in supply of Products and to supply or to
utilize a Third Party to supply Instrument Systems to purchasers of such Products. In furtherance of the foregoing, if this paragraph becomes operable and only during such time (but in no event for a period surviving the termination or expiration of
this Agreement), DHI shall use its best efforts to give Immunicon access to any [*******************] that, absent which, any component of Detection Reagents or Products would [************************], as well as to provide all technical and
proprietary materials, information, know-how and techniques necessary or helpful for Immunicon to produce or arrange an alternative manufacturer of Detection Reagents and Products during such shortfall period, and to provide advice and consultation
in connection therewith. The percentage of Revenue due to Immunicon under Section 3.5.6 during any such shortfall period shall be increased by [***]%. 
 (d) During the period that Immunicon has undertaken to meet the foregoing supply shortfalls under section 6.13.1(c), DHI shall have no obligation to purchase Bulk Reagents from Immunicon necessary to manufacture
Products. If DHI thereafter is able to fully resume its supply obligations hereunder, DHI shall resume its obligations under this Agreement to purchase Bulk Reagents from Immunicon, and DHI shall again have the exclusive right to distribute Products
and Instrument Systems under this Agreement commencing with the [***********] of such resumption. 
 6.13.2 Force Majeure Events. If
either party is prevented from performing any of its obligations hereunder due to any cause which is beyond the non-performing party’s reasonable control, including fire, explosion, flood, or other acts of God; acts, regulations, or laws of any
government; war or civil commotion; strike, lock-out or labor disturbances; or failure of public utilities or common carriers (a “Force Majeure Event”), such non-performing party shall not be liable for breach of this Agreement with
respect to such non-performance to the extent any such non-performance is due to a Force Majeure Event. Such non-performance will be excused for three months or as long as such event shall be continuing (whichever occurs sooner), provided that the
non-performing party gives immediate written notice to the other party of the Force Majeure Event. 
  

 23 

 Such non-performing party shall exercise all reasonable efforts to eliminate the Force Majeure Event and to resume
performance of its affected obligations as soon as practicable. 
 6.14 Product Labeling; Artwork 
 DHI, subject to approval of the Management Board, shall have the right to determine the appearance and text of any labeling and packaging used in
connection with any Product. 
 6.15 Bulk Reagent and Instrument System Representations and Warranties 
 6.15.1 Immunicon represents and warrants to DHI that all Bulk Reagents or Instrument Systems, as the case may be, supplied in connection with this
Agreement shall be of merchantable quality, free from defects in material and workmanship and shall be manufactured and provided in accordance and conformity with the applicable specifications and in compliance with this Agreement. Immunicon
represents and warrants that it shall comply with all present and future statutes, laws, ordinances and regulations relating to the manufacture and supply of Bulk Reagents and Instrument Systems, including, without limitation, those enforced by the
United States Food and Drug Administration (including compliance with good manufacturing practices) and International Standards Organization Rules. 
 6.15.2 DHI represents and warrants to Immunicon that all Detection Reagents and Products shall be of merchantable quality, free from defects in material and workmanship and shall be manufactured and provided in accordance and conformity
with the applicable specifications and in compliance with this Agreement. DHI represents and warrants that it shall comply with all present and future statutes, laws, ordinances and regulations relating to the manufacture and supply of Detection
Reagents and Products, including, without limitation, those enforced by the United States Food and Drug Administration (including compliance with good manufacturing practices) and International Standards Organization Rules. 
 6.16 Compliance 
 In the performance of this
Agreement, the parties agree to comply with the applicable provisions of any law and all executive orders, rules and regulations issued thereunder, whether now or hereafter in force, and any provisions, representations or agreements required thereby
to be included in this Agreement are hereby incorporated by reference. If any Bulk Reagents or Instrument Systems, as the case may be, are ordered or contracted for sale by DHI under U.S. government contracts, Immunicon agrees that all applicable
federal statutes and regulations applying to DHI as a U.S. government contractor are accepted and binding upon Immunicon insofar as Immunicon may be deemed a subcontractor and DHI shall give Immunicon prior notice of its entering into any such
government contracts and the terms thereof to enable Immunicon to take such steps to comply with such statutes and regulations. 
 6.17 Taxes

 If DHI is required under applicable law to withhold any amount otherwise payable to Immunicon under this Agreement, it shall promptly pay
such amount to the appropriate 

  

 24 

 
governmental authority on behalf of Immunicon, and DHI shall furnish Immunicon with proof of payment of such tax, together with official or other appropriate
evidence issued by the appropriate governmental authority, sufficient to enable Immunicon to support a claim for income tax credit with respect of any sum so withhold. Any such tax required to be withheld shall be an expense of and borne by
Immunicon. 
  

	7.	INTELLECTUAL PROPERTY/LICENSE 

 7.1 Ownership of
Inventions 
 All right, title, and interest in and to any intellectual property rights of either party hereto existing as of the date of
this Agreement, will be retained by the current holder. All right, title, and interest in and to Inventions invented solely by Immunicon personnel, as determined by U.S. Patent Law, during the term of this Agreement shall be owned by Immunicon. All
right, title, and interest in and to Inventions invented solely by DHI personnel, as determined by U.S. Patent Law, during the term of this Agreement shall be owned by DHI. Title to all Inventions made jointly by employees or agents of Immunicon, on
the one hand, and employees or agents of DHI, on the other hand, shall be jointly owned by Immunicon and DHI as tenants in common. 
 7.2 License
Grants 
 7.2.1 Immunicon hereby grants to DHI and its Affiliates during the Term of this Agreement, an exclusive right
and license in the United States of America and Canada and their respective territories and possessions, under Immunicon Inventions to make, have made, use, sell, and have sold Products and Instrument Systems within the Field, subject to the
limitations and terms and conditions set forth elsewhere in this Agreement. DHI shall not have the right to sublicense the aforementioned rights and licenses to Third Parties except as may be approved in writing by Immunicon. For the resolution of
doubt, the grant of this license shall have no effect on Immunicon’s rights outside the Field. 
 7.2.2 DHI hereby grants
to Immunicon and its Affiliates during the Term of this Agreement a fully paid up, non-royalty bearing, exclusive right and license in the United States of America and Canada and their respective territories and possessions, under all intellectual
property and other proprietary rights owned by or licensed to DHI, to use and have used [******] and [********] for the development, manufacture and supply of Bulk Reagents for use with the Products within the Field, subject to the limitations and
terms and conditions set forth elsewhere in this Agreement. Immunicon shall not have the right to sublicense the aforementioned rights and license to Third Parties except as may be approved in writing by DHI. For the resolution of doubt, the grant
of this license shall have no effect on DHI’s rights outside the Field. 
 7.2.3 (a) Each party acknowledges that it
desires to grant additional rights and licenses to those granted as provided in Sections 7.2.1 and 7.2.2 above, under its respective intellectual property and other proprietary rights as described in this Agreement, to the other party in order that
Instrument Systems and Products may be commercialized in countries 

  

 25 

 
outside the United States and Canada and their respective territories and possessions (the “Extended Territory”). Accordingly, the parties agree to
use their respective best efforts to negotiate commercially reasonable terms and conditions for the grant of such additional rights and licenses in the Extended Territory, such negotiations to commence within a reasonable period of time following
the end of the Initial Feasibility Period. 
 (b) The parties recognize that at the Effective Date of this Agreement they
cannot determine the conditions and circumstances, or the form of agreement, under which such additional rights in the Extended Territory may be granted, including but not limited to potential success of additional anticipated products, costs of
development of such additional products and anticipated revenue therefrom. Notwithstanding the foregoing, Immunicon agrees that it will accept a license fee of no more than an additional $[******] in total under any and all such Extended Territory
agreements for the grant to DHI of exclusive rights to make, have made, use, sell and have sold Products and Instrument Systems in the Extended Territory. All other terms and conditions of such Extended Territory agreement shall be negotiated in
good faith between the parties. Each of the parties further agrees that for a period of [*****] ([***]) months following the commencement of the Commercial Period that it will not grant or negotiate to grant to any Third Party any such rights and
licenses in the Extended Territory; provided, however, that a party shall not be subject to such restriction in the event the other party is in Material Breach of this Agreement. 
 7.3 Third Party Licenses  
 Immunicon shall be responsible for and shall bear all costs, fees,
royalties, or other payments associated with obtaining any license from a Third Party that upon reasonable advice of Immunicon’s counsel is required to develop, manufacture, use or commercialize Bulk Reagents or Instrument Systems in accordance
with this Agreement. DHI shall be responsible for and shall bear all costs, fees, royalties, or other payments associated with obtaining any license from a Third Party that upon reasonable advice of DHI’s counsel is required to develop,
manufacture, use or commercialize Detection Reagents in accordance with this Agreement or to develop, manufacture and use [********] and [**********] and to supply them to Immunicon as contemplated by this Agreement, and to commercialize [*********]
and [***********] as components of Bulk Reagents and Products. DHI has informed Immunicon [**********************************************************************************************************
*********************************************************************************************************** *******************************************]. 
 [********************************************************************************************************** ************************]; provided, however, that anything in this Section 7.3 or elsewhere in this Agreement to the contrary
notwithstanding, neither DHI nor Immunicon shall be required to obtain any license from a Third Party if the costs, fees, royalties and other payments under such license and any and all other required Third Party licenses would exceed, in the
aggregate, [***]% of the revenues to be received by DHI and/or Immunicon from the sale of the Product or Product component for which such licenses are required. 
  

 26 

	8.	PATENTS 

 8.1 Prosecution. Each party shall promptly
report to the other all Inventions in the Field whether or not such Inventions are patentable. DHI and Immunicon shall jointly select Inventions jointly made for which they wish to file patent applications or perfect other intellectual property
rights therein. Upon such selection, Immunicon shall, using patent counsel of its choice, reasonably acceptable to DHI, take all necessary steps to file, prosecute and maintain, the requested patent protection on such joint Inventions. Either party
shall have the right upon thirty (30) days prior written notice to the other party, at its sole cost and expense, to file and prosecute a patent application or maintain a patent covering all or a part of any jointly-held Invention in any
country which such other party does not select as set forth above, unless upon receipt of such notice and before the end of the notice period, such other party selects such country. 
 8.2 Each party shall provide to the other copies of all applications covering joint Inventions, all prior art searches relating to such patent applications, and all correspondence to and from the United States Patent
and Trademark Office relating to the same. Upon request, the party prosecuting a patent application shall make available to the other party all related correspondence with other patent offices. 
 8.3 Each party shall promptly inform the other party of all patent applications filed on its Inventions in the Field and shall provide to such other party copies of all
such applications, all prior art searches relating to such patent applications, and all correspondence to and from the United States Patent and Trademark Office relating to the same. Upon the request of either party, the other party shall make
available to the requesting party related correspondence with other patent offices. 
 8.4 Assuming Prosecution for Joint Inventions 
 In the event that a party wishes to discontinue or abandon prosecution of any patent or patent application on any joint Invention, or elects to cease
paying maintenance fees of any resulting patent, it shall promptly inform the other party; such other party shall then be entitled to continue the prosecution of any such application, pay any expense or cost, and take any other action necessary to
continue the prosecution of such patent application or keep any resulting patent in force on behalf of the parties. In the event that any Product or Instrument System subsequently released into the stream of commerce comes within the scope of any
patent whose prosecution or maintenance has been so assumed, then the party that elected to discontinue or abandon prosecution or maintenance shall refund to the other party the costs borne by the other party in taking such actions with respect to
the patent(s) in question. 
 8.5 Costs. All patent attorney fees and all patent registration, patent filing, patent translation and patent
maintenance fees, costs and expenses with respect to the Patents and the Inventions solely owned by a party shall be borne by that party. All such fees, costs, and expenses with respect to Patents and the Inventions owned jointly by the parties
shall be shared equally by the parties. 
 8.6 In all events concerning patent prosecution of the application under this Section, DHI and Immunicon shall
cooperate with each other. 
  

 27 

	9.	THIRD PARTY INFRINGEMENT 

 9.1 Enforcement. If either
party becomes aware that any of the Patents are being or have been infringed by any Third Party, such party shall promptly notify the other party hereto in writing describing the facts relating thereto in reasonable detail. Except as provided below,
Immunicon shall have the initial right, but not the obligation, to institute, prosecute and control any action, suit or proceeding (an “Action”) with respect to such infringement, including any declaratory judgment action, at its expense,
using counsel of its choice. DHI shall cooperate with Immunicon and provide such non-monetary assistance as Immunicon may reasonably request in connection with any such Action. Any recovery of damages by Immunicon for any such Action shall be
applied first in satisfaction of any costs incurred by Immunicon relating to the Action (including attorneys’ and expert fees) and the balance remaining from any recovery shall be recovered by Immunicon. Notwithstanding the foregoing, with
respect to any infringement relating to any intellectual property or other proprietary right in or to [******] and [********] or Patents owned or licensed by DHI, including but not limited to infringement of any patent relating solely to [********]
and [**********], DHI shall have the right to institute, prosecute and control any Action with respect to such infringement, including any declaratory judgment action, at its expense, using counsel of its choice. Immunicon shall cooperate with DHI
and provide such non-monetary assistance as DHI may reasonably request in connection with any such Action. Any recovery of damages by DHI for any such Action shall be applied first in satisfaction of any costs incurred by DHI relating to the Action
(including attorneys’ and expert fees) and the balance remaining from any recovery shall be recovered by DHI. 
 9.2 Joint Enforcement. In the
event that a party initiates an Action pursuant to Section 9.1 above, the other party shall have the right to intervene in such Action and the initiating party shall not oppose such intervention, provided that (i) the intervening party
notifies the court of its intention to intervene within one hundred twenty (120) days of its receipt of notice of the commencement of such Action, and (ii) the intervening party shares equally with the initiating party the total costs
incurred by the initiating party (including, without limitation, attorneys’ and expert fees) of conducting such Action. The parties shall cooperate and provide each other such assistance as either may reasonably request in connection with any
such Action, provided, the initiating party shall retain the control of the conduct and settlement of any such Action. Any recovery of damages for any such suit shall be applied first in satisfaction of any actual out-of-pocket costs and expenses
incurred by either of the parties relating to the Action (including, without limitation, attorneys’ and expert fees), and the balance remaining from any recovery shall be divided into fifty (50%) percent to each party. 
 9.3 Enforcement by DHI. In the event that Immunicon fails to initiate or defend any Action involving the Patents in the Field within [****************] ([***])
days of receiving notice of any alleged infringement, DHI may, at its option, initiate and control such an Action (including Actions for past infringements), and Immunicon shall cooperate with DHI and provide such non-monetary assistance as DHI may
reasonably request in connection with any such Action. Any recovery of damages by DHI for any such suit shall be applied first in satisfaction of any costs incurred by DHI relating to the Action (including attorneys’ and expert fees), and the
balance remaining from any recovery shall be divided as follows: (a) DHI shall recover [******] percent ([***]%) of such remaining balance, and (b) Immunicon shall be entitled to [****]% of such remaining balance. In addition to the
foregoing, DHI shall have the right to be included as a co-plaintiff or named plaintiff in any litigation involving Inventions in the Field for the purpose of calculating and obtaining damages due under the law or in equity adequate to compensate
DHI for its losses. 
  

 28 

 9.4 Costs. The costs of litigation referred to in this Section 9 shall include but not be limited to such
out-of-pocket expenses as court costs and court fees, reasonable travel expenses, reasonable charges for the professional services of outside counsel and experts, and shall exclude only the time that regular employees of DHI or Immunicon devote to
such litigation. 
 9.5 Assistance. Immunicon agrees that in the event that DHI chooses to prosecute an action for infringement of a Patent under
Section 9.3 herein but cannot do so in its own name, to sign and give to, within thirty (30) days after request by DHI, all necessary documents in order for DHI to prosecute such infringement in the name of Immunicon. Immunicon also agrees
to cooperate with DHI, at DHI expense for out-of-pocket costs, in the prosecution of such infringement. 
  

	10.	THIRD PARTY CLAIM OF INFRINGEMENT 

 10.1 If a claim of patent
infringement or misappropriation or wrongful use of a trade secret or other proprietary right is brought against a party hereto in any country by reason of any act conducted in the furtherance of this Agreement, or if a party becomes aware of any
potentially-infringing patent or other proprietary right owned by a Third Party in any country, such party shall promptly give notice thereof to the other party and provide it with all information in its possession regarding such claim or potential
infringement. 
 10.2 Each party shall indemnify, defend and hold harmless the other party against any damages, costs, expenses and liabilities (including
reasonable attorneys’ fees and expenses) arising out of a claim of patent infringement or misappropriation or wrongful use of a trade secret or other proprietary right based on the manufacture, use, or anticipated sale of any Product that
embodies the indemnifying party’s Invention. The indemnifying party shall conduct the defense of any such suit for infringement, misappropriation, or misuse at its expense. The indemnified party may participate in such defense, at its option
and expense, and shall furnish to the indemnifying party such assistance as it may reasonably need and request from time to time for the conduct of the defense of such suit. Neither party shall dispose of or settle any such claim in any manner which
may compromise or affect the validity of any of the other party’s Inventions , without that party’s prior written consent, which shall not be unreasonably withheld. No indemnification of any claim for infringement, misappropriation, or
misuse shall apply under this Section 10.2 where the claim arises out of the manufacture, use, or anticipated sale of products embodying joint Inventions. 
  

	11.	PATENT MARKING 

 DHI shall mark Products with
appropriate patent numbers or indicia at Immunicon’s instruction and election, as, when and where DHI may reasonably accommodate same, given packaging, printing schedules and other factors, in those countries where such markings have notice
value as against infringing persons. 
  

 29 

	12.	CONFIDENTIALITY AND PUBLICATION 

 12.1 Confidential
Information. All Confidential Information disclosed by one party to the other shall not be used by the receiving party except in connection with the activities contemplated by this Agreement, shall be maintained in confidence by the receiving
party, and shall not be disclosed by the receiving party to any other person, firm or agency, governmental or private, without the prior written consent of the disclosing party, except to the extent Confidential Information is: 
 (1) known by or in possession of the receiving party at the time of its receipt as documented in written records; 
 (2) independently developed outside the scope of this Agreement by employees of the receiving party having no access to or knowledge of the Confidential
Information disclosed hereunder as documented in written records; 
 (3) in the public domain at the time of its receipt or thereafter
becomes part of the public domain through no fault of the receiving party; 
 (4) received without an obligation of confidentiality from a
Third Party having the right to disclose such information; 
 (5) required to be disclosed to governmental agencies, or disclosure is
otherwise required by law, regulation or governmental or court order or the requirements of any securities exchange upon which a party’s securities are traded (so long as the receiving party provides notice of such disclosure, seeks to obtain
protective orders or other available confidentiality treatment and, in the case of disclosures to the SEC, seeks confidential treatment to the extent reasonably requested by the disclosing party); 
 (6) released from the restrictions of this Section by the express written consent of the disclosing party; or 
 (7) disclosed to agents, consultants, assignees, sublicensees or subcontractors of DHI or Immunicon or their Affiliates which have a need to know such
information in connection with the performance of this Agreement, provided that such persons are or agree to be subject to the provisions of this Section or substantially similar provisions. 
 12.2 Publication. Prior to public disclosure or submission for publication of a manuscript or other work describing the result of any aspect of scientific or
clinical activity or collaboration between DHI and Immunicon relating to any activity under the terms of this Agreement, the party disclosing or submitting such a manuscript (“Disclosing Party”) shall send the other party (“Responding
Party”) a copy of the manuscript to be submitted and shall allow the Responding Party not less than thirty (30) calendar days in which to determine whether the manuscript contains subject matter for which patent protection should be sought
prior to publication of such manuscript for the purpose of protecting an invention of commercial value to the Responding Party, or whether the manuscript contains confidential information belonging to the Responding Party, or whether the manuscript
contains information that should not yet be revealed for other business reasons. After the expiration of such thirty (30) calendar day period, if the Responding Party has not objected, the Disclosing Party may submit such manuscript for
publication and publish or otherwise disclose to 

  

 30 

 
the public such research results. If the Responding Party believes the subject matter of the manuscript contains confidential information or a patentable
invention of commercial value to the Responding Party or should not yet be otherwise revealed, then prior to the expiration of such thirty (30) calendar day period, the Responding Party shall notify the Disclosing Party in writing of its
determination. Upon receipt of such written notice from the Responding party, the Disclosing Party shall delay public disclosure of such information or submission of the manuscript for an additional period of sixty (60) calendar days to permit
preparation and filing of a patent application on the disclosed subject matter or for such other period and for such other reasons as the parties shall mutually agree. The Disclosing Party shall thereafter be free to publish or disclose such
information, except that the Disclosing Party may not disclose any Confidential Information of the Responding Party without the prior written consent of the Responding Party. 
  

	13.	TERM AND TERMINATION 

 13.1 Term. Unless earlier
terminated pursuant to a right of termination provided elsewhere in this Agreement, the Term of this Agreement shall commence on the Effective Date and shall remain in effect for a period ending on the fifth anniversary of the date of commencement
of the Commercial Period (the “Original Term”). Thereafter, either party may elect to extend the Original Term for one additional five (5) year period (the “Extended Term”) by giving written notice of such extension to the
other party at least ninety (90) days prior to the expiration of the Original Term; provided, however, that neither DHI nor Immunicon shall have the right to elect to extend the Original Term if it is in Material Breach of the Agreement at the
time it makes such election. The Original Term together with the Extended Term, if any, is herein referred to as the “Term.” 
 13.2 Termination
by Mutual Agreement. This Agreement may be terminated at any time upon the mutual agreement of the parties in writing. 
 13.3 Termination for
Breach. In the event of a Material Breach by either party, then the other party may terminate this Agreement by giving such party notice of such Material Breach. The party receiving such notice shall have ninety (90) days from the date of
receipt thereof to cure such Material Breach. If such Material Breach is not curable or is not cured within such ninety (90) day period, then the non-breaching party shall have the right to terminate this Agreement effective as of the end of
such period. In the event such Material Breach is cured during such period, such notice shall be of no force or effect and this Agreement shall not be terminated. 
 13.4 Early Termination. This Agreement shall automatically terminate in the event the Commercial Period does not commence on or before July 1, 2009. 
 13.5 Termination by Either Party. Either DHI or Immunicon, not earlier than eighteen (18) months after the Effective Date may terminate this Agreement upon written notice to the other party, for any reason
or for no reason; provided, however, that neither party make exercise its right to terminate this Agreement under this Section 13.5 if a Clinical Trial Plan for the first Initial Product has been submitted to the FDA and the payment provided
for in Section 3.5.1(b) has been made. In the event of termination of this Agreement in accordance with this Section 13.5, the provisions of Section 13.6 (c) shall apply. 
  

 31 

 13.6 Effect of Termination. 
 (a) Termination under Sections 13.2 or 13.4. Following expiration of the Term or the termination of this Agreement pursuant to
Section 13.2 or Section 13.4, neither DHI nor Immunicon shall have any rights under the licenses granted to them in Section 7.2 and such licenses shall thereafter be null and void, and all rights granted to each party by the other
party shall immediately upon such termination revert to the granting party without the necessity of any further written agreement. 
 (b) Termination under Section 13.3. In the event of termination of this Agreement pursuant to Section 13.3, the breaching party shall have no rights under the license granted to it in Section 7.2 and such license shall
thereafter be null and void, and all rights granted hereunder to such breaching party by the other party hereto shall immediately upon such termination revert to the granting party without the necessity of any further written instrument. The
non-breaching party shall have the right, by giving written notice to the breaching party within thirty (30) days of the effective date of such termination, to retain the license granted to it pursuant to Section 7.2 for the remainder of
the Original Term or then applicable Extended Term. In the event that the non-breaching party elects to retain such license it shall pay to the other party an amount equal to [***] percent ([***]%) of the net revenues (calculated in accordance with
the calculation applicable to Revenue hereunder) from the sale of products or the performance of services by the non-breaching party utilizing such right and license. If Immunicon is the non-breaching party and elects to retain the license granted
to it in Section 7.2 as provided for in the preceding sentence, DHI will use commercially reasonable efforts (which shall in no event include the payment of any transfer or other fee other than the royalty provided above) to license, provide
access or to transfer to Immunicon [***********************************************************] as well as any [****************************************************************] in the possession of DHI or any of its Affiliates necessary or useful
for Immunicon to make, use, import/export, market and sell Products and Instrument Systems. If DHI is the non-breaching party and elects to retain the license granted to it in Section 7.2, Immunicon will use commercially reasonable efforts to
continue to supply Instrument Systems and Bulk Reagents to DHI under the terms and conditions of this Agreement and the Distribution Agreement. If Immunicon is unable to supply Instrument Systems or Bulk Reagents to DHI pursuant to the immediately
preceding sentence, then DHI shall be free to make or have made Bulk Reagents or Instrument Systems. In such case, Immunicon shall use commercially reasonable efforts (which shall in no event include the payment of any transfer or other fee other
than the royalty provided above) to license, provide access or transfer to DHI any product registrations or Regulatory Approvals that may be registered in the name of Immunicon or any of its Affiliates as well as any trademarks, licenses and all
intellectual property and technology, know-how, software, permits, approvals, relevant manufacturing information and other information in the possession of Immunicon or any of its Affiliates necessary or useful for DHI to make, have made, use,
import/export, market and sell Instrument Systems and Products and to make, have made and use Bulk Reagents in the manufacture of Products as contemplated by this Agreement. The breaching party will also provide advice and consultation to the
non-breaching party with respect to its use of the technology and other property of the breaching party pursuant to this paragraph. 
  

 32 

 (c) Termination under Section 13.5. In the event of termination of this
Agreement pursuant to Section 13.5, the right and license granted to the terminating party under Section 7.2 shall thereafter be null and void, and shall immediately upon such termination revert to the granting party without the necessity
of any further written instrument; provided, however, that the non-terminating party shall have the right, upon giving written notice to the terminating party within thirty (30) days following the receipt of notice of termination from the
terminating party in accordance with Section 13.5, to retain the right and license granted to it pursuant to Section 7.2, subject to and as modified by this Section 13.6(c), by electing in such written notice one of the following
options: 
 (i) If the non-terminating party is DHI, DHI may elect to retain the exclusive right and license granted under
Section 7.2.1, in which case such exclusive right and license shall continue for a period of [****] ([***]) [****] from the commencement of the Commercial Period (the “DHI Exclusivity Period”), after which period, unless DHI elects
one of the additional options set forth in this paragraph, such right and license shall be null and void, and shall immediately revert to Immunicon without the necessity of any further written instrument. In the event that DHI elects to retain such
exclusive right and license, DHI shall pay to Immunicon during the DHI Exclusivity Period a royalty in an amount equal to forty one percent (41%) of Revenues (as defined below) until the total amount of royalty paid equals [********]
($[*********]), at which time the royalty payable will be reduced to an amount equal to [******] percent ([***]%) of Revenues. Such royalty shall be due and payable within thirty (30) days after the end of each calendar quarter. Prior to the
end of the DHI Exclusivity Period, DHI may elect, by written notice to Immunicon given at least ninety (90) days prior to the last day of the DHI Exclusivity Period, either (A) to maintain such exclusive right and license, in which case
DHI shall pay to Immunicon a one-time lump-sum payment of [*************] ($[********]) within thirty (30) days after the last day of the DHI Exclusivity Period in addition to continuing to pay to Immunicon a royalty of [*****] percent ([***]%)
of Revenues payable as above, in which case such exclusive right and license shall continue until the last to expire of the [******] included in [************] or so long as a license is required by DHI to utilize the [************] to make, have
made, use, import/export, market and sell [***********] and to make, have made and use [***********] in the manufacture of [*********], or (B) to convert such exclusive right and license to a non-exclusive right and license by paying to
Immunicon a lump-sum payment of [*********] ($[*****]) within thirty (30) days after the last day of the DHI Exclusivity Period and thereafter paying to Immunicon a royalty equal to [***] percent ([**]%) of Revenues. Such non-exclusive right
and license shall continue until the last to expire of the [********] included in [************] or so long as a license is required by DHI to utilize the [***********] to make, have made, use, import/export, market and sell [*************] and to
make, have made and use [***********] in the manufacture of [*******]. Any royalty payable under this paragraph (i) shall be due and payable within thirty (30) days after the end of each calendar quarter. 
 (ii) If the non-terminating party is DHI, DHI may elect to convert the exclusive right and license granted under Section 7.2.1 to a
non-exclusive license, in which case such non-exclusive right and license shall continue until the last to expire of the [********] included in [**********] or so long as a license is required by DHI to utilize the [************]] to make, have
made, use, import/export, market and sell [*************] and to make, have made and use [*********] in the manufacture of [******]. In the event that DHI elects such non-exclusive right and license, 

  

 33 

 
DHI shall pay to Immunicon a lump-sum payment of [**********] dollars ($[*******]) within thirty (30) days after the Agreement termination date and a
royalty equal to [***] percent ([***]%) of Revenues. Any royalty payable under this paragraph (ii) shall be due and payable within thirty (30) days after the end of each calendar quarter following the Agreement termination date.

 (iii) If the non-terminating party is Immunicon, Immunicon may elect to retain the exclusive right and license granted
under Section 7.2.2, in which case such exclusive right and license will continue for a period of [***] ([***]) [***] from the commencement of the Commercial Period (the “Immunicon Exclusivity Period”), after which period, unless
Immunicon elects one of the additional options set forth in this paragraph, such right and license shall thereafter be null and void, and shall immediately revert to DHI without the necessity of any further written instrument. In the event that
Immunicon elects to retain such exclusive right and license, Immunicon shall pay to DHI during the Immunicon Exclusivity Period a royalty in an amount equal to [*****] percent ([***]%) of Revenues until the total amount of royalty paid equals
[*********] ($[*****]), at which time the royalty payable will be reduced to an amount equal to [******] percent ([***]%) of Revenues. Prior to the end of the Immunicon Exclusivity Period, Immunicon may elect, by written notice to DHI given at least
ninety (90) days prior to the lat day of such period, either (A) to maintain such exclusive right and license, in which case Immunicon shall pay to DHI a lump-sum payment of [***************] ($[********]) within thirty (30) days
after the last day of the Immunicon Exclusivity Period in addition to continuing to pay to DHI a royalty equal to [*****] percent ([***]%) of Revenues, in which case such exclusive right and license shall continue for [**********] of the
intellectual property and other proprietary rights owned by or licensed to DHI related to [*********] and [**********], or (B) to convert such exclusive right and license to a non-exclusive right and license by paying to DHI a lump-sum payment
of [***********] ($[*****]) within thirty (30) days after the last day of the Immunicon Exclusivity Period and thereafter paying to DHI a royalty equal to [***] percent ([***]%) of Revenues. Such non-exclusive right and license shall continue
for [*********] of the intellectual property and other proprietary rights owned by or licensed to DHI related to [*********] and [**********]. Any royalty payable under this paragraph (iii) shall be due and payable within thirty (30) days
after the end of each calendar quarter. 
 (iv) If the non-terminating party is Immunicon, Immunicon may elect to convert the
exclusive right and license granted under Section 7.2.2 to a non-exclusive license, in which case such non-exclusive right and license shall continue for [*********] of the intellectual property and other proprietary rights owned by or licensed
to DHI related to [***********] and [********]. In the event that Immunicon elects a non-exclusive right and license, Immunicon shall pay to DHI a lump-sum payment of [***********] ($[*****]) within thirty (30) days after the Agreement
termination date and a royalty equal to [****] percent ([***]%) of Revenues. Any royalty payable under this paragraph (iv) shall be due and payable within thirty (30) days after the end of each calendar quarter following the Agreement
termination date. 
 (d) In the event the terminating party under Section 13.5 is Immunicon and DHI elects to retain a
right and license under Sections 13.6 (c) (i) or (ii), Immunicon will use commercially reasonable efforts (which shall in no event include the payment of any transfer or other fee other than the royalty provided above) to license, provide
access or transfer to DHI [******************************************] as well as any 

  

 34 

 
[*********************************************************************] necessary or useful for DHI to make or have made, use, import/export, market and sell
Instrument Systems and Products and to make and use Bulk Reagents in the manufacture of Products. In the event the terminating party under Section 13.5 is DHI and Immunicon elects to retain a right and license under Sections 13.6(c)(iii) or
(iv), DHI will use commercially reasonable efforts (which shall in no event include the payment of any transfer or other fee other than the royalty provided above) to license, provide access or to transfer to Immunicon [***************************]
as well as any [********], [********], [************], [***********] and all other [*****************] in the possession of DHI or any of its Affiliates necessary or useful for Immunicon to make or have made, use, import/export, market and sell
Products and Instrument Systems. The terminating party will also provide advice and consultation to the non-terminating party with respect to its use of the technology and other property of the terminating party pursuant to this Section. The
provisions of Section 7.3 of the Agreement shall continue to be applicable to technology rights licensed by DHI. 
 (e)
For purposes of Section 13.6(d) and notwithstanding the definitions given to such terms in Section 2 of this Agreement, the following terms shall have the respective meanings set forth below: 
 (i) “Product(s)” shall have the meaning given to that term in Section 2 of this Agreement, except that it shall include all
Products, including the Products listed as “Additional Products” in Exhibit A hereto, whether or not any such Product shall have been approved by the Management Board prior to the time of termination of this Agreement. When reference is
made in Section 13.6(d) to a right and license granted to a party under Section 7.2.1 or Section 7.2.1 of this Agreement, the term “Products” as used in such Section 7.2.1 or Section 7.2.2, as the case may be,
shall be deemed to refer to the definition of the term “Products” provided for in the immediately preceding sentence. 
 (ii) “Revenues” shall have the meaning given to such term in Section 2 of this Agreement, except that (i) when such term is used in Section 13.6(d) in reference to amounts received by Immunicon all references to DHI
and/or its Affiliates in such Section 2 definition of “Revenues” shall be deemed to refer to Immunicon and/or its Affiliates and (ii) all references to “Products” in such Section 2 definition of
“Revenues” shall be deemed to refer to Products as defined in this Section 13.6(e). 
 (f) During the DHI
Exclusivity Period, Immunicon shall not manufacture, promote, market, sell or distribute, or license any of its intellectual property so that a Third Party may manufacture, promote, market, sell or distribute, any Products (as defined in
Section 13.6(e)) or Instrument Systems (whether or not previously approved by the Management Board) for use in the Field. During the Immunicon Exclusivity Period, DHI shall not manufacture, promote, market, sell or distribute, or license any of
its intellectual property so that a Third Party may manufacture, promote, market, sell or distribute, any Products (as defined in Section 13.6(e)) for use in the Field. 
 (g) Termination of this Agreement for any reason shall not release any party hereto from any liability (or obligation assumed and
substantially undertaken but not yet accrued) which, at the time of such termination, has already accrued to the other party or which is attributable to a period 

  

 35 

 
prior to such termination, nor preclude either party from pursuing any rights and remedies it may have hereunder at law or in equity which accrued or are
based upon any event occurring prior to such termination, subject to any limitations on damages expressly set forth herein. 
  

	14.	DISPUTE RESOLUTION 

 14.1 Any dispute, except a dispute
involving infringement of Third Party intellectual property rights or any intellectual property rights owned or controlled by a party, shall be submitted to arbitration, which shall be exclusive, final, binding, and conducted by three arbitrators in
accordance with the rules of the American Arbitration Association (“AAA”) applicable to commercial disputes. The decision of the arbitrators shall be final and in writing setting forth the award and the reasons therefor. All hearings in
the arbitration shall be held in Wilmington, Delaware and the arbitrators shall apply the substantive law of Delaware (except where the law conflicts with this clause) except that the interpretation and enforcement of this arbitration provision
shall be governed by the Federal Arbitration Act. The arbitrators shall be neutral, independent, disinterested, impartial and shall abide by the Code of Ethics for Arbitrators in Commercial Disputes approved by the AAA. Within thirty (30) days
of initiation of arbitration, the parties shall reach agreement upon and thereafter follow procedures assuring that the arbitration will be concluded and the award rendered within no more than three (3) months from selection of the arbitrators.
Failing such agreement, the AAA will design and the parties will follow procedures that meet such a time schedule. Each party has the right before or, if the arbitrators cannot hear the matter within an acceptable period, during the arbitration to
seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc., to avoid irreparable harm, maintain the status quo or preserve the subject matter of the arbitration. Depositions shall not
be permitted in any arbitration unless the arbitrators decide otherwise upon good cause shown by a party. Each party shall bear its own fees and expenses, including attorneys’ fees. The fees and expenses of the arbitrators and the cost of the
arbitration shall be borne equally by the parties. THE ARBITRATORS SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES. NO PARTY MAY SEEK OR
OBTAIN PREJUDGMENT INTEREST OR ATTORNEYS’ FEES OF COSTS. Any decision of the arbitrators may be entered as a judgment in any court of competent jurisdiction and may be enforced as such in accordance with the provisions of the award. This
agreement to arbitrate shall be specifically enforceable by the parties. 
 14.2 Any dispute involving infringement of Third Party intellectual property
rights or any intellectual property rights owned or controlled by a party, will be resolved exclusively in the Federal courts located in the State of Delaware. Each of the parties hereby expressly submits to the personal jurisdiction of the
foregoing courts located in Delaware and waives any objection or defense based on personal jurisdiction or venue that might otherwise be asserted to proceedings in such courts. The parties further hereby irrevocably waive, to the fullest extent
permitted by law, all rights to trial by jury in any action, proceeding or counterclaim (whether in contract, statute, tort (including negligence) or otherwise) relating to or arising from the Agreement. In any litigation, each party shall bear its
own fees and expenses, including attorneys’ fees. 
  

 36 

	15.	REPRESENTATIONS, INDEMNIFICATION, NON-COMPETITION 

 15.1
Representations of Immunicon. Immunicon represents and warrants to DHI that: 
 15.1.1 The execution, delivery and
performance of this Agreement by Immunicon will not, with or without notice, the passage of time or both, result in any violation of, be in conflict with, or constitute a default under, any contract, obligation or commitment to which Immunicon is a
party or by which it is bound, or to Immunicon’s knowledge, any statute, rule or governmental regulation applicable to Immunicon. 
 15.1.2 Immunicon has all requisite legal and corporate power and authority to enter into this Agreement and to carry out and perform its obligations under the terms of this Agreement. All corporate action on the part
of Immunicon and its employees, agents, officers, directors and stockholders necessary for the performance of Immunicon’s obligations hereunder has been taken. This Agreement constitutes a valid and binding obligation of Immunicon, enforceable
in accordance with its terms, except as (i) the enforceability hereof may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights and remedies generally, (ii) the
availability of equitable remedies (e.g., specific performance, injunctive relief, and other equitable remedies) may be limited by equitable principles of general applicability, and (iii) that no representation is made regarding the effect of
laws relating to competition, antitrust or misuse. 
 15.1.3 Immunicon, as of the Effective Date, is not a party to any
material contract (other than this Agreement) with a Third Party with respect to the Field. 
 15.2 Representations of DHI. DHI represents and
warrants to Immunicon that: 
 15.2.1 The execution, delivery and performance of this Agreement by DHI will not, with or
without notice, the passage of time or both, result in any violation of, be in conflict with, or constitute a default under any contract, obligation or commitment to which DHI is a party or by which it is bound, or to DHI’s knowledge, any
statute, rule or governmental regulation applicable to DHI. 
 15.2.2 DHI has all requisite legal and corporate power and
authority to enter into this Agreement and to carry out and perform its obligations under the terms of this Agreement. All corporate action on the part of DHI and its employees, agents, officers and directors necessary for the performance of its
obligations hereunder has been taken. This Agreement constitutes a valid and binding obligation of each such party, enforceable in accordance with its terms, except as (i) the enforceability hereof may be limited by applicable bankruptcy laws
and other similar laws affecting creditors’ rights and remedies generally, (ii) the availability of equitable remedies (e.g. specific performance, injunctive relief and other equitable remedies) may be limited by equitable principles of
general applicability, and (iii) that no representation is made regarding the effects of laws relating to competition, antitrust or misuse. 
  

 37 

 15.2.3 DHI, as of the Effective Date, is not a party to any material contract (other than this Agreement)
with a Third Party with respect to the manufacture or sale of Products or Instrument Systems in the Field. 
 15.3 Indemnification by DHI. DHI shall
at all times, during the term of this Agreement and thereafter, indemnify and hold harmless Immunicon and its Affiliates, stockholders, directors, officers, agents and employees from any claim, proceeding, loss, expense, and liability of any kind
whatsoever (including but not limited to those resulting from death, personal injury, illness or property damage and including reasonable legal expenses and attorneys’ fees) (collectively, “Damages”) arising out of or resulting from
(a) the material inaccuracy of any representation or the breach of any warranty, covenant or agreement made by DHI in this Agreement or (b) the negligence or willful misconduct of DHI or any of its employees or agents in connection with
activities undertaken by DHI under this Agreement; provided, however that there shall be apportionment in accordance with responsibility when such indemnity obligation derives in part from acts of DHI and in part from acts of Immunicon
(and the parties hereby agree to split all third party product liability or personal injury claims arising from the sale, use or distribution of any Product or Instrument System that meets the applicable specifications and is not otherwise defective
as agreed to by the parties and if the parties are unable to reach such agreement then such matter shall be determined in accordance with the arbitration procedures set forth herein and the arbitrators shall make such determination in accordance
with the relative fault of the parties); provided, further, however, Immunicon shall bear all Damages which arise out of or result from the sale, use or distribution of any Product or Instrument System that does not meet the applicable
specifications or is otherwise defective or not consistent with any warranty as to Bulk Reagents or Instrument Systems made by Immunicon hereunder. 
 15.4
Indemnification by Immunicon. Immunicon shall at all times, during the term of this Agreement and thereafter, indemnify and hold harmless DHI and its Affiliates, stockholders, directors, officers, agents and employees from any claim,
proceeding, loss, expense, and liability of any kind whatsoever (including but not limited to those resulting from death, personal injury, illness or property damage and including reasonable legal expenses and attorneys’ fees) arising out of or
resulting from (a) the material inaccuracy of any representation or the breach of any warranty, covenant or agreement made by Immunicon in this Agreement or (b) the negligence or willful misconduct of Immunicon or any of its employees or
agents in connection with activities undertaken by Immunicon pursuant to this Agreement; provided, however, that there shall be apportionment in accordance with responsibility when such indemnity obligation derives in part from acts of
DHI and in part from acts of Immunicon in the manner provided for in Section 15.3. 
 15.5 Claims. In any claim for indemnification (an
“Indemnity Claim”), the indemnified party agrees to give the indemnifying party prompt written notice of any matter upon which such indemnified party intends to base such a claim under this Agreement. The indemnifying party shall have the
right to participate jointly with the indemnified party in the indemnified party’s defense, settlement or other disposition of any Indemnity Claim. With respect to any Indemnity Claim relating solely to the payment of money damages and which
could not result in the indemnified party’s becoming subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified party in any manner, and as to which the indemnifying party shall have
acknowledged in writing the obligation to indemnify the indemnified party hereunder, the 

  

 38 

 
indemnifying party shall have the sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such terms as the indemnifying party, in its
sole discretion, shall deem appropriate; provided that the indemnifying party shall provide reasonable evidence of its ability to pay any damages claimed and with respect to any such settlement shall obtain the written release of the indemnified
party from the Indemnity Claim. The indemnifying party shall obtain the written consent of the indemnified party prior to ceasing to defend, settling or otherwise disposing of any Indemnity Claim if as a result thereof the indemnified party would
become subject to injunctive or other equitable relief or the business of the indemnified party would be adversely affected in any manner. In the event that any such indemnity obligation shall be apportioned between the parties, Immunicon shall have
the right to control the Indemnity Claim, subject to the participation and involvement of DHI, but no settlement of any such Indemnity Claim shall be made without the consent of both Immunicon and DHI. 
 15.6 Non-Competition. During the Term, except pursuant to the terms of this Agreement, neither DHI nor Immunicon shall manufacture, promote, market, sell or
distribute, or license any of its intellectual property so that [**********] may manufacture, promote, market, sell or distribute in the United States of American and Canada and their respective territories and possessions, any [*********] or
[**********] or any [***************] (as defined below) for use in the Field. In the event of the termination of this Agreement pursuant to Section 13.3, the breaching party shall continue to be subject to the restrictions of the preceding
sentence for a period of [************] following the termination of this Agreement. For purposes of this Section 15.6, a “*********” refers to a testing system, including instruments, software, and consumable or disposable items,
that can be used to test for any of the [**********] identified in [********] and which incorporates and uses [**********] and [************] and [************] for [*********]. For avoidance of doubt, a fluorescent or light microscope is
specifically excluded from the definition of an [*************] or [************] and kits of the type currently included in DHI’s product catalog as of the Effective Date are excluded from the non-competition provisions of this
Section 15.6 and the [***********] shall be deemed an [***********] for purposes of this Section 15.6 only. 
  

	16.	MISCELLANEOUS 

 16.1 Notices. Any notice to be given
hereunder by DHI to Immunicon or by Immunicon to DHI shall be in writing and delivered personally, or sent by national overnight delivery service or postage pre-paid registered or certified U.S. mail, and shall be deemed given: when delivered, if by
personal delivery or overnight delivery service; or upon if so sent by U.S. mail, three business days after deposit in the mail, and shall be addressed: 
 If to DHI, to DHI’s address set forth above, to the attention of the Chief Executive Officer; with a copy to Chief Financial Officer. 
 If to
Immunicon, to Immunicon’s address set forth above, to the attention of the Chief Executive Officer; with a copy to: Chief Counsel; 
 or to such other
address as any party shall hereafter designate by notice given in accordance with this Section. 
  

 39 

 16.2 Payment of Expenses. Except as expressly set forth herein, all costs and expenses related to this Agreement
and the related transactions, including the fees and expenses of legal counsel, accountants, brokers and other representatives and consultants, shall be borne by the party incurring such costs and expenses, whether or not such transactions are
consummated. 
 16.3 Assignment. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by either party
without the prior written consent of the other party which consent shall not be unreasonably withheld; except that either party without the consent of the other party may assign this Agreement and all of such rights, interests and obligations to a
Third Party who acquires all or substantially all of the business and assets, and assumes all or substantially all of the obligations and liabilities, of the assigning party, including all of the obligations and liabilities of the assigning party
under this Agreement; provided, however, that any such assignee shall provide written acknowledgment to the non-assigning party to this Agreement at the time of such assignment of the foregoing assumption of all of the obligations and liabilities of
the assigning party under this Agreement in a form substantially as set forth in Exhibit C. 
 16.4 Public Statements and Press Releases. The parties
hereto covenant and agree that, except as otherwise expressly set forth in this Agreement, each will not, from and after the Effective Date, make, issue or release any public announcement, press release, statement or acknowledgment of the existence
of, or reveal publicly the terms, conditions and status of, the transactions contemplated herein, without the prior written consent of the other party as to the content and time of release of and the media in which such statement or announcement is
to be made; provided, however, that in the case of announcements, statements, acknowledgments or revelations which either party is required by law or regulation to make, issue or release, the making, issuing or releasing of any such
announcement, statement, acknowledgment or revelation by the party so required to do so by law shall not constitute a breach of this Agreement so long as the issuing or releasing party, to the extent reasonably possible, gives the other party an
opportunity to review and comment on any such written announcement or statement prior to its release. 
 16.5 Modifications and Amendments. This
Agreement shall not be modified or otherwise amended except pursuant to an instrument in writing executed by each of the parties hereto. 
 16.6
Headings. The Article and Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning and interpretation of this Agreement. 
 16.7 Waiver. The failure of either party to require the performance of any provision of this Agreement, or the waiver of either party of any breach of any
provision of this Agreement, shall not prevent a subsequent exercise or enforcement of such provision or be deemed a waiver of any subsequent breach of the same or any other provision of this Agreement. 
 16.8 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 
 16.9 Invalidity. In the event that any one or more of the provisions (or any part thereof) of this
Agreement or in any other instrument referred to herein, shall, for any reason, be held to be invalid, 

  

 40 

 
illegal or unenforceable in any respect, then to the maximum extent permitted by law, such invalidity, illegality or unenforceability shall not affect any
other provision of this Agreement or any other such instrument. 
 16.10 Construction/Governing Law. The parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring
or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, without giving effect to conflicts of law or
choice of law provisions. 
 16.11 Incorporation of Exhibits and Schedules. The Exhibits, Schedules and other instruments referred to in this
Agreement are incorporated herein by reference and made a part hereof. In the event of any conflict between the provisions of any such Exhibit, Schedule or other instrument and those of the body of this Agreement, the provisions of the body of this
Agreement shall govern and prevail. 
 16.12 Entire Agreement. It is the desire and intent of the parties to provide certainty as to their future
rights and remedies against each other by defining the extent of their undertakings herein. This Agreement constitutes and sets forth the entire agreement and understanding between the parties with respect to the subject matter hereof and is
intended to define the full extent of the legally enforceable undertakings of the parties hereto, and no promise, agreement or representation, written or oral, which is not set forth explicitly in this Agreement is intended by either party to be
legally binding. Each party acknowledges that in deciding to enter into this Agreement and to consummate the transactions contemplated hereby it has not relied upon any statements, promises or representations, written or oral, express or implied,
other than those explicitly set forth in this Agreement. This Agreement supersedes all previous understandings, agreements and representations between the parties, written or oral, with respect to the subject matter hereof. 
 16.13 Survival of Certain Provisions. In addition to any other provisions of this Agreement that expressly survive termination of this Agreement, to the extent
applicable the following Sections shall survive termination of this Agreement along with any remedies for the breach thereof: Section 7.1 (Ownership of IP), accrued rights under Section 8 (Patents), 9 (Third Party Infringement), 10
(Infringement), 11 (Marking), 12 (Confidentiality), 14 (Dispute Resolution), 15.1 and 15.2 (Representations), 15.3 and 15.4 (Indemnification) and 15.5 (Claims). 
 16.14 No Agency. Nothing in this Agreement shall be construed to make the relationship of the parties herein a joint venture, an association, or a partnership, or to make the parties agents of one another. This Agreement shall not be
construed to authorize the parties to act as agents of one another as to any matter set forth herein or to make any representations to any third parties indicating or implying the existence of any such agency relationship, and the status of the
parties shall be that of independent contractors for all purposes hereunder. 
 16.15 Rights Upon Insolvency. All rights and licenses granted under or
pursuant to this Agreement by one party (“Licensor”) to the other party (“Licensee”) are, for all purposes of Section 365(n) of 

  

 41 

 
Title 11 of the U.S. Code (“Title 11”), licenses of rights to intellectual property as defined in Title 11. Each party agrees during the term of
this Agreement to create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, of all such Inventions. If a case is commenced by or against any party hereto under Title 11, then, unless
and until this Agreement is rejected as provided in Title 11, such party (in any capacity, including debtor-in-possession) and its successors and assigns (including, without limitation, a Title 11 trustee) shall either perform all of the obligations
provided in this Agreement to be performed by such party or provide to the other party all such intellectual property (including all embodiments thereof) held by such party and such successors and assigns, as the other party may elect in a written
request, immediately upon such request. If a Title 11 case is commenced by or against a party, this Agreement is rejected as provided in Title 11 and the other party elects to retain its rights hereunder as provided in Title 11, then such party (in
any capacity, including debtor-in-possession) and its successors and assigns (including, without limitation, a Title 11 trustee) shall provide to the other party all such intellectual property (including all embodiments thereof) held by such party
and such successors and assigns immediately upon the other party’s written request therefor. All rights, powers and remedies of any party, as a Licensee hereunder, provided herein are in addition to and not in substitution for any and all other
rights, powers and remedies now or hereafter existing at law or in equity (including, without limitation, Title 11) in the event of the commencement of a Title 11 case by or against the other party. Licensee, in addition to the rights, powers and
remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including Title 11) in such event. 
 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have each caused this Agreement to be duly executed as of the date first above
written. 
  

			
	IMMUNICON CORPORATION
		
	By	 	/s/ Byron D. Hewett
		 	Byron D. Hewett
		 	President and CEO
	
	DIAGNOSTIC HYBRIDS, INC.
		
	By	 	/s/ David R. Scholl
		 	David R. Scholl
		 	President and CEO

  

 42 

 EXHIBIT A 
 Initial Products 
 The following Initial Products will be developed for the following Target Entities and Infectious Diseases:

 Respiratory Viruses: 
  

	 	•	 	 Launch Menu Target Entity Focus 

  

	 	•	 	 [*********] 

  

	 	•	 	 [*********] 

  

	 	•	 	 [*********] 

  

	 	•	 	 [*********] 

  

	 	•	 	 Potential Product Descriptions for these Launch Menu Target Entities: 

  

	 	•	 	 Single Target Entity Products 

  

	 	•	 	 [***********] 

	 	•	 	 [***********] 

  

	 	•	 	 Combination Target Entity Products ([*********]) 

  

	 	•	 	 [**********] 

  

	 	•	 	 [**********] 

  

	 	•	 	 [**********] 

 Sexually
Transmitted Disease/[**********]: 
  

	 	•	 	 Launch Menu Target Entity Focus 

  

	 	•	 	 [************] 

  

	 	•	 	 [************] 

  

	 	•	 	 Potential Product Descriptions for these Launch Menu Target Entities: 

  

	 	•	 	 Single Target Entity Products 

  

	 	•	 	 [********] 

  

	 	•	 	 [********] 

  

	 	•	 	 Combination Target Entity Products ([*********]) 

  

	 	•	 	 [************] 

  

	 	•	 	 [************] 

 Additional Products

 Immunicon and DHI currently contemplate the Product Development and commercialization under a Commercialization Plan approved by the Management
Board of Additional Products for the Target Entities and Infectious Diseases described below. These Additional Products would be added to the Products subject to the Agreement. 
  

 43 

 Family Menu of Additional Products 
 Respiratory Viruses: 

	 	•	 	 Family Menu Target Entity Focus 

  

	 	•	 	 [************] 

  

	 	•	 	 [************] 

  

	 	•	 	 [************] 

  

	 	•	 	 [************] 

 Sexually
Transmitted Disease/[********]: 
  

	 	•	 	 Family Menu Target Entity Focus 

  

	 	•	 	 [*********] 

  

	 	•	 	 [*********] 

  

	 	•	 	 [*********] 

 Emerging Opportunity Menu of
Additional Products 
 Respiratory Viruses: 
  

	 	•	 	 Emerging Opportunity Target Entity Focus 

  

	 	•	 	 [*******] 

  

	 	•	 	 [*******] 

  

	 	•	 	 [*******] 

  

	 	•	 	 [*******] 

  

	 	•	 	 [*******] 

 Sexually Transmitted
Disease/[*********]: 
  

	 	•	 	 Emerging Opportunity Target Entity Focus 

  

	 	•	 	 [***********] 

 Procedures for Introducing
Additional Products 
 DHI currently intends to develop Detection Reagents for one or more of the Additional Products identified in
the Family Menu or the Emerging Opportunities Menu above. If DHI is successful in developing at least [***] Detection Reagent for an Additional Product and has demonstrated such success to Immunicon, it may thereafter propose from time to time to
the Management Board that one or more of the Additional Products identified in the Family Menu and/or the Emerging Opportunity Menu above be developed and commercialized as a Product or Products under the Agreement. DHI will give written notice (the
“DHI Proposal”) to the Management Board of its desire to develop and commercialize an Additional Product, which notice shall include a forecast of estimated revenue from the sale of such Additional Product for the first three years of the
Additional Product’s Commercial Period. If the Management Board then decides to develop a Project Plan for such Additional Product, DHI and Immunicon will negotiate in good faith commercially reasonable terms and conditions for the sharing of
costs associated with such Project Plan within sixty days (60) following the decision of the Management Board to develop the Project Plan. Immunicon will not seek [***********] for the development and commercialization of the Additional
Products. 
  

 44 

 If DHI and Immunicon reach agreement on the terms and conditions for sharing the costs associated with a
Additional Product Project Plan and a decision is made to pursue the development and commercialization of such Additional Product, the Management Board will follow substantially the same procedures as would be applicable if such Additional Product
was an Initial Product including the determination of Initial Feasibility, conducting Product Development and the development of a Commercialization Plan, and including forecast sales of such Additional Product in the applicable strategic forecast
and twelve-month forecast. 
 If, within [*********] of the Effective Date, DHI has not developed a Detection Reagent for at least [***]
Additional Product and submitted a DHI Proposal to the Management Board, the provisions of this Exhibit A with respect to the development of Additional Products shall no longer be effective. 
  

 45 

 Exhibit B 
 Distribution Agreement (Distribution Agreement”) with respect to Distribution of Immunicon Corporation (“Immunicon”) Instrument Systems by Diagnostic Hybrids, Inc. (“Distributor”)

  

	1.	Instrument Systems. The Instrument System(s) of Immunicon which are the subject of this Distribution Agreement are defined in and described in detail in the agreement
(“Master Agreement”) to which this Distribution Agreement is annexed as Exhibit B, and shall additionally include upgraded or improved Instrument Systems that may become available from Immunicon during the term of this Distribution
Agreement. All Instrument Systems shall conform to Immunicon’s standard specifications, as may be set forth in the Master Agreement. All shipping cartons and packaging material shall conform to applicable laws and specifications. This
Distribution Agreement shall be executed by the parties as of the commencement of the Commercial Period (as defined in the Master Agreement). Capitalized terms used in this Distribution Agreement without definition shall have the meanings given to
them in the Master Agreement. 

  

	2.	Distribution Rights/No Agency. Immunicon grants to Distributor the exclusive right to distribute the Instrument Systems in the United States of America and Canada
(including their respective territories) (the “Primary Territory”), subject to the terms and conditions of the Master Agreement. Distributor shall be permitted to distribute the Instrument Systems through a third party subcontractor only
with the prior written consent of Immunicon, such consent not to be unreasonably withheld, and any such subcontractor shall in any event agree in writing to be bound to the terms and conditions of this Distribution Agreement and the relevant terms
and conditions of the Master Agreement to the same extent as Distributor hereunder. It is understood and agreed that Distributor is an independent contractor for all purposes under this Distribution Agreement and is not, and shall not be construed
to be, an agent of Immunicon for any purpose. Distributor shall not hold itself out to third parties or represent itself as the agent of Immunicon for any purpose, or hold itself out to Third Parties as having the authority to enter into or incur on
behalf of Immunicon, any contractual obligation, expense, or liability whatsoever. It is specifically understood and agreed that employees or agents of Distributor are not eligible to participate in or to exercise rights under any of
Immunicon’s compensation or benefit plans that Immunicon provides for its employees. 

  

	3.	Pricing. The prices to Distributor for Instrument Systems to be distributed under this Distribution Agreement shall be as set forth in Appendix A hereto. No minimum
orders shall be required with respect to volume or cost, except as may be otherwise set forth in Appendix A or in the Master Agreement, in which case such minimums shall apply. The prices determined as set forth in Appendix A shall include all
packaging and shipping costs. 

  

 46 

	4.	Payment Terms. Payment terms shall be net thirty (30) days from the receipt of a valid invoice by Distributor. Immunicon may charge one and one half percent per
month interest on the total amount due on any unpaid invoices more than thirty (30) days past due. 

  

	5.	Shipping. Immunicon shall ship all Instrument Systems FOB shipping point. 

  

	6.	Information Exchange. Upon the request of Distributor, Immunicon shall use reasonable efforts to implement full electronic data interchange for receipt of purchase
orders and transmission of invoices. 

  

	7.	Term. The term of this Distribution Agreement shall be concurrent with the Master Agreement, and, unless otherwise provided in the Master Agreement, shall expire or
terminate upon the expiration or termination of the Master Agreement. All terms and conditions of the Master Agreement applicable to the purchase, sale and distribution of Instrument Systems are hereby incorporated in this Distribution Agreement by
reference. 

  

	8.	Breach. A material breach by Distributor or Immunicon of any of the terms and conditions of this Distribution Agreement, which breach is not cured by the
breaching party within ninety (90) days of its receipt of written notice of the breach, shall be deemed a Material Breach of the Master Agreement and the non-breaching party shall have the rights provided for in Section 13.3 of the Master
Agreement. 

  

	9.	Warranties. Immunicon will honor the terms and conditions of any warranties which may be given by Immunicon on Instrument Systems. A copy of any such warranties is
attached hereto as Appendix B and incorporated herein by reference. The terms and conditions of any such warranties shall survive the termination of this Distribution Agreement. 

  

	10.	Trademarks/Intellectual Property. Immunicon’s trademarks, brands, and goodwill associated with Instrument Systems and all other intellectual property and other
proprietary rights therein shall remain the sole property of Immunicon. Except as otherwise provided in the Master Agreement, no right or license under any intellectual property or other proprietary rights of Immunicon, or in or to any underlying
technology embodied in Instrument Systems, or their use, is granted or is to be implied under this Agreement. 

  

	11.	Promotion. Distributor shall use its commercially reasonable efforts to sell the Instrument Systems in the Primary Territory, and shall do so in accordance with any
commercially reasonable restrictions or conditions that may be imposed by Immunicon on the use of the Instrument Systems (provided such conditions are not inconsistent with the Master Agreement) and communicated in writing to Distributor and/or as
may be specified by Immunicon in Appendix A or in the Master Agreement. All activities of Distributor shall be conducted in accordance with applicable law and regulation, and in conformance with representations and warranties made by Immunicon in
its advertising, product labeling and literature. 

  

	12.	 Confidentiality. The parties expressly agree to hold as confidential any information (“Confidential Information”) which is provided by one
party to the other hereunder and 

  

 47 

	 	 
designated in writing as confidential by the disclosing party at the time of disclosure thereof. In the event Confidential Information is exchanged according
to these guidelines, such Confidential Information shall be retained by the receiving party in confidence for a period of five (5) years from the date of disclosure. The transmittal of such Confidential Information is and shall be upon the
express condition that the Confidential Information is to be used solely to effectuate this Distribution Agreement and the Master Agreement; and the receiving party shall not use, publish, or disclose such Confidential Information, in whole or in
part, for any purpose other than that stated herein or therein. Notwithstanding the foregoing, the above restrictions on disclosure and use shall not apply to any Confidential Information which the receiving party can show by competent evidence was
known to it at the time of receipt, or which may be obtained from a Third Party who is not bound by an obligation of confidentiality to the disclosing party, or which is in the public domain at the time of disclosure to the receiving party or
thereafter becomes in the public domain through no fault of the receiving party. 

  

	13.	Entire Agreement. Except for the Master Agreement, this Distribution Agreement constitutes the entire agreement and understanding of the parties with respect to the
matters set forth herein. Any and all understandings and expectations for and from either party are of no effect unless expressly set forth herein. Any amendment of this Distribution Agreement must be in writing and executed by both parties hereto.

  

	14.	Assignment, Succession and Waiver. This Distribution Agreement and any part thereof is not assignable by either party without first obtaining the express written
consent of the other party, except that Immunicon or Distributor may assign this Distribution Agreement without such consent to a purchaser of all or substantially all of its assets and business who assumes substantially all of its liabilities,
including its obligations under the Master Agreement and this Agreement, under the same terms and conditions applicable to the assignment of the Master Agreement. Any such permitted assignment shall not constitute a modification or amendment of the
terms and conditions of the Master Agreement, all of which terms and conditions shall remain in effect notwithstanding any such assignment. This Distribution Agreement shall be binding upon and shall inure to the benefit of the parties and their
respective successors and assigns. No express waiver or any prior breach of this Distribution Agreement shall constitute a waiver of any subsequent breach hereof and no such waiver shall be implied. In the event that any provision of this
Distribution Agreement conflicts or is inconsistent with the terms of the Master Agreement, the terms of the Master Agreement shall control. 

 Appendix A to Distribution Agreement 
 The Transfer Price of the Instrument Systems to DHI will be a price that yields a
gross margin of [***]% to Immunicon. Immunicon will provide DHI from time to time upon its request documentation sufficient to support Immunicon’s calculation of the Transfer Price of the Instrument Systems. Appendix A will set forth the
procedure by which Immunicon will determine and 

  

 48 

 
communicate the Transfer Price to DHI. Once so determined, the Transfer Price will remain in effect for a period of twelve months before it is revised,
if necessary. 
 Notwithstanding the foregoing, the Transfer Price of an Instrument System shall not exceed $[******] per unit, irrespective of the gross
margin to Immunicon, unless the Management Board approves material modifications to the first commercialized version of the Instrument System (the “Original System”) or authorizes the use of an Instrument System that is materially
different from the Original System, in which case Immunicon and DHI will review whether the costs associated with the development and manufacture of the modified or materially different Instrument System are significantly greater than those
associated with the Original System, and if such costs are significantly greater, the $[*****] cap on price of the Instrument System shall no longer be applicable. 
 Appendix B 
 Warranties 
 To be agreed by the parties at time of execution of the Distribution Agreement. 
  

 49 

 Schedule 2 
 Schedule 2 – Patents 
  

											
						
	 Patent Number
	  	 Issue Date
	  	 Appl. Number
	  	 Filing
 Date
	  	 Title
	  	 Inventors

						
	 [*******]
	  	[*******]	  	[*******]	  	[*******]	  	[*******]	  	[*******]
						
	 [*******]
	  	[*******]	  	[*******]	  	[*******]	  	[*******]	  	[*******]
						
	 [*******]
	  	[*******]	  	[*******]	  	[*******]	  	[*******]	  	[*******]
						
	 [*******]
	  	[*******]	  	[*******]	  	[*******]	  	[*******]	  	[*******]

 Schedule 5.1.1 - Specifications 
 Bulk Reagent Specifications 
 To be determined by the parties 
  

 50 

 EXHIBIT C 
 This is to certify that [Acquirer], being the successor to all or substantially all of the business and assets of the [assigning party], and to all or substantially all of the obligations and liabilities of the [assigning party], hereby
irrevocably assumes, subject to the right of Acquirer to exercise all of the rights and benefits of the assigning party thereunder, all of the obligations and liabilities of the [assigning party] under the certain agreement entitled “License,
Development, Supply and Distribution Agreement, by and between Immunicon Corporation and DHI and having an Effective Date as provided therein of
                    , including the same as may be amended from time to time by written agreement of the parties thereto (the
“Agreement”); and further provided that the Acquirer hereby agrees to abide by all of the terms and conditions of the Agreement applicable to the assigning party subject to its right to exercise the rights of the assigning party under the
Agreement. 
  

 51Exhibit 10.1

 Exhibit 10.1 
  

 CUSIP Number:
                                 
 SECOND AMENDED AND RESTATED LOAN AGREEMENT 
 Dated as of March 9, 2007 
 among 
 MOHEGAN TRIBAL GAMING AUTHORITY, 
 as the Borrower, 
 THE MOHEGAN TRIBE OF INDIANS OF CONNECTICUT, 
 as an additional party with respect to certain 
 representations, warranties and covenants 
 BANK OF AMERICA, N.A., 
 as
Administrative Agent and L/C Issuer, 
 and 
 The Other Lenders Party Hereto 
 BANC OF AMERICA SECURITIES LLC, 
 RBS SECURITIES CORPORATION 
 and

 CALYON NEW YORK BRANCH 
 As Joint Lead Arrangers and Joint Book Managers 
 CITIZENS BANK OF CONNECTICUT and CALYON NEW YORK BRANCH 

as Co-Syndication Agents 
 and 

CITICORP NORTH AMERICA, INC. and WELLS FARGO BANK, N.A 
 as Co-Documentation Agents 
  

 TABLE OF CONTENTS 
  

									
	 	 	 	  	Page
		 	 ARTICLE I DEFINITIONS AND ACCOUNTING TERMS
	  	1
		 		  	1.01	  	 Defined Terms
	  	1
		 		  	 1.02
	  	 Other Interpretive Provisions
	  	37
		 		  	 1.03
	  	 Accounting Terms
	  	37
		 		  	 1.04
	  	 Rounding
	  	38
		 		  	 1.05
	  	 Times of Day
	  	38
		 		  	 1.06
	  	 Letter of Credit Amount
	  	38
			
		 	 ARTICLE II THE COMMITMENTS AND CREDIT EXTENSIONS
	  	39
		 		  	 2.01
	  	 Revolving Loans
	  	39
		 		  	 2.02
	  	 Term Loan Conversion
	  	39
		 		  	 2.03
	  	 Borrowings, Conversions and Continuations of Loans
	  	39
		 		  	 2.04
	  	 Letters of Credit
	  	41
		 		  	 2.05
	  	 Voluntary Prepayments
	  	49
		 		  	 2.06
	  	 Termination or Reduction of Revolving Commitments; Voluntary Prepayments of the Term Loans
	  	49
		 		  	 2.07
	  	 Mandatory Payments and Prepayments; Repayment of Loans
	  	50
		 		  	 2.08
	  	 Interest
	  	51
		 		  	 2.09
	  	 Fees
	  	52
		 		  	 2.10
	  	 Computation of Interest and Fees
	  	52
		 		  	 2.11
	  	 Evidence of Debt
	  	52
		 		  	 2.12
	  	 Payments Generally; Administrative Agent’s Clawback
	  	53
		 		  	 2.13
	  	 Sharing of Payments by Lenders
	  	55
		 		  	 2.14
	  	 Increase in Commitments
	  	55
		 		  	 2.15
	  	 Collateral
	  	57
		 		  	 2.16
	  	 Concerning the Tax Exempt Loans
	  	57
			
		 	 ARTICLE III TAXES, YIELD PROTECTION AND ILLEGALITY
	  	59
		 		  	 3.01
	  	 Taxes
	  	59
		 		  	 3.02
	  	 Illegality
	  	59
		 		  	 3.03
	  	 Inability to Determine Rates
	  	60
		 		  	 3.04
	  	 Increased Costs
	  	60
		 		  	 3.05
	  	 Compensation for Losses
	  	61
		 		  	 3.06
	  	 Increased Capital Requirements
	  	62
		 		  	 3.07
	  	 Replacement of Lenders
	  	62
		 		  	 3.08
	  	 Survival
	  	62
			
		 	 ARTICLE IV CONDITIONS PRECEDENT TO CREDIT EXTENSIONS
	  	63
		 		  	 4.01
	  	 Conditions of Initial Credit Extension
	  	63
		 		  	 4.02
	  	 Conditions to all Credit Extensions
	  	65

  

 -i- 

							
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE TRIBE
	  	67
		  	 5.01
	  	 Existence and Qualification; Power; Compliance With Laws
	  	67
		  	 5.02
	  	 Authority; Compliance With Other Agreements and Instruments and Government Regulations
	  	67
		  	 5.03
	  	 No Governmental Approvals Required
	  	68
		  	 5.04
	  	 The Nature of the Borrower
	  	68
		  	 5.05
	  	 No Management Contract
	  	68
		  	 5.06
	  	 Title to and Location of Property
	  	69
		  	 5.07
	  	 Real Property
	  	69
		  	 5.08
	  	 Governmental Regulation
	  	69
		  	 5.09
	  	 Binding Obligations
	  	69
		  	 5.10
	  	 No Default
	  	69
		  	 5.11
	  	 Disclosure
	  	69
		  	 5.12
	  	 Gaming Laws
	  	70
		  	 5.13
	  	 Security Interests
	  	70
		  	 5.14
	  	 Arbitration
	  	70
		  	 5.15
	  	 Recourse Obligations
	  	70
		
	 ARTICLE VI REPRESENTATIONS AND WARRANTIES OF THE BORROWER
	  	71
		  	 6.01
	  	 Existence, Qualification and Power
	  	71
		  	 6.02
	  	 Authorization; No Contravention
	  	71
		  	 6.03
	  	 Governmental Authorization; Other Consents
	  	72
		  	 6.04
	  	 Binding Effect
	  	72
		  	 6.05
	  	 Financial Statements; No Material Adverse Effect; No Internal Control Event
	  	73
		  	 6.06
	  	 Litigation
	  	74
		  	 6.07
	  	 No Default
	  	74
		  	 6.08
	  	 Ownership of Property; Liens
	  	74
		  	 6.09
	  	 Environmental Compliance
	  	74
		  	 6.10
	  	 Insurance
	  	75
		  	 6.11
	  	 Taxes
	  	75
		  	 6.12
	  	 ERISA Compliance
	  	75
		  	 6.13
	  	 Subsidiaries; Equity Interests
	  	75
		  	 6.14
	  	 Margin Regulations; Investment Company Act
	  	75
		  	 6.15
	  	 Disclosure
	  	75
		  	 6.16
	  	 Compliance with Laws
	  	76
		  	 6.17
	  	 Taxpayer Identification Number
	  	76
		  	 6.18
	  	 Intangible Assets
	  	76
		  	 6.19
	  	 The Nature of the Borrower
	  	76
		  	 6.20
	  	 No Management Contract
	  	76
		  	 6.21
	  	 Real Property Underlying Mohegan Sun
	  	77
		  	 6.22
	  	 Projections
	  	77
		  	 6.23
	  	 Employee Matters
	  	77
		  	 6.24
	  	 Security Interests
	  	77
		  	 6.25
	  	 Arbitration
	  	78
		  	 6.26
	  	 Deposit Accounts
	  	78
		  	 6.27
	  	 Tax Shelter Regulations
	  	78
		  	 6.28
	  	 Construction Plans and Budget
	  	78

  

 -ii- 

							
	 ARTICLE VII AFFIRMATIVE COVENANTS OF THE TRIBE
	  	79
		  	 7.01
	  	 Continual Operation of Mohegan Sun
	  	79
		  	 7.02
	  	 Remittance of Available Cash Flow
	  	79
		  	 7.03
	  	 Sovereign Immunity; Jurisdiction and Venue
	  	79
		  	 7.04
	  	 The Lease and the Landlord Consent
	  	79
		  	 7.05
	  	 Preservation of Existence; Operation
	  	79
		  	 7.06
	  	 Ownership of Mohegan Sun and Pocono Downs; Management
	  	79
		  	 7.07
	  	 Prohibited Transactions
	  	80
		  	 7.08
	  	 Amendments to Certain Documents
	  	80
		  	 7.09
	  	 Impairment of Contracts; Imposition of Governmental Charges
	  	80
		  	 7.10
	  	 Segregation of Authority Property
	  	81
		  	 7.11
	  	 Trust Property
	  	81
		  	 7.12
	  	 Liens on Authority Property
	  	81
		  	 7.13
	  	 Bankruptcy Matters; Etc.
	  	81
		  	 7.14
	  	 Impairment of Contracts
	  	81
		
	 ARTICLE VIII AFFIRMATIVE COVENANTS OF THE BORROWER
	  	82
		  	 8.01
	  	 Financial Statements
	  	82
		  	 8.02
	  	 Certificates; Other Information
	  	83
		  	 8.03
	  	 Notices
	  	85
		  	 8.04
	  	 Payment of Obligations
	  	86
		  	 8.05
	  	 Preservation of Existence, Etc.
	  	86
		  	 8.06
	  	 Maintenance of Properties
	  	86
		  	 8.07
	  	 Maintenance of Insurance
	  	87
		  	 8.08
	  	 Compliance with Laws
	  	88
		  	 8.09
	  	 Books and Records
	  	88
		  	 8.10
	  	 Inspection Rights
	  	88
		  	 8.11
	  	 Use of Proceeds
	  	88
		  	 8.12
	  	 Hazardous Materials Laws
	  	89
		  	 8.13
	  	 Deposit and Brokerage Accounts
	  	89
		  	 8.14
	  	 Continual Operation of Mohegan Sun
	  	89
		  	 8.15
	  	 Future Subsidiaries and Collateral
	  	89
		  	 8.16
	  	 Leasehold Mortgage
	  	90
		  	 8.17
	  	 Construction Covenants; Plans, Budget and Timetable
	  	90
		
	 ARTICLE IX NEGATIVE COVENANTS
	  	92
		  	9.01	  	 Liens; Negative Pledges
	  	92
		  	9.02	  	 Investments
	  	92
		  	9.03	  	 Indebtedness
	  	94
		  	9.04	  	 Fundamental Changes
	  	95
		  	9.05	  	 Dispositions of Property Associated with Mohegan Sun
	  	96
		  	9.06	  	 Distributions
	  	96
		  	9.07	  	 Change in Nature of Business
	  	97
		  	9.08	  	 Transactions with Affiliates
	  	97
		  	9.09	  	 Prepay Other Obligations
	  	97
		  	9.10	  	 Burdensome Agreements
	  	98
		  	9.11	  	 Use of Proceeds
	  	98

  

 -iii- 

							
		  	 9.12
	  	 Authority Expenditures
	  	98
		  	 9.13
	  	 Financial Covenants
	  	98
		  	 9.14
	  	 Hostile Tender Offers
	  	100
		  	 9.15
	  	 Deposit Accounts
	  	100
		  	 9.16
	  	 WNBA Subsidiary Operations and Indebtedness
	  	100
		  	 9.17
	  	 Capital Expenditures
	  	100
		  	 9.18
	  	 Construction Covenants; Plans, Budget and Timetable
	  	101
		  	 9.19
	  	 Tax Exempt Loans
	  	101
		
	 ARTICLE X EVENTS OF DEFAULT AND REMEDIES
	  	105
		  	 10.01
	  	 Events of Default
	  	105
		  	 10.02
	  	 Remedies Upon Event of Default
	  	108
		  	 10.03
	  	 Application of Funds
	  	108
		
	 ARTICLE XI ADMINISTRATIVE AGENT
	  	110
		  	 11.01
	  	 Appointment and Authority
	  	110
		  	 11.02
	  	 Rights as a Lender
	  	110
		  	 11.03
	  	 Exculpatory Provisions
	  	110
		  	 11.04
	  	 Reliance by Administrative Agent
	  	111
		  	 11.05
	  	 Delegation of Duties
	  	111
		  	 11.06
	  	 Resignation of Administrative Agent
	  	111
		  	 11.07
	  	 Non-Reliance on Administrative Agent and Other Lenders
	  	112
		  	 11.08
	  	 No Other Duties, Etc.
	  	113
		  	 11.09
	  	 Administrative Agent May File Proofs of Claim
	  	113
		  	 11.10
	  	 SNDA’s
	  	113
		  	 11.11
	  	 Collateral and Guaranty Matters
	  	113
		
	 ARTICLE XII MISCELLANEOUS
	  	115
		  	 12.01
	  	 Amendments, Etc.
	  	115
		  	 12.02
	  	 Notices; Effectiveness; Electronic Communication
	  	116
		  	 12.03
	  	 No Waiver; Cumulative Remedies
	  	118
		  	 12.04
	  	 Expenses; Indemnity; Damage Waiver
	  	118
		  	 12.05
	  	 Payments Set Aside
	  	120
		  	 12.06
	  	 Successors and Assigns
	  	120
		  	 12.07
	  	 Treatment of Certain Information; Confidentiality
	  	125
		  	 12.08
	  	 Right of Setoff
	  	126
		  	 12.09
	  	 Interest Rate Limitation
	  	127
		  	 12.10
	  	 Counterparts; Integration; Effectiveness
	  	127
		  	 12.11
	  	 Survival of Representations and Warranties
	  	127
		  	 12.12
	  	 Severability
	  	127
		  	 12.13
	  	 Replacement of Lenders
	  	128
		  	 12.14
	  	 Governing Law
	  	128
		  	 12.15
	  	 Arbitration Reference
	  	129
		  	 12.16
	  	 PURPORTED ORAL AMENDMENTS
	  	129
		  	 12.17
	  	 WAIVER OF RIGHT TO TRIAL BY JURY
	  	130
		  	 12.18
	  	 WAIVER OF SOVEREIGN IMMUNITY; CONSENT TO JURISDICTION
	  	130

  

 -iv- 

							
		 	 12.19
	  	 Lender Covenant
	  	131
		 	 12.20
	  	 PREJUDGMENT REMEDY WAIVER
	  	131
		 	 12.21
	  	 No Advisory or Fiduciary Responsibility
	  	132
		 	 12.22
	  	 USA PATRIOT Act Notice
	  	133
		 	 12.23
	  	 Time of the Essence
	  	133
		 	 12.24
	  	 Designation as Senior Debt
	  	133
		 	 12.25
	  	 ENTIRE AGREEMENT
	  	133
		 	 12.26
	  	 Release of Liens
	  	133

  

 -v- 

 SECOND AMENDED AND RESTATED LOAN AGREEMENT 
 This SECOND AMENDED AND RESTATED LOAN AGREEMENT is entered into as of March 9, 2007, among THE MOHEGAN TRIBE OF INDIANS OF CONNECTICUT, a federally
recognized Indian Tribe and Native American sovereign nation (the “Tribe”), the MOHEGAN TRIBAL GAMING AUTHORITY, a governmental instrumentality of the Tribe (the “Borrower”), each lender from time to time party
hereto (the “Lenders” ), CITIZENS BANK OF CONNECTICUT and CALYON NEW YORK BRANCH, as Co-Syndication Agents, CITICORP NORTH AMERICA, INC. and WELLS FARGO BANK, N.A., as Co-Documentation Agents, and BANK OF AMERICA, N.A., as
Administrative Agent and L/C Issuer. BANK OF AMERICA SECURITIES LLC, RBS SECURITIES CORPORATION and CALYON NEW YORK BRANCH, have served as Joint Lead Arrangers and Joint Book Managers for the credit facilities described herein. This Agreement amends
and restates the Existing Loan Agreement referred to herein in its entirety, but without novation. 
 In consideration of the mutual
covenants and agreements herein contained, the parties hereto covenant and agree as follows: 
 ARTICLE I 
 DEFINITIONS AND ACCOUNTING TERMS 
 1.01 Defined Terms. As used in this Agreement, the following terms shall have the meanings set forth below: 
 “Acceptable Swap Counterparties” means counterparties to Swap Agreements entered into by Borrower who are (a) Lenders, (b) Affiliates of Lenders or (c) on an unsecured basis, other Persons which have
investment grade status (BBB- as rated by Standard & Poor’s or Baa3 as rated by Moody’s). 
 “Administrative
Agent” means Bank of America in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent. 
 “Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 12.02 attached hereto, or such other address or account as
the Administrative Agent may from time to time designate by notice to the Borrower and the Lenders. 
 “Administrative
Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent. 
 “Affiliate”
means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (and the correlative terms, “controlled by”
and “under common control with”) shall mean possession, directly or indirectly, of the power to direct, or cause the direction of, management or policies (whether through ownership of securities or partnership or other ownership interests,
by contract or otherwise). 
  

 -1- 

 “Aggregate Credit Exposures” means, at any time, the sum of (i) the unused portion
of the Aggregate Revolving Commitments then in effect, (ii) the Total Revolving Outstandings at such time and (iii) the aggregate Outstanding Amount of Term Loans and Tax Exempt Loans. 
 “Aggregate Revolving Commitments” means the Revolving Commitments of all the Lenders. 
 “Agreement” means this Second Amended and Restated Loan Agreement either as originally executed or as it may from time to time be
supplemented, modified, amended, restated or extended. 
 “Amortization Amount” means as to each Amortization Date,
$750,000, provided that if additional Term Loans are hereafter made pursuant to Section 2.14, then the Amortization Amount for each Amortization Date subsequent to the making of the applicable additional Term Loans shall be ratably increased in
the same proportion that such additional Term Loans bear to $300,000,000. 
 “Amortization Date” means the last Business Day
of the first full Fiscal Quarter of the Borrower ending following the Conversion Date and the last Business Day of each Fiscal Quarter of the Borrower thereafter while there is an Outstanding Amount of Term Loans. 
 “Annualized EBITDA” means, as of each date of determination, EBITDA for the period of four Fiscal Quarters ending on that date, provided
that, as of the last day of such period, if Mohegan Sun Phase III, Pocono Downs Phase I or Pocono Downs Phase II has then been open for business to gaming patrons for at least one full Fiscal Quarter, then its results of operations
shall be included on an annualized basis for each of the first three full Fiscal Quarters after its respective opening, by determining the amount, if any, by which its results of operations increase EBITDA over that of Mohegan Sun or Pocono Downs,
as applicable (when compared to the same Fiscal Quarters immediately preceding such determination) and by annualizing the amount of such change on a straight line basis. 
 “Applicable Percentage” means with respect to any Lender at any time, (a) the percentage (carried out to the ninth decimal place) of the Aggregate Revolving Commitments represented by such
Lender’s Revolving Commitment at such time, or (b) where the context requires, the percentage (carried out to the ninth decimal place) of the aggregate outstanding principal amount of the Term Loans and Tax Exempt Loans held by such Lender
at such time. If the commitment of each Lender to make Revolving Loans and the obligation of the L/C Issuer to make L/C Credit Extensions have been terminated pursuant to Section 10.02 or if the Aggregate Revolving Commitments have expired,
then the Applicable Percentage of the Aggregate Revolving Commitments of each Lender shall be determined based on the Applicable Percentage of such Lender most recently in effect, giving effect to any subsequent assignments. The initial Applicable
Percentage of each Lender of the Aggregate Revolving Commitments is set forth opposite the name of such Lender on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable. 

 

 -2- 

 “Applicable Rate” means the following percentages per annum, based upon the Total
Leverage Ratio as set forth in the most recent Compliance Certificate or Pricing Certificate received by the Administrative Agent pursuant to Sections 8.02(b) or (c): 
  

									
	 Applicable
Rate

	 Pricing Level
	  	Total Leverage
Ratio	  	Commitment
Fee	 	 Eurodollar
Rate and
 Letters of
Credit
	 	Base Rate
Margin
	 1
	  	<4.00:1	  	0.20%	 	1.250%	 	0.000%
	 2
	  	34.00:1 but
<4.50:1	  	0.25%	 	1.375%	 	0.125%
	 3
	  	34.50:1 but
<5.00:1	  	0.25%	 	1.625%	 	0.375%
	 4
	  	35.00:1 but
<5.50:1	  	0.30%	 	1.875%	 	0.625%
	 5
	  	35.50:1 but
<6.00:1	  	0.30%	 	2.125%	 	0.875%
	 6
	  	36.00:1	  	0.35%	 	2.375%	 	1.125%

 Any increase or decrease in the Applicable Rate resulting from a change in the Total Leverage
Ratio shall become effective as of the first Business Day of the first calendar month immediately following the date a Compliance Certificate or Pricing Certificate is delivered pursuant to Section 8.02(b) or (c); provided, however, that
if a Compliance Certificate or Pricing Certificate is not delivered when due in accordance with such Section, then Pricing Level 6 shall apply as of the first Business Day after the date on which such Compliance Certificate or Pricing Certificate
was required to have been delivered until the Compliance Certificate or Pricing Certificate is delivered. The Applicable Rate in effect from the Closing Date through the delivery of the Compliance Certificate for the Fiscal Quarter ending
March 31, 2007, shall be determined based upon Pricing Level 2. 
 “Appropriate Investment” means any
“investment” of the type described in section 1.148-1(b) of the Tax Regulations. 
 “Approved Fund” means any
Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. 
 “Assignee Group” means two or more Eligible Assignees that are Affiliates of one another or two or more Approved Funds managed by the
same investment advisor. 
 “Assignment and Assumption” means an assignment and assumption entered into by a Lender and an
assignee (with the consent of any party whose consent is required by Section 12.06(b)), and accepted by the Administrative Agent, in substantially the form of Exhibit A or any other form approved by the Administrative Agent. 
  

 -3- 

 “Attributable Indebtedness” means, on any date, (a) in respect of any capital lease
of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b) in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining
lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a capital lease. 
 “Audited Financial Statements” means the audited consolidated balance sheet of the Borrower and its Subsidiaries for the Fiscal Year
ended September 30, 2006, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such Fiscal Year of the Borrower and its Subsidiaries, including the notes thereto. 
 “Authority Property” means any and all now owned or hereafter acquired real, mixed and personal Property of the Borrower (whether or not
otherwise designated as property of the Borrower) and its Restricted Subsidiaries which is reflected on the balance sheet described in Section 6.05 or any subsequent balance sheet hereafter delivered by the Borrower to the Administrative Agent
or the Lenders in connection herewith. “Authority Property” in any event includes, without limitation, (a) Mohegan Sun and Pocono Downs, (b) all gaming revenues of the Borrower and all gaming and other revenues of its Restricted
Subsidiaries, and (c) all tangible Property located within the area described on Schedule 5.07 (other than the Lahaniatis Property), provided that neither (i) the Property of the WNBA Subsidiary and the Borrower’s ownership
interests in the WNBA Subsidiary, (ii) the Property of any Unrestricted Subsidiaries, nor (iii) the Pennsylvania Tax Revenues, shall be considered to be Authority Property. It is expressly understood and agreed that assets and operations
of Unrestricted Subsidiaries or other Persons shall not be considered to be Authority Property merely by reason of their inclusion in consolidated or consolidating financial statements of the Borrower, but the Borrower shall provide the
Administrative Agent and the Lenders with appropriate breakouts of such Unrestricted Subsidiaries’ financial position and results of operations in connection with financial statements delivered hereunder. 
 “Availability Period” means the period from and including the Closing Date to the earliest of (a) the Maturity Date, (b) the
date of termination of the Aggregate Revolving Commitments pursuant to Section 2.06, and (c) the date of termination of the commitment of each Lender to make Revolving Loans and of the obligation of the L/C Issuer to make L/C Credit
Extensions pursuant to Section 10.02. 
 “Available Cash Flow” means, for any calendar month (a) EBITDA for that
month, minus (b) the amount of Maintenance Capital Expenditures made during that month, minus (c) any principal repayments with respect to Indebtedness and Capital Leases constituting Recourse Obligations required to be made
during that period in cash (other than any such principal payments required in respect of Public Indebtedness), minus (d) the amount of cash Interest Charges during that month, and minus (e) (without duplication) the
aggregate amount, if any, of federal and state taxes on, or measured by, income of the Borrower and its Restricted Subsidiaries (whether or not payable during that period, and excluding any amount payable to the State of Connecticut under the
Compact). 
 “Bank of America” means Bank of America, N.A. and its successors. 
  

 -4- 

 “Base Rate” means for any day a fluctuating rate per annum equal to the higher of
(a) the Federal Funds Rate plus one-half of one percent and (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate.” The “prime rate” is a rate set
by Bank of America based upon various factors including Bank of America’s costs and desired return, general economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below
such announced rate. Any change in such rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change. 
 “Base Rate Loan” means a Loan that bears interest based on the Base Rate. 
 “Base Rate Revolving Loan” means a Revolving Loan that is a Base Rate Loan. 
 “Borrower” has the meaning specified in the introductory paragraph hereto. 
 “Borrower Materials” has the meaning specified in Section 8.02. 
 “Borrowing” means (a) a Revolving Borrowing or (b) the conversion of a portion of the Revolving Loans to a Term Loan on the
Conversion Date, as contemplated by Section 2.02, or (c) the making of any additional Term Loan or a Tax Exempt Loan, as the context may require. 
 “Bureau of Indian Affairs” means the United States Department of the Interior, Bureau of Indian Affairs, and each successor agency. 
 “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws
of, or are in fact closed in, the state where the Administrative Agent’s Office is located and, if such day relates to any Eurodollar Rate Loan, means any such day on which dealings in Dollar deposits are conducted by and between banks in the
London interbank eurodollar market. 
 “Capital Expenditure” means any expenditure that is considered a capital expenditure
under GAAP, including any amount that is required to be treated as an asset subject to a Capital Lease. 
 “Capital Lease”
means, as to any Person, a lease of any Property by that Person as lessee that is recorded as a “capital lease” on the balance sheet of that Person prepared in accordance with GAAP (or should be so recorded in accordance with Financial
Accounting Standards Board Statement No. 13, as amended from time to time, or if such Statement is not then in effect, such other Statement of the Financial Accounting Standards Board as may be applicable. 
 “Capital Markets Amount” means $200,000,000 minus the principal amount of any Indebtedness incurred after the Closing Date by the
Borrower and its Restricted Subsidiaries pursuant to Sections 9.03(b) and (d). 
 “Cash Collateralize” has the meaning
specified in Section 2.04(g). 
 “Cash Equivalents” means, when used in connection with any Person, that Person’s
Investments in: 
 (a) Government Securities due within one year after the date of the making of the Investment; 

 

 -5- 

 (b) readily marketable direct obligations of any State of the United States of America or
any political subdivision of any such State given on the date of such investment a credit rating of at least Aa by Moody’s Investors Service, Inc. or AA by Standard & Poor’s Ratings Group or AA by Fitch, Inc., in each case due
within one year after the date of the making of the Investment; 
 (c) certificates of deposit issued by, bank deposits in,
eurodollar deposits through, bankers’ acceptances of, and reverse repurchase agreements covering Government Securities executed by, any Lender or any other bank, savings and loan or savings bank doing business in and incorporated under the Laws
of the United States of America or any State thereof and having on the date of such Investment combined capital, surplus and undivided profits of at least $250,000,000, in each case due within one year after the date of the making of the Investment;

 (d) certificates of deposit issued by, bank deposits in, eurodollar deposits through, bankers’ acceptances of, and
reverse repurchase agreements covering Government Securities executed by, any branch or office located in the United States of America of a bank incorporated under the Laws of any jurisdiction outside the United States of America having on the date
of such Investment combined capital, surplus and undivided profits of at least $500,000,000, in each case due within one year after the date of the making of the Investment; and 
 (e) readily marketable commercial paper of corporations doing business in and incorporated under the Laws of the United States of America
or any State thereof given on the date of such Investment the highest credit rating by Moody’s Investors Service, Inc. and Standard & Poor’s Corporation, in each case due within 270 days after the date of the making of the
Investment. 
 “Change in Law” means the occurrence, after the date of this Agreement, of any of the following: (a) the
adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation or application thereof by any Governmental Authority, (c) the making or
issuance of any request, guideline or directive (whether or not having the force of law) by any Governmental Authority or (d) the existence or occurrence of circumstances affecting the Designated Market generally that are beyond the reasonable
control of the Lenders. 
 “Closing Date” means the first date all the conditions precedent in Section 4.01 are
satisfied or waived in accordance with Section 12.01. 
 “Co-Documentation Agents” means Citicorp North America, Inc.
and Wells Fargo Bank, N.A. 
 “Code” means the Internal Revenue Code of 1986 as at any time amended. 
  

 -6- 

 “Collateral Assignments” means the Collateral Assignments executed and delivered by the
Borrower and applicable Restricted Subsidiaries pursuant to which the architectural agreements with the architect of record, the construction contracts with the general contractor, and, if applicable, the construction management agreements with the
construction manager, in each case related to Mohegan Sun Phase III and Pocono Downs Phase II, as the case may be, are assigned to the Administrative Agent, including the executed consents of the counterparties to such agreements, either
as originally executed or as they may from time to time be supplemented, modified, amended, extended or supplanted. 
 “Collateral
Documents” means, collectively, the Security Agreements, the Pledge Agreement, the Collateral Assignments, each Deposit Account Agreement, any Leasehold Mortgage, the Pocono Downs Mortgages and any other pledge agreement, hypothecation
agreement, security agreement, assignment, deed of trust, mortgage or similar instrument executed by the Borrower or a Restricted Subsidiary in favor of the Administrative Agent or any Creditor to secure the Obligations. 
 “Commission” means the National Indian Gaming Commission. 
 “Compact” means the tribal-state Compact entered into between the Tribe and the State of Connecticut pursuant to IGRA, dated April 25, 1994, together with that certain Memorandum of Understanding
dated May 17, 1994, as such may be amended. 
 “Completion Date” means, as to each Project (and as the context may
require), the date upon which each of the following has occurred: 
 (a) a temporary certificate of occupancy or other
evidence indicating that occupancy may lawfully commence has been obtained for all material portions of such Project; 
 (b)
the Administrative Agent shall have received appropriate endorsements to its ALTA policies of title insurance relating to such Project, at the sole expense of the Borrower, insuring against any mechanics liens, materialmen’s liens and other
similar claims, if applicable, and insuring that the completed Project does not encroach upon any adjacent property; and 
 (c) the Project and all substantial amenities contemplated by the relevant Construction Plans shall be legally open for business for customers. 
 “Compliance Certificate” means a certificate substantially in the form of Exhibit B. 
 “Computation Date” has the meaning set forth in section 1.148-1(b) of the Tax Regulations. 
 “Constitution” means the Constitution of the Tribe adopted by the Tribe and ratified by the Tribe’s members by Tribal Referendum dated April 12, 1996, as amended August 10, 2002, as amended September 6,
2003, as amended May 2, 2004, as it may be amended from time to time. 
  

 -7- 

 “Construction Budget” means, (a) the construction budgets for Pocono Downs
Phase II and Mohegan Sun Phase III delivered pursuant to Section 8.01(c), and (b) each update thereto thereafter delivered pursuant to Section 8.01(d). 
 “Construction Period” means the period beginning on the Closing Date and ending on June 30, 2010, or, if later, the projected final
opening date of Mohegan Sun Phase III then set forth in the most recent Construction Timetable for Mohegan Sun Phase III (but in any event not later than December 31, 2010). 
 “Construction Plans” means, (a) the construction plans for Pocono Downs Phase II and Mohegan Sun Phase III delivered in
accordance with Section 8.01(c), and (b) each update thereto thereafter pursuant to Section 8.01(d). 
 “Construction
Timetables” means, (a) the construction timetables for Pocono Downs Phase II and Mohegan Sun Phase III delivered in accordance with Section 8.01(c), and (b) each update thereto thereafter pursuant to
Section 8.01(d). 
 “Consumer Price Index” means the Consumer Price Index for All Urban Consumers (CPI U) for the U.S.
City Average for All Items, 1982-1984=100, as compiled and released by the Bureau of Labor Statistics. 
 “Contingent
Obligation” means, as to any Person, any (a) direct or indirect guarantee of Indebtedness of, or other obligation performable by, any other Person, including any endorsement (other than for collection or deposit in the ordinary course
of business), co-making or sale with recourse of the obligations of any other Person or (b) contractual assurance (not arising solely by operation of Law) given to an obligee with respect to the performance of an obligation by, or the financial
condition of, any other Person, whether direct, indirect or contingent, including any purchase or repurchase agreement covering such obligation or any collateral security therefor, any agreement to provide funds (by means of loans, capital
contributions or otherwise) to such other Person, any agreement to support the solvency or level of any balance sheet item to such other Person, or any other arrangement of whatever nature having the effect of assuring or holding harmless any
obligee against loss with respect to any obligation of such other Person including without limitation any “keep-well”, “take-or-pay” or “through put” agreement or arrangement. As of each date of determination, the
amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation (unless the Contingent Obligation is limited by its terms to a lesser amount, in which case to the
extent of such amount) or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the Person in good faith. 
 “Contractual Obligation” means, as to any Person, any provision of any outstanding Securities issued by such Person or of any material agreement, instrument or other undertaking to which such Person
is a party or by which it or any of its property is bound. 
 “Control” means the possession, directly or indirectly, of the
power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings
correlative thereto. 
  

 -8- 

 “Conversion Date” means the date upon which the aggregate outstanding principal balance
of the Revolving Loans (exclusive of L/C Obligations) first equals or exceeds $300,000,000. 
 “Cost to Complete” means, as
of each date of determination, and in respect of each Project, the then unexpended portion of the currently effective Construction Budget for that Project. 
 “Credit Extension” means each of the following: (a) a Borrowing and (b) an L/C Credit Extension. 
 “Creditors” means, collectively, the Administrative Agent, the Lenders, the L/C Issuer, and to the extent of the obligations under any Secured Swap Contract each Affiliate of a Lender which at any
time enters into a Secured Swap Contract. 
 “Debtor Relief Laws” means the Bankruptcy Code of the United States, and all
other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from
time to time in effect and affecting the rights of creditors generally. 
 “Default” means any event or condition that
constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default. 
 “Default Rate” means (a) when used with respect to Obligations other than Letter of Credit Fees, an interest rate equal to (i) the Base Rate plus (ii) the Applicable Rate, if any, applicable to Base
Rate Loans plus (iii) two percent per annum; provided, however, that with respect to a Eurodollar Rate Loan, the Default Rate shall be an interest rate equal to the interest rate (including any Applicable Rate) otherwise
applicable to such Loan plus two percent per annum, and (b) when used with respect to Letter of Credit Fees, a rate equal to the Applicable Rate plus two percent per annum. 
 “Defaulting Lender” means any Lender that (a) has failed to fund any portion of any Revolving Loan or participation in an L/C
Obligation required to be funded by it hereunder within one Business Day of the date required to be funded by it hereunder unless such failure has been cured, (b) has otherwise failed to pay over to the Administrative Agent or any other Lender
any other amount required to be paid by it hereunder within one Business Day of the date when due, unless the subject of a good faith dispute or unless such failure has been cured, or (c) has been deemed insolvent or become the subject of a
bankruptcy or insolvency proceeding. 
 “Deposit Account Agreement” means a control agreement among Borrower or a Restricted
Subsidiary, as applicable, the Administrative Agent and the depositary for each Operating Account, substantially in the form of Exhibit C or in another form reasonably acceptable to the Administrative Agent. 
  

 -9- 

 “Designated Market” means, for any Eurodollar Rate Loan, the London Eurodollar Market,
provided that if the Administrative Agent determines that the London Eurodollar Market is unavailable or reasonably inconvenient, “Designated Market” means such other offshore market for deposits in dollars as the Administrative
Agent may reasonably designate. 
 “Disposition” or “Dispose” means the sale, transfer or other disposition
of Authority Property in any single transaction or series of related transactions of any individual asset, or group of related assets, that has or have at the date of the Disposition a book value or fair market value (which shall be deemed to be
equal to the sales price for such asset or assets upon a sale to a Person that is not an Affiliate of the Tribe) of $10,000,000 or more, other than (i) the sale or other disposition of inventory in the ordinary course of business,
(ii) the sale or other disposition of equipment or other personal property that is replaced by equipment or personal property, as the case may be, performing substantially the same function not later than ninety days after such sale or
disposition, (iii) the sale or other disposition of obsolete equipment or superseded or worn-out assets, and (iv) any sale or other disposition to the Borrower or any of its Restricted Subsidiaries. The parties acknowledge that certain
real estate, improvements, furniture, fixtures and equipment (the “Erie Assets”) located at 7700 Peach Street, Erie, Pennsylvania, and used in connection with an off-track wagering operation commonly known as “The Downs” operated
at that location, are subject to a purchase right in favor of a third party. Notwithstanding anything contained herein to the contrary: (i) the existence of such a purchase right in respect of the Erie Assets will not be deemed to violate the
Loan Documents, and (ii) the subsequent sale or other disposition thereof will not be considered a Disposition. 
 “Distribution” means (a) any transfer of cash or other Property from the Borrower or any of its Restricted Subsidiaries, or from any account of the Borrower or any of its Restricted Subsidiaries to the Tribe or any of
its members or Outside Affiliates or to their respective accounts (but not the making of arm’s length payments for goods and services provided by the Tribe, its members or any of its Affiliates to the Borrower or any of its Restricted
Subsidiaries in the manner contemplated by Section 9.08), (b) any retirement, redemption, prepayment of principal, purchase or other acquisition for value by the Borrower or any of its Restricted Subsidiaries of any Securities or other
obligations of the Tribe or any of its Outside Affiliates (or of any other Person to the extent that such Securities or other obligations are guaranteed by the Tribe or any of its Outside Affiliates), (c) the declaration or payment by the
Borrower or any of its Restricted Subsidiaries of any dividend or distribution to the Tribe or any of its members or any of its Outside Affiliates in cash or in Property (but not the making of arm’s length payments for goods and services
provided by the Tribe, its members or any of its Affiliates to the Borrower or any of its Restricted Subsidiaries in the manner contemplated by Section 9.08), (d) any Investment (whether by means of loans, advances or otherwise) by the
Borrower or any of its Restricted Subsidiaries in Securities or other obligations of the Tribe or any of its Outside Affiliates, or (e) any other payment, assignment or transfer, whether in cash or other Property, from the Borrower or any of
its Restricted Subsidiaries to the Tribe or any of its members or Outside Affiliates, including the payment of any tax, fee, charge or assessment imposed by the Tribe on the Borrower, its Restricted Subsidiaries, their revenues or the Authority
Property, provided that, (A) the making of payments by the Borrower or any of its Restricted Subsidiaries to the Tribe or any of its Affiliates or members in consideration of goods and services provided to the Borrower or any of its Restricted
Subsidiaries by the Tribe or its Affiliates or members in the ordinary course of business, (B) the provision of services by the Borrower or any of its 

  

 -10- 

 
Restricted Subsidiaries to the Tribe, its members or any of its Affiliates in the ordinary course of business in exchange for reasonable consideration to the
Borrower or any of its Restricted Subsidiaries or (C) assessment by the Tribe against the Borrower or any of its Restricted Subsidiaries of the regulatory costs and expenses of the Tribe associated with the Borrower or any of its Restricted
Subsidiaries, shall not be considered Distributions. 
 “Dollar” and “$” mean lawful money of the United
States. 
 “EBITDA” means, for any period, for the Borrower and its Restricted Subsidiaries on a consolidated basis, an
amount equal to (a) Net Income for that period, plus (b) Interest Charges to the extent deducted in determining such Net Income, plus (c) (without duplication) the aggregate amount, if any, of federal and state taxes on
or measured by income of the Borrower and its Restricted Subsidiaries (whether or not payable during that period, and excluding any amount payable to the State of Connecticut under the Compact) to the extent deducted in determining such Net Income,
plus (d) depreciation and amortization of the Borrower and its Restricted Subsidiaries to the extent deducted in determining such Net Income, plus (e) accretion expense with respect to the relinquishment liability,
relinquishment liability re-assessments and all similar obligations of the Borrower and its Restricted Subsidiaries under the Relinquishment Agreement, in each case to the extent deducted in determining such Net Income, plus (f) to the
extent deducted in determining Net Income, the premium and related costs of tender offers and consent solicitations described in Section 9.09 hereof (including all such costs associated with the redemption of the Senior Notes) and the
associated write off of unamortized debt issuance costs, in each case determined in accordance with GAAP, plus (g) Pre-Opening Expenses for that period, minus (h) relinquishment fees earned under the Relinquishment Agreement
during that period, minus (i) accretion income with respect to the gain recorded in the fiscal year ended September 30, 2006 realized during that period in connection with the amendment of the purchase agreement for the purchase of
the Pocono Downs Subsidiaries with Penn National Gaming, Inc. and certain of its affiliates. 
 “Eligible Assignee” means
any Person that meets the requirements to be an assignee under Section 12.06(b)(iii), (v) and (vi) (subject to such consents, if any, as may be required under Section 12.06(b)(iii)). 
 “Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments,
orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to
hazardous substances or wastes, air emissions and discharges to waste or public systems. 
 “Environmental Liability” means
any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any other Loan Party directly or indirectly resulting from or based upon
(a) violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release
of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 
  

 -11- 

 “Equity Interests” means, with respect to any Person, all of the shares of capital stock
of (or other ownership interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership interests in) such Person, all of the securities
convertible into or exchangeable for shares of capital stock of (or other ownership interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the
other ownership interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of
determination. 
 “ERISA” means the Employee Retirement Income Security Act of 1974. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated) under common control with the Borrower within the meaning of
Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code). 
 “ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) a withdrawal by the Borrower or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA
during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial
withdrawal by the Borrower or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination
under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e) an event or condition which constitutes grounds under Section 4042 of ERISA for the
termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; or (f) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under
Section 4007 of ERISA, upon the Borrower or any ERISA Affiliate. 
 “Eurodollar Base Rate” has the meaning specified in
the definition of Eurodollar Rate. 
 “Eurodollar Rate” means for any Interest Period with respect to a Eurodollar Rate
Loan, a rate per annum determined by the Administrative Agent pursuant to the following formula: 
  

			
		  	 Eurodollar Base Rate

	Eurodollar Rate =	  	1.00 – Eurodollar Reserve Percentage

 Where, 
 “Eurodollar Base Rate” means, for such Interest Period, the rate per annum equal to the British Bankers Association LIBOR
Rate (“BBA LIBOR”), as published by Reuters (or other commercially available source providing quotations of BBA LIBOR as designated by the Administrative Agent from time to time) at approximately 11:00 a.m., 

  

 -12- 

 
London time, two Business Days prior to the commencement of such Interest Period, for Dollar deposits (for delivery on the first day of such Interest Period)
with a term equivalent to such Interest Period. If such rate is not available at such time for any reason, then the “Eurodollar Base Rate” for such Interest Period shall be the rate per annum determined by the Administrative Agent to be
the rate at which deposits in Dollars for delivery on the first day of such Interest Period in same day funds in the approximate amount of the Eurodollar Rate Loan being made, continued or converted by Bank of America and with a term equivalent to
such Interest Period would be offered by Bank of America’s London Branch to major banks in the London interbank eurodollar market at their request at approximately 11:00 a.m. (London time) two Business Days prior to the commencement of such
Interest Period. 
 “Eurodollar Reserve Percentage” means, for any day during any Interest Period, the
reserve percentage (expressed as a decimal, carried out to five decimal places) in effect on such day, whether or not applicable to any Lender, under regulations issued from time to time by the FRB for determining the maximum reserve requirement
(including any emergency, supplemental or other marginal reserve requirement) with respect to Eurocurrency funding (currently referred to as “Eurocurrency liabilities”). The Eurodollar Rate for each outstanding Eurodollar Rate Loan shall
be adjusted automatically as of the effective date of any change in the Eurodollar Reserve Percentage. 
 “Eurodollar Rate
Loan” means each Loan that bears interest at a rate based on the Eurodollar Rate. 
 “Event of Default” has the
meaning specified in Section 10.01. 
 “Existing Leasehold Mortgage” means, collectively, the Amended and Restated
Open-End Leasehold Mortgage Deed, as amended, dated as of March 25, 2003, executed by the Borrower in favor of the Administrative Agent pursuant to the Existing Loan Agreement covering the leasehold interest of the Borrower under the Lease to
the reservation real property described on Schedule 5.07, the related improvements and fixtures used in connection with Mohegan Sun. 
 “Existing Letters of Credit” means each of the letters of credit issued by Bank of America as issuing lender under the Existing Loan Agreement which remain outstanding as of the Closing Date. The Administrative Agent
will advise the Lenders prior to the Closing Date of the amount of the Existing Letters of Credit. 
 “Existing Loan
Agreement” means that certain Amended and Restated Loan Agreement dated as of March 25, 2003, among the Borrower, the Tribe, Bank of America, N.A., as agent, and a syndicate of lenders, as amended. 
 “Existing Senior Indenture” means the Indenture dated as of February 8, 2005 among the Borrower, the Tribe and Wachovia Bank,
National Association, as Trustee, in respect of the Borrower’s $250,000,000 principal amount of 6 1/8% Senior Notes due 2013. 
 “Existing Senior Subordinated Indentures” means, collectively, (a) the Indenture dated as of July 26, 2001 between the Borrower and State Street Bank and Trust Company, as Trustee, in 

  

 -13- 

 
respect of the Borrower’s $150,000,000 principal amount of 8 3/8% Senior Subordinated Notes due 2011, (b) the Indenture dated as of
February 20, 2002 between the Borrower and State Street Bank and Trust Company, as Trustee, in respect of the Borrower’s $250,000,000 principal amount of 8% Senior Subordinated Notes due 2012, (c) the Indenture dated as of
July 9, 2003 between the Borrower and U.S. Bank National Association, as Trustee, in respect of the Borrower’s $330,000,000 principal amount of 6 3/8% Senior Subordinated Notes due 2009, (d) the Indenture dated as of August 3,
2004 between the Borrower and U.S. Bank, National Association, as Trustee, in respect of the Borrower’s $225,000,000 principal amount of 7 1/8% Senior Subordinated Notes due 2014, and (e) the Indenture dated as of February 8, 2005
between the Borrower and U.S. Bank National Association, as Trustee, in respect of the Borrower’s $150,000,000 principal amount of 6 7/8% Senior Subordinated Notes due 2015. 
 “Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight Federal funds
transactions with members of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that (a) if such day is
not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so published on such next
succeeding Business Day, the Federal Funds Rate for such day shall be the average rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to Bank of America on such day on such transactions as determined by the Administrative
Agent. 
 “Fee Letter” means a fee letter of even date herewith between the Borrower and the Administrative Agent and L/C
Issuer. 
 “Fiscal Quarter” means the Fiscal Quarter of the Borrower consisting of a three month fiscal period ending on
each March 31, June 30, September 30 and December 31. 
 “Fiscal Year” means the fiscal year of the
Borrower consisting of a twelve month fiscal period ending on each September 30. 
 “Fixed Charge Coverage Ratio”
means, as of each date of determination, the ratio of: 
 (a) Annualized EBITDA determined as of that date minus
(i) the aggregate amount of any taxes on or measured by consolidated income of the Borrower and its Restricted Subsidiaries for that period (whether or not payable during that period, and excluding any amount payable to the State of Connecticut
under the Compact) to the extent not otherwise deducted in determining Net Income, (ii) Distributions made by the Borrower during the period to the extent that such Distributions are not expenditures which have been deducted in computing EBITDA
for the four relevant Fiscal Quarters, and (iii) Maintenance Capital Expenditures made during that period; to 
 (b) the
sum of (i) Interest Charges with respect to Recourse Obligations to the extent payable in cash during that period, plus (ii) any principal repayments with respect to Indebtedness and Capital Leases constituting Recourse
Obligations required to be made during that period in cash (other than any such principal payments required in respect of Public Indebtedness). 
  

 -14- 

 “Foreign Lender” means any Lender that is organized under the laws of a jurisdiction
other than that in which the Borrower is resident for tax purposes. For purposes of this definition, the United States, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction. 
 “FRB” means the Board of Governors of the Federal Reserve System of the United States. 
 “Fund” means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing
in commercial loans and similar extensions of credit in the ordinary course of its business. 
 “GAAP” means generally
accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial
Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied.

 Gaming Authority Ordinance” means Chapter 2, Article II of the Mohegan Tribe Code, also known as Ordinance No. 95-2
of the Tribe, as enacted on July 15, 1995. 
 “Gaming Board” means, collectively, (a) The Mohegan Tribal Gaming
Commission, (b) the Connecticut Division of Special Revenue, (c) the Commission, and (d) any other Governmental Authority that holds licensing or permit authority over gambling, gaming or casino activities conducted by the Tribe or
the Borrower within its jurisdiction. 
 “Gaming Laws” means IGRA, the Gaming Ordinance, the Gaming Authority Ordinance and
all other Laws pursuant to which any Gaming Board possesses licensing or permit authority over gambling, gaming, or casino activities conducted by the Tribe or the Borrower within its jurisdiction. 
 “Gaming Ordinance” means Chapter 2, Article III of the Mohegan Tribe Code, also known as Ordinance 94-1 of the Tribe, as enacted on
July 28, 1994. 
 “Government Securities” means readily marketable direct full faith and credit obligations of the
United States of America or obligations unconditionally guaranteed by the full faith and credit of the United States of America. 
 “Governmental Authority” means the government of the United States, the Tribe or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory
body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the
European Central Bank). 
  

 -15- 

 “Granting Lender” has the meaning specified in Section 12.06(h). 
 “Gross Proceeds” with respect to any Tax Exempt Notes means any proceeds as defined in section 1.148-1(b) of the Tax Regulations,
and any replacement proceeds as defined in section 1.148-1(c) of the Tax Regulations. 
 “Guaranties” means
(a) the Amended and Restated Guaranty by the Pocono Downs Subsidiaries of the Obligations executed on the Closing Date, (b) the Second Amended and Restated Guaranty by the WNBA Subsidiary of the Obligations executed on the Closing Date,
(c) the Amended and Restated Guaranty by Mohegan Ventures-Northwest, LLC of the Obligations executed on the Closing Date, (d) the Guaranty by Mohegan Golf, LLC, Mohegan Ventures Wisconsin, LLC, and Wisconsin Tribal Gaming, LLC of the
Obligations executed on the Closing Date, and (e) each Guaranty made by each future Restricted Subsidiary of the Borrower of the Obligations, each either as originally executed or as it may from time to time be supplemented, modified, amended,
restated or extended. 
 “Guarantors” means, collectively, the Pocono Downs Subsidiaries, the WNBA Subsidiary, Mohegan
Ventures-Northwest, LLC, Mohegan Golf, LLC, Mohegan Ventures Wisconsin, LLC, Wisconsin Tribal Gaming, LLC and each other Restricted Subsidiary of the Borrower. 
 “Hazardous Materials” means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos
or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law. 
 “Hazardous Materials Laws” means all federal, tribal, Connecticut state or local laws, ordinances, rules or regulations governing the
disposal of Hazardous Materials, to the extent applicable. 
 “Honor Date” has the meaning specified in the
Section 2.04(c)(i). 
 “IGRA” means the federal Indian Gaming Regulatory Act of 1988, as amended, codified at 25 U.S.C.
§ 2701, et seq. 
 “In-Balance Certificate” means a Certificate substantially in the form of Exhibit D.

 “In-Balance Test” means, as of each relevant date, that: 
 (a) the sum of (i) the Borrower’s and its Restricted Subsidiaries’ consolidated cash and Cash Equivalents, (ii) the
Unused Commitment, (iii) the Capital Markets Amount, and (iv) Projected Free Cash Flow, in each case computed as of that date; exceeds 
 (b) the sum of the Cost to Complete Mohegan Sun Phase III, the Pocono Downs Phase II and each other Material Project (to the extent any cost associated with such Material Project is budgeted to be expended
during the Construction Period) determined as of that date. 
  

 -16- 

 “Included Taxes” has the meaning provided in Section 3.01(a). 
 “Indebtedness” means, as to any Person at a particular time, without duplication, all of the following, whether or not included as
indebtedness or liabilities in accordance with GAAP: 
 (a) all obligations of such Person for borrowed money and all
obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments; 
 (b) all
direct or contingent obligations of such Person arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments; 
 (c) net obligations of such Person under any Swap Contract; 
 (d) all obligations of such Person to pay the deferred purchase price of property or services (other than trade accounts payable in the
ordinary course of business); 
 (e) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or
being purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse, but only to the extent of
the lesser of (i) the outstanding principal amount of the obligation (or, with respect to any letter of credit, the amount available for drawing thereunder), and (ii) the fair market value of the assets so subject to the Lien; 

(f) Capital Leases and Synthetic Lease Obligations; 
 (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Equity Interest in
such Person or any other Person, valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends; and 
 (h) all Contingent Obligations of such Person in respect of any of the foregoing; 
 provided, that the obligations of Borrower under the Relinquishment Agreement shall not be treated as Indebtedness except to the extent that the
same are not paid when due. 
 For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or
joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of
any net obligation under any Swap Contract on any date shall be deemed to be the Swap Termination Value thereof as of such date. The amount of any Capital Lease or Synthetic Lease Obligation as of any date shall be deemed to be the amount of
Attributable Indebtedness in respect thereof as of such date. 
  

 -17- 

 “Indemnitees” has the meaning specified in Section 12.04(b). 
 “Indentures” means, collectively, the Existing Senior Indenture, the Existing Senior Subordinated Indentures, and any Indentures
governing future Indebtedness of the Borrower permitted under Section 9.03. 
 “Information” has the meaning specified
in Section 12.07. 
 “Intangible Assets” means assets that are considered to be intangible assets under GAAP, including
customer lists, goodwill, computer software, copyrights, trade names, trademarks, patents, franchises, licenses, unamortized deferred charges, unamortized debt discount and capitalized research and development costs. 
 “Interest Charges” means, with respect to any fiscal period, the sum of (a) all interest, fees, charges and related expenses
payable with respect to that fiscal period to a lender in connection with borrowed money or the deferred purchase price of assets that is treated as interest in accordance with GAAP, plus (b) the portion of rent payable with respect to that
fiscal period under Capital Leases that should be treated as interest in accordance with GAAP; provided however, that the premium and related costs of tender offers and consent solicitations described in Section 9.09 hereof (including
all such costs associated with the redemption of the Senior Notes) and the associated write off of unamortized debt issuance costs shall not be considered to be “Interest Charges.” 
 “Interest Differential” means, with respect to any prepayment of a Eurodollar Rate Loan on a day other than the last day of the
applicable Interest Period and with respect to the failure to borrow a Eurodollar Rate Loan on the date or in the amount specified in a Request for Credit Extension, (a) the per annum interest rate payable pursuant to Section 2.08(a)(i)
with respect to that Eurodollar Rate Loan as of the date of the prepayment or failure to borrow, minus (b) the Eurodollar Base Rate on or as near as practicable to the date of the prepayment or failure to borrow for a Eurodollar Rate
Loan commencing on such date and ending on the last day of the applicable Interest Period; provided that if the Eurodollar Base Rate so prescribed is equal to or within 1/8% less than the Eurodollar Base Rate for the Eurodollar Rate Loan that
was prepaid or not borrowed, then 1/8 of 1% shall be subtracted from the Eurodollar Base Rate so prescribed. The determination of the Interest Differential by the Administrative Agent shall be conclusive in the absence of manifest error.

 “Interest Payment Date” means, (a) as to any Loan other than a Base Rate Loan, the last day of each Interest Period
applicable to such Loan and the Maturity Date; provided, however, that if any Interest Period for a Eurodollar Rate Loan exceeds three months, the last Business Day of each March, June, September and December that occurs
after the beginning of such Interest Period shall also be an Interest Payment Date; and (b) as to any Base Rate Loan, the last Business Day of each March, June, September and December and the Maturity Date. 
 “Interest Period” means, as to each Eurodollar Rate Loan, the period commencing on the date such Eurodollar Rate Loan is disbursed or
converted to or continued as a Eurodollar Rate Loan and ending on the date one, two, three, six or twelve (to the extent made available by each of the Lenders) months thereafter, as selected by the Borrower in its Loan Notice; provided that:

 (a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next
succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day; 
  

 -18- 

 (b) any Interest Period that begins on the last Business Day of a calendar month (or on a
day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and 
 (c) no Interest Period shall extend beyond the Maturity Date. 
 “Internal Control Event” means a material weakness in, or fraud that involves management or other employees who have a significant role
in, the Borrower’s internal controls over financial reporting, in each case as described in the Securities Laws. 
 “Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of capital stock or other securities of another Person,
(b) a loan, advance or capital contribution to, guarantee or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest
in such other Person, or (c) the purchase or other acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit. For purposes of covenant compliance, the amount of any Investment shall
be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment. 
 “IRS” means the United States Internal Revenue Service. 
 “ISP” means, with respect to any Letter
of Credit, the “International Standby Practices 1998” published by the Institute of International Banking Law & Practice (or such later version thereof as may be in effect at the time of issuance). 
 “Issuer Documents” means with respect to any Letter of Credit, the Letter of Credit Application, and any other document, agreement and
instrument entered into by the L/C Issuer and the Borrower (or any Subsidiary) or in favor the L/C Issuer and relating to such Letter of Credit. 
 “Joint Lead Arrangers” means Banc of America Securities LLC, RBS Securities Corporation and Calyon New York Branch, in their capacities as joint lead arrangers and joint book managers. 
 “Lahaniatis Property” means the property identified as such on Schedule 5.07. 
 “Landlord Consent” means the consent executed by the Tribe as a part of the Leasehold Mortgage, and concurrently therewith in favor of
the Administrative Agent, either as originally executed or as it may from time to time be supplemented, modified, amended, restated or extended. 
  

 -19- 

 “Laws” means, collectively, (a) all international, foreign, Federal, tribal, state
and local statutes, treaties, rules, regulations, ordinances, codes and administrative or judicial precedents or authorities, in each case to the extent binding upon any relevant Person, (b) any interpretation or administration of the items
described in clause (a) by any Governmental Authority which has the binding force of law, and (c) all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any
Governmental Authority which any relevant Person is obligated to conform to as a matter of law. 
 “L/C Advance” means, with
respect to each Lender, such Lender’s funding of its participation in any L/C Borrowing in accordance with its Applicable Percentage. 
 “L/C Borrowing” means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the date when made or refinanced as a Borrowing. 
 “L/C Credit Extension” means, with respect to any Letter of Credit, the issuance thereof or extension of the expiry date thereof, or the
increase of the amount thereof. 
 “L/C Issuer” means Bank of America in its capacity as issuer of Letters of Credit
hereunder, or any successor issuer of Letters of Credit hereunder. 
 “L/C Obligations” means, as at any date of
determination, the aggregate amount available to be drawn under all outstanding Letters of Credit plus the aggregate of all Unreimbursed Amounts, including all L/C Borrowings. For purposes of computing the amount available to be drawn under
any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may
still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be “outstanding” in the amount so remaining available to be drawn. 
 “Lease” means the Lease dated September 29, 1995 between the Tribe and the Borrower, as amended by an amendment also dated
September 29, 1995 and by an amendment of even date herewith, with respect to the Real Property underlying Mohegan Sun and the improvements thereon. 
 “Leasehold Mortgage” means, either (a) if the governmental approvals required for the effective delivery of the Leasehold Mortgage are obtained on or prior to the Closing Date, a Second Amended
and Restated Open-End Leasehold Mortgage Deed executed by the Borrower on the Closing Date in the form of Exhibit E in favor of the Administrative Agent for the benefit of the Creditors to amend and restate the Existing Leasehold Mortgage
covering the leasehold interest of the Borrower under the Lease to the reservation real property described on Schedule 5.07, the related improvements and fixtures used in connection with Mohegan Sun, and (b) if the governmental approvals
required for the effective delivery of the Leasehold Mortgage are not obtained on or prior to the Closing Date, but the same are subsequently obtained as contemplated by Section 8.16, an Open-End Leasehold Mortgage Deed substantially in the
form of Exhibit E (but with such changes as may be reasonably required to reflect that it does not 

  

 -20- 

 
amend and restate the Existing Leasehold Mortgage), in each case either as originally executed or as the same may from time to time be supplemented,
modified, amended, renewed, extended or supplanted. 
 “Lender” has the meaning specified in the introductory paragraph
hereto. 
 “Lending Office” means, as to any Lender, the office or offices of such Lender described as such in such
Lender’s Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Borrower and the Administrative Agent. 
 “Letter of Credit” means any standby letter of credit issued hereunder and shall include the Existing Letters of Credit. 
 “Letter of Credit Application” means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the L/C Issuer. 
 “Letter of Credit Expiration Date” means the day that is seven days prior to the Maturity Date then in effect (or, if such day is not a
Business Day, the next preceding Business Day). 
 “Letter of Credit Fee” has the meaning specified in Section 2.04(i).

 “Letter of Credit Sublimit” means an amount equal to $100,000,000. The Letter of Credit Sublimit is part of, and not in
addition to, the Aggregate Revolving Commitments. 
 “Lien” means any mortgage, pledge, hypothecation, assignment, deposit
arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or
other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing). 
 “Loan” means, collectively, (a) an extension of credit by a Lender to the Borrower under Article II in the form of a Revolving
Loan, and (b) any Term Loans and Tax Exempt Loans made hereunder. 
 “Loan Documents” collectively, this Agreement, the
Notes, each Letter of Credit, the Collateral Documents, the Landlord Consent, any Request for Loan, any Request for Letter of Credit, the Fee Letter, the Guaranties, and any other agreements of any type or nature heretofore or hereafter executed and
delivered by the Borrower, the Tribe or any of its Affiliates to the Administrative Agent or to any Lender (including, in the case of any Secured Swap Contract, any Affiliate of any Lender) in any way relating to or in furtherance of this Agreement,
including any Secured Swap Contract, in each case either as originally executed or as the same may from time to time be supplemented, modified, amended, restated, extended or supplanted. 
 “Loan Notice” means a notice of (a) a Borrowing, (b) a conversion of Revolving Loans from one Type to the other, or (c) a
continuation of Eurodollar Rate Loans, pursuant to Section 2.03(a), which, if in writing, shall be substantially in the form of Exhibit F. 
  

 -21- 

 “Loan Parties” means the Borrower and each Guarantor. 
 “Maintenance Capital Expenditure” means a Capital Expenditure for the maintenance, repair, restoration or refurbishment of those
portions of Mohegan Sun or Pocono Downs which are open for business on the Closing Date (or, as of the date of the Capital Expenditure, will have been open for business for a period in excess of one year), but excluding any Capital Expenditure which
adds to Mohegan Sun or Pocono Downs. 
 “Management Board” means the Management Board of the Borrower, as established
pursuant to the Gaming Authority Ordinance. 
 “Material Adverse Effect” means any set of circumstances or events which
(a) may reasonably be expected to have any material adverse effect whatsoever upon the validity or enforceability of any Loan Document, (b) may reasonably be expected to be material and adverse to the condition (financial or otherwise) or
business operations or Properties or to the prospects of the Borrower and its Restricted Subsidiaries, taken as a whole, (c) materially impairs or may reasonably be expected to materially impair the ability of the Tribe or the Borrower and the
other Loan Parties, taken as a whole, to perform their Obligations or (d) materially impairs or could reasonably be expected to materially impair the ability of the Lenders or the Administrative Agent to enforce the principal benefits intended
to be created and conveyed by the Loan Documents, including, without limitation, the Liens created by the Collateral Documents. 
 “Material Documents” means, collectively, the Lease, the Relinquishment Agreement, the Constitution, the Compact, the Gaming Ordinance, the Gaming Authority Ordinance, the Town Agreement and the UCC Ordinance. 

“Material Project” means each capital project other than Mohegan Sun Phase III or Pocono Downs Phase II for which the
Borrower and its Restricted Subsidiaries hereafter become legally obligated to make Capital Expenditures which are in excess of $7,500,000 (as to each such Project) during the Construction Period (whether directly or by means of legal obligations to
make Investments in other Persons), it being understood that the existence of one or more conditions to the contractual obligations of the Borrower or its Restricted Subsidiaries will not exclude any such capital project from this definition unless
the condition is not reasonably expected to be fulfilled during the Construction Period. It is specifically understood and agreed that any project the costs of which are considered Maintenance Capital Expenditures shall be excluded from the
definition of Material Project. 
 “Material Restricted Subsidiary” means, collectively (a) Downs Racing, L.P., a
Pennsylvania limited partnership, and each other Restricted Subsidiary of Borrower which owns any interest in the principal fixed assets used in connection with the gaming, lodging and entertainment activities conducted at Mohegan Sun or Pocono
Downs (but specifically excluding any Restricted Subsidiary which is a passive landowner of property which is not actively used in such activities), and (b) as of any date of determination, any Restricted Subsidiary whose consolidated assets
and operations, as of the last day of the then most recently ended Fiscal Quarter for which financial statements have been delivered pursuant to Section 8.01(b), account for 5% or more of the consolidated total assets of the Borrower and its
Restricted Subsidiaries as of that date or 5% or more of consolidated EBITDA of Borrower and its Restricted Subsidiaries for the twelve month period ending on that date. 
  

 -22- 

 “Maturity Date” means March 9, 2012; provided, however, that if such
date is not a Business Day, the Maturity Date shall be the next preceding Business Day. 
 “Maximum Foreseeable Loss” means
the maximum foreseeable casualty loss associated with the Mohegan Sun determined from time to time by AON Risk Services or another professional insurance consultant retained by the Borrower and reasonably acceptable to the Administrative Agent,
provided that the amount thereof shall not be less than $500,000,000. As of the Closing Date, the Maximum Foreseeable Loss has been determined to be $1,072,084,349, but the Borrower shall have the right to engage AON Risk Services or another
professional insurance consultant retained by the Borrower and reasonably acceptable to the Administrative Agent to reassess the Maximum Foreseeable Loss from time to time during the term of this Agreement. 
 “Mohegan Sun” means the casino property and related transportation, retail, dining and entertainment facilities and hotel described in
the Gaming Ordinance and commonly known as “Mohegan Sun Resort Casino” owned by the Borrower and located in Uncasville, Connecticut (including any future expansions thereof), which facilities are located upon the real property described on
Schedule 5.07. 
 “Mohegan Sun Phase III” means the proposed expansion project of the Mohegan Sun consisting of
approximately 1,300,000 square feet of additional amenities for Mohegan Sun including: 
 (a) the “Sunrise Square”
containing approximately 10,000 square feet of new space and 12,000 square feet of renovated space, with related food and beverage outlets and a specially dedicated Asian bus lobby; 
 (b) the “Casino of the Wind”, including approximately 42,000 square feet of additional gaming space and approximately 20,000
square feet of additional dining and retail amenities; 
 (c) an approximately 15,000 square foot entertainment venue (1,500
capacity), an approximately 9,600 square foot themed casual dining restaurant, and an approximately 3,000 square foot special events room and a retail shop; 
 (d) a hotel tower with approximately 1,000 rooms, an approximately 7,500 square foot nightclub and lounge and a swimming pool and spa;

 (e) approximately 115,000 square feet of new retail and food and beverage amenities; and 
 (f) additional structured parking, valet parking and surface parking, totaling approximately 6000 spaces. 
  

 -23- 

 “Mohegan Tribe Code” means the Mohegan Tribe of Indians of Connecticut Code of
Ordinances codified through Ordinance No. 2006-2, enacted September 8, 2006, as in effect from time to time. 
 “Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which the Borrower or any ERISA Affiliate makes or is obligated to make contributions, or during the
preceding five plan years, has made or been obligated to make contributions. 
 “Negative Pledge” means any covenant binding
upon Authority Property that prohibits the creation of Liens on any Authority Property, except a covenant contained in an instrument creating a Lien or a Permitted Right of Others permitted under Section 9.01. 
 “Net Cash Proceeds” means: with respect to any Disposition by the Borrower or any of its Restricted Subsidiaries, the excess, if any, of
(i) the sum of cash and Cash Equivalents received in connection with such transaction (including any cash or Cash Equivalents received by way of deferred payment pursuant to, or by monetization of, a note receivable or otherwise, but only as
and when so received) over (ii) the sum of (A) the principal amount of any Indebtedness that is secured by the applicable asset and that is required to be repaid in connection with such transaction (other than Indebtedness under the Loan
Documents), (B) the reasonable and customary out-of-pocket expenses incurred by the Borrower or such Restricted Subsidiary in connection with such transaction and (C) income taxes reasonably estimated to be actually payable within two
years of the date of the relevant transaction as a result of any gain recognized in connection therewith; provided that, if the amount of any estimated taxes pursuant to subclause (C) exceeds the amount of taxes actually required to be paid in
cash in respect of such Disposition, the aggregate amount of such excess shall constitute Net Cash Proceeds. 
 “Net Income”
means, with respect to any fiscal period, the consolidated net income from continuing operations before extraordinary or non-recurring items of the Borrower and its Restricted Subsidiaries for that period, determined in accordance with GAAP.

 “Note” means a Revolving Note, a Term Loan Note or a Tax Exempt Note. 
 “Obligations” means all advances to, and debts, liabilities and obligations of, the Tribe, the Borrower or any other Loan Party arising
under any Loan Document or otherwise with respect to any Loan or Letter of Credit, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including
interest and fees payable under any Loan Document that accrue after the commencement by or against the Tribe, the Borrower or any Loan Party of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding,
regardless of whether such interest and fees are allowed claims in such proceeding. 
 “Operating Accounts” means the
deposit accounts of the Borrower and the Restricted Subsidiaries (excluding the WNBA Subsidiary) described on Schedule 6.26, and each other deposit, savings, brokerage or similar account hereafter established by the Borrower and the Restricted
Subsidiaries (excluding the WNBA Subsidiary), provided that Operating Accounts shall not include the accounts designated on Schedule 6.26 as “Operating Account Exclusions” 

  

 -24- 

 
or any other deposit, savings, brokerage or similar account hereafter established by the Borrower or the Restricted Subsidiaries (excluding the WNBA
Subsidiary) for the purpose of collecting or disbursing funds for the payment of payroll, medical insurance and workmen’s compensation claims, tip money belonging to employees, money belonging to patrons and other disbursements of a similar
nature, or accounts for the short-term investment of such funds pending their disbursement. 
 “Organization Documents”
means, (a) with respect to the Tribe, the Constitution, (b) with respect to the Borrower, the Gaming Authority Ordinance, (c) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent
or comparable constitutive documents with respect to any non-U.S. jurisdiction); (d) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement; and (e) with respect to
any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in
connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity. 
 “Outside Affiliates” means those Affiliates of the Tribe other than the Borrower and its Restricted Subsidiaries. 
 “Outstanding Amount” means (i) with respect to Revolving Loans, Term Loans and Tax Exempt Loans outstanding on any date, the
aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of Revolving Loans, Term Loans and Tax Exempt Loans, as the case may be, occurring on such date; and (ii) with respect to any L/C
Obligations on any date, the amount of such L/C Obligations on such date after giving effect to any L/C Credit Extension occurring on such date and any other changes in the aggregate amount of the L/C Obligations as of such date, including as a
result of any reimbursements by the Borrower of Unreimbursed Amounts. 
 “Participant” has the meaning specified in
Section 12.06(d). 
 “PBGC” means the Pension Benefit Guaranty Corporation. 
 “PCAOB” means the Public Company Accounting Oversight Board. 
 “Pennsylvania Tax Revenues” means the portion of the revenues of Downs Racing, L.P. which is required to be paid to the Commonwealth of
Pennsylvania as a tax under Chapter 14 of the Pennsylvania Race Horse Development and Gaming Act. 
 “Pension Plan” means
any “employee pension benefit plan” (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by the Borrower or any ERISA Affiliate
or to which the Borrower or any ERISA Affiliate contributes or has an obligation to contribute, or in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately
preceding five plan years. 
  

 -25- 

 “Permitted Dispositions” means Dispositions made during the term of this Agreement of
Authority Property which have, as of each date of determination, an aggregate book value not in excess of 5% of the aggregate value of the assets comprising Mohegan Sun as of each such date, determined with reference to the then most recent audited
financial statements of the Borrower. 
 “Permitted Encumbrances” means: 
 (a) inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or maintenance of real
property, now or hereafter filed of record for which adequate accounting reserves have been set aside and which are being contested in good faith by appropriate proceedings and have not proceeded to judgment, provided that, by reason of
nonpayment of the obligations secured by such Liens, no such real property is subject to a material risk of loss or forfeiture; 
 (b) Liens for taxes and assessments on Property which are not yet past due, or Liens for taxes and assessments on Property for which adequate reserves have been set aside and are being contested in good faith by appropriate proceedings and
have not proceeded to judgment, provided that, by reason of nonpayment of the obligations secured by such Liens, no such Property is subject to a material risk of loss or forfeiture; 
 (c) minor defects and irregularities in title to any real property which in the aggregate do not materially impair the fair market value
or use of the real property for the purposes for which it is or may reasonably be expected to be held; 
 (d) easements,
exceptions, reservations, or other agreements granted or entered into after the date hereof for the purpose of pipelines, conduits, cables, wire communication lines, power lines and substations, streets, trails, walkways, drainage, irrigation,
water, and sewerage purposes, dikes, canals, ditches, the removal of oil, gas, coal, or other minerals, and other like purposes affecting real property which in the aggregate do not materially burden or impair the fair market value or use of such
real property for the purposes for which it is or may reasonably be expected to be held; 
 (e) rights reserved to or vested
in any Governmental Authority by Law to control or regulate, or obligations or duties under Law to any Governmental Authority with respect to, the use of any real property; 
 (f) rights reserved to or vested in any Governmental Authority by Law to control or regulate, or obligations or duties under Law to any
Governmental Authority with respect to, any right, power, franchise, grant, license, or permit; 
 (g) present or future
zoning laws and ordinances or other laws and ordinances restricting the occupancy, use, or enjoyment of real property; 
 (h)
statutory Liens, other than those described in clauses (a) or (b) above, arising in the ordinary course of business with respect to obligations which are not delinquent or are being contested in good faith by appropriate proceedings,
provided that, if delinquent, adequate reserves have been set aside with respect thereto and, by reason of nonpayment, no Property is subject to a material risk of loss or forfeiture; 
  

 -26- 

 (i) Liens consisting of pledges or deposits made in connection with obligations under
workers’ compensation laws, unemployment insurance or similar legislation, including Liens of judgments thereunder which are not currently dischargeable; 
 (j) Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases made in the ordinary
course of business to which Borrower is a party as lessee, provided the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed 10% of the annual fixed rentals payable under such
lease; 
 (k) Liens consisting of deposits of Property to secure statutory obligations of Borrower in the ordinary course of
its business; 
 (l) Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in
proceedings to which Borrower is a party in the ordinary course of its business; 
 (m) Liens created by or resulting from any
litigation or legal proceeding involving Borrower in the ordinary course of its business which is currently being contested in good faith by appropriate proceedings, provided that adequate reserves have been set aside with respect thereto,
and such Liens are discharged or stayed within 60 days of creation and no Property is subject to a material risk of loss or forfeiture; 
 (n) encumbrances consisting of the rights of tenants under retail, restaurant or other commercial leases at Mohegan Sun, Pocono Downs or any other property owned by a Loan Party and associated rights of such tenants
under SNDA’s; and 
 (o) the Lien of the mortgage referred to in the definition of Permitted Transaction. 
 “Permitted Right of Others” means a Right of Others consisting of (a) an interest (other than a legal or equitable co-ownership
interest, an option or right to acquire a legal or equitable co-ownership interest and any interest of a ground lessor under a ground lease) that does not materially impair the value or use of property for the purposes for which it is or may
reasonably be expected to be held, (b) an option or right to acquire a Lien that would be a Permitted Encumbrance, and (c) the reversionary interest of a landlord under a lease of Property. 
 “Permitted Transaction” means the transaction pursuant to which the Tribe sells or leases the Lahaniatis Property to the Borrower, or
the Tribe and the Borrower enter into an easement, occupancy or other arrangement concerning the Lahaniatis Property such that such property can be incorporated into Mohegan Sun Phase III in a manner satisfactory to the Borrower, provided that
if such transaction takes the form of a sale, such sale may involve the payment of cash and the assumption of existing Indebtedness secured by an existing mortgage lien on such property, further provided that in the event such transaction takes the
form of a sale, the aggregate amount of cash paid and existing Indebtedness assumed by the Borrower in connection therewith shall not exceed $8,000,000. 
  

 -27- 

 “Person” means any natural person, corporation, limited liability company, trust, joint
venture, association, company, partnership, tribe, Governmental Authority or other entity. 
 “Plan” means any
“employee benefit plan” (as such term is defined in Section 3(3) of ERISA) established by the Borrower or, with respect to any such plan that is subject to Section 412 of the Code or Title IV of ERISA, any ERISA Affiliate.

 “Platform” has the meaning specified in Section 8.02. 
 “Pledge Agreement” means a pledge agreement to be executed and delivered by the Borrower and each Restricted Subsidiary owning any
Equity Interests in any other Restricted Subsidiary with respect to all Equity Interests held by each such Person in a Restricted Subsidiary (excluding the WNBA Subsidiary), either as originally executed or as it may from time to time be
supplemented, modified, amended, restated or extended. 
 “Pocono Downs” means the harness racetrack and casino known as
Mohegan Sun at Pocono Downs located in Plains Township, Pennsylvania, and related assets. 
 “Pocono Downs Mortgages” means
the Amended and Restated Open-End Mortgage and Security Agreements executed by those of the Pocono Downs Subsidiaries owning real property interests underlying Pocono Downs with respect thereto. 
 “Pocono Downs Phase I” means the initial gaming facility at Pocono Downs which opened to the public for business on
November 14, 2006. 
 “Pocono Downs Phase II” means the expansion project of Pocono Downs consisting of: a new
approximately 280,000 square foot entertainment facility featuring additional slot machines, expected to bring the total number of slot machines at Pocono Downs to approximately 2,500, as well as restaurants, a 300 seat buffet, food court and other
related amenities. 
 “Pocono Downs Subsidiaries” means, collectively, (a) Downs Racing, L.P., a Pennsylvania limited
partnership, Backside, L.P., a Pennsylvania limited partnership, Mill Creek Land, L.P., a Pennsylvania limited partnership, Northeast Concessions, L.P., a Pennsylvania limited partnership, and Mohegan Commercial Ventures PA, LLC, a Pennsylvania
limited liability company, and their respective successors, and (b) any other Persons formed as Restricted Subsidiaries of the Borrower for the purpose of owning or operating Pocono Downs and the businesses related thereto. 
 “Pre-Construction Documents” has the meaning set forth in Section 6.28. 
 “Pre-Opening Expenses” means, for any fiscal period, pre-opening expenses of the Projects during that period, determined in accordance
with GAAP. 
 “Preliminary Construction Documents” means construction materials referred to in Section 6.28, and
delivered to the Administrative Agent pursuant to Section 4.01(a)(xiv). 
 “Pricing Certificate” means a certificate
substantially in the form of Exhibit G, setting forth in summary form the calculation of the Total Leverage Ratio as of the last day of the fourth Fiscal Quarter of the Borrower in each Fiscal Year, properly completed and signed by a Senior
Officer of the Borrower. 
  

 -28- 

 “Priority Distribution Agreement” means the Priority Distribution Agreement dated as of
August 1, 2001, between the Tribe and the Borrower, as originally executed, a true, correct and complete copy of which has been provided to the Administrative Agent. 
 “Priority Distribution Limit” means, for each calendar year, the amount calculated by adjusting the baseline amount of $14,000,000 for the calendar year 2000 for each subsequent year by the same
percentage as the Consumer Price Index adjustment for the most recently ended calendar year. The parties stipulate that for the calendar year 2007, the Priority Distribution Limit is $16,941,175.51. 
 “Priority Distributions” means Distributions made by the Borrower to the Tribe during any calendar year in the aggregate amount which
does not exceed the Priority Distribution Limit for such calendar year. 
 “Pro Forma Fixed Charge Coverage Ratio” means, as
of the date of any Distribution, the ratio which results from making adjustments to the Fixed Charge Coverage Ratio (determined as of the then most recently ended Fiscal Quarter for which the Borrower is obliged to have delivered a Compliance
Certificate) to give pro forma effect to all Distributions which have occurred since the date for which the Fixed Charge Coverage Ratio was determined. 
 “Pro Forma Total Leverage Ratio” means, as of the date of the making of any Investment, the ratio of (a) Total Debt as of the date of the making of that Investment (after giving effect to any
Indebtedness to be incurred on that date), to (b) Annualized EBITDA for the four Fiscal Quarter period ending on the last day of the then most recently ended Fiscal Quarter for which the Borrower is obliged to have delivered a Compliance
Certificate or Pricing Certificate. 
 “Projected Free Cash Flow” means, as of the last day of any Fiscal Quarter, an amount
equal to: 
 (a) the result of (i) Annualized EBITDA for the twelve-month period then ended, minus (ii) the amount of Interest
Charges and scheduled payments of principal with respect to Indebtedness during that period paid in cash during that period (other than the final maturity of the Borrower’s $330,000,000 principal amount of 6 3/8% Senior Subordinated Notes due
2009), minus (iii) Distributions made by the Borrower and its Restricted Subsidiaries to the Tribe in Cash during that period, minus Maintenance Capital Expenditures during that period, and minus any taxes paid by Borrower and its
Restricted Subsidiaries with respect to their income in respect of that period, if any; divided by 
 (b) four; and times

 (c) the then remaining number of Fiscal Quarters which will occur in the Construction Period. 
  

 -29- 

 “Projections” means the financial projections which are a part of the Confidential
Offering Memorandum dated November, 2006 distributed by Banc of America Securities LLC and the Borrower to the Lenders. 
 “Projects” means Mohegan Sun Phase III and Pocono Downs Phase II. 
 “Property” means
any interest in any kind of property or asset, whether real, personal or mixed, or tangible or intangible. 
 “Public
Indebtedness” means, collectively, any Indebtedness under the Existing Senior Indenture, the Existing Senior Subordinated Indentures, or any other Indebtedness which is hereafter issued pursuant to Section 9.03(b) or 9.03(d).

 “Real Property” means, collectively, (a) the real property and improvements underlying Mohegan Sun described on
Schedule 5.07 and (b) the real property and improvements underlying Pocono Downs described on Schedule 6.21. 
 “Rebatable Amount” has the meaning set forth in section 1.148-1(b) of the Tax Regulations. 
 “Recourse Obligations” means, as of each date of determination, and without duplication for the Borrower and its Restricted Subsidiaries, (a) all Indebtedness and Contingent Obligations as to which the Borrower or any
of its Restricted Subsidiaries has any direct or indirect liability or obligation (whether as the primary obligor or as a surety, and whether or not the Borrower is the nominal obligor with respect thereto), including, without limitation,
indebtedness for borrowed money, obligations with respect to Capital Leases, amounts available for drawing under letters of credit and other similar instruments, and the aggregate amount drawn under letters of credit and other similar instruments
not then reimbursed, (b) all Indebtedness, Contingent Obligations and other obligations secured by any Lien upon any Authority Property, and (c) all Indebtedness, Contingent Obligations and other obligations held by any Person who may take
recourse to any Authority Property for the satisfaction of such Indebtedness and other obligations, provided that the obligations of the Borrower under the Priority Distribution Agreement shall not be deemed to be Recourse Obligations. Without
limitation on this definition, the Obligations and the Indebtedness evidenced by the Indentures constitute Recourse Obligations. As in effect on the Closing Date, the Lenders acknowledge that the Tribe’s Indebtedness in respect of the Tax
Exempt Bonds does not constitute a Recourse Obligation. 
 “Register” has the meaning specified in Section 12.06(c).

 “Registered Public Accounting Firm” has the meaning specified in the Securities Laws and shall be independent of the
Borrower as prescribed by the Securities Laws. 
 “Related Parties” means, with respect to any Person, such Person’s
Affiliates and the partners, directors, officers, employees, agents and advisors of such Person and of such Person’s Affiliates. 
 “Related Businesses” means (a) Class II and Class III Casino gaming (as defined in IGRA), (b) any resort business, any activity or business incidental, directly related or similar 

  

 -30- 

 
thereto, or any business or activity that is a reasonable extension, development or expansion thereof, including any hotel, entertainment, recreation or
other activity or business, in each case designed to promote, market, support, develop, construct or enhance the casino gaming and resort business operated by Borrower at Mohegan Sun. 
 “Relinquishment Agreement” means the Relinquishment Agreement dated as of February 7, 1998, among the Borrower, the Tribe and TCA,
as amended from time to time. 
 “Reportable Event” means any of the events set forth in Section 4043(c) of ERISA,
other than events for which the 30 day notice period has been waived. 
 “Request for Credit Extension” means (a) with
respect to a Borrowing, conversion or continuation of Loans, a Loan Notice, and (b) with respect to an L/C Credit Extension, a Letter of Credit Application. 
 “Required Lenders” means, as of any date of determination, Lenders having at least 51% of the sum of: 
 (a) the Aggregate Revolving Commitments (or, if the Revolving Commitments have been terminated, the Total Revolving Outstandings) with the aggregate amount of each Lender’s risk participation and funded
participation in L/C Obligations being deemed “held” by such Lender for purposes of this definition; and 
 (b) the
aggregate Outstanding Amount of all Term Loans and Tax Exempt Loans; 
 provided that the Outstanding Amount of Term Loans, Tax Exempt Loans and the
Revolving Commitment of, and the portion of the Total Revolving Outstandings held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders. 
 “Requirement of Law” means, as to any Person, the Organization Documents of such Person, and any Law, or judgment, award, decree, writ
or determination of a Governmental Authority, in each case applicable to or binding upon such Person or any of its Property or to which such Person or any of its Property is subject. 
 “Restricted Subsidiary” means (a) the Pocono Downs Subsidiaries, Mohegan Ventures-Northwest, LLC, the WNBA Subsidiary, Mohegan
Golf, LLC, Mohegan Ventures Wisconsin, LLC, and Wisconsin Tribal Gaming, LLC and (b) each other Subsidiary of Borrower, whether now formed or hereafter acquired, which is not designated an Unrestricted Subsidiary. 
 “Revolving Borrowing” means a borrowing consisting of simultaneous Revolving Loans of the same Type and, in the case of Eurodollar Rate
Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.01. 
 “Revolving Commitment”
means, as to each Lender, its obligation to (a) make Revolving Loans to the Borrower pursuant to Section 2.01, and (b) purchase participations in L/C Obligations, in an aggregate principal amount at any one time outstanding not to
exceed the 

  

 -31- 

 
amount set forth opposite such Lender’s name on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party
hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. 
 “Revolving
Loan” has the meaning specified in Section 2.01. 
 “Revolving Note” means the promissory note made by the
Borrower in favor of a Lender evidencing Revolving Loans made by such Lender, substantially in the form of Exhibit H. 
 “Right
of Others” means, as to any Property in which a Person has an interest, (a) any legal or equitable right, title or other interest (other than a Lien) held by any other Person in or with respect to that Property, and (b) any option
or right held by any other Person to acquire any right, title or other interest in or with respect to that Property, including any option or right to acquire a Lien. 
 “Sarbanes-Oxley” means the Sarbanes-Oxley Act of 2002. 
 “SEC” means the
Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions. 
 “Secured Swap
Contracts” means one or more Swap Contracts between the Borrower and one or more of the Lenders or Affiliates of a Lender in respect of the Obligations hereunder on terms mutually acceptable to the Borrower and that Lender or Lenders or
Affiliates of a Lender. Each Secured Swap Contract shall be a Loan Document and shall be secured by the Liens created by the Collateral Documents to the extent set forth in Section 2.15. 
 “Securities” means any capital stock, share, voting trust certificate, bonds, debentures, notes or other evidences of indebtedness,
limited partnership interests, or any warrant, option or other right to purchase or acquire any of the foregoing. 
 “Securities
Laws” means the Securities Act of 1933, the Securities Exchange Act of 1934, Sarbanes-Oxley and the applicable accounting and auditing principles, rules, standards and practices promulgated, approved or incorporated by the SEC or the PCAOB.

 “Security Agreements” means (a) the Second Amended and Restated Security Agreement of even date herewith executed by
Borrower in favor of the Administrative Agent for the ratable benefit of the Creditors, (b) the Amended and Restated Security Agreement of even date herewith executed by Mohegan Ventures-Northwest, LLC in favor of the Administrative Agent for
the ratable benefit of the Creditors, (c) the Amended and Restated Security Agreement of even date herewith executed by the Pocono Downs Subsidiaries in favor of the Administrative Agent for the ratable benefit of the Creditors, (d) the
Security Agreement of even date herewith executed by Mohegan Golf, LLC, Mohegan Ventures Wisconsin, LLC, and Wisconsin Tribal Gaming, LLC in favor of the Administrative Agent for the ratable benefit of the Creditors, and (e) each Security
Agreement made by each future Restricted Subsidiary of the Borrower in favor of the Administrative Agent for the ratable benefit of the Creditors, in each case either as originally executed or as each may from time to time be supplemented, modified,
amended, restated or extended. 
  

 -32- 

 “Senior Leverage Ratio” means, as of each date of determination, the ratio of
(a) Total Debt as of that date minus Subordinated Obligations as of that date, to (b) Annualized EBITDA determined as of that date. 
 “Senior Notes” means the senior notes issued pursuant to the Existing Senior Indenture, including any exchange notes issued thereunder. 
 “Senior Officer” means (a) as to the Tribe, the Chairman, Vice-Chairman and Treasurer of the Tribal Council of the Tribe, the Chief Operating Officer of the Tribe, the Chief Financial Officer of
the Tribe and the Attorney General of the Tribe, (b) as to the Borrower, the Chairman, Vice-Chairman and Treasurer of the Management Board, the Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer and the Vice
President of Finance, and (c) as to each other Loan Party, the chief executive officer, president and chief financial officer of such Loan Party (or such Loan Party’s manager, sole member or general partner as applicable). 
 “Senior Subordinated Notes” means (a) the senior subordinated notes issued pursuant to the Existing Senior Subordinated Indentures,
including any exchange notes issued thereunder, and (b) any additional senior subordinated notes issued in compliance with the terms of Section 9.03(d) and the other applicable provisions of this Agreement. 
 “SNDA” means a subordination, non-disturbance and attornment agreement, substantially in the form of Exhibit I hereto, or such
other form of subordination, non-disturbance and attornment agreement as the Administrative Agent may approve in its reasonable discretion, in each case executed by the Administrative Agent and a tenant of the Borrower or any of its Restricted
Subsidiaries at Mohegan Sun, Pocono Downs or other venues comprising Authority Property operated by the Borrower or any of its Restricted Subsidiaries. 
 “SPC” has the meaning specified in Section 12.06(h). 
 “Subordinated
Obligations” means, collectively (a) the Senior Subordinated Notes, and (b) any Indebtedness issued pursuant to Section 9.03(d). 
 “Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the shares of securities or other interests having
ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or the management of which is
otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or
Subsidiaries of the Borrower. 
 “Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit
derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or
forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot
contracts, or any other similar transactions or any 

  

 -33- 

 
combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject
to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and
Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations
or liabilities under any Master Agreement. 
 “Swap Termination Value” means, in respect of any one or more Swap Contracts,
after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance
therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other
readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender). 
 “Synthetic Lease Obligation” means the monetary obligation of a Person under any synthetic lease, tax retention lease or other similar arrangement which, though treated as a lease under GAAP is treated as a loan for
purposes of the Code. The Borrower’s good faith determination of whether a particular arrangement constitutes a Synthetic Lease Obligation shall be determinative in the absence of manifest error. 
 “Tax Certificate” means a tax certificate in a form reasonably acceptable to the Administrative Agent and the Tax Exempt Lenders
demonstrating the tax exempt nature of any Tax Exempt Loans and the propriety of the assets financed with such Tax Exempt Loans for tax exempt financing in accordance with the Tax Regulations. 
 “Tax Exempt Bonds” means the Indebtedness of the Tribe under the Indenture of Trust dated as of August 1, 2001 between the Tribe
and First Union National Bank, as Trustee, a true, correct and complete copy of which has been provided to the Administrative Agent, either as originally executed, or as amended, supplemented, modified or refinanced. 
 “Tax Exempt Lender” means each Lender holding outstanding Tax Exempt Loans from time to time. 
 “Tax Exempt Loan” means each Loan made pursuant to this Agreement and a Tax Exempt Note by means of any increase to the credit
facilities hereunder made pursuant to Section 2.14. 
 “Tax Exempt Note” means each promissory note made by Borrower to
a Lender evidencing the Tax Exempt Loans made by that Lender. 
 “Tax Opinion” an opinion of counsel to the Borrower,
addressed to the Administrative Agent and the Tax Exempt Lenders, setting forth customary opinions regarding the tax exempt nature of any Tax Exempt Loans. 
  

 -34- 

 “Tax Regulations” means the United States Treasury Regulations promulgated pursuant to
sections 103 and 141 through 150 of the Code. 
 “Taxes” means all present or future taxes, levies, imposts, duties,
deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 
 “TCA” means Trading Cove Associates, a Connecticut general partnership, its successors and assigns. 
 “Term Loan Note” means any of the promissory notes made by the Borrower in favor of a Lender evidencing Term Loans made by such Lender,
substantially in the form of Exhibit J. 
 “Term Loans” means any term loans resulting from conversion of Revolving
Loans pursuant to Section 2.02, and any incremental term loans made pursuant to Section 2.15. 
 “Title Company”
means Chicago Title Insurance Company. 
 “to the knowledge of” means, when modifying a representation, warranty or other
statement of any Person, that the fact or situation described therein is known by the Person (or, in the case of a Person other than a natural Person, known by a Senior Officer of that Person) making the representation, warranty or other statement,
or with the exercise of reasonable due diligence under the circumstances (in accordance with the standard of what a reasonable Person in similar circumstances would have done) should have been known by the Person (or, in the case of a Person other
than a natural Person, should have been known by a Senior Officer of that Person). In the case of the Tribe, knowledge of any material information by any Senior Officer of the Borrower or of the Tribe shall be attributed to the Tribe. 
 “Total Debt” means, as of each date of determination, all Recourse Obligations other than (a) the Borrower’s liability for
payments under the Relinquishment Agreement and (b) the Borrower’s and its Restricted Subsidiaries’ obligations under any guarantees and other similar support arrangements which benefit holders of Indebtedness of collectively not more
than $100,000,000, except to the extent that such obligations are required to be quantified on the Borrower’s or any of its Restricted Subsidiaries balances sheets on such date in accordance with GAAP. 
 “Total Leverage Ratio” means, as of each date of determination, the ratio of (a) Total Debt as of that date, to (b) Annualized
EBITDA determined as of that date. 
 “Total Revolving Outstandings” means the aggregate Outstanding Amount of all Revolving
Loans and all L/C Obligations. 
 “Town Agreement” means the Agreement dated as of June 16, 1994 between the Tribe and
the Town of Montville, Connecticut, as amended as of the Closing Date. 
 “Tribal Council” means the Tribal Council of the
Tribe elected in accordance with the Constitution. 
  

 -35- 

 “Tribe” means The Mohegan Tribe of Indians of Connecticut, a federally recognized Indian
Tribe. 
 “Type” means, with respect to each Loan, its character as a Base Rate Loan or a Eurodollar Rate Loan. 

“UCC Ordinance” means Chapter 7, Article III of the Mohegan Tribe Code, also known as Ordinance Number 98-7 of the Tribe.

 “United States” and “U.S.” mean the United States of America. 
 “Unreimbursed Amount” has the meaning specified in Section 2.04(c)(i). 
 “Unrestricted Subsidiary” means (a) any Subsidiary of the Borrower that at the time of determination shall be designated an
Unrestricted Subsidiary by the Management Board, and (b) any Subsidiary of an Unrestricted Subsidiary. As of the Closing Date, there are no Unrestricted Subsidiaries. The Management Board may designate any Restricted Subsidiary (including any
newly acquired or newly formed Subsidiary of the Borrower) to be an Unrestricted Subsidiary, provided that (i) such Restricted Subsidiary does not own any Equity Interests in, or own or hold any Lien on any property of, the Borrower or any
other Restricted Subsidiary, (ii) either (A) the Subsidiary to be so designated has total assets of $1,000 or less or (B) if such Subsidiary has assets greater than $1000, the disposition of such assets would be a Permitted
Disposition, (iii) in no event shall any licenses issued under applicable Gaming Laws be transferred to an Unrestricted Subsidiary, and (iv) no Default or Event of Default shall have occurred and then be continuing or would occur as a
consequence thereof. 
 “Unused Commitment” means, as of each date of determination, the difference between (a) the
aggregate Revolving Commitment on that date (taking into account any increases therein made pursuant to Section 2.14) and (b) the sum of (i) the outstanding principal amount of the Loans made under the Revolving Commitment,
(ii) the amount available for drawing under outstanding Letters of Credit, and (iii) the aggregate amount of all unreimbursed draws with respect to Letters of Credit. 
 “WNBA Agreements” means, collectively, the WNBA Membership Agreement between WNBA, LLC, a Delaware limited liability company and the
WNBA Subsidiary, the WNBA Note and the related guaranty executed by the Borrower in favor of WNBA, LLC, in each case as in effect on January 28, 2003, and with any amendments thereto which do not increase the Investment of the Tribe or the
Borrower in respect of the WNBA Subsidiary to an amount in excess of that permitted by Section 9.03(h). 
 “WNBA Note”
means a promissory note dated as of January 28, 2003, in the principal amount of $8,000,000 made by the WNBA Subsidiary in favor of WNBA, LLC as a portion of the consideration payable by the WNBA Subsidiary for its acquisition of a WNBA
franchise. 
 “WNBA Subsidiary” means Mohegan Basketball Club, LLC, a limited liability company formed under the Laws of the
Tribe and a wholly-owned Subsidiary of the Borrower, which is the owner and operator of the Women’s National Basketball Association franchise known as the Connecticut Sun. 
  

 -36- 

 “Yield” in respect of (a) any Appropriate Investment, means the yield of any
investment as described in section 1.148-5 of the Tax Regulations; and (b) any issue of the Tax Exempt Notes, has the meaning set forth in section 1.148-4 of the Tax Regulations. 
 1.02 Other Interpretive Provisions. With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such
other Loan Document: 
 (a) The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.
Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by
the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise, (i) any definition of or reference
to any agreement, instrument or other document (including any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any
restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words
“herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision
thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Loan Document in which such references appear,
(v) any reference to any law shall include all statutory and regulatory provisions consolidating, amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or
regulation as amended, modified or supplemented from time to time, and (vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and
intangible assets and properties, including cash, securities, accounts and contract rights. 
 (b) In the computation of periods of time from
a specified date to a later specified date, the word “from” means “from and including;” the words “to” and “until” each mean “to but excluding;” and the word
“through” means “to and including.” 
 (c) Section headings herein and in the other Loan Documents are
included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document. 
 1.03
Accounting Terms. 
 (a) Generally. All accounting terms not specifically or completely defined herein shall be construed in
conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP, as in effect from time to time, applied in a manner
consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein. 
  

 -37- 

 (b) Changes in GAAP. If at any time any change in GAAP would affect the computation of any
financial ratio or requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders, the Tribe and the Borrower shall negotiate in good faith and agree to amend this
Agreement in such respects as are necessary to conform those covenants as criteria for evaluating the Borrower’s financial condition to substantially the same criteria as were effective prior to such change in GAAP and the Borrower shall be
deemed to be in compliance with the financial covenants contained in Sections 9.13 and 9.17 during the 60 day period following any such change in GAAP if and to the extent that the Borrower would have been in compliance therewith under GAAP as
in effect immediately prior to such change; provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the
Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after
giving effect to such change in GAAP. 
 (c) Consolidation of Variable Interest Entities. All references herein to consolidated
financial statements of the Borrower and its Subsidiaries or to the determination of any amount for the Borrower and its Subsidiaries on a consolidated basis or any similar reference shall, in each case, be deemed to include each variable interest
entity that the Borrower is required to consolidate pursuant to FASB Interpretation No. 46 – Consolidation of Variable Interest Entities: an interpretation of ARB No. 51 (January 2003) as if such variable interest entity were a
Subsidiary as defined herein. 
 1.04 Rounding. Any financial ratios required to be maintained by the Borrower pursuant to this
Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest
number (with a rounding-up if there is no nearest number). 
 1.05 Times of Day. Unless otherwise specified, all references herein to
times of day shall be references to Central time (daylight or standard, as applicable). 
 1.06 Letter of Credit Amount. Unless
otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its
terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after
giving effect to all such increases, whether or not such maximum stated amount is in effect at such time. 
  

 -38- 

 ARTICLE II 
 THE COMMITMENTS AND CREDIT EXTENSIONS 
 2.01 Revolving Loans. Subject to the terms and
conditions set forth herein, each Lender severally agrees to make loans (each such loan, a “Revolving Loan”) to the Borrower from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed
at any time outstanding the amount of such Lender’s Revolving Commitment; provided, however, that after giving effect to any Revolving Borrowing, (a) the Total Revolving Outstandings shall not exceed the Aggregate Revolving
Commitments, and (b) the aggregate Outstanding Amount of the Revolving Loans of any Lender, plus such Lender’s Applicable Percentage of the Outstanding Amount of all L/C Obligations shall not exceed such Lender’s Revolving
Commitment. Within the limits of each Lender’s Revolving Commitment, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.01, prepay under Section 2.05, and reborrow under this
Section 2.01. Revolving Loans may be Base Rate Loans or Eurodollar Rate Loans, as further provided herein. 
 2.02 Term Loan
Conversion. On the Conversion Date, a $300,000,000 portion of the outstanding Revolving Loans shall immediately be converted to Term Loans without further action of the parties hereto. Revolving Loans held by the Lenders shall be converted
ratably in accordance with their respective Applicable Percentages. Concurrently with such conversion, the Revolving Commitments of each of the Lenders shall be ratably reduced in an aggregate principal amount equal to $300,000,000. No portion of
the Term Loans which is repaid may be reborrowed, but the outstanding principal balance of the Term Loans may be converted or continued in the manner set forth in Section 2.03. The Term Loans shall bear interest in the manner set forth in
Section 2.08, and shall be payable as set forth in Section 2.07. Effective as of the Conversion Date, all Revolving Notes will be replaced with new Revolving Notes which appropriately reflect the revised Revolving Commitments, and each
Lender desiring a Term Loan Note will be issued a Term Loan Note in the appropriate principal amount. 
 2.03 Borrowings, Conversions and
Continuations of Loans. 
 (a) Each Borrowing, each conversion of Loans from one Type to the other, and each continuation of Eurodollar
Rate Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent, which may be given by telephone. Each such notice must be received by the Administrative Agent not later than 12:00 noon (i) three Business Days
prior to the requested date of any Borrowing of, conversion to or continuation of Eurodollar Rate Loans or of any conversion of Eurodollar Rate Loans to Base Rate Loans, and (ii) on the requested date of any Borrowing of Base Rate Loans. Each
telephonic notice by the Borrower pursuant to this Section 2.03(a) must be confirmed promptly by delivery to the Administrative Agent of a written Loan Notice, appropriately completed and signed by a Senior Officer of the Borrower. Each
Borrowing of, conversion to or continuation of Eurodollar Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $1,000,000 in excess thereof or, if less, the entire amount thereof. Except as provided in Section 2.04(c),
each Borrowing of or conversion to Base Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $1,000,000 in excess thereof or, if less, the entire amount thereof. Each Loan Notice (whether telephonic or 

  

 -39- 

 
written) shall specify (i) whether the Borrower is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of
Eurodollar Rate Loans, (ii) the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (iii) the principal amount of Loans to be borrowed, converted or continued, (iv) the Type
of Loans to be borrowed or to which existing Loans are to be converted, and (v) if applicable, the duration of the Interest Period with respect thereto. If the Borrower fails to specify a Type of Loan in a Loan Notice or if the Borrower fails
to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest
Period then in effect with respect to the applicable Eurodollar Rate Loans. If the Borrower requests a Borrowing of, conversion to, or continuation of Eurodollar Rate Loans in any such Loan Notice, but fails to specify an Interest Period, it will be
deemed to have specified an Interest Period of one month. 
 (b) Following receipt of a Loan Notice, the Administrative Agent shall promptly
notify each Lender of the amount of its Applicable Percentage of the applicable Loans, and if no timely notice of a conversion or continuation is provided by the Borrower, the Administrative Agent shall notify each Lender of the details of any
automatic conversion to Base Rate Loans described in the preceding subsection. In the case of a Borrowing, each Lender shall make the amount of its Loan available to the Administrative Agent in immediately available funds at the Administrative
Agent’s Office not later than 1:00 p.m. on the Business Day specified in the applicable Loan Notice. Upon satisfaction of the applicable conditions set forth in Section 4.02 (and, if such Borrowing is the initial Credit Extension,
Section 4.01), the Administrative Agent shall make all funds so received available to the Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the Borrower on the books of Bank of America
with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower. 
 (c) Except as otherwise provided herein, a Eurodollar Rate Loan may be continued or converted only on the last day of an Interest Period for such
Eurodollar Rate Loan. During the existence of a Default, no Loans may be requested as, converted to or continued as Eurodollar Rate Loans without the consent of the Required Lenders. 
 (d) The Administrative Agent shall promptly notify the Borrower and the Lenders of the interest rate applicable to any Interest Period for Eurodollar
Rate Loans upon determination of such interest rate. At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrower and the Lenders of any change in Bank of America’s prime rate used in determining the Base
Rate promptly following the public announcement of such change. 
 (e) After giving effect to all Borrowings, all conversions of Loans from
one Type to the other, and all continuations of Loans as the same Type, there shall not be more than twelve Interest Periods in effect. 
  

 -40- 

 2.04 Letters of Credit. 
 (a) The Letter of Credit Commitment. 
 (i) Subject to the terms and conditions set forth herein, (A) the L/C Issuer agrees, in reliance upon the agreements of the Lenders set forth in this Section 2.04, (1) from time to time on any Business Day during the period
from the Closing Date until the Letter of Credit Expiration Date, to issue Letters of Credit for the account of the Borrower or its Subsidiaries, and to amend or extend Letters of Credit previously issued by it, in accordance with subsection
(b) below, and (2) to honor drawings under the Letters of Credit; and (B) the Lenders severally agree to participate in Letters of Credit issued for the account of the Borrower or its Subsidiaries and any drawings thereunder;
provided that after giving effect to any L/C Credit Extension with respect to any Letter of Credit, (x) the Total Revolving Outstandings shall not exceed the Aggregate Revolving Commitments, (y) the aggregate Outstanding Amount of
the Revolving Loans of any Lender, plus such Lender’s Applicable Percentage of the Outstanding Amount of all L/C Obligations shall not exceed such Lender’s Revolving Commitment, and (z) the Outstanding Amount of the L/C
Obligations shall not exceed the Letter of Credit Sublimit. Each request by the Borrower for the issuance or amendment of a Letter of Credit shall be deemed to be a representation by the Borrower that the L/C Credit Extension so requested complies
with the conditions set forth in the proviso to the preceding sentence. Within the foregoing limits, and subject to the terms and conditions hereof, the Borrower’s ability to obtain Letters of Credit shall be fully revolving, and accordingly
the Borrower may, during the foregoing period, obtain Letters of Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed. All Existing Letters of Credit shall be deemed to have been issued pursuant hereto,
and from and after the Closing Date shall be subject to and governed by the terms and conditions hereof. 
 (ii) The L/C
Issuer shall not issue any Letter of Credit, if: 
 (A) the expiry date of such requested Letter of Credit would occur more
than twelve months after the date of issuance, unless the Required Lenders have approved such expiry date (except that any Letters of Credit providing for automatic renewal shall not be deemed to violate this limitation); or 
 (B) the expiry date of such requested Letter of Credit would occur after the Letter of Credit Expiration Date, unless all the Lenders have
approved such expiry date. 
 (iii) The L/C Issuer shall not be under any obligation to issue any Letter of Credit if:

 (A) any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or
restrain the L/C Issuer from issuing such Letter of Credit, or any Law applicable to the L/C Issuer or any request or directive (whether or not having the force of law) from any 

  

 -41- 

 
Governmental Authority with jurisdiction over the L/C Issuer shall prohibit, or request that the L/C Issuer refrain from, the issuance of letters of credit
generally or such Letter of Credit in particular or shall impose upon the L/C Issuer with respect to such Letter of Credit any restriction, reserve or capital requirement (for which the L/C Issuer is not otherwise compensated hereunder) not in
effect on the Closing Date, or shall impose upon the L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date and which the L/C Issuer in good faith deems material to it; 
 (B) the issuance of such Letter of Credit would violate one or more policies of the L/C Issuer applicable to letters of credit generally;

 (C) except as otherwise agreed by the Administrative Agent and the L/C Issuer, such Letter of Credit is in an initial
stated amount less than $100,000; 
 (D) such Letter of Credit is to be denominated in a currency other than Dollars;

 (E) such Letter of Credit contains any provisions for automatic reinstatement of the stated amount after any drawing
thereunder; or 
 (F) a default of any Lender’s obligations to fund under Section 2.04(c) exists or any Lender is at
such time a Defaulting Lender hereunder, unless the L/C Issuer has entered into satisfactory arrangements with the Borrower or such Lender to eliminate the L/C Issuer’s risk with respect to such Lender. 
 (iv) The L/C Issuer shall not amend any Letter of Credit if the L/C Issuer would not be permitted at such time to issue such Letter of
Credit in its amended form under the terms hereof. 
 (v) The L/C Issuer shall be under no obligation to amend any Letter of
Credit if (A) the L/C Issuer would have no obligation at such time to issue such Letter of Credit in its amended form under the terms hereof, or (B) the beneficiary of such Letter of Credit does not accept the proposed amendment to such
Letter of Credit. 
 (vi) The L/C Issuer shall act on behalf of the Lenders with respect to any Letters of Credit issued by it
and the documents associated therewith, and the L/C Issuer shall have all of the benefits and immunities (A) provided to the Administrative Agent in Article XI with respect to any acts taken or omissions suffered by the L/C Issuer in
connection with Letters of Credit issued by it or proposed to be issued by it and Issuer Documents pertaining to such Letters of Credit as fully as if the term “Administrative Agent” as used in Article XI included the L/C Issuer with
respect to such acts or omissions, and (B) as additionally provided herein with respect to the L/C Issuer. 
  

 -42- 

 (b) Procedures for Issuance and Amendment of Letters of Credit. 
 (i) Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the Borrower delivered to the L/C Issuer
(with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Senior Officer of the Borrower. Such Letter of Credit Application must be received by the L/C Issuer and the
Administrative Agent not later than 12:00 noon at least two Business Days (or such later date and time as the Administrative Agent and the L/C Issuer may agree in a particular instance in their sole discretion) prior to the proposed issuance date or
date of amendment, as the case may be. In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L/C Issuer: (A) the proposed issuance date of
the requested Letter of Credit (which shall be a Business Day); (B) the amount thereof; (C) the expiry date thereof; (D) the name and address of the beneficiary thereof; (E) the documents to be presented by such beneficiary in
case of any drawing thereunder; (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder; and (G) such other matters as the L/C Issuer reasonably may require. In the case of a request for
an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L/C Issuer (W) the Letter of Credit to be amended; (X) the proposed date of amendment thereof (which
shall be a Business Day); (Y) the nature of the proposed amendment; and (Z) such other matters as the L/C Issuer reasonably may require. Additionally, the Borrower shall furnish to the L/C Issuer and the Administrative Agent such
other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as the L/C Issuer or the Administrative Agent may require. 
 (ii) Promptly after receipt of any Letter of Credit Application, the L/C Issuer will confirm with the Administrative Agent (by telephone
or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the Borrower and, if not, the L/C Issuer will provide the Administrative Agent with a copy thereof. Unless the L/C Issuer has received written
notice from any Lender, the Administrative Agent or any Loan Party, at least one Business Day prior to the requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in
Article IV shall not then be satisfied, then, subject to the terms and conditions hereof, the L/C Issuer shall, on the requested date, issue a Letter of Credit for the account of the Borrower (or the applicable Subsidiary) or enter into the
applicable amendment, as the case may be, in each case in accordance with the L/C Issuer’s usual and customary business practices. Immediately upon the issuance of each Letter of Credit, each Lender shall be deemed to, and hereby irrevocably
and unconditionally agrees to, purchase from the L/C Issuer a risk participation in such Letter of Credit in an amount equal to the product of such Lender’s Applicable Percentage times the amount of such Letter of Credit. 
 (iii) Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto
or to the beneficiary thereof, the L/C Issuer will also deliver to the Borrower and the 

  

 -43- 

 
Administrative Agent a true and complete copy of such Letter of Credit or amendment. The Issuing Bank shall promptly provide to each Lender which requests
the same copies of all Letters of Credit and amendments thereto issued and outstanding from time to time. 
 (c) Drawings and
Reimbursements; Funding of Participations. 
 (i) Upon receipt from the beneficiary of any Letter of Credit of any notice
of a drawing under such Letter of Credit, the L/C Issuer shall notify the Borrower and the Administrative Agent thereof. If the L/C Issuer provides notice of a drawing to the Borrower no later than the Business Day prior to the Honor Date, then not
later than 10:00 a.m. on the date of any payment by the L/C Issuer under a Letter of Credit (each such date, an “Honor Date”), the Borrower shall reimburse the L/C Issuer through the Administrative Agent in an amount equal to the
amount of such drawing. If the L/C Issuer provides such notice on or after the Honor Date, then the Borrower shall so reimburse the L/C Issuer on the Business Day following the date of such notice. If the Borrower fails to so reimburse the L/C
Issuer by such time, the Administrative Agent shall promptly notify each Lender of the Honor Date, the amount of the unreimbursed drawing (the “Unreimbursed Amount”), and the amount of such Lender’s Applicable Percentage
thereof. In such event, the Borrower shall be deemed to have requested a Borrowing of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in
Section 2.03 for the principal amount of Base Rate Loans, but subject to the amount of the unutilized portion of the Aggregate Revolving Commitments and the conditions set forth in Section 4.02 (other than the delivery of a Loan Notice).
Any notice given by the L/C Issuer or the Administrative Agent pursuant to this Section 2.04(c)(i) may be given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect
the conclusiveness or binding effect of such notice. 
 (ii) Each Lender shall upon any notice pursuant to
Section 2.04(c)(i) make funds available to the Administrative Agent for the account of the L/C Issuer at the Administrative Agent’s Office in an amount equal to its Applicable Percentage of the Unreimbursed Amount not later than 1:00 p.m.
on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.04(c)(iii), each Lender that so makes funds available shall be deemed to have made a Base Rate Revolving Loan to the
Borrower in such amount. The Administrative Agent shall remit the funds so received to the L/C Issuer. 
 (iii) With respect
to any Unreimbursed Amount that is not fully refinanced by a Borrowing of Base Rate Loans because the conditions set forth in Section 4.02 cannot be satisfied or for any other reason, the Borrower shall be deemed to have incurred from the L/C
Issuer an L/C Borrowing in the amount of the Unreimbursed Amount that is not so refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate. In such event, each
Lender’s payment to the Administrative Agent for the account of the L/C Issuer pursuant to Section 2.04(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such
Lender in satisfaction of its participation obligation under this Section 2.04. 
  

 -44- 

 (iv) Until each Lender funds its Revolving Loan or L/C Advance pursuant to this
Section 2.04(c) to reimburse the L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lender’s Applicable Percentage of such amount shall be solely for the account of the L/C Issuer. 
 (v) Each Lender’s obligation to make Revolving Loans or L/C Advances to reimburse the L/C Issuer for amounts drawn under Letters of
Credit, as contemplated by this Section 2.04(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Lender may have
against the L/C Issuer, the Borrower or any other Person for any reason whatsoever; (B) the occurrence or continuance of a Default, or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing;
provided, however, that each Lender’s obligation to make Revolving Loans pursuant to this Section 2.04(c) is subject to the conditions set forth in Section 4.02 (other than delivery by the Borrower of a Loan Notice). No
such making of an L/C Advance shall relieve or otherwise impair the obligation of the Borrower to reimburse the L/C Issuer for the amount of any payment made by the L/C Issuer under any Letter of Credit, together with interest as provided herein.

 (vi) If any Lender fails to make available to the Administrative Agent for the account of the L/C Issuer any amount
required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.04(c) by the time specified in Section 2.04(c)(ii), the L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative
Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the L/C Issuer at a rate per annum equal to the greater of the Federal Funds
Rate and a rate determined by the L/C Issuer in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by the L/C Issuer in connection with the foregoing. If such
Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s Revolving Loan included in the relevant Borrowing or L/C Advance in respect of the relevant L/C Borrowing, as the case may be. A
certificate of the L/C Issuer submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (vi) shall be conclusive absent manifest error. 
 (d) Repayment of Participations. 
 (i) At any time after the L/C Issuer has made a payment under any Letter of Credit and has received from any Lender such Lender’s L/C Advance in respect of such payment in accordance with Section 2.04(c), if
the Administrative Agent receives for the account of the L/C Issuer any payment in respect of the related Unreimbursed Amount or interest thereon (whether directly from the Borrower or otherwise, including proceeds of Cash Collateral applied thereto
by the Administrative Agent), the Administrative Agent will promptly distribute to such Lender its Applicable Percentage thereof in the same funds as those received by the Administrative Agent. 
  

 -45- 

 (ii) If any payment received by the Administrative Agent for the account of the L/C
Issuer pursuant to Section 2.04(c)(i) is required to be returned under any of the circumstances described in Section 12.05 (including pursuant to any settlement entered into by the L/C Issuer in its discretion), each Lender shall pay to
the Administrative Agent for the account of the L/C Issuer its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Lender, at a rate per
annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement. 
 (e) Obligations Absolute. The obligation of the Borrower to reimburse the L/C Issuer for each drawing under each Letter of Credit and to
repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following: 
 (i) any lack of validity or enforceability of such Letter of Credit, this Agreement, or any other Loan Document; 
 (ii) the existence of any claim, counterclaim, setoff, defense or other right that the Borrower or any Subsidiary may have at any time
against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), the L/C Issuer or any other Person, whether in connection with this Agreement, the transactions
contemplated hereby or by such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction; 
 (iii) any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any
loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit; 
 (iv) any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit; or any payment made by the L/C Issuer under such Letter of
Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit,
including any arising in connection with any proceeding under any Debtor Relief Law; or 
 (v) any other circumstance or
happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, the Borrower or any Subsidiary. 
  

 -46- 

 The Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is
delivered to it and, in the event of any claim of noncompliance with the Borrower’s instructions or other irregularity, the Borrower will promptly notify the L/C Issuer. The Borrower shall be conclusively deemed to have waived any such claim
against the L/C Issuer and its correspondents unless such notice is given as aforesaid. 
 (f) Role of L/C Issuer. Each Lender
and the Borrower agree that, in paying any drawing under a Letter of Credit, the L/C Issuer shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit)
or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor
any correspondent, participant or assignee of the L/C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Required Lenders, as applicable;
(ii) any action taken or omitted in the absence of gross negligence or willful misconduct; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer
Document. The Borrower hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to its use of any Letter of Credit; provided, however, that this assumption is not intended to, and shall not,
preclude the Borrower’s pursuing such rights and remedies as it may have against the beneficiary or transferee at law or under any other agreement. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor
any correspondent, participant or assignee of the L/C Issuer shall be liable or responsible for any of the matters described in clauses (i) through (v) of Section 2.04(e); provided, however, that anything in such clauses
to the contrary notwithstanding, the Borrower may have a claim against the L/C Issuer, and the L/C Issuer may be liable to the Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered
by the Borrower which the Borrower proves were caused by the L/C Issuer’s willful misconduct or gross negligence or the L/C Issuer’s willful failure to pay under any Letter of Credit after the presentation to it by the beneficiary of a
sight draft and certificate(s) strictly complying with the terms and conditions of a Letter of Credit. In furtherance and not in limitation of the foregoing, the L/C Issuer may accept documents that appear on their face to be in order, without
responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuer shall not be responsible for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or
assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason. 
 (g) Cash Collateral. Upon the request of the Administrative Agent, (i) if the L/C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in an L/C
Borrowing, or (ii) if, as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, the Borrower shall, in each case, immediately Cash Collateralize the full amount of such L/C Borrowing or such L/C
Obligation. Sections 2.07 and 10.02(c) set forth certain additional requirements to deliver Cash Collateral hereunder. For purposes of this Section 2.04, Section 2.07 and Section 10.02(c), “Cash Collateralize”
means to pledge and deposit with or deliver to the Administrative Agent, for the benefit of the L/C Issuer and the Lenders, as collateral for the applicable L/C Obligations, cash or deposit account balances pursuant to documentation in form and
substance reasonably 

  

 -47- 

 
satisfactory to the Administrative Agent and the L/C Issuer (which documents are hereby consented to by the Lenders). Derivatives of such term have
corresponding meanings. The Borrower hereby grants to the Administrative Agent, for the benefit of the L/C Issuer and the Lenders, a security interest in all such cash, deposit accounts and all balances therein and all proceeds of the foregoing.
Cash Collateral shall be maintained in blocked, non-interest bearing deposit accounts at Bank of America. 
 (h) Applicability of
ISP. Unless otherwise expressly agreed by the L/C Issuer and the Borrower when a Letter of Credit is issued (including any such agreement applicable to an Existing Letter of Credit), the rules of the ISP shall apply to each standby Letter
of Credit. 
 (i) Letter of Credit Fees. The Borrower shall pay to the Administrative Agent for the account of each Lender in
accordance with its Applicable Percentage a Letter of Credit fee (the “Letter of Credit Fee”) for each Letter of Credit equal to the Applicable Rate times the daily amount available to be drawn under such Letter of Credit.
For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. Letter of Credit Fees shall be (i) due and payable on the
first Business Day after the end of each March, June, September and December, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand and
(ii) computed on a quarterly basis in arrears. If there is any change in the Applicable Rate during any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate
separately for each period during such quarter that such Applicable Rate was in effect. Notwithstanding anything to the contrary contained herein, upon the request of the Required Lenders, while any Event of Default exists, all Letter of Credit Fees
shall accrue at the Default Rate. 
 (j) Fronting Fee and Documentary and Processing Charges Payable to L/C Issuer. The
Borrower shall pay directly to the L/C Issuer for its own account a fronting fee with respect to each Letter of Credit, at the rate per annum specified in the Fee Letter, computed on the daily amount available to be drawn under such Letter of Credit
on a quarterly basis in arrears. Such fronting fee shall be due and payable on the tenth Business Day after the end of each March, June, September and December in respect of the most recently-ended quarterly period (or portion thereof, in
the case of the first payment), commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand. For purposes of computing the daily amount available to be
drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. In addition, the Borrower shall pay directly to the L/C Issuer for its own account the customary issuance, presentation,
amendment and other processing fees, and other standard costs and charges, of the L/C Issuer relating to letters of credit as from time to time in effect. Such customary fees and standard costs and charges are due and payable on demand and are
nonrefundable. 
 (k) Conflict with Issuer Documents. In the event of any conflict between the terms hereof and the terms of any
Issuer Document, the terms hereof shall control. 
  

 -48- 

 (l) Letters of Credit Issued for Subsidiaries. Notwithstanding that a Letter of Credit issued or
outstanding hereunder is in support of any obligations of, or is for the account of, a Subsidiary, the Borrower shall be obligated to reimburse the L/C Issuer hereunder for any and all drawings under such Letter of Credit. The Borrower hereby
acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Borrower, and that the Borrower’s business derives substantial benefits from the businesses of such Subsidiaries. 
 2.05 Voluntary Prepayments. The Borrower may, upon notice to the Administrative Agent, at any time or from time to time voluntarily prepay
Revolving Loans in whole or in part without premium or penalty; provided that (a) such notice must be received by the Administrative Agent not later than 10:00 a.m. (i) three Business Days prior to any date of prepayment of
Eurodollar Rate Loans and (ii) one Business Day prior to the date of prepayment of Base Rate Revolving Loans; (b) any prepayment of Eurodollar Rate Loans shall be in a principal amount of $1,000,000 or a whole multiple of $1,000,000 in
excess thereof; and (c) any prepayment of Base Rate Revolving Loans shall be in a principal amount of $1,000,000 or a whole multiple of $1,000,000 in excess thereof or, in each case, if less, the entire principal amount thereof then
outstanding. Each such notice shall specify the date and amount of such prepayment and the Type(s) of Revolving Loans to be prepaid and, if Eurodollar Rate Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will
promptly notify each Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable Percentage of such prepayment. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount
specified in such notice shall be due and payable on the date specified therein. Any prepayment of a Eurodollar Rate Loan shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to
Section 3.05. Each such prepayment shall be applied to the Revolving Loans of the Lenders in accordance with their respective Applicable Percentages and shall not be applied to the Term Loans or to the Tax Exempt Loans or reduce the
Amortization Amount. 
 2.06 Termination or Reduction of Revolving Commitments; Voluntary Prepayments of the Term Loans. The Borrower
may, from time to time upon notice to the Administrative Agent, (a) terminate the Aggregate Revolving Commitments, (b) permanently reduce the Aggregate Revolving Commitments, (c) prepay the Term Loans or (d) prepay the Tax Exempt
Loans (provided that any prepayment of the Tax Exempt Loans is made in a manner consistent with applicable Tax Regulations); provided that (i) any such notice shall be received by the Administrative Agent not later than 10:00 a.m. five
Business Days prior to the date of termination, reduction or prepayment, (ii) any such partial reduction or prepayment shall be in an aggregate amount of $1,000,000 or any whole multiple of $1,000,000 in excess thereof or, if less, the entire
amount thereof, and (iii) the Borrower shall not terminate or reduce the Aggregate Revolving Commitments if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Revolving Outstandings would exceed the Aggregate
Revolving Commitments. The Administrative Agent will promptly notify the Lenders of any such notice of termination or reduction of the Aggregate Revolving Commitments and each prepayment of the Term Loans or Tax Exempt Loans. Any reduction of the
Aggregate Revolving Commitments shall be applied to the Revolving Commitment of each Lender according to its Applicable Percentage of the Aggregate Revolving Commitments. Each prepayment of the Term Loans 

  

 -49- 

 
shall be applied to the Term Loans of each Lender according to its Applicable Percentage of the Term Loans. Each prepayment of the Tax Exempt Loans shall be
applied to the Tax Exempt Loans of each Lender according to its Applicable Percentage of the Tax Exempt Loans. All fees accrued until the effective date of any termination of the Aggregate Revolving Commitments shall be paid on the effective date of
such termination. 
 2.07 Mandatory Payments and Prepayments; Repayment of Loans. 
 (a) If for any reason the Total Revolving Outstandings at any time exceed the Aggregate Revolving Commitments then in effect, the Borrower shall
immediately prepay Revolving Loans and/or Cash Collateralize the L/C Obligations in an aggregate amount equal to such excess; provided, however, that the Borrower shall not be required to Cash Collateralize the L/C Obligations pursuant to this
Section 2.07(a) unless after the prepayment in full of the Loans the Total Revolving Outstandings exceed the Aggregate Revolving Commitments then in effect. 
 (b) On the Maturity Date, the Borrower shall repay to the Lenders the aggregate principal amount of Revolving Loans outstanding on such date. 
 (c) The Borrower shall repay the principal amount of the Term Loans on each Amortization Date in an aggregate principal amount equal to the Amortization
Amount, and shall in any event repay the remaining principal balance of the Term Loans on the Maturity Date. 
 (d) Upon the Disposition of
all or substantially all of Pocono Downs (whether by sale of the underlying assets, the sale of Equity Interests in the Pocono Downs Subsidiaries or otherwise) the Borrower shall prepay an aggregate principal amount of Loans equal to 75% of all Net
Cash Proceeds received therefrom immediately upon receipt thereof by the Borrower or any of its Subsidiaries. Each such prepayment of the Loans shall be applied: 
 (i) first, to the repayment of any then outstanding Term Loans (or, if the Conversion Date has not yet occurred, to the repayment of
Revolving Loans) in each case in an aggregate principal amount which shall not exceed the lesser of (A) $200,000,000, or (B) the aggregate amount of the Capital Expenditures made by Borrower and its Restricted Subsidiaries in respect of
Pocono Downs during the period between September 30, 2006 and the date of such Disposition; and 
 (ii) then, to the
repayment of outstanding Revolving Loans. 
 Each prepayment of the Term Loans made pursuant to this clause (d) shall be applied to installments in the
inverse order of their maturity. Each repayment of Revolving Loans pursuant to clause (d)(i) above shall result in a concurrent and automatic reduction in the Aggregate Revolving Commitments, however repayment of Revolving Loans pursuant to clause
(d)(ii) shall not reduce the Revolving Commitments. 
 (e) Upon the Disposition of any Authority Property (other than as set forth in (d),
above), the Borrower shall prepay an aggregate principal amount of Loans, equal to the amount by which 75% of the aggregate amount of Net Cash Proceeds received from all such Dispositions of Authority Property since the Closing Date exceeds
$50,000,000, immediately upon receipt thereof by the Borrower or one of its Subsidiaries. Each such prepayment of the Loans shall first be applied: 
 (i) first, to the repayment of any then outstanding Term Loans until paid in full (or, if the Conversion Date has not yet occurred, to the repayment of Revolving Loans); and 
  

 -50- 

 (ii) then, to the repayment of outstanding Revolving Loans. 
 Each prepayment of the Term Loans made pursuant to this clause (e) shall be applied to installments in the inverse order of their maturity. Each repayment of
Revolving Loans pursuant to clause (e)(i) above shall result in a concurrent and automatic reduction in the Aggregate Revolving Commitments, however repayment of Revolving Loans pursuant to clause (e)(ii) shall not reduce the Revolving Commitments.

 2.08 Interest. 
 (a)
Subject to the provisions of subsection (b) below, (i) each Eurodollar Rate Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Eurodollar Rate for such Interest
Period plus the Applicable Rate; and (ii) each Base Rate Revolving Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the
Applicable Rate. 
 (b) (i) If any amount of principal of any Loan is not paid when due (without regard to any applicable grace periods),
whether at stated maturity, by acceleration or otherwise, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. 
 (ii) If any amount (other than principal of any Loan) payable by the Borrower under any Loan Document is not paid when due (without regard
to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the
Default Rate to the fullest extent permitted by applicable Laws. 
 (iii) Upon the request of the Required Lenders, while any
Event of Default exists, the Borrower shall pay interest on the principal amount of all outstanding Obligations hereunder at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable
Laws. 
 (iv) Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and
payable upon demand. 
 (c) Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at
such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law. 

 

 -51- 

 2.09 Fees. In addition to certain fees described in subsections (i) and (j) of
Section 2.04: 
 (a) Commitment Fee. The Borrower shall pay to the Administrative Agent for the account of each Lender in
accordance with its Applicable Percentage, a commitment fee equal to the Applicable Rate times the actual daily amount by which the Aggregate Revolving Commitments exceed the sum of (i) the Outstanding Amount of Revolving Loans and
(ii) the Outstanding Amount of L/C Obligations. The commitment fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in Article IV is not met, and shall be due and
payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period. The commitment fee shall be
calculated quarterly in arrears, and if there is any change in the Applicable Rate during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such
Applicable Rate was in effect. 
 (b) Other Fees.  
 (i) The Borrower shall pay to the Joint Lead Arrangers and the Administrative Agent for their own respective accounts fees in the amounts
and at the times specified in the letter agreements with the Joint Lead Arrangers. 
 (ii) On the Closing Date, the Borrower
shall pay to the Lenders upfront fees in amounts agreed upon by the Borrower in the Fee Letter. The Administrative Agent has advised each Lender of the amount of the upfront fees payable to that Lender. 
 (iii) The fees described in this clause (b) shall be fully earned when paid and shall not be refundable for any reason whatsoever.

 2.10 Computation of Interest and Fees. All computations of interest for Base Rate Loans shall be made on the basis of a year of 365
or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if
computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that
any Loan that is repaid on the same day on which it is made shall, subject to Section 2.13(a), bear interest for one day. Each determination by the Administrative Agent of an interest rate or fee hereunder shall be presumed correct. 

2.11 Evidence of Debt. (a) The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such
Lender and by the Administrative Agent in the ordinary course of business. The accounts or records maintained by the Administrative Agent and each Lender of the amount of the Credit Extensions made by the Lenders to the Borrower and the interest and
payments thereon shall be presumed correct. Any 

  

 -52- 

 
failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing
with respect to the Obligations. In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the
Administrative Agent shall be presumed correct. Upon the request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) Notes, which shall evidence such
Lender’s Loans in addition to such accounts or records. Each Lender may attach schedules to its Notes and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto. 
 (b) In addition to the accounts and records referred to in subsection (a), each Lender and the Administrative Agent shall maintain in accordance with its
usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit. In the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and
records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall be presumed correct. 
 2.12
Payments Generally; Administrative Agent’s Clawback. 
 (a) General. All payments to be made by the Borrower shall be made
without condition or deduction for any counterclaim, defense, recoupment or setoff. Except as otherwise expressly provided herein, all payments by the Borrower hereunder shall be made to the Administrative Agent, for the account of the respective
Lenders to which such payment is owed, at the Administrative Agent’s Office in Dollars and in immediately available funds not later than 2:00 p.m. on the date specified herein. The Administrative Agent will promptly distribute to each Lender
its Applicable Percentage (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office. All payments received by the Administrative Agent after 2:00 p.m. shall be
deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue. If any payment to be made by the Borrower shall come due on a day other than a Business Day, payment shall be made on the next following
Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be. 
 (b) (i) Funding by
Lenders; Presumption by Administrative Agent. Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing of Eurodollar Rate Loans (or, in the case of any Borrowing of Base Rate Loans,
prior to 12:00 noon on the date of such Borrowing) that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on
such date in accordance with Section 2.03 (or, in the case of a Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.03) and may, in reliance upon such
assumption, make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally
agree to pay to the Administrative Agent forthwith on demand such corresponding amount in immediately available funds with interest thereon, for each day from and including the date such amount is made 

  

 -53- 

 
available to the Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender,
the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by the
Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Borrower, the interest rate selected by the Borrower in the applicable Loan Notice. If the Borrower and such Lender shall pay such
interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. If such Lender pays its share of the
applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s Revolving Loan included in such Borrowing. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have
against a Lender that shall have failed to make such payment to the Administrative Agent. 
 (ii) Payments by the Borrower;
Presumptions by Administrative Agent. Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L/C Issuer
hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the L/C
Issuer, as the case may be, the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders or the L/C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand
the amount so distributed to such Lender or the L/C Issuer, in immediately available funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative
Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this subsection (b) shall be conclusive, absent manifest error. 
 (c) Failure to Satisfy Conditions Precedent. If any Lender makes available to the Administrative Agent funds for any Loan to be made by such
Lender as provided in the foregoing provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in Article IV are not
satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest. 
 (d) Obligations of Lenders Several. The obligations of the Lenders hereunder to make Revolving Loans, to fund participations in Letters of Credit
and to make payments pursuant to Section 12.04(c) are several and not joint. The failure of any Lender to make any Revolving Loan, to fund any such participation or to make any payment under Section 12.04(c) on any date required hereunder
shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Revolving Loan, to purchase its participation or to make its payment
under Section 12.04(c). 
  

 -54- 

 (e) Funding Source. Nothing herein shall be deemed to obligate any Lender to obtain the funds for
any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner. 
 2.13 Sharing of Payments by Lenders. If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in
respect of any principal of or interest on any of the Loans made by it, or the participations in L/C Obligations held by it resulting in such Lender’s receiving payment of a proportion of the aggregate amount of such Revolving Loans or
participations and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater proportion shall (a) notify the Administrative Agent of such fact, and
(b) purchase (for cash at face value) participations in the Revolving Loans and subparticipations in L/C Obligations of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be
shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Revolving Loans and other amounts owing them, provided that: 
 (i) if any such participations or subparticipations are purchased and all or any portion of the payment giving rise thereto is recovered,
such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and 
 (ii) the provisions of this Section shall not be construed to apply to (x) any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or (y) any payment
obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Revolving Loans or subparticipations in L/C Obligations to any assignee or participant, other than to the Borrower or any Subsidiary thereof (as to
which the provisions of this Section shall apply). 
 The Borrower consents to the foregoing and agrees, to the extent it may
effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of setoff and counterclaim with respect to such participation as fully as if such
Lender were a direct creditor of the Borrower in the amount of such participation. Notwithstanding the foregoing, each Lender agrees that it shall not exercise any right of setoff or counterclaim referred to herein without first obtaining the
consent of the Required Lenders. 
 2.14 Increase in Commitments. 
 (a) Request for Increase. Provided there exists no Default, upon notice to the Administrative Agent (which shall promptly notify the Lenders), the
Borrower may from time to time following the Closing Date, request an increase in the Aggregate Revolving Commitments, may request the making of incremental Term Loans (on identical terms to the existing Term Loans), or may request the making of Tax
Exempt Loans in an aggregate principal amount not to 

  

 -55- 

 
exceed $75,000,000 (or any combination of the foregoing) by an amount (for all such requests) not exceeding $250,000,000; provided that (i) any
such request for an increase in the Aggregate Revolving Commitments or for incremental Term Loans shall be in a minimum amount of $50,000,000, and the Borrower may make a maximum of three such requests, and (ii) any such request for Tax Exempt
Loans shall be in a minimum amount of $10,000,000, and the Borrower may make a maximum of three such requests. 
 (b) Notification by
Administrative Agent; Additional Lenders. The Administrative Agent shall notify the Borrower and each Lender of the Lenders’ responses to each request made hereunder. The Borrower may also nominate additional Eligible Assignees, which are
reasonably acceptable to the Administrative Agent to become Lenders pursuant to a joinder agreement in form and substance reasonably satisfactory to the Administrative Agent and its counsel. 
 (c) Effective Date and Allocations. If the Aggregate Revolving Commitments are increased or additional Term Loans are made in accordance with this
Section, the Administrative Agent and the Borrower shall determine the effective date (the “Increase Effective Date”) and the final allocation of such increase. The Administrative Agent shall promptly notify the Borrower and the
Lenders of the final allocation of such increase and the Increase Effective Date. 
 (d) Conditions to Effectiveness of Increase. As a
condition precedent to such increase: 
 (1) the Borrower shall deliver to the Administrative Agent a certificate of each Loan
Party and the Tribe dated as of the Increase Effective Date (in sufficient copies for each Lender) signed by a Senior Officer of such Loan Party or the Tribe, as applicable (i) certifying and attaching the resolutions adopted by such Loan Party
approving or consenting to such increase, (ii) in the case of the Tribe, certifying that, before and after giving effect to such increase, the representations and warranties contained in Article V are true and correct on and as of the
Increase Effective Date, and (iii) in the case of the Borrower, certifying that, before and after giving effect to such increase, (A) the representations and warranties contained in Article VI and the other Loan Documents are true and
correct on and as of the Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that for purposes of
this Section 2.14, the representations and warranties contained in subsections (a) and (b) of Section 6.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of
Section 8.01, and (B) no Default or Event of Default exists; 
 (2) the Borrower and the Tribe shall deliver to the
Administrative Agent such amendments to this Agreement and the Loan Documents as the Administrative Agent or the Lenders providing the increased Loans may request to reflect such increase, which in the case of any Tax Exempt Loans, shall in any
event include a Tax Certificate and Tax Opinion; 
  

 -56- 

 (3) if the increase consists of additional Revolving Commitments, the Borrower shall
prepay any Revolving Loans outstanding on the Increase Effective Date (and pay any additional amounts required pursuant to Section 3.05) to the extent necessary to keep the outstanding Revolving Loans ratable with any revised Applicable
Percentages arising from any nonratable increase in the Commitments under this Section; 
 (4) if the increase consists of Tax
Exempt Loans, the Tax Exempt Notes governing the same shall (i) provide for a maturity which is not shorter than the Maturity Date, (ii) provide for rates of interest determined by the Administrative Agent to yield the substantial tax
equivalent yield to the related Tax Exempt Lenders as are associated with the other Loans under this Agreement, and (iii) have the benefit of customary representations, warranties, tax indemnities and other provisions commonly associated with
Indian tribal government tax exempt loan facilities. 
 (e) Conflicting Provisions. This Section shall supersede any provisions
in Section 2.13 or 12.01 to the contrary. 
 2.15 Collateral. The Loans (including any Term Loans and Tax Exempt Loans hereafter
made pursuant hereto), together with all other Obligations, shall be secured by the Liens created by the Collateral Documents and shall be entitled to the benefit of each of the Guaranties in respect of the Obligations. Each Secured Swap Contract
shall be secured by the Lien of the Collateral Documents (a) on a pari passu basis to the extent of the associated Swap Termination Value, and (b) to the extent of any excess, on a basis which is in all respects subordinated to all other
Obligations. 
 2.16 Concerning the Tax Exempt Loans. In the event that any Tax Exempt Loans are hereafter made, and any Tax Exempt
Lender notifies the Administrative Agent and Borrower that such Lender has: 
 (a) received notice that the United States Internal Revenue
Service, or any court of the United States, has determined that interest on any Tax Exempt Loan is includable in the gross income of the owner thereof for federal income tax purposes; or 
 (b) received an opinion of an attorney nationally recognized as knowledgeable in the issuance of tax-exempt obligations by states, local governments and
Indian tribes that interest on any Tax Exempt Loan is includable in the gross income of the owner thereof for federal income tax purposes; then: 
 (x) the interest rate borne by such Tax Exempt Loan shall be increased, retroactive to the date as of which such interest is so includable in gross income, to the Base Rate, plus 2.00% per annum; and 

(y) Borrower shall, within thirty days of the receipt of such notice, pay to the Administrative Agent for the account of that Lender an
amount equal to the difference between the interest actually paid on such Tax Exempt Loan and the amount of interest that would have been paid thereon had such Tax Exempt Loan borne interest at the rate described in the foregoing clause
(x) from the date as of which such interest is so includable in gross income. 
  

 -57- 

 The obligation of Borrower to make the payment described in the foregoing clause (y) shall survive for five years
following the date on which the Commitments are terminated and all Tax Exempt Loans are fully paid. 
 The Tax Exempt Loans may not be prepaid in any manner
which would violate the Treasury Regulations, or cause any amount to be due under the foregoing clause (b). 
  

 -58- 

 ARTICLE III 
 TAXES, YIELD PROTECTION AND ILLEGALITY 
 3.01 Taxes. 
 (a) Withholding Gross-Up. Each payment of any amount payable by the Borrower or any other Loan Party under this Agreement or any other Loan
Document shall be made free and clear of, and without reduction by reason of, any Taxes, excluding (i) Taxes imposed on or measured in whole or in part by overall net income, gross income or gross receipts, (ii) franchise Taxes
imposed on any Lender by (A) any jurisdiction (or political subdivision thereof) in which it is organized or maintains its principal office or Lending Office for Eurodollar Rate Loans or (B) any jurisdiction (or political subdivision
thereof) in which it is “doing business”, (iii) any withholding Taxes or other Taxes based on gross income imposed by the United States of America that are not attributable to any change in any Law or the interpretation or
administration of any Law by any Governmental Authority and (iv) any withholding Tax or other Taxes based on gross income imposed by the United States of America for any period with respect to which it has failed to provide the Borrower with
the appropriate form or forms required by Section 3.01(b), to the extent such forms are then available under applicable Laws (all such non-excluded Taxes being hereinafter referred to as “Included Taxes”). To the extent that the
Borrower or any other Loan Party is obligated by applicable Laws to make any deduction or withholding on account of Included Taxes from any amount payable to any Lender under this Agreement, they shall (i) make such deduction or withholding and
pay the same to the relevant Governmental Authority and (ii) pay such additional amount to that Lender as is necessary to result in that Lender’s receiving a net after-Included Tax amount equal to the amount to which that Lender would have
been entitled under this Agreement absent such deduction or withholding. If and when receipt of such payment results in an excess payment or credit to that Lender on account of such Included Taxes, that Lender shall promptly refund such excess to
the Borrower or the relevant Loan Party. 
 (b) Tax Withholding Exemption Certificates. On or before the Closing Date, each Lender
which is organized outside the United States of America shall deliver to the Borrower a properly completed and duly executed Internal Revenue Service Form W-8ECI or Form W-8BEN and any other certificate or statement required by applicable
Laws to establish that payments due to such Lender under the Loan Documents are (a) not subject to withholding under the Code because such payments are effectively connected with the conduct of a trade or business in the United States of
America or (b) totally exempt from United States tax under the provisions of an applicable tax treaty. 
 3.02 Illegality. If,
after the date hereof, the existence or occurrence of a Change in Law shall, in the opinion of any Lender, make it unlawful, impossible or impracticable for such Lender or its Lending Office for Eurodollar Rate Loans to make, maintain or fund its
portion of any Eurodollar Rate Loan, or materially restrict the ability of such Lender to purchase or sell, or to take deposits of, dollars in the Designated Market, or to determine or charge interest rates based upon the Eurodollar Rate, and such
Lender shall so notify the Administrative Agent, then such Lender’s obligation to make Eurodollar Rate Loans shall be suspended for the duration of 
  

 -59- 

 
such illegality, impossibility or impracticability and the Administrative Agent forthwith shall give notice thereof to the other Lenders and the Borrower.
Upon receipt of such notice, the outstanding principal amount of such Lender’s Eurodollar Rate Loans, together with accrued interest thereon, automatically shall be converted to Base Rate Loans on either (1) the last day of the
Interest Period(s) applicable to such Eurodollar Rate Loans if such Lender may lawfully continue to maintain and fund such Eurodollar Rate Loans to such day(s) or (2) immediately if such Lender may not lawfully continue to fund and maintain
such Eurodollar Rate Loans to such day(s), provided that in such event the conversion shall not be subject to payment of compensation under Section 3.05. In the event that any Lender is unable, for the reasons set forth above, to make,
maintain or fund its portion of any Eurodollar Rate Loan, such Lender shall fund such amount as a Base Rate Loan for the same period of time, and such amount shall be treated in all respects as a Base Rate Loan. 
 3.03 Inability to Determine Rates If, with respect to any proposed Eurodollar Rate Loan: 
 (a) the Administrative Agent reasonably determines that, by reason of circumstances affecting the Designated Market generally that are beyond the
reasonable control of the Lenders, deposits in dollars (in the applicable amounts) are not being offered to each of the Lenders in the Designated Market for the applicable Interest Period; or 
 (b) the Required Lenders advise the Administrative Agent that the Eurodollar Rate as determined by the Administrative Agent (i) does not represent
the effective pricing to such Lenders for deposits in dollars in the Designated Market in the relevant amount for the applicable Interest Period, or (ii) will not adequately and fairly reflect the cost to such Lenders of making the applicable
Eurodollar Rate Loans; 
 then the Administrative Agent forthwith shall give notice thereof to the Borrower and the Lenders, whereupon until the
Administrative Agent notifies the Borrower that the circumstances giving rise to such suspension no longer exist, the obligation of the Lenders to make any future Eurodollar Rate Loans shall be suspended. If at the time of such notice there is then
pending a request for a Borrowing that specifies a Eurodollar Rate Loan, such request shall be deemed to specify a Base Rate Loan. 
 3.04
Increased Costs. If, after the date hereof, the existence or occurrence of any Change in Law: 
 (a) shall subject any Lender or its
Lending Office for Eurodollar Rate Loans to any tax, duty or other charge or cost with respect to any Eurodollar Rate Loan, any Note or its obligation to make Eurodollar Rate Loans, or shall change the basis of taxation of payments to any Lender of
the principal of or interest on any Eurodollar Rate Loan or any other amounts due under this Agreement in respect of any Eurodollar Rate Loan, any Note or its obligation to make Eurodollar Rate Loans (except for changes in any tax on the
overall net income, gross income or gross receipts of such Lender or its Lending Office for Eurodollar Rate Loans); 
 (b) shall impose,
modify or deem applicable any reserve (including, without limitation, any reserve imposed by the Board of Governors of the Federal Reserve System), special deposit or similar requirements against assets of, deposits with or for the account
of, or credit extended by, any Lender or its Lending Office for Eurodollar Rate Loans; or 
  

 -60- 

 (c) shall impose on any Lender or its Lending Office for Eurodollar Rate Loans or the Designated Market
any other condition affecting any Eurodollar Rate Loan, any Note, its obligation to make Eurodollar Rate Loans or this Agreement, or shall otherwise affect any of the same; 
 and the result of any of the foregoing, as determined by such Lender, increases the cost to such Lender or its Lending Office for Eurodollar Rate Loans of making or maintaining any Eurodollar Rate Loan or in respect
of any Eurodollar Rate Loan, any Note or its obligation to make Eurodollar Rate Loans or reduces the amount of any sum received or receivable by such Lender or its Lending Office for Eurodollar Rate Loans with respect to any Eurodollar Rate Loan,
any Note or its obligation to make Eurodollar Rate Loans (assuming such Lender’s Lending Office for Eurodollar Rate Loans had funded 100% of its Eurodollar Rate Loan in the Designated Market), then, upon demand by such Lender (with a copy to
the Administrative Agent), the Borrower shall pay to such Lender such additional amount or amounts as will compensate such Lender for such increased cost or reduction (determined as though such Lender’s Lending Office for Eurodollar Rate Loans
had funded 100% of its Eurodollar Rate Loan in the Designated Market). A statement of any Lender claiming compensation under this subsection, providing supporting calculation, and setting forth the additional amount or amounts to be paid to it
hereunder shall be conclusive in the absence of manifest error. Each Lender agrees to endeavor promptly to notify the Borrower of any event of which it has actual knowledge occurring after the Closing Date, which will entitle such Lender to
compensation pursuant to this Section 3.04, and agrees to designate a different Lending Office for Eurodollar Rate Loans promptly if such designation will avoid the need for or reduce the amount of such compensation and will not, in the
judgment of such Lender, otherwise be disadvantageous to such Lender. If any Lender claims compensation under this Section, the Borrower may at any time, upon at least four Business Days’ prior notice to the Administrative Agent and such Lender
and upon payment in full of the amounts provided for in this Section 3.04 through the date of such payment plus any compensation required by Section 3.05, pay in full the affected Eurodollar Rate Loans of such Lender or request that
such Eurodollar Rate Loans be converted to Base Rate Loans. 
 3.05 Compensation for Losses. Upon payment or prepayment of any
Eurodollar Rate Loan (other than as the result of a conversion required under Section 3.02), on a day other than the last day in the applicable Interest Period (whether voluntarily, involuntarily, by reason of acceleration, or otherwise), or
upon the failure of the Borrower to borrow on the date or in the amount specified for a Eurodollar Rate Loan in any request for a Borrowing, the Borrower shall pay to the appropriate Lender a prepayment fee or failure to borrow fee, as the case may
be, calculated as follows (and determined as though 100% of the Eurodollar Rate Loan had been funded in the Designated Market): 
 (a)
principal amount of the Eurodollar Rate Loan, times the number of days between the date of prepayment or failure to borrow and the last day in the applicable Interest Period, divided by 360, times the applicable
Interest Differential; plus 
  

 -61- 

 (b) all actual out-of-pocket expenses (other than those taken into account in the calculation of the
Interest Differential) incurred by the Lender (excluding allocations of any expense internal to that Lender) and reasonably attributable to such payment, prepayment or failure to borrow; 
 provided that no prepayment fee or failure to borrow fee shall be payable (and no credit or rebate shall be required) if the product of the foregoing formula is
not a positive number. Each Lender’s determination of the amount of any prepayment fee or failure to borrow fee payable under this Section 3.05 shall be based upon the Administrative Agent’s determination of the applicable Interest
Differential but shall otherwise be conclusive in the absence of manifest error. 
 3.06 Increased Capital Requirements. If any Lender
shall have determined that the introduction after the date hereof of any applicable law, rule, regulation or guideline regarding capital adequacy, or any change therein or any change in the interpretation or administration thereof by any central
bank or other Governmental Authority charged with the interpretation or administration thereof, or compliance by that Lender (or its Lending Office for Eurodollar Rate Loans) or any corporation controlling that Lender, with any request, guidelines
or directive regarding capital adequacy (whether or not having the force of law) of any such central bank or other authority, affects or would affect the amount of capital required or expected to be maintained by that Lender or any corporation
controlling that Lender and (taking into consideration such Lender’s or such corporation’s policies with respect to capital adequacy and such Lender’s desired return on capital) determines that the amount of such capital is increased
as a consequence of its obligations under this Agreement, then, upon demand of such Lender, Borrower shall immediately pay to that Lender, from time to time as specified by that Lender, additional amounts sufficient to compensate that Lender for
such increase. 
 3.07 Replacement of Lenders. If any Lender requests compensation under Section 3.04, or if the Borrower is
required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if any Lender does not consent to a requested waiver or amendment hereof that requires the approval of
all of the Lenders and which is consented to by the Required Lenders, the Borrower may replace such Lender in accordance with Section 12.13. 
 3.08 Survival. All of the Borrower’s obligations under Sections 3.02, 3.03, 3.04, 3.05 and 3.06 shall survive for one year following the date on which all Loans hereunder are fully paid; provided, however, that such
obligations shall not, from and after the date on which all Loans hereunder are fully paid, be deemed secured Obligations for any purpose under the Loan Documents. 
  

 -62- 

 ARTICLE IV 
 CONDITIONS PRECEDENT TO CREDIT EXTENSIONS 
 4.01 Conditions of Initial Credit Extension. The
obligation of the L/C Issuer and each Lender to make its initial Credit Extension hereunder is subject to satisfaction of the following conditions precedent: 
 (a) The Administrative Agent’s receipt of the following, each of which shall be originals or telecopies unless otherwise specified, each properly executed by a Senior Officer of the Tribe, the Borrower or the
other signing Loan Party, each dated the Closing Date (or, in the case of certificates of governmental officials, a recent date before the Closing Date) and each in form and substance reasonably satisfactory to the Administrative Agent and each of
the Lenders: 
 (i) executed counterparts of this Agreement sufficient in number for distribution to the Administrative Agent,
each Lender, the Tribe and the Borrower; 
 (ii) a Revolving Note executed by the Borrower in favor of each Lender requesting
a Revolving Note, each in a principal amount equal to that Lender’s pro rata share of the Revolving Commitment; 
 (iii)
the Guaranties executed by the Guarantors; 
 (iv) the Security Agreements executed by the Borrower and each of its Restricted
Subsidiaries, other than the WNBA Subsidiary, together with sufficient copies of financing statements on Form UCC 1 (including such fixture filings as may be appropriate) for filing in every jurisdiction necessary for the perfection of the security
interests granted thereby; 
 (v) the Pledge Agreement executed by the Borrower and each Restricted Subsidiary owning any
Equity Interests in any other Restricted Subsidiary together with stock or limited liability company membership certificates representing 100% of the Equity Interests in the Restricted Subsidiaries pledged thereunder (to the extent certificated),
together with appropriate stock or equivalent powers; 
 (vi) in the event that all required approvals of the Bureau of Indian
Affairs and all other governmental approvals required for the execution and delivery thereof have been obtained as of the Closing Date, the Leasehold Mortgage shall have been executed and delivered to the Administrative Agent in a form suitable for
recordation with the Land Title and Records Office of the Bureau of Indian Affairs and with the Town of Montville, Connecticut, and the Title Company shall have issued its written commitment to issue an endorsement to the policy of title insurance
heretofore delivered to the Administrative Agent insuring the continued priority and perfection of the Existing Leasehold Mortgage (as amended and restated on the Closing Date) in the amount of $600,000,000. It is understood and agreed that if any
such governmental approvals have not then been obtained, then on the Closing Date the Administrative 

  

 -63- 

 
Agent shall instead execute such documents as may be reasonably required to evidence the termination of the Existing Leasehold Mortgage immediately prior to
the making of the initial Loans hereunder; 
 (vii) the Pocono Downs Mortgages executed by the applicable Pocono Downs
Subsidiaries; 
 (viii) assurance from the Title Company that it is committed to issue form endorsements to the lenders title
insurance policies with respect to the Pocono Downs Mortgages, insuring the continued validity and priority of the Lien of the Pocono Downs Mortgages, subject only to those exceptions approved by the Administrative Agent in connection with the
Existing Loan Agreement and such other exceptions as may be reasonably acceptable to the Administrative Agent, in the aggregate amount of $300,000,000 and with such endorsements as to coverage as the Administrative Agent may reasonably require;

 (ix) evidence that the Title Company has obtained the commitment of insurers acceptable to the Administrative Agent to
provide appropriate reinsurance with rights of direct access with respect to the policies of title insurance referred to herein; 
 (x) Deposit Account Agreements in favor of the Administrative Agent executed by the Borrower or the applicable Loan Party which is the owner of each applicable Operating Account and by the depository for each such Operating Account;

 (xi) such documentation as the Administrative Agent may reasonably require to establish the existence of the Tribe as a
federally recognized Indian Tribe, the formation, valid existence and good standing of the Borrower and each other Loan Party, each Loan Party’s and the Tribe’s authority to execute, deliver and perform any Loan Document, and the identity,
authority and capacity of each Senior Officer authorized to act on their behalf, including, without limitation, certified copies of the Constitution, the Gaming Ordinance, the Gaming Authority Ordinance and each Guarantor’s charter and bylaws,
and amendments thereto, resolutions, incumbency certificates, Certificates of Senior Officers, and the like; 
 (xii) the
favorable written legal opinions of Hogan & Hartson LLP, special counsel to the Borrower and Rome McGuigan, P.C., special Connecticut counsel to the Borrower, addressed to the Administrative Agent and each Lender, substantially in the forms
set forth in Exhibit K and such other matters concerning the Tribe, the Borrower the other Loan Parties and the Loan Documents as the Required Lenders may reasonably request; 
 (xiii) a certificate of a Senior Officer or Secretary of the Tribe and each Loan Party either (A) attaching copies of all consents,
licenses and approvals required in connection with the execution, delivery and performance by the Tribe or such Loan Party and the validity against the Tribe or such Loan Party of the Loan Documents to which it is a party, and such consents,
licenses and approvals shall be in full force and effect, or (B) stating that no such consents, licenses or approvals are so required; 
  

 -64- 

 (xiv) a certificate signed by a Senior Officer of the Borrower certifying (A) that
the conditions specified in Sections 4.02(a) and (b) have been satisfied, and (B) attaching the Preliminary Construction Documents; 
 (xv) an In-Balance Certificate dated as of the Closing Date; 
 (xvi) evidence that all
insurance required to be maintained pursuant to the Loan Documents has been obtained and is in effect, together with an executed lenders loss payable endorsement and additional insured endorsement, as applicable, with respect thereto; 
 (xvii) a Certificate signed by a Senior Officer or Secretary of the Tribe and the Borrower attaching true, correct and complete copies of
each of the Material Documents (including, in each case, any amendments or modifications of the terms thereof entered into as of the Closing Date); and 
 (xviii) such other assurances, certificates, documents, consents or opinions as the Administrative Agent, the L/C Issuer or the Required Lenders reasonably may require. 
 (b) Any fees required to be paid on or before the Closing Date shall have been paid. 
 Without limiting the generality of the provisions of Section 11.04, for purposes of determining compliance with the conditions specified in this
Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or
satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto. 
 4.02 Conditions to all Credit Extensions. The obligation of each Lender to honor any Request for Credit Extension (other than a Loan Notice requesting only a conversion of Loans from one Type to the other, or a
continuation of Eurodollar Rate Loans) is subject to the following conditions precedent: 
 (a) The representations and warranties of the
Tribe and each Loan Party contained in Articles V and VI and any other Loan Document, and which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct on and as of the date of
such Credit Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date, and except that for purposes of this Section 4.02,
the representations and warranties contained in subsections (a) and (b) of Section 6.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 8.01.

 (b) No Default or Event of Default shall exist, or would result from such proposed Credit Extension or from the application of the
proceeds thereof. 
  

 -65- 

 (c) The Administrative Agent and, if applicable, the L/C Issuer shall have received a Request for Credit
Extension in accordance with the requirements hereof. 
 Each Request for Credit Extension (other than a Loan Notice requesting only a
conversion of Revolving Loans to the other Type or a continuation of Eurodollar Rate Loans) submitted by the Borrower shall be deemed to be a representation and warranty that the conditions specified in Sections 4.02(a) and (b) have been
satisfied on and as of the date of the applicable Credit Extension. 
  

 -66- 

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES OF THE TRIBE 
 In order to induce the Creditors to enter into this
Agreement and the other Loan Documents to be executed as of the Closing Date, the Tribe represents and warrants to the Creditors that, as of the Closing Date (but not as of any date subsequent thereto). 
 5.01 Existence and Qualification; Power; Compliance With Laws. The Tribe is federally recognized as an Indian Tribe pursuant to a determination of
the Assistant Secretary - Indian Affairs, dated March 7, 1994, published in the Federal Register on March 15, 1994, as amended by a correction dated July 1, 1994, published in the Federal Register on July 20, 1994, and as an
Indian Tribal government pursuant to Sections 7701(a)(40)(A) and 7871(a) of Title 26 of the Code. The Borrower is an unincorporated governmental instrumentality of the Tribe. As of the Closing Date, each of the Tribe, the Borrower and their
Restricted Subsidiaries is a non-taxable entity for purposes of federal income taxation under the Code, and the gaming and other revenues of the Borrower and its Restricted Subsidiaries are exempt from federal income taxation. To the extent required
by Law, the Borrower and its Restricted Subsidiaries are qualified to do business and are in good standing under the laws of each jurisdiction in which they are required to be qualified by reason of the location or the conduct of their business,
except where failure to qualify would not have a Material Adverse Effect. The Tribe and the Borrower each have all requisite power and authority to execute and deliver each Loan Document to which they are a party and to perform their respective
Obligations. The Tribe and the Borrower are in material compliance with the terms of the Compact, the Gaming Authority Ordinance, the Gaming Ordinance and with all Laws and other legal requirements applicable to their existence and business
(including, without limitation, IGRA and all Gaming Laws), have obtained all authorizations, consents, approvals, orders, licenses and permits from, and have accomplished all filings, registrations and qualifications with, or obtained exemptions
from any of the foregoing from, any Governmental Authority that are necessary for the transaction of their business, except, in each case, where the failure so to comply, to obtain such authority, consents, approvals, orders, licenses and permits,
or to file, register, qualify or obtain exemptions does not constitute a Material Adverse Effect. 
 5.02 Authority; Compliance With Other
Agreements and Instruments and Government Regulations. The execution, delivery and performance by the Tribe and by the Borrower of the Loan Documents have been duly authorized by all necessary Tribal Council, Management Board and other action,
and do not: 
 (a) require any consent or approval not heretofore obtained of any enrolled tribal member, Tribal Council member, Management
Board member, security holder or creditor; 
 (b) violate or conflict with any provision of the Constitution, charter, bylaws or other
governing documents of the Tribe or of the Borrower; 
 (c) result in or require the creation or imposition of any Lien (other than pursuant
to the Collateral Documents) upon or with respect to any Authority Property now owned or leased or hereafter acquired; 
  

 -67- 

 (d) violate any Law or Requirement of Law, including any Gaming Law, applicable to the Tribe or the
Borrower in any material respect; 
 (e) constitute a “transfer of an interest” or an “obligation incurred” that is
avoidable by a trustee under Section 548 of the Bankruptcy Code of the United States, as amended, or constitute a “fraudulent conveyance,” “fraudulent obligation” or “fraudulent transfer” within the meanings of the
Uniform Fraudulent Conveyances Act or Uniform Fraudulent Transfer Act, as enacted in any applicable jurisdiction; 
 (f) result in a material
breach of or default under, or would, with the giving of notice or the lapse of time or both, constitute a material breach of or default under, or cause or permit the acceleration of any obligation owed under, any mortgage, indenture or loan or
credit agreement or any other Contractual Obligation to which the Tribe or the Borrower is a party or by which the Tribe, the Borrower or any of their Property is bound or affected; or 
 (g) require any consent or approval of any Governmental Authority, or any notice to, registration or qualification with any Governmental Authority, not
heretofore obtained or obtained concurrently with the Closing Date (or, as to the Leasehold Mortgage, as hereafter may be obtained); 
 and the Tribe and the
Borrower are not in violation of, or default under, any Requirement of Law or Contractual Obligation, or any indenture, loan or credit agreement described in Section 5.02(f) in any respect that constitutes a Material Adverse Effect. 

5.03 No Governmental Approvals Required. Except for any required consents of the U.S. Secretary of the Interior as to the Leasehold Mortgage
(which consent is being requested concurrently with the execution and delivery of this Agreement if the Leasehold Mortgage is being executed concurrently herewith, but is not otherwise required), no authorization, consent, approval, order, license
or permit from, or filing, registration or qualification with, any Governmental Authority is required to authorize or permit under applicable Laws the execution, delivery and performance by the Tribe and the Borrower of the Loan Documents to which
they are parties. 
 5.04 The Nature of the Borrower. All activities of the Tribe constituting or relating to the ownership and
operation of gaming facilities (including all Class II and Class III gaming activities within the meaning of IGRA) at Mohegan Sun and all activities of the Tribe constituting or relating to the ownership of hotel, restaurant, entertainment and
resort facilities included within Mohegan Sun are conducted on behalf of the Tribe by the Borrower pursuant to the authority granted to the Borrower in the Gaming Authority Ordinance, other than the basketball operations carried on by, and the
related assets owned by, the WNBA Subsidiary. 
 5.05 No Management Contract. Neither this Agreement nor the other Loan Documents,
taken individually or as a whole, constitute “management contracts” or “management agreements” within the meaning of Section 12 of IGRA, or deprive the Borrower of the sole proprietary interest and responsibility of the
conduct of gaming activity at Mohegan Sun. 
  

 -68- 

 5.06 Title to and Location of Property. As of the Closing Date, the Borrower and its Restricted
Subsidiaries have good and valid title to all the Authority Property other than immaterial items of Property subsequently sold or disposed of in the ordinary course of business, free and clear of all Liens and Rights of Others, other than as set
forth in Schedule 9.01, provided that the title to the Real Property comprising the Mohegan Sun either is held by the United States in trust on behalf of the Tribe or owned in fee simple by the Tribe. 
 5.07 Real Property. As of the Closing Date, Schedule 5.07 sets forth a summary description of all real property owned by the Tribe which is
Authority Property, including all of the land underlying Mohegan Sun, and of all real property leasehold estates held by the Borrower from the Tribe, which summary is accurate and complete in all material respects. Except as set forth in
Schedule 5.07, the leases creating such real property leasehold estates are in full force and effect and create a valid leasehold estate on the terms of such lease, and neither the Borrower nor the Tribe is in default or breach of any material
provision thereof. The copies of such real property leases heretofore furnished to the Administrative Agent are true copies and there are no amendments thereto as of the Closing Date copies of which have not been furnished to the Administrative
Agent. Under 25 U.S.C. § 177, the Borrower’s Lease of Mohegan Sun may not be encumbered by the Borrower without the consent of the United States of America; however consent to the Leasehold Mortgage has been requested prior to the
execution and delivery of this Agreement. The Authority Property includes all real, mixed and personal property which is operationally integral to the on-reservation gaming activities of the Borrower. 
 5.08 Governmental Regulation. Except for any consents of the Bureau of Indian Affairs of the types described in Sections 5.02 and 5.03 and
except for Laws applicable to the Pennsylvania Tax Revenues, the Borrower and its Restricted Subsidiaries are not subject to any Laws limiting or regulating their ability to incur Indebtedness for money borrowed, to grant Liens to secure their
obligations with respect to such Indebtedness or to otherwise perform the Obligations. 
 5.09 Binding Obligations. The Loan Documents
contemplated by Section 4.01 and Section 4.02 have been executed and delivered by the Tribe, the Borrower and its Restricted Subsidiaries, as applicable, and constitute the legal, valid and binding obligations of the Tribe, the Borrower
and its Restricted Subsidiaries, as applicable, enforceable against the Tribe, the Borrower and its Restricted Subsidiaries, as applicable, in accordance with their terms (subject to the understanding that the amended version of the Leasehold
Mortgage will not be delivered unless and until all appropriate and required governmental approvals have been obtained). The provisions of Section 12.15 are specifically enforceable against the Tribe, the Borrower and its Restricted
Subsidiaries. 
 5.10 No Default. No event has occurred and is continuing that is a Default or an Event of Default. 
 5.11 Disclosure. No written statement made by or on behalf of the Tribe or the Borrower to the Administrative Agent or any Lender in connection
with this Agreement, or in connection with any Loan or Letter of Credit, contains any untrue statement of a material fact or omits a material fact necessary in order to make the statement made not misleading in light of all the circumstances
existing at the date the statement was made. There is no fact known to the 
  

 -69- 

 
Tribe or the Borrower (other than matters of a general economic nature or matters generally applicable to businesses of the types engaged in by the Borrower
and its Restricted Subsidiaries) which would constitute a Material Adverse Effect that has not been disclosed in writing to the Administrative Agent and the Lenders. 
 5.12 Gaming Laws. The Borrower, its Restricted Subsidiaries and the Tribe are in material compliance with all applicable Gaming Laws. 
 5.13 Security Interests. The Liens created by the Security Agreements are perfected and of first priority to the fullest extent that the same may
be perfected by the filing of financing statements under the applicable state versions of the Uniform Commercial Code and the UCC Ordinance, to the extent applicable, or other applicable state Uniform Commercial Code with respect to each of the
other Restricted Subsidiaries executing a Security Agreement. Following the date of the execution, delivery (and consent thereto by the U.S. Secretary of the Interior) and recordation of the Leasehold Mortgage, the Leasehold Mortgage creates a valid
and perfected Lien in the collateral described therein securing the Obligations. Each of the Liens described in this Section are of first priority, subject only to Liens permitted under Section 9.01 and matters described in
Schedule 9.01. 
 5.14 Arbitration. Pursuant to the Constitution, to the extent that any dispute among the parties to the Loan
Documents is initiated in or referred to the Tribal Court, (i) such court lacks discretion to refuse to compel arbitration among the parties to the dispute, and (ii) such court is obligated to honor and enforce any award by the arbitrator,
without review of any nature by such court. 
 5.15 Recourse Obligations. Under current Law, no obligation of the Tribe of any type or
nature may constitute a Recourse Obligation unless and to the extent that the Borrower has become an express obligor with respect thereto, and the Tribe has no authority, independent of the Borrower, to incur any obligation on behalf of the
Borrower, to bind any Authority Property, or to grant Liens upon any Authority Property. 
  

 -70- 

 ARTICLE VI 
 REPRESENTATIONS AND WARRANTIES OF THE BORROWER 
 The Borrower represents and warrants to the
Administrative Agent and the Lenders that: 
 6.01 Existence, Qualification and Power. The Tribe is federally recognized as a Indian
Tribe pursuant to a determination of the Assistant Secretary - Indian Affairs, dated March 7, 1994, published in the Federal Register on March 15, 1994, as amended by a correction dated July 1, 1994, published in the Federal Register
on July 20, 1994, and as an Indian Tribal government pursuant to Sections 7701(a)(40)(A) and 7871(a) of the Code. The Borrower is an unincorporated governmental instrumentality of the Tribe. As of the Closing Date, each of the Tribe, the
Borrower and their Restricted Subsidiaries is a non-taxable entity for purposes of federal income taxation under the Code and the gaming and other revenues of the Borrower and its Restricted Subsidiaries are exempt from federal income taxation. To
the extent required by Law, the Borrower and its Restricted Subsidiaries are qualified to do business and are in good standing under the laws of each jurisdiction in which they are required to be qualified by reason of the location or the conduct of
their business, except where failure to so qualify would not have a Material Adverse Effect. The Tribe, the Borrower and their Restricted Subsidiaries each have all requisite power and authority to conduct their respective businesses, to own and
lease their respective Properties, to execute and deliver each Loan Document to which they are a Party and to perform their respective Obligations. As of the Closing Date, the chief executive offices of the Borrower are located in Uncasville,
Connecticut at the address for notices set forth on the signature pages hereto. The Tribe, the Borrower and its Restricted Subsidiaries are in material compliance with the terms of the Compact, the Gaming Ordinance, the Gaming Authority Ordinance
and with all Laws and other legal requirements applicable to their existence and business (including, without limitation, IGRA and all Gaming Laws), have obtained all authorizations, consents, approvals, orders, licenses and permits from, and have
accomplished all filings, registrations and qualifications with, or obtained exemptions from any of the foregoing from, any Governmental Authority that are necessary for the transaction of their business, except, in each case, where the failure so
to comply, to obtain such authority, consents, approvals, orders, licenses and permits, or to file, register, qualify or obtain exemptions does not constitute a Material Adverse Effect. 
 6.02 Authorization; No Contravention. The execution, delivery and performance by the Tribe and by the Borrower and their Restricted Subsidiaries
of the Loan Documents have been duly authorized by all necessary Tribal Council, Management Board and other action, and do not: 
 (a) require
any consent or approval not heretofore obtained of any enrolled tribal member or Tribal Council member, Management Board member, security holder or creditor; 
 (b) violate or conflict with any provision of the Constitution, charter, bylaws or other governing documents of the Tribe, the Borrower or its Restricted Subsidiaries; 
  

 -71- 

 (c) result in or require the creation or imposition of any Lien (other than pursuant to the Collateral
Documents) upon or with respect to any Authority Property now owned or leased or hereafter acquired; 
 (d) violate any Law or Requirement of
Law, including any Gaming Law, applicable to the Tribe, the Borrower or its Restricted Subsidiaries; 
 (e) constitute a “transfer of an
interest” or an “obligation incurred” that is avoidable by a trustee under Section 548 of the Bankruptcy Code of the United States, as amended, or constitute a “fraudulent conveyance,” “fraudulent obligation”
or “fraudulent transfer” within the meanings of the Uniform Fraudulent Conveyances Act or Uniform Fraudulent Transfer Act, as enacted in any applicable jurisdiction; 
 (f) result in a material breach of or default under, or would, with the giving of notice or the lapse of time or both, constitute a material breach of or
default under, or cause or permit the acceleration of any obligation owed under, any mortgage, indenture or loan or credit agreement or any other Contractual Obligation to which the Tribe, the Borrower or any of its Restricted Subsidiaries is a
party or by which the Tribe, the Borrower, its Restricted Subsidiaries or any of their Property is bound or affected; or 
 (g) require any
consent or approval of any Governmental Authority, or any notice to, registration or qualification with any Governmental Authority, not heretofore obtained or obtained concurrently with the Closing Date (or, as to the Leasehold Mortgage, as
hereafter may be obtained); 
 and the Tribe, the Borrower and its Restricted Subsidiaries are not in violation of, or default under, any Requirement of Law
or Contractual Obligation, or any indenture, loan or credit agreement described in Section 6.02(f), in any respect that constitutes a Material Adverse Effect. 
 6.03 Governmental Authorization; Other Consents. Except for any required consents of the U.S. Secretary of the Interior as to the Leasehold Mortgage (which consent is being requested concurrently with
the execution and delivery of this Agreement if the Leasehold Mortgage is being executed concurrently herewith, but is not otherwise required), no authorization, consent, approval, order, license or permit from, or filing, registration or
qualification with, any Governmental Authority is required to authorize or permit under applicable Laws the execution, delivery and performance by the Tribe, the Borrower and its Restricted Subsidiaries of the Loan Documents to which they are
parties. 
 6.04 Binding Effect. The Loan Documents to which the Borrower and its Restricted Subsidiaries are party have been executed
and delivered by the Borrower and its Restricted Subsidiaries, as applicable. Each of the Loan Documents executed by the Tribe, the Borrower and its Restricted Subsidiaries constitute the legal, valid and binding obligations of the Tribe, the
Borrower and its Restricted Subsidiaries, as applicable, enforceable against the Tribe, Borrower and its Restricted Subsidiaries, as applicable, in accordance with their terms. 
  

 -72- 

 6.05 Financial Statements; No Material Adverse Effect; No Internal Control Event. 
 (a) The Audited Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as
otherwise expressly noted therein; (ii) fairly present the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently
applied throughout the period covered thereby, except as otherwise expressly noted therein; and (iii) show all material indebtedness and other liabilities, direct or contingent, of the Borrower and its Subsidiaries as of the date thereof,
including liabilities for taxes, material commitments, Indebtedness and Recourse Obligations whether or not the Borrower is described as the borrower or obligor with respect thereto. 
 (b) The consolidated balance sheets of the Borrower and its Subsidiaries dated December 31, 2006, and the related consolidated statements of income
or operations, shareholders’ equity and cash flows for the Fiscal Quarter ended on that date (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein,
and (ii) fairly present the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of clauses (i) and (ii), to the absence of
footnotes and to normal year-end audit adjustments. 
 (c) As of the Closing Date, the Borrower and its Restricted Subsidiaries do not have
any material liability or material contingent liability not reflected or disclosed in the financial statements described in Section 6.05(b) or the notes to the financial statements described in Section 6.05(a). Each financial statement of
the Borrower which is hereafter delivered in accordance with Section 8.01 includes as liabilities of the Borrower, all then existing Recourse Obligations, whether or not the Borrower is described as the borrower or obligor with respect thereto.
No Property which is not Authority Property is described as an asset of the Borrower or any of its Restricted Subsidiaries on any balance sheet or other financial statement of the Borrower provided to the Administrative Agent or the Lenders.

 (d) Since the date of the Audited Financial Statements, there has been no event or circumstance, either individually or in the aggregate,
that has had or could reasonably be expected to have a Material Adverse Effect. As of the date of each Borrowing made and each Letter of Credit issued subsequent to the Closing Date, no event or circumstance has occurred since the date of the
Audited Financial Statements that constitutes a Material Adverse Effect. 
 (e) To the knowledge of each Senior Officer of the Borrower, no
Internal Control Event exists or has occurred since the date of the Audited Financial Statements that has resulted in or could reasonably be expected to result in a misstatement, in any material respect, in any financial information delivered or to
be delivered to the Administrative Agent or the Lenders, of (i) covenant compliance calculations provided hereunder or (ii) the assets, liabilities, financial condition or results of operations of the Borrower and its Restricted
Subsidiaries on a consolidated basis. 
  

 -73- 

 6.06 Litigation. Except for (a) any matter fully covered (subject to applicable
deductibles and retentions) by insurance and with respect to which the insurance carrier has not denied coverage, nor issued any denial of claim, nor any other statement that the claim is in excess of coverage, (b) any matter, or series of
related matters, not fully covered by insurance (subject to applicable deductibles and retentions) involving a claim against the Borrower or its Restricted Subsidiaries which is, in the reasonable opinion of their legal counsel, in an amount less
than $5,000,000, and (c) as of the Closing Date, matters set forth in Schedule 6.06, there are no actions, suits, proceedings or investigations pending as to which the Borrower or its Restricted Subsidiaries has been served or have
received notice or, to the knowledge of each Senior Officer of the Borrower, threatened against or affecting the Borrower, its Restricted Subsidiaries or any of their Property before any Governmental Authority. There is no reasonable basis to
believe that any of the matters described on Schedule 6.06 may result in or constitute a Material Adverse Effect. 
 6.07 No
Default. No event has occurred and is continuing that is a Default or an Event of Default. 
 6.08 Ownership of Property; Liens.
As of the Closing Date, the Borrower and its Restricted Subsidiaries have good and valid title to all the Authority Property reflected in the financial statements described in Section 6.05 other than immaterial items of Property subsequently
sold or disposed of in the ordinary course of business, free and clear of all Liens and Rights of Others, other than Liens permitted by Section 9.01 and Permitted Rights of Others, provided that title to the real property comprising a portion
of Mohegan Sun is held by the United States in trust on behalf of the Tribe. 
 6.09 Environmental Compliance. Except as described in
Schedule 6.09, neither the Borrower nor, to the knowledge of each Senior Officer of the Borrower, any predecessor in title or any third person at any time occupying or present on the Real Property at any time has disposed of, discharged,
released or threatened the release of any material amount of Hazardous Materials on, from or under such real property in any manner that violates any Hazardous Materials Law except for such violations that would not, individually or in the
aggregate, have a Material Adverse Effect. Except as described in Schedule 6.09, no condition exists that violates any Hazardous Material Law affecting the Real Property except for such violations that would not, individually or in the
aggregate, have a Material Adverse Effect. Except as described in Schedule 6.09, the Real Property and each portion thereof is not and has not been utilized by the Borrower or any of its Subsidiaries as a site for the manufacture of any
Hazardous Materials, except as may not reasonably be expected to result in any material liability to the Borrower and its Subsidiaries. As of the Closing Date, the Real Property is in compliance with all Hazardous Materials Law, except as may not
reasonably be expected to result in any material liability to the Borrower and its Subsidiaries. As of each date following the Closing Date, the Real Property is in compliance with all Hazardous Materials Laws, except to the extent that any
non-compliance could not reasonably be expected to have a Material Adverse Effect. Except as described in Schedule 6.09, to the extent that any Hazardous Materials have been, or are, used, generated or stored by the Borrower or any of its
Restricted Subsidiaries on any Real Property, or transported to or from such Real Property by the Borrower or any of its Restricted Subsidiaries, such use, generation, storage and transportation have been and are in compliance with all Hazardous
Materials Laws except to the extent that any such non-compliance could not reasonably be expected to have a Material Adverse Effect 
  

 -74- 

 6.10 Insurance. The properties of the Borrower and its Restricted Subsidiaries are insured with
financially sound and reputable insurance companies not Affiliates of the Borrower, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in
localities where the Borrower or the applicable Restricted Subsidiary operates. 
 6.11 Taxes. The Borrower and its Restricted
Subsidiaries have filed all tax returns which are required to be filed, and has paid, or made provision for the payment of, all taxes with respect to the periods, Property or transactions covered by said returns, or pursuant to any assessment
received by the Borrower or a Restricted Subsidiary, except such taxes, if any, as are being contested in good faith by appropriate proceedings and as to which adequate reserves have been established and maintained. 
 6.12 ERISA Compliance. As of the Closing Date neither the Borrower nor any ERISA Affiliate maintains, contributes to or is required to contribute
to any “employee pension benefit plan” that is subject to Title IV of ERISA. 
 6.13 Subsidiaries; Equity Interests. As
of the Closing Date, Schedule 6.13 correctly sets forth the names, form of legal entity, number of shares of capital stock or other equity interests issued and outstanding, and the record owner thereof and jurisdictions of organization of all
Subsidiaries of the Borrower and designates which Subsidiaries are Unrestricted Subsidiaries. All of the outstanding shares of capital stock, or all of the units of equity interest, as the case may be, of each Restricted Subsidiary are owned
directly or indirectly by the Borrower, there are no outstanding options, warrants or other rights to purchase capital stock of any such Restricted Subsidiary, and all such shares or equity interests so owned are duly authorized, validly issued,
fully paid and non assessable, and were issued in compliance with all applicable state and federal securities and other Laws, and are free and clear of all Liens, except for Liens permitted under Section 9.01. 
 6.14 Margin Regulations; Investment Company Act. 
 (a) No part of the proceeds of any Loan or other extension of credit hereunder will be used to purchase or carry, or to extend credit to others for the purpose of purchasing or carrying, any “margin stock”
(as such term is defined in Regulations T, U and X of the FRB) in violation of Regulations T, U and X. The Borrower and its Subsidiaries are not engaged principally, or as one of their important activities, in the business of extending credit for
the purpose of purchasing or carrying any such “margin stock.” 
 (b) Neither the Borrower, any Person Controlling the Borrower,
the Tribe nor any Restricted Subsidiary is or is required to be registered as an “investment company” under the Investment Company Act of 1940. 
 6.15 Disclosure. No written statement made by or on behalf of the Tribe, the Borrower or any of their Subsidiaries to the Administrative Agent or any Lender in connection with the transactions contemplated by
this Agreement, or in connection with any Loan, Letter of 

  

 -75- 

 
Credit or other Loan Document, contains any untrue statement of a material fact or omits a material fact necessary in order to make the statement made not
misleading in light of all the circumstances existing at the date the statement was made. There is no fact known to the Borrower or its Restricted Subsidiaries (other than matters of a general economic nature or matters generally applicable to
businesses of the types engaged in by the Borrower and its Restricted Subsidiaries) which would constitute a Material Adverse Effect that has not been disclosed in writing to the Administrative Agent and the Lenders. 
 6.16 Compliance with Laws. 
 (a)
Except for any consents of the Bureau of Indian Affairs of the types described in Section 6.03, the Borrower and its Restricted Subsidiaries are not subject to any Laws limiting or regulating their ability to incur Indebtedness for money
borrowed, to grant Liens to secure their obligations with respect to such Indebtedness or to otherwise perform the Obligations. 
 (b) As of
the Closing Date, the Borrower, its Restricted Subsidiaries and the Tribe are in material compliance with all applicable Gaming Laws. 
 (c)
As of each date following the Closing Date, the Borrower, its Restricted Subsidiaries and the Tribe are in compliance with all applicable Gaming Laws, except for any failure to be in compliance that could not reasonably be expected to have a
Material Adverse Effect. 
 6.17 Taxpayer Identification Number. The Borrower’s true and correct U.S. taxpayer identification
number is set forth on Schedule 12.02. 
 6.18 Intangible Assets. The Borrower and its Restricted Subsidiaries own, or possess
the right to use to the extent necessary in their business, all trademarks, trade names, copyrights, patents, patent rights, computer software, licenses and other Intangible Assets that are used in the conduct of the business of the Borrower and its
Restricted Subsidiaries as now operated and which are material to the condition (financial or otherwise), business or operations of the Borrower and its Restricted Subsidiaries, and no such Intangible Asset conflicts with the valid trademark, trade
name, copyright, patent, patent right or Intangible Asset of any other Person to the extent that such conflict constitutes a Material Adverse Effect. 
 6.19 The Nature of the Borrower. All activities of the Tribe constituting or relating to the ownership and operation of gaming facilities (including all Class II and Class III gaming activities within
the meaning of IGRA) included within Mohegan Sun and all activities of the Tribe constituting or relating to the ownership of hotel, restaurant, entertainment and resort facilities included within Mohegan Sun are conducted on behalf of the Tribe by
the Borrower pursuant to the authority granted to the Borrower in the Gaming Authority Ordinance, other than the basketball operations carried on by, and the related assets owned by, the WNBA Subsidiary. 
 6.20 No Management Contract. Neither this Agreement nor the other Loan Documents, taken individually or as a whole, constitute
“management contracts” or “management agreements” within the meaning of Section 12 of IGRA, or deprive the Borrower 
 of the sole
proprietary interest and responsibility of the conduct of gaming activity at Mohegan Sun. 
  

 -76- 

 6.21 Real Property Underlying Mohegan Sun. As of the Closing Date, Schedule 5.07 sets forth a
summary description of all real property owned by the Tribe which is Authority Property, including all of the Real Property underlying the Mohegan Sun, and of all real property leasehold estates held by the Borrower from the Tribe, which summary is
accurate and complete in all material respects. Schedule 6.21 sets forth a summary description of all real property owned by the Pocono Downs Subsidiaries. Except as set forth in Schedule 5.07, the leases creating such real property
leasehold estates are in full force and effect and create a valid leasehold estate on the terms of such lease, and neither the Borrower nor the Tribe is in default or breach of any material provision thereof. The copies of such real property leases
heretofore furnished to the Administrative Agent are true copies and there are no amendments thereto existing as of the Closing Date copies of which have not been furnished to the Administrative Agent. Under 25 U.S.C. § 177 such real property
may not be encumbered by the Tribe or the Borrower without the consent of the United States of America; however consent to the Leasehold Mortgage has been requested prior to the execution and delivery of this Agreement. The Authority Property
includes all real, mixed and personal property which is operationally integral to the on-reservation gaming activities of the Tribe. 
 6.22 Projections. As of the Closing Date, to the knowledge of each Senior Officer of the Borrower, the assumptions set forth in the Projections are reasonable and consistent with each other and with all facts known to the Tribe or
the Borrower and no material assumption is omitted as a basis for the Projections, and the Projections are reasonably based on such assumptions. Nothing in this Section shall be construed as a representation, warranty or covenant that the
Projections in fact will be achieved. 
 6.23 Employee Matters. There is no strike or work stoppage in existence or, to the
Borrower’s knowledge, threatened involving the Borrower or any of its Restricted Subsidiaries that would constitute a Material Adverse Effect. 
 6.24 Security Interests. The Liens created by the Security Agreements are perfected and of first priority to the fullest extent that the same may be perfected by the filing of financing statements under the applicable state versions
of the Uniform Commercial Code and the UCC Ordinance, to the extent applicable, or other applicable state Uniform Commercial Code with respect to each of the other Restricted Subsidiaries executing a Security Agreement. Following the date of the
execution, delivery (and consent thereto by the U.S. Secretary of the Interior) and recordation of the Leasehold Mortgage, the Leasehold Mortgage creates a valid and perfected Lien in the collateral described therein securing the Obligations.
Following the date of the execution, delivery and recordation of the Pocono Downs Mortgages, the Pocono Downs Mortgages create a valid and perfected Lien in the collateral described therein securing the Obligations of the applicable Pocono Downs
Subsidiaries. The Pledge Agreement creates a valid Lien in the pledged collateral described therein and, upon delivery to the Administrative Agent of any certificated Equity Interest described therein and the filing of financing statements under the
applicable state Uniform Commercial Code, all action necessary to perfect the Liens so created and to render them first priority Liens against the collateral secured thereby shall have been taken and completed. The Deposit Account Agreements create
a valid and perfected Lien 

  

 -77- 

 
in the Operating Accounts securing the Obligations. Each of the Liens described in this Section are of first priority, subject only to Liens permitted
under Section 9.01 and matters described in Schedule 9.01. Each of the other Collateral Documents creates a valid Lien on the collateral described therein, securing the Obligations. 
 6.25 Arbitration. To the extent that any dispute among the parties to the Loan Documents is initiated in or referred to the Tribal Court,
(i) such court lacks discretion to refuse to compel arbitration among the parties to the dispute, and (ii) such court is obligated to honor and enforce any award by the arbitrator, without review of any nature by such court. 
 6.26 Deposit Accounts. The Borrower and its Restricted Subsidiaries do not maintain any Operating Account which is not listed on
Schedule 6.26 or the existence of which has not been disclosed to the Administrative Agent and the Lenders in writing. 
 6.27 Tax
Shelter Regulations. The Borrower does not intend to treat the Loan and/or Letters of Credit and related transactions as being a “reportable transaction” (within the meaning of Treasury Regulation Section 1.6011-4). 
 6.28 Construction Plans and Budget. 
 (a) As of the Closing Date, the Borrower has delivered to the Administrative Agent and the Lenders Preliminary Construction Documents, which conceptually represent the anticipated manner in which the Projects are to be designed and
constructed, and outlining the anticipated costs and timing of the Projects. It is acknowledged that the Preliminary Construction Documents are subject to change and refinement. 
 (b) By delivering the Construction Plans, Construction Budget and Construction Timetable for each Project pursuant to Section 8.01(c), and by
delivery of each update thereto pursuant to Section 8.01(d), the Borrower represents and warrants that, to the knowledge of the Borrower as of the date of each such delivery, the Construction Plans, Construction Budget and Construction
Timetables so delivered are (a) reasonably achievable, (b) include all material elements of the relevant Project, and (c) include all material costs incident to the design, development, equipping and other material required costs
associated with the relevant Project, including “hard” and “soft” costs, fees and expenses. 
  

 -78- 

 ARTICLE VII 
 AFFIRMATIVE COVENANTS OF THE TRIBE 
 So long as any Lender shall have any Revolving Commitment
hereunder, any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than the obligations referenced in Sections 3.01, 3.04, 3.05, 12.04 and 12.05), or any Letter of Credit shall remain outstanding, the Tribe shall, and
shall cause the Borrower to unless the Administrative Agent (with the approval of the Required Lenders) otherwise consents: 
 7.01
Continual Operation of Mohegan Sun. Cause the Borrower to continuously operate the Mohegan Sun and refrain from conducting any gaming activities on the Tribe’s reservation near Uncasville, Connecticut (including without limitation all Class
II and Class III gaming activities (as defined in IGRA)) through any Person, agency or instrumentality other than the Borrower. 
 7.02
Remittance of Available Cash Flow. Cause the Borrower, to the extent that Available Cash Flow exists, promptly and in any event within two Business Days following demand by the Administrative Agent (with such demand to be made only following the
date upon which any such payment is due hereunder and has not been made by the Borrower), to remit to the Administrative Agent from Available Cash Flow all payments of principal, interest, fees and other amounts payable to the Creditors under the
Loan Documents. 
 7.03 Sovereign Immunity; Jurisdiction and Venue. Refrain from asserting that the provisions of this Article and
Sections 12.14, 12.15, 12.17 and 12.18 are not valid, binding and legally enforceable against the Tribe, the Borrower and its Restricted Subsidiaries, as applicable, and reaffirm in writing upon request the valid, binding and enforceable nature
of the provisions of this Article and Sections 12.14, 12.15, 12.17 and 12.18. 
 7.04 The Lease and the Landlord Consent.
Continuously abide by the terms of the Lease and the Landlord Consent in all material respects. 
 7.05 Preservation of Existence;
Operation. 
 (a) Do all things necessary to maintain the existence of the Tribe as a federally recognized Indian Tribe under 25 C.F.R.
Part 83 and as an Indian Tribal government pursuant to Sections 7701(a)(40)(A) and 7871(a) of Title 26 of the Code; and 
 (b)
Continuously maintain the existence of the Borrower as a governmental instrumentality of the Tribe. 
 7.06 Ownership of Mohegan Sun and
Pocono Downs; Management. Not form or acquire any corporation or other business entity for the purpose of directly or indirectly owning Mohegan Sun or any interest therein, or engage any manager for Mohegan Sun, provided that the Borrower
shall be entitled to form one or more Restricted Subsidiaries for the purpose of owning or operating Authority Property (other than Mohegan Sun, which always shall be owned by a wholly-owned Restricted Subsidiary) to the extent that concurrently
with their formation the provisions of Section 8.15 are satisfied. 
  

 -79- 

 7.07 Prohibited Transactions. Not knowingly accept any Distribution or other payment from the
Borrower or its Restricted Subsidiaries the making of which is prohibited hereunder (the Tribe hereby agreeing that any such payment or Distribution, whether knowingly or unknowingly accepted, will be held by the Tribe in trust for the benefit of
the Administrative Agent and the Lenders, and shall be paid forthwith over and delivered, upon the request of the Administrative Agent or the Borrower, to the Borrower), or enter into any transaction with the Borrower or any of its Restricted
Subsidiaries which is prohibited by Section 9.08. 
 7.08 Amendments to Certain Documents. 
 (a) Not amend, modify or waive any term or provision of any Material Document, or waive any rights thereunder in any respect which is materially adverse
to the interests of the Administrative Agent or the Lenders, provided that the UCC Ordinance provides and shall provide that any amendment to the Uniform Commercial Code as enacted from time to time by Connecticut shall be automatically incorporated
in the Tribe’s Uniform Commercial Code. 
 (b) In any event, not consent to any amendment, modification, or waiver of any term or
provision of any Material Document in any manner without thirty days’ prior written notice to the Lenders. 
 7.09 Impairment of
Contracts; Imposition of Governmental Charges. The Tribe shall not: 
 (a) Adopt, enact, promulgate or otherwise place into effect any
tribal Law which impairs or interferes, or could impair or interfere, in any manner, with any right or remedy of the Creditors, the Obligations of the Tribe or the Loan Parties under this Agreement or the other Loan Documents (it being understood
and agreed that any such tribal Law which is adopted, enacted, promulgated or otherwise placed into effect without the consent of all of the Lenders shall, with respect to the Loan Documents, the rights and remedies of the Creditors thereunder, and
the Obligations, be void and of no effect); or 
 (b) Demand, impose or receive any tax, charge, assessment, fee or other imposition (except
as specifically contemplated by Sections 9.05, 9.06 or 9.08) or impose any regulatory or licensing requirement, against the Borrower, its Restricted Subsidiaries or their customers or guests, their operations or Authority Property (including,
without limitation, Mohegan Sun or Pocono Downs), the Creditors, the employees, officers, directors, patrons or vendors of the Borrower and its Restricted Subsidiaries, other than (i) as provided in the Gaming Ordinance, (ii) charges upon
the Borrower and the Restricted Subsidiaries to pay the actual and reasonable regulatory expenditures of the Mohegan Tribal Gaming Commission under the Gaming Ordinance, (iii) fees imposed on the Borrower and its Restricted Subsidiaries by the
Commission under IGRA, (iv) the actual costs to the Tribe of services provided to the Borrower under the Town Agreement, and (v) sales, use, room occupancy and related excise taxes, including admissions and cabaret taxes and any other
taxes imposed by the Tribe at rates which are not 

  

 -80- 

 
more onerous than corresponding or similar taxes which may be imposed by the State of Connecticut or local governments in the surrounding area, provided that
the Tribe shall not impose any taxes which are the functional equivalent of property taxes, gross receipts or gross revenues taxes, business franchise taxes or income taxes upon the Borrower and its Restricted Subsidiaries, and any such taxes shall
(x) be of general application to all similarly situated persons, (y) not be duplicative of payments made by the Borrower and its Restricted Subsidiaries for services provided by the Tribe to the Borrower and its Restricted Subsidiaries and
permitted under Section 9.06(c), and (z) be rationally related to the overall tax policy of the Tribe. 
 7.10 Segregation of
Authority Property. The Tribe shall not: 
 (a) Fail to segregate all Authority Property, including all funds and bank accounts, from the
Property of the Tribe; or 
 (b) Commingle any Authority Property (including any funds or bank accounts) with any other Property of the Tribe
or its Affiliates which is not Authority Property. 
 7.11 Trust Property. The Tribe shall not convey into trust with the federal
government of the United States of America, to be held for the benefit of the Tribe or any of its Affiliates, any Authority Property other than interests in real property and improvements thereon associated with Mohegan Sun in the vicinity of
Uncasville, Connecticut. 
 7.12 Liens on Authority Property. The Tribe shall not create, incur, assume or suffer to exist any Lien or
other encumbrance upon Authority Property which is not permitted by Section 9.01. 
 7.13 Bankruptcy Matters; Etc. 
 (a) The Tribe will not enact any bankruptcy or similar law for the relief of debtors that would impair, limit, restrict, delay or otherwise adversely
affect any of the rights and remedies of the Creditors provided for in the Loan Documents; 
 (b) The Tribe will not, or permit the Borrower,
its Restricted Subsidiaries or any of the Tribe’s representatives, political subunits, agencies, instrumentalities or councils to, exercise any power of eminent domain over the Mohegan Sun. Except as required by state or federal Law, the Tribe
will not enact any statute, law, ordinance or rule that would have a material adverse effect upon the rights of the Creditors under the Loan Documents; and 
 (c) The Tribe agrees that upon any payment or distribution of assets upon any liquidation, dissolution, winding up, reorganization, assignment for the benefit of creditors, marshaling of assets or any bankruptcy,
insolvency or similar proceedings of or with respect to the Borrower and its Restricted Subsidiaries, the Creditors shall be entitled to receive payment in full of all Obligations before any payment or distribution is made to the Tribe. 

7.14 Impairment of Contracts. The Tribe agrees that any action taken in violation of Sections 7.08, 7.09 or 7.13 shall be deemed in
contravention of Article XIV (entitled “Non-Impairment of Contracts”) of the Constitution. 
  

 -81- 

 ARTICLE VIII 
 AFFIRMATIVE COVENANTS OF THE BORROWER 
 So long as any Lender shall have any Revolving Commitment
hereunder, any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than the obligations referenced in Sections 3.01, 3.04, 3.05, 12.04 and 12.05), or any Letter of Credit shall remain outstanding, the Borrower shall,
and shall (except in the case of the covenants set forth in Sections 8.01, 8.02, and 8.03) cause each of its Restricted Subsidiaries to: 
 8.01 Financial Statements. Deliver to the Administrative Agent and each Lender, in form and detail reasonably satisfactory to the Administrative Agent and the Required Lenders: 
 (a) as soon as available, but in any event within 90 days after the end of each Fiscal Year of the Borrower (commencing with the Fiscal Year ended
September 30, 2007), an audited consolidated balance sheet of the Borrower and its Restricted Subsidiaries (which may also include Unrestricted Subsidiaries and other Persons) as at the end of such Fiscal Year, and the related audited
consolidated statements of income or operations, retained earnings, and cash flows for such Fiscal Year, all in reasonable detail and prepared in accordance with GAAP, such consolidated statements to be audited and accompanied by (i) a report
and opinion of a Registered Public Accounting Firm of nationally recognized standing reasonably selected by the Borrower and reasonably acceptable to the Required Lenders, which report and opinion shall be prepared based on an audit conducted in
accordance with GAAP as at such date, and which opinion shall be an unqualified opinion without additional explanatory or non-standard wording which the Required Lenders determine is unacceptable and with no limitation as to the scope of their audit
and (ii) appropriate breakouts of the financial position and results of operations of Unrestricted Subsidiaries and other Persons whose assets or results of operations are included in such financial statements but are not Authority Property.

 (b) as soon as available, but in any event within 45 days after the end of each Fiscal Quarter of each Fiscal Year of the Borrower
(commencing with the Fiscal Quarter ended March 31, 2007), other than the fourth Fiscal Quarter of each Fiscal Year of the Borrower, a consolidated balance sheet of the Borrower and its Restricted Subsidiaries (which may also include
Unrestricted Subsidiaries and other Persons) as at the end of such Fiscal Quarter, and the related consolidated statements of income or operations, retained earnings and cash flows for such Fiscal Quarter and for the portion of the Borrower’s
Fiscal Year then ended, all in reasonable detail, such consolidated statements to be certified by a Senior Officer of the Borrower as fairly presenting the financial condition, results of operations and changes in financial position or cash flows of
the Borrower and its Restricted Subsidiaries in accordance with GAAP (other than any requirement for footnote disclosures) consistently applied, as at such date and for such periods, subject only to normal year-end accruals and audit adjustments,
together with breakouts of the financial position and results of operations of Unrestricted Subsidiaries or other Persons whose assets or results of operations are included in such financial statements but are not Authority Property. 
  

 -82- 

 (c) prior to the commencement of any significant construction activities in respect of a Project, the
reasonably final Construction Plans, Construction Budget and Construction Timetable for that Project (all of which are subject to updating pursuant to the terms of this Agreement). 
 (d) as soon as available, and in any event within 45 days after the end of each Fiscal Quarter ending after the commencement of significant construction
activities in respect of a Project, the updated Construction Plans, Construction Budget and Construction Timetable (or a summary thereof reasonably acceptable to the Administrative Agent) for such Project and, if any changes thereto have resulted in
a deferral of the projected date of the public opening of Mohegan Sun Phase III in a manner which would lengthen the period described in the definition of “Construction Period,” written notice of the change of such date. 

8.02 Certificates; Other Information. Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the
Administrative Agent and the Required Lenders: 
 (a) concurrently with the delivery of the financial statements referred to in
Section 8.01(a) and (b), commencing with the Fiscal Quarter ending March 31, 2007, a written discussion and analysis of the financial condition and results of operations of the Borrower and its Restricted Subsidiaries (which may also
include Unrestricted Subsidiaries and other Persons) in reasonable detail, including in the case of any such report delivered in connection with the financial statements referred to in Section 8.01(a), an explanation of any material
variance from operational results or balance sheet items contained in projections previously delivered to the Lenders; 
 (b) concurrently
with the delivery of the financial statements referred to in Sections 8.01(a) and (b), a duly completed Compliance Certificate at the Borrower’s sole expense signed by the chief executive officer, chief operating officer or chief financial
officer of the Borrower; 
 (c) as soon as practicable, and in any event within 45 days after the end of the fourth Fiscal Quarter in each
Fiscal Year, a completed Pricing Certificate; 
 (d) as soon as practicable, and in any event within 45 days after the end of each Fiscal
Quarter ending prior to the date upon which both of the Projects are substantially complete and open for business to the general public (and in any during the Construction Period), (i) an In-Balance Certificate signed by the chief executive
officer, chief operating officer or chief financial officer of the Borrower certifying that the In-Balance Test has been met as of the last day of such Fiscal Quarter, and (ii) a reconciliation of Capital Expenditures made in respect of each of
the Projects to the then effective Construction Budget for such Project; 
 (e) as soon as practicable, and in any event within 20 days after
the end of each calendar month, a monthly revenue report showing revenues for the prior calendar month associated with each gaming category, occupancy percentage, average hotel room rental rates experienced by the Mohegan Sun and Pocono Downs, to
the extent applicable, during such monthly period and a breakout of the Mohegan Sun operations, Pocono Downs operations and any other material operations of the Borrower; 
  

 -83- 

 (f) as soon as practicable, and in any event within 90 days after the commencement of each Fiscal Year,
consolidated projected financial statements by Fiscal Quarter through the end of the Construction Period, including, in each case, projected balance sheets, statements of income and retained earnings and statements of cash flow of the Borrower, each
of which shall be in reasonable detail and reasonably acceptable to the Administrative Agent and in any event shall include (i) the projected Distributions to be made to the Tribe by the Borrower, the amount of EBITDA projected for the
remainder of the Construction Period, (iii) the amount of Interest Charges anticipated to be incurred during the Construction Period, and (iv) projected Capital Expenditures and Maintenance Capital Expenditures and a breakout by property
and category. 
 (g) promptly following receipt thereof, copies of any detailed audit reports or recommendations submitted to the Tribe or
the Borrower by independent accountants in connection with the accounts or books of the Borrower or any of its Restricted Subsidiaries or any audit of the Borrower or any of its Restricted Subsidiaries; 
 (h) promptly following the filing thereof (i) copies of each monthly revenue report filed by the Borrower or any of its Restricted Subsidiaries (or
by the Tribe in respect of its gaming operations or any Authority Property) with any Governmental Agency; and (ii) all reports which the Borrower is required to file with the National Indian Gaming Commission under 25 C.F.R. Part 514;

 (i) promptly after the same are available, a copy of the Form 5500 series report of each Pension Plan maintained by the Borrower or any
ERISA Affiliate as filed with the Internal Revenue Service for each Fiscal Year; 
 (j) promptly, such additional data and information
regarding the business, financial or corporate affairs of the Borrower or any Subsidiary, the Mohegan Sun, Pocono Downs, or compliance with the terms of the Loan Documents, as the Administrative Agent or the Required Lenders may from time to time
reasonably request; and 
 (k) such information concerning the Tribe, the Borrower and the Restricted Subsidiaries as the Administrative
Agent may reasonably request. 
 Documents required to be delivered pursuant to Section 8.01(a) or (b) may be delivered
electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Borrower posts such documents, or provides a link thereto on the Borrower’s website on the Internet at the website address listed on
Schedule 12.02; or (ii) on which such documents are posted on the Borrower’s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website
or whether sponsored by the Administrative Agent); provided that: (i) the Borrower shall deliver paper copies of such documents to the Administrative Agent or any Lender that requests the Borrower to deliver such paper copies until a
written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (ii) the Borrower shall notify the Administrative Agent (by telecopier or electronic mail) of the posting of any such documents and provide
to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. Notwithstanding anything contained herein, in every instance the Borrower 

  

 -84- 

 
shall be required to provide paper copies of the Compliance Certificates required by Section 8.02(b) to the Administrative Agent. Except for such
Compliance Certificates, the Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any
such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents. 
 Each of the Tribe and the Borrower hereby acknowledges that (a) the Administrative Agent and/or the Joint Lead Arrangers will make available to the Lenders and the L/C Issuer materials and/or information provided by or on behalf of the
Borrower hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks or another similar electronic system (the “Platform”) and (b) certain of the Lenders may be
“public-side” Lenders (i.e., Lenders that do not wish to receive material non-public information with respect to the Borrower or its securities) (each, a “Public Lender”). Each of the Tribe and the Borrower hereby
agrees that so long as it is the issuer of any outstanding debt or equity securities that are registered or issued pursuant to a private offering or are actively contemplating issuing any such securities (w) all Borrower Materials that are to
be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (x) by marking Borrower
Materials “PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent, the Joint Lead Arrangers, the L/C Issuer and the Lenders to treat such Borrower Materials as not containing any material non-public information
with respect to the Borrower or its securities for purposes of United States Federal and state securities laws (provided, however, that to the extent such Borrower Materials constitute Information, they shall be treated as set forth in
Section 12.07); (y) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Investor;” and (z) the Administrative Agent and the Joint Lead
Arrangers shall be entitled to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not designated “Public Investor.” 
 8.03 Notices. Promptly notify the Administrative Agent: 
 (a) and in any event within five Business Days after a Senior Officer of the Tribe or the Borrower becomes aware of the existence of any condition or event which constitutes a Default or Event of Default, written
notice specifying the nature and period of existence thereof and specifying what action the Tribe and the Borrower are taking or propose to take with respect thereto; 
 (b) as soon as practicable, and in any event not less than five Business Days (or, if acceptable to the Administrative Agent, a shorter period) prior to the proposed effective date thereof, written notice of any
proposed amendment, modification or waiver of the terms and provisions of any of the Material Documents; 
 (c) Promptly upon a Senior
Officer of the Borrower becoming aware that (i) any Person has commenced a legal proceeding with respect to a claim against the Borrower or its Restricted Subsidiaries that is, in the reasonable opinion of their independent legal counsel,
$10,000,000 or more in excess of the amount thereof that is fully covered by insurance (subject 

  

 -85- 

 
to applicable deductibles and retentions), (ii) any creditor or lessor under a written credit agreement with respect to Indebtedness in excess of
$10,000,000 or lease involving unpaid rent in excess of $10,000,000 has asserted a default thereunder on the part of the Borrower or its Restricted Subsidiaries, (iii) any Person commenced a legal proceeding with respect to a claim against the
Borrower or its Restricted Subsidiaries under a contract that is not a credit agreement or lease in excess of $10,000,000, (iv) any labor union has notified the Borrower or its Restricted Subsidiaries of its intent to strike the Borrower or its
Restricted Subsidiaries on a date certain, which strike could reasonably be expected to have a Material Adverse Effect, or (v) any other event or circumstance occurs or exists that would constitute a Material Adverse Effect, in each case a
written notice describing the pertinent facts relating thereto and what action the Borrower is taking or propose to take with respect thereto; 
 (d) promptly after the Borrower has notified Administrative Agent of any intention by the Borrower to treat the Loans and/or Letters of Credit and related transactions as being a “reportable transaction” (within the meaning of
Treasury Regulation Section 1.6011-4), a duly completed copy of IRS Form 8886 or any successor form; 
 (e) of the occurrence of any
ERISA Event; 
 (f) of any material change in accounting policies or financial reporting practices by the Borrower or any Restricted
Subsidiary; 
 (g) of the determination by the Registered Public Accounting Firm providing the opinion required under Section 8.01(a)
(in connection with its preparation of such opinion) or the Borrower’s determination at any time of the occurrence or existence of any Internal Control Event. 
 Each notice pursuant to this Section 8.03 shall be accompanied by a statement of a Senior Officer of the Borrower setting forth details of the occurrence referred to therein and stating what action the Borrower
has taken and proposes to take with respect thereto. Each notice pursuant to Section 8.03(a) shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached. 
 8.04 Payment of Obligations. Pay and discharge as the same shall become due and payable, all its obligations and liabilities, including all tax
liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are
being maintained by the Borrower or such Restricted Subsidiary. 
 8.05 Preservation of Existence, Etc. (a) Preserve, renew and
maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 9.04 or 9.05; and (b) take all reasonable action to maintain all
rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. 
 8.06 Maintenance of Properties. (a) Maintain, preserve and protect all of its material properties, intellectual property and equipment used
in the operation of its business in good 

  

 -86- 

 
working order and condition, subject to wear and tear in the ordinary course of business, except that the failure to maintain, preserve and protect a
particular item of depreciable Property that is not of significant value, either intrinsically or to the operations of the Borrower and its Restricted Subsidiaries shall not constitute a violation of this covenant; (b) make all necessary
repairs thereto and renewals and replacements thereof except where the failure to do so could not reasonably be expected to have a Material Adverse Effect; (c) maintain its ownership of all intellectual property and licenses thereof
necessary for the operation of Mohegan Sun and Pocono Downs; and (d) use the standard of care typical in the industry in the operation and maintenance of its facilities. 
 8.07 Maintenance of Insurance. (a) Maintain liability, casualty and other insurance with respect to itself and all Authority Property
(subject to customary deductibles and retention) with responsible insurance companies against such risks as is carried by responsible companies engaged in similar businesses and owning similar assets in the general areas in which the Borrower
operates and, in any event, (i) workers’ compensation insurance, to the extent required to comply with all applicable state, territorial and United States laws and regulations, (ii) comprehensive general liability insurance with
minimum limits of $2,000,000, (iii) umbrella liability insurance providing excess liability coverages over and above the foregoing underlying insurance policies up to a minimum limit of $100,000,000 and (iv) property insurance protecting
the Mohegan Sun and Pocono Downs for possible damage by fire, lightening, wind-storm other damage, vandalism, riot, earthquake, civil commotion, malicious mischief, hurricane and such other risks and hazards as are from time to time covered by an
“all risk” policy or a property policy covering “special” causes of loss. The insurance referred to in clause (iv) shall provide coverage which is not less than (i) the Maximum Foreseeable Loss (as determined from time
to time) in respect of the Mohegan Sun and related improvements and (ii) $1,500,000,000 in the aggregate in respect of the Mohegan Sun and the Pocono Downs and all related improvements and other Property with a deductible no greater than
$500,000 (other than earthquake insurance for which the deductible may be up to 10% of the Maximum Foreseeable Loss). 
 (b) In any event,
the Loan Parties shall maintain and keep in force, at all times during any period of construction of any Project or Material Project, and with respect to any property affected by such construction, a policy or policies of builder’s “all
risk” insurance in nonreporting form in an amount not less than the full insurable completed value of such portion of the affected property on a replacement cost basis. All such insurance shall be carried through sound and reputable insurance
companies. 
 (c) Each policy required by this Section shall name the Administrative Agent as an additional insured and mortgagee, and
shall to the extent relevant, include a waiver of subrogation against the Administrative Agent and the Lenders, contain a provision that provides for a severability of interests, and shall provide that an act or omission by one of the insured shall
not reduce or void coverage with respect to the other insureds, insure against loss or damage by hazards customarily included within “all risk” and “extended coverage” policies and any other risks or hazards which the
Administrative Agent or the Required Lenders may reasonably specify (and shall include fire, sprinkler leakage, windstorm, hurricane, international and domestic acts of terrorism, earthquake, steam boiler, pressurized vessel and machinery insurance
insuring both against breakdown and explosion or other losses to personal property resulting from the use or maintenance thereof), shall contain a Lender’s Loss Payable Endorsement in a 

  

 -87- 

 
form acceptable to the Administrative Agent in favor of the Administrative Agent and shall be primary and noncontributory with any other insurance carried by
the Administrative Agent or the Lenders. 
 (d) The Loan Parties shall supply the Administrative Agent with certificates of each policy
required hereunder, and, if requested, an original or underlyer of each such policy and all endorsements thereto. Prior to the expiration of any insurance policy required hereunder, the Loan Parties shall furnish the Administrative Agent with proof
acceptable to the Administrative Agent that the policy has been reinstated, renewed or a new policy issued or continuing in force the insurance. If any Loan Party fails to pay any such premium, the Administrative Agent shall have the right, but not
the obligation, to obtain reasonable replacement coverage and advance funds to pay the premiums for it on behalf of the Lenders. The Borrower shall repay the Administrative Agent immediately on demand for any advance for such premiums, which shall
be considered to be an additional loan bearing interest from the date of demand at the Default Rate. 
 8.08 Compliance with Laws.
Comply in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (a) such requirement of Law or order, writ,
injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (b) the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect. 
 8.09 Books and Records. (a) Maintain proper books of record and account, in which full, true and correct entries in conformity with GAAP
shall be made of all financial transactions and matters involving the assets and business of the Borrower and its Restricted Subsidiaries, as the case may be; and (b) maintain such books of record and account in material conformity with
all applicable requirements of any Governmental Authority having regulatory jurisdiction over the Borrower and its Restricted Subsidiaries, as the case may be. 
 8.10 Inspection Rights. Subject to applicable regulatory requirements, upon reasonable notice, at any time during regular business hours and as often as requested (but not so as to unreasonably interfere with
the business of the Borrower and its Restricted Subsidiaries), permit the Administrative Agent or any Lender, or any authorized employee, agent or representative thereof, at the sole expense of the Borrower, to examine, audit and make copies and
abstracts from the records and books of account of, and to visit and inspect Mohegan Sun, Pocono Downs and the other material properties of the Borrower and its Restricted Subsidiaries, and to discuss the affairs, finances and accounts of the
Borrower and its Restricted Subsidiaries with any of its officers, key employees, and accountants, and, upon request, furnish promptly to the Administrative Agent or any Lender true copies of all financial information made available to the senior
management of the Borrower. 
 8.11 Use of Proceeds. Use the proceeds of the Loans and Letters of Credit (a) to refinance all of
the Loans outstanding under the Existing Loan Agreement on the Closing Date, and (b) to provide for working capital availability and other general purposes of the Borrower and its Restricted Subsidiaries, including without limitation
(i) paying the costs and expenses associated with the design, development and construction of Mohegan Sun Phase III, (ii) paying 

  

 -88- 

 
the costs and expenses associated with the design, development and construction of Pocono Downs Phase II, (iii) the making of Distributions to the
Tribe (to the extent not prohibited by Section 9.06), (iv) the repayment or prepayment of Indebtedness to the extent permitted by Section 9.09 and (v) making the other Capital Expenditures and Investments by the Borrower and its
Restricted Subsidiaries not prohibited by this Agreement. 
 8.12 Hazardous Materials Laws. Keep and maintain the Real Property and
each portion thereof in compliance in all material respects with all Hazardous Materials Laws and promptly advise Administrative Agent in writing of (a) any and all enforcement, cleanup, removal or other governmental or regulatory actions
instituted, completed or threatened in writing pursuant to any applicable Hazardous Materials Laws, (b) any and all claims made or threatened in writing, and received by the Borrower, by any third party against the Borrower or the Real Property
relating to damage, contribution, cost recovery, compensation, loss or injury resulting from any Hazardous Materials and (c) discovery by any Senior Officer of the Tribe or the Borrower of any occurrence or condition on any real property
adjoining or in the vicinity of the Real Property that could reasonably be expected to cause the Real Property or any part thereof to be subject to any restrictions on the ownership, occupancy, transferability or use of the Real Property under any
Hazardous Materials Laws, provided that the good faith failure of the Borrower to comply with Hazardous Materials Laws shall not constitute a breach of the covenants in this Section 8.12 if (x) the Borrower is diligently attempting to
comply therewith, and (y) such non-compliance would not have, individually or in the aggregate, a Material Adverse Effect. 
 8.13
Deposit and Brokerage Accounts. Within thirty days following the opening of each Operating Account, enter into and cause its Restricted Subsidiaries, except the WNBA Subsidiary, to enter into a Deposit Account Agreement with respect to each
Operating Account hereafter established. 
 8.14 Continual Operation of Mohegan Sun. Continuously operate the Mohegan Sun
substantially in the manner operated as of the Closing Date (or as contemplated on the Closing Date to be operated) and in any event in material compliance with the Gaming Ordinance, the Gaming Authority Ordinance all applicable Laws and the
Compact, and refrain from conducting any gaming activities (including without limitation all Class II and Class III gaming activities (as defined in IGRA)) at any location on the Tribe’s current reservation near Uncasville, Connecticut, other
than Mohegan Sun. 
 8.15 Future Subsidiaries and Collateral. 
 (a) Cause each Person which is at any time a Restricted Subsidiary to promptly execute and deliver to the Administrative Agent a guarantee of the
Obligations, and Collateral Documents, similar in form and content (including without limitation exceptions and qualifications) to the Guaranties and Collateral Documents and otherwise reasonably acceptable to the Administrative Agent and any and
all other documents reasonably required by the Administrative Agent in connection with the Loan Documents. 
 (b) Execute, and cause each of
its Restricted Subsidiaries other than the WNBA Subsidiary to execute, and to deliver to the Administrative Agent, promptly upon request 

  

 -89- 

 
of the Administrative Agent, such Collateral Documents as are reasonably required by the Administrative Agent to create a valid and perfected Lien upon any
material property which they hereafter acquire (excluding property not required to be encumbered by the existing Collateral Documents), provided that: 
 (1) Borrower and its Restricted Subsidiaries will not be required to pledge their respective interests under third-party management,
development or other related agreements entered into by Borrower or its Restricted Subsidiaries with respect to third-party gaming facilities; and 
 (2) Borrower and its Restricted Subsidiaries will not be required to pledge their equity interests in any Person which is an Unrestricted Subsidiary or which is not wholly-owned, directly or indirectly, by the Tribe,
Borrower or its Restricted Subsidiaries. 
 (c) Promptly deliver to the Administrative Agent in pledge all of the Equity Interests held by
the Borrower and any of its Restricted Subsidiaries in any Person which hereafter becomes a Restricted Subsidiary, but not the Equity Interests in the WNBA Subsidiary. 
 (d) Promptly upon entering into architectural agreements with the architect of record, the construction contracts with the general contractor, and, if applicable, the construction management agreements with the
construction manager, in each case related to Mohegan Sun Phase III and Pocono Downs Phase II, execute and to deliver to the Administrative Agent Collateral Assignments with respect to such agreements (including the executed consents of the
counterparties to such agreements). 
 8.16 Leasehold Mortgage. If and to the extent that the necessary governmental approvals have
not been obtained prior to the Closing Date, the Borrower shall continue to use its good faith reasonable efforts following the Closing Date to obtain all governmental approvals necessary for the Borrower’s execution and delivery of the
Leasehold Mortgage to the Administrative Agent. If and when such approvals are obtained, the Borrower shall promptly (a) deliver the Leasehold Mortgage to Administrative Agent and (b) deliver to Administrative Agent an ALTA policy of title
insurance with respect to the Leasehold Mortgage in form and substance substantially similar to the title insurance delivered in connection with the Existing Loan Agreement or, if different, otherwise satisfactory to Administrative Agent.

 8.17 Construction Covenants; Plans, Budget and Timetable. 
 (a) Construct each of the Projects in material conformity with the Construction Plans and Construction Budget then in effect for that Project, as amended
from time to time in accordance with the terms of this Agreement; 
 (b) Use commercially reasonable efforts to maintain a Construction
Timetable for Mohegan Sun Phase III that allows the Borrower to achieve the Completion Date for Mohegan Sun Phase III not later than December 31, 2010; and 
  

 -90- 

 (c) Use commercially reasonable efforts to maintain a Construction Timetable for Pocono Downs
Phase II that allows Downs Racing, L.P. to achieve the Completion Date for Pocono Downs Phase II not later than March 31, 2009. 
  

 -91- 

 ARTICLE IX 
 NEGATIVE COVENANTS 
 So long as any Lender shall have any Revolving Commitment hereunder, any Loan or
other Obligation hereunder shall remain unpaid or unsatisfied (other than the obligations referenced in Sections 3.01, 3.04, 3.05, 12.04 and 12.05), or any Letter of Credit shall remain outstanding, the Borrower shall not, nor shall it permit
any Restricted Subsidiary to, directly or indirectly: 
 9.01 Liens; Negative Pledges. Create, incur, assume or suffer to exist any
Lien upon any of the Authority Property, assets or revenues, whether now owned or hereafter acquired or suffer to exist any Negative Pledge with respect to any Authority Property other than the following: 
 (a) Liens and Negative Pledges pursuant to any Loan Document; 
 (b) Liens, Negative Pledges and Rights of Others existing on the date hereof and listed on Schedule 9.01 and any renewals or extensions thereof, provided that (i) the property covered thereby is not
changed, (ii) the amount secured or benefited thereby is not increased, (iii) the direct or any contingent obligor with respect thereto is not changed, and (iv) any renewal or extension of the obligations secured or benefited thereby
is permitted by Section 9.03(e); 
 (c) Liens securing judgments for the payment of money not constituting an Event of Default under
Section 10.01(h) or (i); 
 (d) Liens and Negative Pledges securing Indebtedness permitted under Section 9.03(g); provided
that (i) such Liens do not at any time encumber any property other than the property financed by such Indebtedness and (ii) the Indebtedness secured thereby does not exceed the cost or fair market value, whichever is lower, of the property
being acquired on the date of acquisition; 
 (e) Liens and Negative Pledges in respect of assets of the WNBA Subsidiary in favor of WNBA,
LLC or its designees to secure obligations of the WNBA Subsidiary under the WNBA Agreements; 
 (f) Permitted Encumbrances and Permitted
Rights of Others; and 
 (g) Rights of others granted pursuant to the WNBA Agreements consisting of the right to use the Mohegan Sun Arena
for scheduled home games of the Connecticut Sun and related basketball activities. 
 9.02 Investments. Make any Investments, except:

 (a) Investments in the form of Cash Equivalents; 
  

 -92- 

 (b) Investments consisting of payroll advances to employees of the Borrower and its Subsidiaries for
travel, entertainment and relocation expenses in the ordinary course of business in an aggregate amount not to exceed $1,000,000 at any one time outstanding; 
 (c) Investments in the WNBA Subsidiary, the Pocono Downs Subsidiaries and Mohegan Ventures-Northwest, LLC provided that such Investments are not increased unless otherwise permitted hereunder; 
 (d) Investments in the WNBA Subsidiary, the Pocono Downs Subsidiaries, Mohegan Ventures-Northwest, LLC and its other Restricted Subsidiaries to the
extent in compliance with Section 7.06, provided that the aggregate Investments in the WNBA Subsidiary shall not exceed $50,000,000; 
 (e) Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business, and Investments received in satisfaction or partial
satisfaction thereof from financially troubled account debtors to the extent reasonably necessary in order to prevent or limit loss; 
 (f)
other Investments, the aggregate outstanding amount of which does not exceed, as of the date of the making of any such Investment, the sum of: 
 (1) $150,000,000, plus 
 (2) 25% of EBITDA for the then most recently ended twelve month
period ending on the last day of a Fiscal Quarter for which the Borrower has delivered a Compliance Certificate or Pricing Certificate; plus, 
 (3) if both the Completion Date for Mohegan Sun Phase III has occurred and giving effect to such Investment, the Pro Forma Total Leverage Ratio is less than 5.50:1.00; an additional $100,000,000; 
 provided that the Investments made pursuant to this clause (f) in Persons whose primary business is not the conduct of gaming activities shall not exceed
$50,000,000 in the aggregate at any one time outstanding; 
 (g) Investments in Swap Contracts with Acceptable Swap Counterparties in respect
of Indebtedness having an aggregate notional amount not to exceed $700,000,000 at any one time outstanding; 
 (h) Investments consisting of
Property received in connection with any Permitted Disposition; and 
 (i) the Investment contemplated in connection with the Permitted
Transaction. 
 Without limitation on the foregoing provisions of this Section, the Tribe or the Borrower may form or acquire one or more Persons for the
purpose of conducting gaming, including, without limitation, Class II and Class III gaming activities (as defined in IGRA) at locations which are 

  

 -93- 

 
not a part of the Tribe’s reservation, provided that: (i) the financial position and results of operations of any such Person shall not be
reflected in the financial statements of Borrower which are delivered to the Lenders from time to time except to the extent that either (A) such Persons are Restricted Subsidiaries, or (B) as to Unrestricted Subsidiaries or other Persons
the assets of which are not Authority Property, concurrently with the delivery of such financial statements, the Borrower provides the Administrative Agent and the Lenders with appropriate breakouts of the financial position and results of
operations of each such Unrestricted Subsidiary or Person whose financial position and results of operations are reflected in such financial statements; (ii) the holders of Indebtedness and Contingent Obligations of such Persons shall not have
or obtain recourse, contractual or otherwise, to the assets and revenues of the Borrower or any of its other Restricted Subsidiaries, (iii) the assets of such Persons which are Unrestricted Subsidiaries shall not be deemed to constitute
Authority Property, (iv) to the extent formed or acquired by Borrower, rather than by the Tribe, any Investments of the Borrower in such Persons shall be in compliance with the provisions of this Section, (v) no such Person which is not a
Restricted Subsidiary shall be obligated to issue any guaranty of the Obligations or any Collateral Documents, and (vi) no portion of the Capital Expenditures which the Borrower is permitted to make pursuant to Section 7.15 shall be made
in respect of the Property of any such Persons which are not Restricted Subsidiaries, provided that any such Person shall be free to make its own Capital Expenditures using funds which are the subject of permitted Investments by Borrower pursuant to
this Section 9.02. 
 9.03 Indebtedness. Create, incur, assume or suffer to exist any Indebtedness, except: 
 (a) Indebtedness under the Loan Documents; 
 (b) existing Indebtedness under the Existing Senior Indenture, and additional or replacement unsecured senior Indebtedness of the Borrower which has no amortization prior to the date which is one year after the Maturity Date, a final
maturity which is not less than one year later than the Maturity Date, and is subject to agreements having covenants and defaults which are substantially similar to the covenants applicable to senior obligations contained in the Existing Senior
Indenture as in effect on the date of this Agreement (as determined by the Administrative Agent in its reasonable discretion), provided that the aggregate principal amount of all Indebtedness outstanding under this clause (b) shall not exceed
$500,000,000 at any time; 
 (c) the Indebtedness outstanding as of the Closing Date under the Existing Senior Subordinated Indentures;

 (d) additional subordinated obligations (i) that are incurred when no Default or Event of Default has occurred or would result from
the incurrence thereof (without the requirement of any approval by the Required Lenders), have no amortization prior to the date which is one year after the Maturity Date, have a final maturity which is not less than one year later than the Maturity
Date, and have subordination provisions, covenants and defaults which are substantially similar to those contained in the Borrower’s Existing Senior Subordinated Notes due 2015 (as determined by the Administrative Agent in its reasonable
discretion), or (ii) the incurrence of which is approved by the Required Lenders; 
  

 -94- 

 (e) Indebtedness outstanding on the date hereof and listed on Schedule 9.03 and any refinancings,
refundings, renewals or extensions thereof; provided that (i) the amount of such Indebtedness is not increased at the time of such refinancing, refunding, renewal or extension except by an amount equal to a reasonable premium or other
reasonable amount paid, and fees and expenses reasonably incurred, in connection with such refinancing and by an amount equal to any existing commitments unutilized thereunder and (ii) the terms relating to principal amount, amortization,
maturity, collateral (if any) and subordination (if any), and other material terms taken as a whole, of any such refinancing, refunding, renewing or extending Indebtedness, and of any agreement entered into and of any instrument issued in connection
therewith, are no less favorable in any material respect to the Loan Parties or the Lenders than the terms of any agreement or instrument governing the Indebtedness being refinanced, refunded, renewed or extended; 
 (f) obligations (contingent or otherwise) of the Borrower or any Subsidiary existing or arising under any Swap Contract subject to the limitations in
Section 9.02(g); 
 (g) Indebtedness in respect of Capital Leases, Synthetic Lease Obligations and purchase money obligations for fixed
or capital assets within the limitations set forth in Section 9.01(i); provided, however, that the aggregate amount of all such Indebtedness at any one time outstanding shall not exceed $100,000,000; 
 (h) Contingent Obligations of Borrower consisting of a guarantee of the obligations of the WNBA Subsidiary under the WNBA Agreements, and additional
Contingent Obligations of the Borrower in respect of obligations of the WNBA Subsidiary, provided that the aggregate amount of the obligations supported by such Contingent Obligations, plus the Capital Expenditures permitted pursuant to
Section 9.17(d) shall not exceed $50,000,000; and 
 (i) unsecured Recourse Obligations, including Contingent Obligations, in an
aggregate principal amount not to exceed $50,000,000 at any time outstanding; 
 (j) other Contingent Obligations in respect of Indebtedness
in an aggregate principal amount not to exceed $100,000,000 at any time outstanding, or if lower, the maximum principal amount which may be demanded under such Contingent Obligations; and 
 (k) Indebtedness assumed in connection with the Permitted Transaction. 
 9.04 Fundamental Changes. Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets
(whether now owned or hereafter acquired) to or in favor of any Person, except that, so long as no Default exists or would result therefrom: 
 (a) any Subsidiary may merge with (i) the Borrower, provided that the Borrower shall be the continuing or surviving Person, or (ii) any one or more other Subsidiaries, provided that when any Guarantor is merging with
another Subsidiary, the Guarantor shall be the continuing or surviving Person and provided that the WNBA Subsidiary may not merge with any other Guarantor unless such other Guarantor shall be the continuing or surviving Person; and 
  

 -95- 

 (b) any Subsidiary may Dispose of all or substantially all of its assets (upon voluntary liquidation or
otherwise) to the Borrower or to another Subsidiary; provided that if the transferor in such a transaction is a Guarantor, then the transferee must either be the Borrower or a Guarantor other than the WNBA Subsidiary. 
 9.05 Dispositions of Property Associated with Mohegan Sun. Make any Disposition or enter into any agreement to make any Disposition of any assets
comprising Mohegan Sun, except: 
 (a) Permitted Dispositions made when no Default or Event of Default exists or would result therefrom; and

 (b) Dispositions of Property specifically contemplated by Sections 9.04, 9.06, 9.08 or 9.09. 
 9.06 Distributions. Make any Distribution, whether from capital, income or otherwise, and whether in cash or other Property, except: 

(a) Priority Distributions; 
 (b)
Distributions made during any calendar month which (i) are in an aggregate amount which, when added to the Priority Distributions made during such calendar month, do not exceed $4,000,000, (ii) are in an aggregate amount which does not
exceed Available Cash Flow for the immediately preceding calendar month; (iii) which after giving effect thereto do not result in a Pro Forma Fixed Charge Coverage Ratio which is less than 1.00:1.00, (iv) which are made when no payment
default in respect of any Recourse Obligations exists, and (v) are made when no Default or Event of Default then in existence has remained continuing for a period in excess of one Fiscal Quarter; 
 (c) Distributions consisting of payments to the Tribe for governmental services provided to the Borrower or any of its Restricted Subsidiaries by the
Tribe or any of its representatives, political subunits, councils, agencies or instrumentalities, in each case to the extent included in the calculation of EBITDA or included in Capital Expenditures pursuant to Section 9.17 (including charges
for utilities, police and fire department services, health and emergency medical services, gaming commission and surveillance services, gaming disputes court and legal services, workers compensation and audit committee services, human resources
services, finance and information technology services, construction, development and environmental related services, rental or lease agreements, the pro rata portion of Tribal Council costs and salaries attributable to the operations of the
Borrower, and similar pro rata costs of other tribal departments, in each case, to the extent that the costs of such departments are reasonably attributable to the operations of the Borrower), provided that such payments are not duplicative of taxes
imposed by the Tribe upon the Borrower and its operations; 
 (d) additional Distributions to the Tribe made when no Default or Event of
Default exists or would result therefrom, which are (i) made during any calendar month in an amount not to exceed Available Cash Flow for the immediately preceding calendar month, and (ii) do not result in the Pro Forma Fixed Charge
Coverage Ratio being less than the required ratio set forth in Section 9.13(c); 
  

 -96- 

 (e) Distributions consisting of cash or other Property received by the Borrower from the WNBA Subsidiary
or any other Subsidiary of the Borrower; and 
 (f) Distributions contemplated in connection with the Permitted Transaction. 
 9.07 Change in Nature of Business. Engage in any material business which is not fundamentally related to the operation of Mohegan Sun, Pocono
Downs or the business of the Restricted Subsidiaries (which may include off-reservation gaming and other non-gaming activities on or in the general area of the Tribe’s reservation in the vicinity of Uncasville, Connecticut), use any material
Authority Property for a purpose which is not permitted by this Agreement, or make any fundamental change to the nature of the business operations of the Borrower and its Restricted Subsidiaries, taken as a whole. 
 9.08 Transactions with Affiliates. Enter into any transaction of any kind with any Affiliate of the Borrower other than (a) employment of
enrolled tribal members, and the immediate family members of tribal members, on terms consistent with the past practices of the Borrower (including the payment of employment bonuses in accordance with past practices), (b) transactions involving
Property having an aggregate value of not more than $2,000,000 for all such transactions, (c) transactions which are on commercially reasonable terms entered into with Native American suppliers and vendors in accordance with the affirmative
action provisions of the Tribe’s Employment Rights Ordinance (in the case of any such transactions or series of related transactions involving more than $2,000,000, on terms disclosed to the Lenders), (d) other transactions on terms at
least as favorable to the Borrower as would be the case in an arm’s-length transaction between unrelated parties of equal bargaining power, the terms of which are disclosed to the Lenders in writing, (e) transactions pursuant to the
Relinquishment Agreement, (f) transactions with the WNBA Subsidiary contemplated by the WNBA Agreements, (g) transactions amongst the Borrower and its Restricted Subsidiaries, or amongst Restricted Subsidiaries, in each case which are not
prohibited under Section 9.02, and (h) Distributions expressly permitted under Section 9.06 and (i) the Permitted Transaction. 
 9.09 Prepay Other Obligations. Prepay any principal (including sinking fund payments), interest or any other amount with respect to any Senior Notes or Subordinated Obligations, or purchase or redeem (or offer to purchase or redeem)
any Senior Notes or Subordinated Obligations, or deposit any monies, securities or other Property with any trustee or other Person to provide assurance that the principal or any portion thereof of any Senior Notes or Subordinated Obligations will be
paid when due or otherwise provide for the defeasance of any Senior Notes or Subordinated Obligations, provided that if no Default or Event of Default exists or would result therefrom, Borrower may: 
 (a) Prepay from any source all or any portion of the remaining principal balance of approximately $16,345,000 of the 8-3/8% Senior Subordinated Notes due
2011 issued under the Indenture dated as of July 26, 2001 between the Borrower and U.S. Bank National Association (formerly State Street Bank and Trust Company), as Trustee; 
 (b) prepay any Senior Notes to the extent that such prepayment is made using the proceeds of (i) unsecured Senior Notes hereafter issued pursuant to
Section 9.03(b) concurrently with the issuance of such Senior Notes (it being understood that any premiums, 

  

 -97- 

 
related costs of issuance, tender offer and solicitation and other transaction costs may concurrently be paid from Available Cash Flow), or
(ii) unsecured Subordinated Obligations hereafter issued pursuant to Section 9.03(d); and 
 (c) prepay any Subordinated
Obligations to the extent that such prepayment is made using the proceeds of unsecured Subordinated Obligations hereafter issued pursuant to Section 9.03(d) concurrently with the issuance of such Subordinated Obligations (it being understood
that any premiums, related costs of issuance, tender offer and solicitation and other transaction costs may concurrently be paid from Available Cash Flow). 
 9.10 Burdensome Agreements. Enter into any Contractual Obligation (other than this Agreement or any other Loan Document) that (a) limits the ability of any Restricted Subsidiary to make
Distributions to the Borrower or any Guarantor or to otherwise transfer property to the Borrower or any Guarantor; or (b) prohibits the granting of any Lien to secure the Obligations or conditions the granting of a Lien to secure the
Obligations upon the grant of a Lien to secure the obligations of the Borrower or any of its Subsidiaries to the beneficiary of that Contractual Obligation. 
 9.11 Use of Proceeds. Use the proceeds of any Credit Extension, whether directly or indirectly, and whether immediately, incidentally or ultimately, to purchase or carry margin stock (within the meaning of
Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose. 
 9.12 Authority Expenditures. Use any Authority Property for a purpose which is not related to the business of the Borrower or its Restricted
Subsidiaries or specifically permitted hereby, expend any funds constituting Authority Property for any purpose which does not directly or indirectly benefit the Borrower and its Restricted Subsidiaries, or make any Capital Expenditure using funds
of the Borrower or its Restricted Subsidiaries or other Authority Property except to add to, further improve, maintain, repair, restore or refurbish Mohegan Sun and Related Businesses. 
 9.13 Financial Covenants. 
 (a)
Maximum Total Leverage Ratio. Permit the Total Leverage Ratio, as of the last day of any Fiscal Quarter described in the matrix below, to exceed, subject to Section 9.13(d) below, the ratio set forth opposite that Fiscal Quarter:

  

			
	 Fiscal Quarters Ending
	  	Maximum Ratio
	 March 31, 2007 through June 30, 2007
	  	5.00:1.00
		
	 September 30, 2007 and December 31, 2007
	  	5.50:1.00
		
	 March 31, 2008 and June 30, 2008
	  	5.75:1.00
		
	 September 30, 2008 and December 31, 2008
	  	6.00:1.00
		
	 March 31, 2009
	  	6.25:1.00
		
	 June 30, 2009 through March 31, 2010
	  	6.75:1.00
		
	 June 30, 2010
	  	6.50:1.00
		
	 September 30, 2010
	  	6.00:1.00
		
	 December 31, 2010 and March 31, 2011
	  	5.50:1.00
		
	 June 30, 2011 and September 30, 2011
	  	5.00:1.00
		
	 December 31, 2011 and thereafter
	  	4.75:1.00

  

 -98- 

 (b) Senior Leverage Ratio. Permit the Senior Leverage Ratio, as of the last day of any Fiscal
Quarter described in the matrix below, to exceed, subject to Section 9.13(d) below, the ratio set forth opposite that Fiscal Quarter: 
  

			
	 Fiscal Quarters Ending
	  	Maximum Ratio
	 March 31, 2007 through June 30, 2007
	  	2.00:1.00
		
	 September 30, 2007 and December 31, 2007
	  	2.25:1.00
		
	 March 31, 2008 and June 30, 2008
	  	2.75:1.00
		
	 September 30, 2008 and December 31, 2008
	  	3.00:1.00
		
	 March 31, 2009
	  	3.25:1.00
		
	 June 30, 2009 through March 31, 2010
	  	3.75:1.00
		
	 June 30, 2010 and September 30, 2010
	  	3.50:1.00
		
	 December 31, 2010 through June 30, 2011
	  	3.00:1.00
		
	 September 30, 2011 and thereafter
	  	2.50:1.00

 (c) Minimum Fixed Charge Coverage Ratio. Permit the Fixed Charge Coverage Ratio as of the
last day of any Fiscal Quarter ending following the Closing Date described below to be less than, subject to Section 9.13(d) below, the ratio set forth opposite that Fiscal Quarter: 
  

			
	 Fiscal Quarters Ending
	  	Maximum Ratio
	 March 31, 2007 through June 30, 2009
	  	1.10:1.00
		
	 September 30, 2009 through June 30, 2010
	  	1.05:1.00
		
	 September 30, 2010 and thereafter
	  	1.10:1.00

  

 -99- 

 (d) Deferral Option. In order to accommodate any delay in the completion of Mohegan Sun
Phase III or Pocono Downs Phase II, at any time prior to December 31, 2007, the Borrower shall have a one-time option to delay, for either one Fiscal Quarter or two Fiscal Quarters, each of the subsequent step-ups and step-downs for
the applicable financial ratios set forth in Sections 9.13(a), (b) and (c) above. The Borrower may exercise this option by providing the Administrative Agent written notice of its election to exercise this option prior to
December 31, 2007, which notice shall be irrevocable upon the Administrative Agent’s receipt thereof. If not exercised by the Borrower prior to December 31, 2007, this option shall expire, time being of the essence of this covenant.

 9.14 Hostile Tender Offers. Use the proceeds of the Loans or any funds of the Borrower or any of its Restricted Subsidiaries to
directly or indirectly finance any offer to purchase or acquire, or to consummate a purchase or acquisition of, 5% or more of the capital stock of any corporation or other business entity if the board of directors or management of such corporation
or business entity has notified the Borrower or any of its Restricted Subsidiaries that it opposes such offer or purchase. 
 9.15 Deposit
Accounts. Fail, within thirty days following the opening of each Operating Account, to execute and deliver to the Administrative Agent a Deposit Account Agreement granting Liens in such Operating Account. 
 9.16 WNBA Subsidiary Operations and Indebtedness. The Borrower will not permit the WNBA Subsidiary to enter into any substantial operations other
than the operation of a WNBA franchise, nor permit the WNBA Subsidiary to own any substantial assets other than the WNBA franchise and the assets related to its operations. The Borrower and its other Restricted Subsidiaries will not, either directly
or indirectly, be liable for any obligations of the WNBA Subsidiary, or have any continuing obligations to the Women’s National Basketball Association or its Affiliates, other than (a) obligations of the Borrower to honor scheduled arena
dates for home games of the WNBA franchise and related basketball activities, and (b) obligations under the Borrower’s guarantee of the WNBA Subsidiary’s obligations under the WNBA Agreements. 
 9.17 Capital Expenditures. Make, or become legally obligated to make, any Capital Expenditure other than: 
 (a) Capital Expenditures made during the term of this Agreement in respect of Mohegan Sun Phase III in an aggregate amount not to exceed
$800,000,000, excluding capitalized interest; 
 (b) Capital Expenditures made during the term of this Agreement in respect of Pocono Downs
Phase II in an aggregate amount not to exceed $200,000,000, excluding capitalized interest and excluding, to the extent characterized as a Capital Expenditure, the $50,000,000 license fee payments previously paid to the Commonwealth of
Pennsylvania; 
  

 -100- 

 (c) Maintenance Capital Expenditures in an aggregate amount not to exceed $125,000,000 in any Fiscal
Year; 
 (d) Capital Expenditures made during the term of this Agreement for or for the benefit of the WNBA Subsidiary in an aggregate amount
which does not exceed $15,000,000; 
 (e) Capital Expenditures made during the term of this Agreement in respect of the Mohegan Sun,
including cost overruns or scope changes with respect to Mohegan Sun Phase III or for Related Businesses in an aggregate amount which does not exceed $125,000,000; and 
 (f) other Capital Expenditures made during the term of this Agreement (excluding any Capital Expenditures associated with Mohegan Sun Phase III), in
an aggregate amount which does not exceed $25,000,000 (which, by way of example, may be used for cost-overruns or scope increases related to Pocono Downs Phase II). 
 9.18 Construction Covenants; Plans, Budget and Timetable. 
 (a) Fail to construct each of the Projects
in material conformity with the Construction Plans and Construction Budget for that Project, as amended from time to time in accordance with the terms of this Agreement; 
 (b) Fail to promptly inform the Administrative Agent and the Lenders in writing of any circumstance or event that occurs which may reasonably be expected to significantly delay the completion of any Project or
cause the Borrower to be unable to satisfy the In-Balance Test; 
 (c) Amend the Construction Budget for either of the Projects in any manner
which would increase the overall amount of such Construction Budget unless the Borrower has previously delivered (or concurrently therewith delivers) to the Administrative Agent an In-Balance Certificate demonstrating that, giving effect to the
proposed increase in such Construction Budget, the In-Balance Test will be satisfied, together with supporting calculations in reasonable detail; 
 (d) Amend the Construction Plans to delete any of the elements of a Project for which the budgeted cost is in excess of $25,000,000 without the written approval of the Administrative Agent; 
 (e) Fail to permit reasonable access on not less than one Business Day’s notice to the Borrower to each of the Projects and any Material Projects to
the Administrative Agent, the Lenders and their representatives. 
 9.19 Tax Exempt Loans. At any time when any Tax Exempt Loans are
outstanding: 
 (a) Fail to take all actions within its control necessary to maintain, or permit any other Person to take any action which
would have the result of adversely affecting, the status of (i) the interest on each Tax Exempt Loan as not includable in the gross income of the Lenders for federal income tax purposes, and (ii) each Tax Exempt Loan as not an
“arbitrage bond” under Section 148 of the Code. 
  

 -101- 

 (b) Use, permit the use of, or omit to use Gross Proceeds or any other amounts (or any property the
acquisition, construction or improvement of which is to be financed directly or indirectly with Gross Proceeds) in a manner that if made or omitted, respectively, would cause the interest on the Tax Exempt Notes to fail to be excluded, pursuant to
section 103(a) of the Code, from the gross income of the owner thereof for federal income tax purposes. Without limiting the generality of the foregoing, unless and until Borrower receives a written opinion of counsel to the effect that failure to
comply with such covenant will not adversely affect the exclusion from gross income of the interest on the Tax Exempt Notes, Borrower shall comply with each of the specific covenants in this Section. 
 (c) Except as would not cause the Tax Exempt Notes to become “private activity bonds” within the meaning of section 141 of the Code and the Tax
Regulations and rulings thereunder: 
 (i) fail to require that one or more state or local governmental agencies (including
Indian tribal governments or subdivisions thereof) exclusively own, operate and possess all property the acquisition, construction or improvement of which is to be financed or refinanced directly or indirectly with Gross Proceeds of the Tax Exempt
Notes, or use or permit the use of such Gross Proceeds (including all contractual arrangements with terms different than those applicable to the general public) or any property acquired, constructed or improved with such Gross Proceeds in any
activity carried on by any nongovernmental Person, unless such use is solely as a member of the general public; or 
 (ii)
permit the direct or indirect imposition of any charge or other payment on or by any non-governmental person or entity (other than a member of the general public) who is treated as using Gross Proceeds of the Tax Exempt Notes or any property the
acquisition, construction or improvement of which is to be financed or refinanced directly or indirectly with such Gross Proceeds, other than taxes of general application within the Tribe or interest earned on investments acquired with such Gross
Proceeds pending application for their intended purposes. 
 Borrower understands and acknowledges that “use” of Gross Proceeds may arise by reason
of an ownership, lease, or management arrangement with respect to the financed property or, more generally, by reason of any arrangement that provides to a nongovernmental Person any rights, priorities or other special legal entitlements with
respect to any financed property different from those enjoyed by members of the general public. Borrower shall not permit any nongovernmental Person to lease any portion of any financed property, or to provide services with respect to a function of
any financed property unless the arrangement for such services satisfies the guidelines set forth in Revenue Procedure 97-13 (pertaining to “qualified management contracts”), unless Borrower shall first have obtained the opinion of counsel
that such arrangements will not adversely affect the exclusion pursuant to section 103(a) of the Code of interest on the Tax Exempt Notes from the gross income of the owners thereof. 
  

 -102- 

 (d) Except as would not cause the Tax Exempt Notes to become a “private activity bond” within
the meaning of section 141 of the Code and the Tax Regulations and rulings thereunder, use or permit the use of Gross Proceeds to make or finance loans to any person or entity other than a state or local government (including Indian tribal
governments or subdivisions thereof). For purposes of this clause (d), such Gross Proceeds are considered to be “loaned” to a person or entity if: (1) property acquired, constructed or improved with such Gross Proceeds is sold or
leased to such person or entity in a transaction that creates a debt for federal income tax purposes; (2) capacity in or service from such property is committed to such person or entity under a take-or-pay, output or similar contract or
arrangement; or (3) indirect benefits, or burdens and benefits of ownership, of such Gross Proceeds or any property acquired, constructed or improved with such Gross Proceeds are otherwise transferred in a transaction that is the economic
equivalent of a loan. 
 (e) Except as would not cause the Tax Exempt Notes to become an “arbitrage bond” within the meaning of
section 148 of the Code and the Tax Regulations and rulings thereunder, at any time prior to the later of the final stated maturity of the Tax Exempt Notes or the date on which the last Tax Exempt Loan is finally repaid not directly or indirectly
invest or permit the investment of Gross Proceeds in any Appropriate Investment, if as a result of such investment the Yield of any Appropriate Investment acquired with Gross Proceeds of that issue of Tax Exempt Notes, whether then held or
previously disposed of, would materially exceed the Yield of the Tax Exempt Notes within the meaning of said section 148. 
 (f) Except to
the extent permitted by section 149(b) of the Code and the Tax Regulations and rulings thereunder, take or omit to take, or permit, any action that would cause the Tax Exempt Notes to be “federally guaranteed” within the meaning of section
149(b) of the Code and the Tax Regulations and rulings thereunder. 
 (g) Fail to timely file or cause to be filed any information required
by section 149(e) of the Code with respect to each Tax Exempt Loan with the Secretary of the Treasury on Form 8038-G or such other form and in such place as the Secretary may prescribe. 
 (h) Except to the extent otherwise provided in section 148(f) of the Code and the Tax Regulations and rulings thereunder: 
 (i) Fail to account for all Gross Proceeds of each issue of Tax Exempt Notes (including all receipts, expenditures and investments
thereof) on its books of account separately and apart from all other funds (and receipts, expenditures and investments thereof) or fail to retain all records of accounting for at least six years after the day on which the last Tax Exempt Loan is
repaid. However, to the extent permitted by law and this Agreement, Borrower may commingle Gross Proceeds with other money of Borrower, provided that Borrower separately accounts for each receipt and expenditure of Gross Proceeds and the obligations
acquired therewith; 
 (ii) Fail to calculate the Rebatable Amount in accordance with rules set forth in section 148(f) of the
Code and the Tax Regulations and rulings thereunder, records of which Borrower shall maintain with its official transcript of proceedings relating to the issuance of the Tax Exempt Loans until six years after the final Computation Date; 

 

 -103- 

 (iii) Fail to make rebate payments at the times and in the amounts as are or may be
required by section 148(f) of the Code and the Tax Regulations and rulings thereunder, if any, which payments shall be accompanied by Form 8038-T or such other forms and information as is or may be required by section 148(f) of the Code and the Tax
Regulations and rulings thereunder; or 
 (iv) Fail to exercise reasonable diligence to assure that no errors are made in the
calculations and payments required by paragraphs (ii) and (iii), or if an error is discovered, to promptly correct such error within a reasonable amount of time thereafter (and in all events within one hundred eighty days after discovery of the
error), including payment to the United States of any additional Rebatable Amount owed to it, interest thereon, and any penalty imposed under section 1.148-3(h) of the Tax Regulations. 
 (i) Except to the extent permitted by section 148 of the Code and the Tax Regulations and rulings thereunder, fail prior to the earlier of the stated
maturity of the Tax Exempt Notes or the date on which the last Tax Exempt Loan is repaid to enter into any transaction that reduces the amount required to be paid to the United States pursuant to clause (h) of this Section because such
transaction results in a smaller profit or a larger loss than would have resulted if the transaction had been at arm’s length and had the Yield of the Tax Exempt Notes not been relevant to either party. 
 (j) Fail to designate an appropriate officer of Borrower to make elections permitted or required pursuant to the provisions of the Code or the Tax
Regulations, as such representative (after consultation with counsel) deems necessary or appropriate in connection with the Tax Exempt Notes, in a Tax Certificate or similar or other appropriate certificate, form or document. 
  

 -104- 

 ARTICLE X 
 EVENTS OF DEFAULT AND REMEDIES 
 10.01 Events of Default. Any of the following shall
constitute an Event of Default: 
 (a) Non-Payment. The Borrower or any other Loan Party fails to pay (i) when and as required to
be paid herein, any amount of principal of any Loan or any L/C Obligation, or (ii) within two Business Days after demand therefor, any interest on any Loan or on any L/C Obligation, or any fee due hereunder, or (iii) within three Business
Days after demand therefor, any other amount payable hereunder or under any other Loan Document; or 
 (b) Specific Covenants. The
Borrower fails to perform or observe any term, covenant or agreement contained in Sections 8.01, 8.02 or 8.03 or Article IX, the Tribe fails to perform or observe any term, covenant or agreement contained in Article VII, or any failure to
comply with Section 8.03(a) that is materially adverse to the interest of the Administrative Agent or the Lenders; or 
 (c) Other
Defaults. Any Loan Party fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above) contained in any Loan Document on its part to be performed or observed within thirty Business Days
after the giving of notice by the Administrative Agent at the request of the Required Lenders of such Default; or 
 (d) Representations
and Warranties. Any representation or warranty made in any Loan Document, or in any certificate delivered pursuant to any Loan Document, shall be materially incorrect when made or reaffirmed (or, in the case of the representations and warranties
contained in Sections 5.13 and 6.24, proves to be incorrect at any time) in any respect that is materially adverse to the interests of the Administrative Agent or the Lenders; or 
 (e) Cross-Default. (i) At any time (A) the Borrower or any Restricted Subsidiary fails to pay the principal, or any principal
installment, of any present or future indebtedness for borrowed money greater than or equal to $50,000,000, or any guaranty of present or future indebtedness for borrowed money greater than or equal to the $50,000,000, on its part to be paid, when
due (or within any stated grace period), whether at the stated maturity, upon acceleration, by reason of required prepayment or otherwise or (B) the Borrower or any Restricted Subsidiary fails to perform or observe any other term, covenant or
agreement on its part to be performed or observed, or suffers any event to occur, in connection with any present or future indebtedness for borrowed money constituting Recourse Obligations of greater than or equal to $50,000,000, or of any guaranty
of present or future indebtedness for borrowed money constituting Recourse Obligations of greater than or equal to $50,000,000, if as a result of such failure or sufferance any holder or holders thereof (or an agent or trustee on its or their
behalf) has the right to declare such indebtedness due before the date on which it otherwise would become due; or (ii) at any time (A) the Tribe fails to pay the principal, or any principal installment, of any present or future
indebtedness for borrowed money constituting Recourse Obligations of greater than or equal to $50,000,000, or any guaranty of present or future indebtedness for borrowed money constituting Recourse Obligations of greater than or equal to 

  

 -105- 

 
$50,000,000, on its part to be paid, when due (or within any stated grace period), whether at the stated maturity, upon acceleration, by reason of required
prepayment or otherwise or (B) the Tribe fails to perform or observe any other term, covenant or agreement on its part to be performed or observed, or suffers any event to occur, in connection with any such present or future indebtedness for
borrowed money of greater than or equal to $50,000,000, or of any guaranty of any such present or future indebtedness for borrowed money of greater than or equal to $50,000,000, if as a result of such failure or sufferance any holder or holders
thereof (or an agent or trustee on its or their behalf) has the right to declare such indebtedness due before the date on which it otherwise would become due; or (iii) there occurs under any Swap Contract an Early Termination Date (as defined
in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which the Borrower or any Restricted Subsidiary is the Defaulting Party (as defined in such Swap Contract) or (B) any Termination Event (as so
defined) under such Swap Contract as to which the Borrower or any Restricted Subsidiary is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by the Borrower or such Restricted Subsidiary as a result thereof is
greater than $50,000,000; or (iv) any event occurs which gives the holder or holders of any Subordinated Obligation (or an agent or trustee on its or their behalf) the right to declare such Subordinated Obligations due before the date on which
it otherwise would become due, or the right to require the issuer thereof to redeem or purchase, or offer to redeem or purchase, all or any portion of any Subordinated Obligations; or the trustee for, or any holder of, Subordinated Obligations
breaches any subordination provision applicable to such Subordinated Obligations; or 
 (f) Insolvency Proceedings, Etc. The Tribe,
the Borrower or any Material Restricted Subsidiary institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any
receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is
appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for 60 calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its
property is instituted without the consent of such Person and continues undismissed or unstayed for 60 calendar days, or an order for relief is entered in any such proceeding; or 
 (g) Inability to Pay Debts; Attachment. (i) The Borrower or any Material Restricted Subsidiary becomes unable or admits in writing its
inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the Authority Property and is not released,
vacated or fully bonded within 30 days after its issue or levy; or 
 (h) Judgments. There is entered against the Borrower or any
Material Restricted Subsidiary one or more final judgments or orders for the payment of money in an aggregate amount (as to all such judgments or orders) exceeding $50,000,000; (to the extent not covered by independent third-party insurance as to
which the insurer does not dispute coverage), and there is a period of 30 consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect (unless the Tribe or Borrower has deposited
the amount of the monetary award associated with such judgment into a court escrow pending determination of an appeal); or 
  

 -106- 

 (i) Judgments against the Tribe. There is entered against the Tribe one or more final judgments or
orders for the payment of money in an aggregate amount (as to all such judgments or orders) exceeding the $50,000,000 which entitles the judgment creditor to exercise any rights in respect of any Authority Property or the revenues of the Mohegan Sun
(to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage), and there is a period of 30 consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or
otherwise, is not in effect (unless the Tribe or Borrower has deposited the amount of the monetary award associated with such judgment into a court escrow pending determination of an appeal); or 
 (j) ERISA. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected
to result in liability of the Borrower or any Material Restricted Subsidiary under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of the $50,000,000, or (ii) the Borrower or any ERISA
Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of
the $50,000,000; or 
 (k) Invalidity of Loan Documents. Any Loan Document, at any time after its execution and delivery and for any
reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all the Obligations, ceases to be in full force and effect or is declared by a court of competent jurisdiction to be null and void, invalid or unenforceable
in any respect which, in any such event, in the reasonable opinion of the Required Lenders, is materially adverse to the interests of the Lenders; or the Tribe or any Loan Party contests in any manner the validity or enforceability of any Loan
Document; or the Tribe or any Loan Party denies that it has any or further liability or obligation under any Loan Document to which it is a party, or purports to revoke, terminate or rescind any provision of any Loan Document; or 
 (l) A final judgment is entered by a court or other tribunal which purports to be of competent jurisdiction that any Subordinated Obligation is not
subordinated in accordance with its terms to the Obligations; or 
 (m) The Tribe at any time ceases to be a federally recognized Indian
Tribe; or 
 (n) The Borrower ceases to be a wholly-owned instrumentality of the Tribe, managed and controlled by the Tribe; or 

(o) The occurrence of any casualty or other similar event or circumstance in respect of the Mohegan Sun which results in the failure of the Borrower
to have any material portion of Mohegan Sun open to conduct Class II or Class III gaming activities for any reason for more than ten consecutive days to the extent that such failure results in a Material Adverse Effect; the occurrence of any
casualty or other similar event or circumstance in respect of the Pocono Downs which results in the failure of the Borrower and its Restricted Subsidiaries to 

  

 -107- 

 
have any material portion of Pocono Downs open to conduct gaming activities then permitted under the Pennsylvania Race Horse Development and Gaming Act for
any reason for more than twenty consecutive days to the extent that such failure results in a Material Adverse Effect. 
 10.02 Remedies
Upon Event of Default. If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions: 
 (a) declare the commitment of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions to be terminated, whereupon
such commitments and obligation shall be terminated; 
 (b) declare the unpaid principal amount of all outstanding Loans, all interest
accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly
waived by the Borrower; 
 (c) require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the then Outstanding
Amount thereof); and 
 (d) exercise on behalf of itself, the Lenders and the L/C Issuer all rights and remedies available to it, the Lenders
and the L/C Issuer under the Loan Documents; 
 provided, however, that upon the occurrence of an actual or deemed entry of an order for relief
with respect to the Borrower under the Bankruptcy Code of the United States, the obligation of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid principal amount of
all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrower to Cash Collateralize the L/C Obligations as aforesaid shall automatically become effective, in each
case without further act of the Administrative Agent or any Lender. 
 10.03 Application of Funds. After the exercise of remedies
provided for in Section 10.02 (or after the Loans have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso to Section 10.02), any
amounts received on account of the Obligations shall be applied by the Administrative Agent in the following order: 
 First, to
payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) payable to the
Administrative Agent in its capacity as such; 
 Second, to payment of that portion of the Obligations constituting fees, indemnities
and other amounts (other than principal, interest and Letter of Credit Fees) payable to the Lenders and the L/C Issuer (including fees, charges and disbursements of counsel to the respective Lenders and the L/C Issuer (including fees and time
charges for attorneys who may be employees of any Lender or the L/C Issuer) and amounts payable under Article III), ratably among them in proportion to the respective amounts described in this clause Second payable to them; 

 

 -108- 

 Third, to payment of that portion of the Obligations constituting accrued and unpaid Letter of
Credit Fees and interest on the Loans, L/C Borrowings and other Obligations (including without limitation Secured Swap Contracts), ratably among the Lenders and the L/C Issuer (and, in the case of any Secured Swap Contracts, any relevant Affiliates
of any Lenders that are counterparties thereto) in proportion to the respective amounts described in this clause Third payable to them; 
 Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans and L/C Borrowings and amounts owing under Secured Swap Contracts, ratably among the Lenders, the L/C Issuer and the Secured Swap
Contract counterparties in proportion to the respective amounts described in this clause Fourth held by them; 
 Fifth, to the
Administrative Agent for the account of the L/C Issuer, to Cash Collateralize that portion of L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit; and 
 Last, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrower or as otherwise required by Law.

 Subject to Section 2.04(c), amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause Fifth
above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to
the other Obligations, if any, in the order set forth above. 
  

 -109- 

 ARTICLE XI 
 ADMINISTRATIVE AGENT 
 11.01 Appointment and Authority. 
 Each of the Lenders and the L/C Issuer hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under
the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are
reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuer, and neither the Borrower nor any other Loan Party shall have rights as a third party beneficiary of
any of such provisions. 
 11.02 Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same
rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless
the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other
advisory capacity for and generally engage in any kind of business with the Tribe, the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to
the Lenders. 
 11.03 Exculpatory Provisions. The Administrative Agent shall not have any duties or obligations except those expressly
set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, the Administrative Agent: 
 (a) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing; 
 (b) shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the
Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents), provided that the
Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable law; and 
 (c) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable
for the failure to disclose, any information relating to the Tribe, the Borrower or any of their Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. 

 

 -110- 

 The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the
consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in
Sections 12.01 and 10.02) or (ii) in the absence of its own gross negligence or willful misconduct. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to
the Administrative Agent by the Borrower, a Lender or the L/C Issuer. 
 The Administrative Agent shall not be responsible for or have any
duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or
thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity,
enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to
confirm receipt of items expressly required to be delivered to the Administrative Agent. 
 11.04 Reliance by Administrative Agent.
The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or
intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone
and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance of a Letter of Credit, that by its
terms must be fulfilled to the satisfaction of a Lender or the L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L/C Issuer unless the Administrative Agent shall have received notice to the
contrary from such Lender or the L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Tribe or the Borrower), independent
accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 
 11.05 Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under
any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their
respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with
the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. 
 11.06 Resignation of
Administrative Agent. The Administrative Agent may at any time give notice of its resignation to the Lenders, the L/C Issuer and the Borrower. Upon receipt 
  

 -111- 

 
of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a
bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days
after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders and the L/C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above;
provided that if the Administrative Agent shall notify the Borrower and the Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice and
(a) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (b) all payments, communications and determinations provided to be made by, to or through the
Administrative Agent shall instead be made by or to each Lender and the L/C Issuer directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this Section. Upon the acceptance of a
successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the retiring
Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section). The fees payable by the Borrower to a successor
Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the
provisions of this Article and Section 12.04 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of
them while the retiring Administrative Agent was acting as Administrative Agent. 
 Any resignation by Bank of America as Administrative
Agent pursuant to this Section shall also constitute its resignation as L/C Issuer. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, (i) such successor shall succeed to and become vested with all of
the rights, powers, privileges and duties of the retiring L/C Issuer, (ii) the retiring L/C Issuer shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents, and (iii) the successor
L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to the retiring L/C Issuer to effectively assume the obligations of the
retiring L/C Issuer with respect to such Letters of Credit. 
 11.07 Non-Reliance on Administrative Agent and Other Lenders. Each
Lender and the L/C Issuer acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made
its own credit analysis and decision to enter into this Agreement. Each Lender and the L/C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties
and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any
document furnished hereunder or thereunder. 
  

 -112- 

 11.08 No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of Joint Lead
Arrangers or Co-Documentation Agents shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or the L/C Issuer hereunder.

 11.09 Administrative Agent May File Proofs of Claim. In case of the pendency of any proceeding under any Debtor Relief Law or
any other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective
of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise: 
 (a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations
and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuer and the Administrative Agent (including any claim for the reasonable
compensation, expenses, disbursements and advances of the Lenders, the L/C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuer and the Administrative Agent under
Sections 2.04(i) and (j), 2.10 and 12.04) allowed in such judicial proceeding; and 
 (b) to collect and receive any
monies or other property payable or deliverable on any such claims and to distribute the same; 
 and any custodian, receiver, assignee, trustee, liquidator,
sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and the L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the
making of such payments directly to the Lenders and the L/C Issuer, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and
any other amounts due the Administrative Agent under Sections 2.10 and 12.04. 
 Nothing contained herein shall be deemed to authorize
the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or the L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or the L/C
Issuer to authorize the Administrative Agent to vote in respect of the claim of any Lender or the L/C Issuer in any such proceeding. 
 11.10 SNDA’s. The Administrative Agent and the Lenders hereby confirm that each SNDA executed in connection with the Existing Credit Agreement shall be deemed to remain in full force and effect. The Administrative Agent is
hereby authorized by the Lenders, without notice to or consent from the Lenders, to execute and deliver SNDA’s in favor of any tenant of the Borrower at the Mohegan Sun, Pocono Downs or any other property. 
 11.11 Collateral and Guaranty Matters. The Lenders and the L/C Issuer irrevocably authorize the Administrative Agent, at its option and in its
discretion, 
  

 -113- 

 (a) to release any Lien on any property granted to or held by the Administrative Agent
under any Loan Document (i) upon termination of the Aggregate Revolving Commitments and payment in full of all Obligations (other than contingent indemnification obligations) and the expiration or termination of all Letters of Credit,
(ii) that is sold or to be sold as part of or in connection with any sale permitted hereunder or under any other Loan Document, or (iii) subject to Section 12.01, if approved, authorized or ratified in writing by the Required Lenders;

 (b) to subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan Document to the
holder of any Lien on such property that is permitted by Section 9.01(i); and 
 (c) to release any Guarantor from its
obligations under its Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted hereunder. 
 Upon request by
the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its
obligations under its Guaranty pursuant to this Section 11.11. 
  

 -114- 

 ARTICLE XII 
 MISCELLANEOUS 
 12.01 Amendments, Etc. No amendment or waiver of any provision of this
Agreement or any other Loan Document, and no consent to any departure by the Tribe, the Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders and the Tribe, the Borrower or the applicable
Loan Party, as the case may be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no
such amendment, waiver or consent shall: 
 (a) waive any condition set forth in Section 4.01(a) without the written consent of each
Lender; 
 (b) extend or increase the Revolving Commitment of any Lender (or reinstate any Revolving Commitment terminated pursuant to
Section 10.02) without the written consent of such Lender, except as provided in Section 2.14; 
 (c) postpone any date fixed by
this Agreement or any other Loan Document for any payment or mandatory prepayment of principal, interest, fees or other amounts due to the Lenders (or any of them) or any scheduled or mandatory reduction of the Aggregate Revolving Commitments
hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; 
 (d) reduce the principal
of, or the rate of interest specified herein on, any Loan or L/C Borrowing, or (subject to clause (iii) of the second proviso to this Section 12.01) any fees or other amounts payable hereunder or under any other Loan Document without the
written consent of each Lender directly affected thereby; provided, however, that only the consent of the Required Lenders shall be necessary (i) to amend the definition of “Default Rate” or to waive any obligation of
the Borrower to pay interest or Letter of Credit Fees at the Default Rate or (ii) to amend any financial covenant hereunder (or any defined term used therein) even if the effect of such amendment would be to reduce the rate of interest on any
Loan or L/C Borrowing or to reduce any fee payable hereunder; 
 (e) impose any greater restriction on the ability of any Lender to assign
any of its rights or obligations hereunder without the written consent of Lenders having more than 50% of the Aggregate Credit Exposures then in effect within each of the following classes of commitments, Loans and other Credit Extensions:
(i) the class consisting of the Revolving Commitment, (ii) the class consisting of the Term Loans and (iii) the class consisting of the Tax Exempt Loans. For purposes of this clause, the aggregate amount of each Lender’s risk
participation and funded participation in L/C Obligations shall be deemed to be held by such Lender. 
 (f) to amend, modify or waive the
provisions of the definitions of “Available Cash Flow” or amend or modify Section 9.09, Article VII, Sections 10.01(f), 10.01(o), this Section, or Sections 12.14, 12.15, 12.17 or 12.18; 
  

 -115- 

 (g) change Section 2.14 or Section 10.03 in a manner that would alter the pro rata sharing of
payments required thereby without the written consent of each Lender; 
 (h) change any provision of this Section or the definition of
“Required Lenders” or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder without the written
consent of each Lender; 
 (i) release all or substantially all of the value of the Guaranties, taken as a whole, without the written consent
of each Lender; or 
 (j) release all or substantially all of the collateral in any transaction or series of related transactions without the
written consent of each Lender provided that the Pocono Downs Mortgages and other Liens upon Pocono Downs and associated property may be released in connection with any Permitted Disposition thereof; 
 and, provided further, that (i) no amendment, waiver or consent shall, unless in writing and signed by the L/C Issuer in addition to the Lenders required
above, affect the rights or duties of the L/C Issuer under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it; (ii) no amendment, waiver or consent shall, unless in writing and signed by the
Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; and (iii) the Fee Letter may be amended, or rights or privileges thereunder
waived, in a writing executed only by the parties thereto. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except that the Revolving
Commitment of such Lender may not be increased or extended without the consent of such Lender. 
 12.02 Notices; Effectiveness; Electronic
Communication. 
 (a) Notices Generally. Except in the case of notices and other communications expressly permitted to be given by
telephone (and except as provided in subsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent
by telecopier as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: 
 (i) if to the Tribe, the Borrower, its Restricted Subsidiaries, the Administrative Agent or the L/C Issuer, to the address, telecopier
number, electronic mail address or telephone number specified for such Person on Schedule 12.02; and 
 (ii) if to any
other Lender, to the address, telecopier number, electronic mail address or telephone number specified in its Administrative Questionnaire. 
 Notices sent
by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by telecopier shall be deemed to have been given when sent (except that, if not given during normal
business hours for the recipient, 

  

 -116- 

 
shall be deemed to have been given at the opening of business on the next business day for the recipient). Notices delivered through electronic
communications to the extent provided in subsection (b) below, shall be effective as provided in such subsection (b). 
 (b)
Electronic Communications. Notices and other communications to the Lenders and the L/C Issuer hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures
approved by the Administrative Agent, provided that the foregoing shall not apply to notices to any Lender or the L/C Issuer pursuant to Article II if such Lender or the L/C Issuer, as applicable, has notified the Administrative Agent
that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications
pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications. 
 Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by
the “return receipt requested” function, as available, return e-mail or other written acknowledgement), provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice
or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed
receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor. 
 (c) The Platform. THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE
ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event
shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Tribe, the Borrower, any Lender, the L/C Issuer or any other Person for losses, claims, damages, liabilities
or expenses of any kind (whether in tort, contract or otherwise) arising out of the Tribe’s, the Borrower’s or the Administrative Agent’s transmission of the Borrower Materials through the Internet, except to the extent that such
losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided,
however, that in no event shall any Agent Party have any liability to the Tribe, the Borrower, any Lender, the L/C Issuer or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual
damages). 
  

 -117- 

 (d) Change of Address, Etc. Each of the Tribe, the Borrower, the Administrative Agent and the L/C
Issuer may change its address, telecopier or telephone number for notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, telecopier or telephone number for notices and other
communications hereunder by notice to the Tribe, the Borrower, the Administrative Agent and the L/C Issuer. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record
(i) an effective address, contact name, telephone number, telecopier number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender. 
 (e) Reliance by Administrative Agent, L/C Issuer and Lenders. The Administrative Agent, the L/C Issuer and the Lenders shall be entitled to
rely and act upon any notices (including telephonic Loan Notices) purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any
other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, the L/C Issuer, each Lender and the Related Parties
of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower. All telephonic notices to and other telephonic communications with the
Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording. 
 12.03 No Waiver; Cumulative Remedies. No failure by any Lender, the L/C Issuer or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder shall operate as a
waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers
and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law. 
 12.04
Expenses; Indemnity; Damage Waiver. 
 (a) Costs and Expenses. The Borrower shall pay (i) all reasonable out-of-pocket
expenses incurred by the Administrative Agent and its Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent including the allocated cost of any internal counsel to the Administrative Agent), in
connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the
provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the L/C Issuer in connection with the issuance, amendment, renewal or
extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket expenses incurred by the Administrative Agent, any Lender or the L/C Issuer (including the fees, charges and disbursements of any counsel for the
Administrative Agent, any Lender or the L/C Issuer), and shall pay all fees and time charges for attorneys who may be employees of the Administrative Agent, any Lender or the L/C Issuer, in connection with the enforcement or protection of its rights
(A) in connection with this Agreement and the other Loan 

  

 -118- 

 
Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such
out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit. 
 (b)
Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and the L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an
“Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), incurred by any
Indemnitee or asserted against any Indemnitee by any third party or by the Tribe, the Borrower or any other Loan Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan
Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder, the consummation of the transactions contemplated hereby or thereby, or, in the
case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Agreement and the other Loan Documents, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom
(including any refusal by the L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or
alleged presence or release of Hazardous Materials on or from any property owned or operated by the Borrower or any of its Restricted Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Restricted
Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Tribe, the Borrower
or any other Loan Party, and regardless of whether any Indemnitee is a party thereto, in all cases, whether or not caused by or arising, in whole or in part, out of the comparative, contributory or sole negligence of the Indemnitee; provided
that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction to have resulted from the gross
negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by the Tribe, the Borrower or any other Loan Party against an Indemnitee for breach in bad faith of such Indemnitee’s obligations hereunder or under any
other Loan Document, if the Tribe, the Borrower or such Loan Party has obtained judgment in its favor on such claim as determined by a court of competent jurisdiction. 
 (c) Reimbursement by Lenders. To the extent that the Borrower for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this Section to be paid by it to the
Administrative Agent (or any sub-agent thereof), the L/C Issuer or any Related Party of any of the foregoing, but without affecting Borrower’s reimbursement obligations with respect thereto, each Lender severally agrees to pay to the
Administrative Agent (or any such sub-agent), the L/C Issuer or such Related Party, as the case may be, such Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of
such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) or the L/C
Issuer in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) or L/C Issuer in connection with such capacity. The obligations of the Lenders under this
subsection (c) are subject to the provisions of Section 2.13(d). 
  

 -119- 

 (d) Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, the
Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a
result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof. No Indemnitee referred to in
subsection (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed to such unintended recipients by such Indemnitee through telecommunications, electronic or
other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the gross negligence or willful misconduct
of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction. 
 (e) Payments. All
amounts due under this Section shall be payable not later than ten Business Days after demand therefor. 
 (f) Survival. The
agreements in this Section shall survive the resignation of the Administrative Agent and the L/C Issuer, the replacement of any Lender, the termination of the Aggregate Revolving Commitments and the repayment, satisfaction or discharge of all
the other Obligations. 
 12.05 Payments Set Aside. To the extent that any payment by or on behalf of the Borrower is made to the
Administrative Agent, the L/C Issuer or any Lender, or the Administrative Agent, the L/C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to
be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, the L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in
connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if
such payment had not been made or such setoff had not occurred, and (b) each Lender and the L/C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or
repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders and the L/C
Issuer under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement. 
 12.06 Successors and Assigns. 
 (a) Successors and Assigns Generally. The provisions of this Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that neither the Tribe, the Borrower nor any other Loan 

  

 -120- 

 
Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each
Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance
with the provisions of subsection (d) of this Section, (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (f) of this Section, or (iv) to an SPC in accordance with the
provisions of subsection (h) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other
than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the
Administrative Agent, the L/C Issuer and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. 
 (b) Assignments by Lenders. Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Revolving Commitment and the Loans
(including for purposes of this subsection (b), participations in L/C Obligations) at the time owing to it); provided that any such assignment shall be subject to the following conditions: 
 (i) Minimum Amounts. 
 (A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Revolving Commitment and the Loans at the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved
Fund, no minimum amount need be assigned; and 
 (B) in any case of any assignments of a Revolving Commitment or Revolving
Loans not described in subsection (b)(i)(A) of this Section, the aggregate amount of the Revolving Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Revolving Commitment is not then in effect, the principal
outstanding balance of the Loans of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date”
is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $1,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each
such consent not to be unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single assignee (or to an
assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met. 
 (C) in any case of any assignments of Term Loans or Tax Exempt Loans, the principal outstanding balance of the Term Loans or Tax Exempt Loans (as applicable) of the assigning Lender subject to each such 

  

 -121- 

 
assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if
“Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $1,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower
otherwise consents (each such consent not to be unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single
assignee (or to an assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met. 
 (ii) Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning
Lender’s rights and obligations under this Agreement with respect to the Loans or the Revolving Commitment assigned; 
 (iii) Required Consents. No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) or (b)(i)(C) of this Section and, in addition: 
 (A) the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of
Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; 
 (B) in respect of the Revolving Commitments, the consent of the Administrative Agent (such consent not to be unreasonably withheld or
delayed) shall be required if such assignment is to a Person that is not a Lender holding a Revolving Commitment, an Affiliate of such a Lender or an Approved Fund with respect to such Lender; 
 (C) in respect of the Term Loans or the Tax Exempt Loans, the consent of the Administrative Agent (such consent not to be unreasonably
withheld or delayed) shall be required if such assignment is to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund with respect to such Lender; and 
 (D) the consent of the L/C Issuer (such consent not to be unreasonably withheld or delayed) shall be required for any assignment that
increases the obligation of the assignee to participate in exposure under one or more Letters of Credit (whether or not then outstanding). 
 (iv) Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of
$3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and 

  

 -122- 

 
recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative
Questionnaire. 
 (v) No Assignment to the Borrower. No such assignment shall be made to the Borrower or any of the
Borrower’s Affiliates or Subsidiaries. 
 (vi) No Assignment to Natural Persons. No such assignment shall be made
to a natural person. 
 Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and
after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a
Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption
covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05, and 12.04 with respect to
facts and circumstances occurring prior to the effective date of such assignment. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender. Any assignment or transfer by a Lender of rights or obligations
under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section.

 (c) Register. The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at the
Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Revolving Commitments of, and principal amounts of the Loans and L/C
Obligations owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive, and the Borrower, the Administrative Agent and the Lenders may treat each Person
whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower and any Lender, at
any reasonable time and from time to time upon reasonable prior notice. 
 (d) Participations. Any Lender may at any time, without the
consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in
all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Revolving Commitment and/or the Loans (including such Lender’s participations in L/C Obligations) owing to it);
provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the
Borrower, the Administrative Agent, the Lenders and the L/C Issuer shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. 
  

 -123- 

 Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such
Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without
the consent of the Participant, agree to any amendment, waiver or other modification described in the first proviso to Section 12.01 that affects such Participant. Subject to subsection (e) of this Section, the Borrower agrees that each
Participant shall be entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this Section. To the extent permitted by law,
each Participant also shall be entitled to the benefits of Section 12.08 as though it were a Lender, provided such Participant agrees to be subject to Section 2.14 as though it were a Lender. 
 (e) Limitations upon Participant Rights. A Participant shall not be entitled to receive any greater payment under Section 3.01 or 3.04 than
the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent. A Participant that
would be a Foreign Lender if it were a Lender shall not be entitled to the benefits of Section 3.01 unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to
comply with Section 3.01(e) as though it were a Lender. 
 (f) Certain Pledges. Any Lender may at any time pledge or assign a
security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided
that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 
 (g) Electronic Execution of Assignments. The words “execution,” “signed,” “signature,” and words of like import in
any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a
paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act,
or any other similar state laws based on the Uniform Electronic Transactions Act. 
 (h) Special Purpose Funding Vehicles.
Notwithstanding anything to the contrary contained herein, any Lender (a “Granting Lender”) may grant to a special purpose funding vehicle identified as such in writing from time to time by the Granting Lender to the Administrative
Agent and the Borrower (an “SPC”) the option to provide all or any part of any Revolving Loan that such Granting Lender would otherwise be obligated to make pursuant to this Agreement; provided that (i) nothing herein
shall constitute a commitment by any SPC to fund any Revolving Loan, and (ii) if an SPC elects not to exercise such option or otherwise fails 

  

 -124- 

 
to make all or any part of such Revolving Loan, the Granting Lender shall be obligated to make such Revolving Loan pursuant to the terms hereof or, if it
fails to do so, to make such payment to the Administrative Agent as is required under Section 2.13(b)(ii). Each party hereto hereby agrees that (i) neither the grant to any SPC nor the exercise by any SPC of such option shall increase the
costs or expenses or otherwise increase or change the obligations of the Borrower under this Agreement (including its obligations under Section 3.04), (ii) no SPC shall be liable for any indemnity or similar payment obligation under this
Agreement for which a Lender would be liable, and (iii) the Granting Lender shall for all purposes, including the approval of any amendment, waiver or other modification of any provision of any Loan Document, remain the lender of record
hereunder. The making of a Revolving Loan by an SPC hereunder shall utilize the Revolving Commitment of the Granting Lender to the same extent, and as if, such Revolving Loan were made by such Granting Lender. In furtherance of the foregoing, each
party hereto hereby agrees (which agreement shall survive the termination of this Agreement) that, prior to the date that is one year and one day after the payment in full of all outstanding commercial paper or other senior debt of any SPC, it will
not institute against, or join any other Person in instituting against, such SPC any bankruptcy, reorganization, arrangement, insolvency, or liquidation proceeding under the laws of the United States or any State thereof. Notwithstanding anything to
the contrary contained herein, any SPC may (i) with notice to, but without prior consent of the Borrower and the Administrative Agent and with the payment of a processing fee in the amount of $3,500 (which processing fee may be waived by the
Administrative Agent in its sole discretion), assign all or any portion of its right to receive payment with respect to any Revolving Loan to the Granting Lender and (ii) disclose on a confidential basis any non-public information relating to
its funding of Revolving Loans to any rating agency, commercial paper dealer or provider of any surety or Contingent Obligation or credit or liquidity enhancement to such SPC. 
 (i) Resignation as L/C Issuer after Assignment. Notwithstanding anything to the contrary contained herein, if at any time Bank of America assigns
all of its Revolving Commitment and Loans pursuant to subsection (b) above, Bank of America may, upon 30 days’ notice to the Borrower and the Lenders, resign as L/C Issuer. In the event of any such resignation as L/C Issuer, the Borrower
shall be entitled to appoint from among the Lenders a successor L/C Issuer; provided, however, that no failure by the Borrower to appoint any such successor shall affect the resignation of Bank of America as L/C Issuer. If Bank of
America resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L/C Issuer and all L/C
Obligations with respect thereto (including the right to require the Lenders to make Base Rate Revolving Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.04(c)). Upon the appointment of a successor L/C Issuer,
(a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer, and (b) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of
Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit. 
 12.07 Treatment of Certain Information; Confidentiality. Each of the Administrative Agent, the Lenders and the L/C Issuer agrees to maintain the
confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates 

  

 -125- 

 
and to its and its Affiliates’ respective partners, directors, officers, employees, agents, advisors and representatives (it being understood that the
Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have
jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to
any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or
thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations
under this Agreement or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (g) with the consent of the Borrower or (h) to the extent such
Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, the L/C Issuer or any of their respective Affiliates on a nonconfidential
basis from a source other than the Borrower. 
 For purposes of this Section, “Information” means all information received
from the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or the L/C Issuer on a nonconfidential
basis prior to disclosure by the Borrower or any Subsidiary, provided that, in the case of information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as
confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the
confidentiality of such Information as such Person would accord to its own confidential information. 
 Each of the Administrative Agent, the
Lenders and the L/C Issuer acknowledges that (a) the Information may include material non-public information concerning the Borrower or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of
material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including Federal and state securities Laws. 
 12.08 Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender, the L/C Issuer and each of their respective
Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any
time held and other obligations (in whatever currency) at any time owing by such Lender, the L/C Issuer or any such Affiliate to or for the credit or the account of the Borrower or any other Loan Party against any and all of the obligations of the
Borrower or such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender or the L/C Issuer, irrespective of whether or not such Lender or the L/C Issuer shall have made any demand under this Agreement or
any other Loan Document and although such obligations of the Borrower or such Loan Party may be contingent or unmatured or are owed to a branch or office of such Lender or the L/C Issuer different from the branch or office holding 
  

 -126- 

 
such deposit or obligated on such indebtedness. The rights of each Lender, the L/C Issuer and their respective Affiliates under this Section are in
addition to other rights and remedies (including other rights of setoff) that such Lender, the L/C Issuer or their respective Affiliates may have. Each Lender and the L/C Issuer agrees to notify the Borrower and the Administrative Agent promptly
after any such setoff and application, provided that the failure to give such notice shall not affect the validity of such setoff and application. 
 12.09 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of
non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the
principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to
the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate,
allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder. 
 12.10 Counterparts; Integration; Effectiveness. This Agreement (and any of the other Loan Documents) may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an
original, but all of which when taken together shall constitute a single contract. This Agreement and the other Loan Documents constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous
agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the
Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an executed counterpart of a signature page of this Agreement by telecopy shall be effective
as delivery of a manually executed counterpart of this Agreement. 
 12.11 Survival of Representations and Warranties. All
representations and warranties made hereunder and in any other Loan Document or other document delivered by the Tribe or any Loan Party pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof
and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that
the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or
unsatisfied or any Letter of Credit shall remain outstanding. 
 12.12 Severability. If any provision of this Agreement or the other
Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or 
  

 -127- 

 
impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid
provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. 
 12.13 Replacement of Lenders. If any Lender requests compensation under Section 3.04, or if the
Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, if any Lender is a Defaulting Lender, or if any Lender does not consent to a requested waiver
or amendment hereof that requires the approval of all of the Lenders and which is consented to by the Required Lenders, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such
Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 12.06), all of its interests, rights and obligations under this Agreement and the related Loan
Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that: 
 (a) the Borrower or the replacement Lender shall have paid to the Administrative Agent the assignment fee specified in Section 12.06(b); 
 (b) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and L/C Advances, accrued interest thereon,
accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the
Borrower (in the case of all other amounts); 
 (c) in the case of any such assignment resulting from a claim for compensation under
Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter; and 
 (d) such assignment does not conflict with applicable Laws. 
 A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and
delegation cease to apply. 
 12.14 Governing Law. Except to the extent otherwise expressly provided therein, each Loan Document shall
be governed by, and construed and enforced in accordance with, the Laws of Connecticut, without regard to the conflicts of law provisions of the Laws of Connecticut, provided however, that if and only to the extent that any security interest granted
to the Administrative Agent for the benefit of the Lenders pursuant to this Agreement or any other Loan Document shall be deemed exempt from the provisions of Article 9 of the Uniform Commercial Code of the State of Connecticut, C.G.S. §
42a-9 101, et seq., by virtue of the Borrower being a governmental entity, then such security interest shall be governed by the corresponding provisions of Article 9 of the Tribe’s Uniform Commercial Code, as adopted by the UCC Ordinance.
The Borrower and each other party hereto each hereby consents to the 
  

 -128- 

 
application of Connecticut civil law to the construction, interpretation and enforcement of this Agreement and the other Loan Documents, and to the
application of Connecticut civil law to the procedural aspects of any suit, action or proceeding relating thereto, including but not limited to legal process, execution of judgments and other legal remedies, except for any procedural matters
governed by or relating to the conduct of arbitration under Section 12.15. 
 12.15 Arbitration Reference. 
 (a) Mandatory Arbitration. At the option of the Administrative Agent (exercised in accordance with consent of the Required Lenders), the Borrower,
any of its Restricted Subsidiaries or, to the extent it is a party to any such controversy or claim, the Tribe, any controversy or claim between or among the parties arising out of or relating to this Agreement, the other Loan Documents or any
agreements or instruments relating hereto or delivered in connection herewith and any claim based on or arising from an alleged tort, shall be determined by arbitration. The arbitration shall be conducted in accordance with the United States
Arbitration Act (Title 9, U.S. Code), notwithstanding any choice of law provision in this Agreement, and under the Commercial Rules of the American Arbitration Association (“AAA”). The arbitrators shall give effect to statutes of
limitation in determining any claim. Any controversy concerning whether an issue is arbitrable shall be determined by the arbitrators. Judgment upon the arbitration award may be entered in any court having jurisdiction. The institution and
maintenance of an action for judicial relief or pursuit of a provisional or ancillary remedy shall not constitute a waiver of the right of any party, including the plaintiff, to submit the controversy or claim to arbitration if any other party
contests such action for judicial relief. 
 (b) Provisional Remedies, Self-Help and Foreclosure. No provision of this section shall
limit the right of any party to this Agreement to exercise self-help remedies such as setoff, to foreclose against or sell any real or personal property collateral or security or to obtain provisional or ancillary remedies from a court of competent
jurisdiction before, after, or during the pendency of any arbitration or other proceeding. The exercise of a remedy does not waive the right of any party to resort to arbitration or reference. At the Required Lenders’ option, foreclosure under
a deed of trust or mortgage may be accomplished either by exercise of power of sale under the deed of trust or mortgage or by judicial foreclosure. 
 (c) Limitation. This Section shall not be construed to require arbitration by the Creditors of any disputes which now exist or hereafter arise amongst themselves which do not involve the Tribe, the Borrower or any of the
Restricted Subsidiaries and are not related to this Agreement and the Loan Documents. 
 (d) Specific Enforcement Representation. Each
party to this Agreement severally represents and warrants to the other parties that this Section 12.15 is specifically enforceable against such party by the other parties. 
 12.16 PURPORTED ORAL AMENDMENTS. THE TRIBE, THE BORROWER AND THE CREDITORS EXPRESSLY ACKNOWLEDGE THAT THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS
MAY ONLY BE AMENDED OR MODIFIED, OR THE PROVISIONS HEREOF OR THEREOF WAIVED OR SUPPLEMENTED, BY AN INSTRUMENT IN WRITING THAT COMPLIES WITH SECTION 12.01. EACH OF THE 
  

 -129- 

 
TRIBE AND BORROWER AGREES THAT IT WILL NOT RELY ON ANY COURSE OF DEALING, COURSE OF PERFORMANCE, OR ORAL OR WRITTEN STATEMENTS BY ANY REPRESENTATIVE OF ANY
CREDITOR THAT DOES NOT COMPLY WITH SECTION 12.01 TO EFFECT AN AMENDMENT, MODIFICATION, WAIVER OR SUPPLEMENT TO THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS. 
 12.17 WAIVER OF RIGHT TO TRIAL BY JURY. EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER ANY LOAN DOCUMENT OR IN ANY
WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO ANY LOAN DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN
CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR
A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. 
 12.18 WAIVER OF SOVEREIGN IMMUNITY; CONSENT TO JURISDICTION. 
 (a) THE BORROWER HEREBY EXPRESSLY AND IRREVOCABLY WAIVES THE
SOVEREIGN IMMUNITY OF THE BORROWER AND EACH OF ITS RESTRICTED SUBSIDIARIES (AND ANY DEFENSE BASED THEREON) FROM ANY SUIT, ACTION OR PROCEEDING OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OF NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN
AID OF EXECUTION, EXECUTION, EXERCISE OF CONTEMPT POWERS, OR OTHERWISE) IN ANY FORUM, WITH RESPECT TO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY, PROVIDED THAT (1) THE WAIVER
CONTAINED IN THIS CLAUSE (A) IS EXPRESSLY LIMITED TO ACTIONS AGAINST THE BORROWER AND ITS RESTRICTED SUBSIDIARIES AND (2) ANY RECOVERY UPON ANY JUDGMENT RESULTING THEREFROM SHALL BE LIMITED TO RECOVERY AGAINST THE AUTHORITY PROPERTY,
INCLUDING THE REVENUES OF THE BORROWER AND ITS RESTRICTED SUBSIDIARIES. 
 (b) THE TRIBE HEREBY EXPRESSLY AND IRREVOCABLY WAIVES ITS OWN
SOVEREIGN IMMUNITY (APPLICABLE TO ITSELF AS AN INDIAN TRIBAL NATION) (AND ANY DEFENSE BASED THEREON) FROM ANY SUIT, ACTION OR PROCEEDING OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OF NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF
EXECUTION, EXECUTION, EXERCISE OF CONTEMPT POWERS, OR OTHERWISE) WITH RESPECT TO THE REPRESENTATIONS AND WARRANTIES OF THE TRIBE SET FORTH IN ARTICLE V, THE COVENANTS OF THE TRIBE SET FORTH IN ARTICLE VII, AND EACH PROVISION OF
SECTION 10.01 WHICH RELATES TO AN EVENT OF 

  

 -130- 

 
DEFAULT CAUSED BY THE TRIBE’S BREACH OF ANY SUCH REPRESENTATION, WARRANTY OR COVENANT, IT BEING EXPRESSLY UNDERSTOOD THAT (1) THE WAIVERS AND
CONSENTS CONTAINED IN THIS CLAUSE (B) ARE NOT LIMITED TO ACTIONS AGAINST THE BORROWER AND ITS RESTRICTED SUBSIDIARIES, (2) ANY ACTION DESCRIBED IN THIS CLAUSE (B) MAY BE BROUGHT AGAINST THE TRIBE, AND (3) ANY RECOVERY UPON ANY
JUDGMENT RESULTING FROM ANY SUCH ACTION MAY BE HAD AGAINST THE ASSETS AND REVENUES OF THE TRIBE IN A MANNER CONSISTENT WITH SECTION 12.19. 
 (c) EACH OF THE TRIBE AND BORROWER HEREBY CONSENTS TO THE NON-EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF CONNECTICUT AND THE COURTS OF THE UNITED STATES SITTING IN THE STATE OF CONNECTICUT. 
 (d) THE WAIVERS AND CONSENTS DESCRIBED IN THIS SECTION SHALL INURE TO THE BENEFIT OF THE CREDITORS AND EACH OTHER PERSON WHO IS ENTITLED TO THE BENEFITS
OF THE LOAN DOCUMENTS (INCLUDING WITHOUT LIMITATION THE INDEMNITEES REFERRED TO IN SECTION 12.04). SUBJECT TO SECTION 12.19 THE CREDITORS AND SUCH OTHER PERSONS SHALL HAVE AND BE ENTITLED TO ALL AVAILABLE LEGAL AND EQUITABLE REMEDIES,
INCLUDING THE RIGHT TO SPECIFIC PERFORMANCE, MONEY DAMAGES AND INJUNCTIVE OR DECLARATORY RELIEF. THE WAIVERS OF SOVEREIGN IMMUNITY AND CONSENTS TO JURISDICTION CONTAINED IN THIS SECTION ARE IRREVOCABLE. 
 12.19 Lender Covenant. In any action or proceeding against the Borrower or any of its Restricted Subsidiaries to enforce the Loan Documents which
is not also an action or proceeding against the Tribe, the Creditors agree that they shall have no recourse to the Tribe or to its property which is not Authority Property. In any action or proceeding to enforce the Loan Documents which includes the
Tribe, the Creditors agree that they shall, to the extent then permitted by applicable Law, take commercially practicable steps to enforce any claim for damages awarded to the Creditors by any court, tribunal, arbitrator or other decision maker
against the Borrower or the Authority Property prior to taking general recourse to the Tribe or any Property thereof which is not Authority Property. The provisions of this Section shall not be construed (a) to create any recourse on the
part of the Creditors against the Tribe, the property of the Tribe which is not Authority Property or revenues except for any breach of the Tribe’s own representations, warranties and covenants set forth in Articles V and VII, or
(b) to require exhaustion by the Creditors of any remedies against the Borrower, its Restricted Subsidiaries or the Authority Property prior to having recourse, in the proper case, against the Tribe and its property which is not Authority
Property. 
 12.20 PREJUDGMENT REMEDY WAIVER. Each of the Tribe and the Borrower represents, warrants and acknowledges that the
transaction of which this Agreement is a part is a commercial transaction and not a consumer transaction. Monies now or in the future to be advanced to or on behalf of the Borrower and its Restricted Subsidiaries are not and will not be used for
personal, family or household purposes. 
  

 -131- 

 THE BORROWER ACKNOWLEDGES THAT IT HAS THE RIGHT UNDER SECTION 52-278a, ET SEQ., OF THE
CONNECTICUT GENERAL STATUTES, SUBJECT TO CERTAIN LIMITATIONS, TO NOTICE OF AND HEARING ON THE RIGHT OF THE CREDITORS TO OBTAIN A PREJUDGMENT REMEDY, SUCH AS ATTACHMENT, GARNISHMENT OR REPLEVIN, UPON COMMENCING ANY LITIGATION AGAINST THE BORROWER.
NOTWITHSTANDING SUCH RIGHT, THE BORROWER HEREBY WAIVES ALL RIGHTS TO NOTICE, JUDICIAL HEARING OR PRIOR COURT ORDER TO WHICH IT MIGHT OTHERWISE HAVE THE RIGHT UNDER SAID STATUTE OR UNDER ANY OTHER STATE OR FEDERAL STATUTE OR CONSTITUTION IN
CONNECTION WITH THE OBTAINING BY THE CREDITORS OF ANY PREJUDGMENT REMEDY IN CONNECTION WITH THIS AGREEMENT. THE BORROWER FURTHER CONSENTS TO THE ISSUANCE OF ANY PREJUDGMENT REMEDIES WITHOUT A BOND AND AGREES NOT TO REQUEST OR FILE MOTIONS SEEKING TO
REQUIRE THE POSTING OF A BOND UNDER PUBLIC ACT 93-431 IN CONNECTION WITH THE CREDITORS’ EXERCISE OF ANY PREJUDGMENT REMEDY. THE BORROWER ALSO WAIVES ANY AND ALL OBJECTION WHICH IT MIGHT OTHERWISE ASSERT, NOW OR IN THE FUTURE, TO THE
EXERCISE OR USE BY THE CREDITORS OF ANY RIGHT OF SETOFF, REPOSSESSION OR SELF HELP AS MAY PRESENTLY EXIST UNDER STATUTE OR COMMON LAW. THIS SECTION SHALL NOT BE CONSTRUED IN DEROGATION OF THE RIGHTS OF THE TRIBE UNDER SECTION 12.19. 

12.21 No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby, the Tribe, the Borrower
and each other Loan Party acknowledges and agrees that: (i) the credit facilities provided for hereunder and any related arranging or other services in connection therewith (including in connection with any amendment, waiver or other
modification hereof or of any other Loan Document) are an arm’s-length commercial transaction between the Tribe, the Borrower and each other Loan Party, on the one hand, and the Administrative Agent and the Joint Lead Arrangers, on the other
hand, and the Tribe, the Borrower and each other Loan Party is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents (including any
amendment, waiver or other modification hereof or thereof); (ii) in connection with the process leading to such transaction, the Administrative Agent and each Joint Lead Arrangers is and has been acting solely as a principal and is not the
financial advisor, agent or fiduciary, for the Tribe, the Borrower or any other Loan Party; (iii) neither the Administrative Agent nor the Joint Lead Arrangers has assumed or will assume an advisory, agency or fiduciary responsibility in favor
of the Tribe, the Borrower or any other Loan Party with respect to any of the transactions contemplated hereby or the process leading thereto, including with respect to any amendment, waiver or other modification hereof or of any other Loan Document
(irrespective of whether the Administrative Agent or the Joint Lead Arrangers have advised or are currently advising the Tribe, the Borrower or any other Loan Party on other matters) and neither the Administrative Agent nor the Joint Lead Arrangers
has any obligation to the Tribe, the Borrower or any other Loan Party with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; (iv) the Administrative Agent and
the Joint Lead Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Tribe, the Borrower or the other Loan Parties, and neither the Administrative Agent nor the
Joint Lead Arrangers has any obligation to disclose any 
  

 -132- 

 
of such interests by virtue of any advisory, agency or fiduciary relationship; and (v) the Administrative Agent and the Joint Lead Arrangers have not
provided and will not provide any legal, accounting, regulatory or tax advice with respect to any of the transactions contemplated hereby (including any amendment, waiver or other modification hereof or of any other Loan Document) and each of the
Tribe, the Borrower and the other Loan Parties has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate. Each of the Tribe, the Borrower and the other Loan Parties hereby waives and releases, to
the fullest extent permitted by law, any claims that it may have against the Administrative Agent and the Joint Lead Arrangers with respect to any breach or alleged breach of agency or fiduciary duty. 
 12.22 USA PATRIOT Act Notice. Each Lender that is subject to the Act (as hereinafter defined) and the Administrative Agent (for itself and not on
behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it is required to obtain, verify and
record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower in accordance
with the Act. 
 12.23 Time of the Essence. Time is of the essence of the Loan Documents. 
 12.24 Designation as Senior Debt. The Borrower hereby irrevocably designates the Obligations as “Designated Senior Indebtedness” and
“Designated Senior Secured Indebtedness” as such terms are defined in the Relinquishment Agreement and irrevocably designates the Obligations as “Designated Senior Indebtedness” as such term is defined in the Senior Subordinated
Indentures. 
 12.25 ENTIRE AGREEMENT. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND
MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES. 
 12.26 Release of Liens. At any time any Loan Party sells or otherwise disposes of an asset to the extent permitted by the Loan Documents, the Administrative Agent shall, subject to receiving any requested
confirmation from the Lenders pursuant to Section 11.11, cause each such asset to be released from the Lien of the applicable Collateral Documents and agrees to take all such actions, including the execution of release instruments, amendments
to UCC filings and other instruments, as any Loan Party may reasonably request to evidence such release, all at the Borrower’s sole expense. 
  

 -133- 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
date first above written. 
  

			
	 MOHEGAN TRIBAL GAMING AUTHORITY

		
	 By:
	 	 /s/ Mitchell Grossinger Etess

	 Name:
	 	Mitchell Grossinger Etess
	 Title:
	 	Chief Executive Officer
	
	 THE MOHEGAN TRIBE OF INDIANS OF
 CONNECTICUT (for the limited purpose of
 joining Articles V and VIII, and Sections 12.14
 through 12.25, as applicable)

		
	 By:
	 	 /s/ Bruce S. Bozsum

	 Name:
	 	Bruce S. Bozsum
	 Title:
	 	Chairman of Management Board

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 BANK OF AMERICA, N.A., as
 Administrative Agent

		
	 By:
	 	 /s/ Maurice E. Washington

	 Name:
	 	Maurice E. Washington
	 Title:
	 	Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 BANK OF AMERICA, N.A., as a Lender and
 L/C Issuer

		
	 By:
	 	 /s/ Brian D. Corum

	 Name:
	 	Brian D. Corum
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 CITIZENS BANK OF CONNECTICUT,
 as a
Lender

		
	 By:
	 	 /s/ Clifford Mellor

	 Name:
	 	Clifford Mellor
	 Title:
	 	Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 CALYON NEW YORK BRANCH,
 as a
Lender

		
	 By:
	 	 /s/ Dianne M. Scott

	 Name:
	 	Dianne M. Scott
	 Title:
	 	Managing Director
		
	 By:
	 	 /s/ Gill Realon

	 Name:
	 	Gill Realon
	 Title:
	 	Director

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 WELLS FARGO BANK, NATIONAL
 ASSOCIATION, as a Lender

		
	 By:
	 	 /s/ Peitty Chou

	 Name:
	 	Peitty Chou
	 Title:
	 	Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 BANK OF SCOTLAND, NEW YORK
 BRANCH,
as a Lender

		
	 By:
	 	 /s/ Joseph Frayus

	 Name:
	 	Joseph Frayus
	 Title:
	 	First Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 CITICORP NORTH AMERICA, INC.,
 as a
Lender

		
	 By:
	 	 /s/ Jeffrey Rothman

	 Name:
	 	Jeffrey Rothman
	 Title:
	 	Managing Director

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 COMMERZBANK AG, NEW YORK AND
 GRAND
CAYMAN BRANCHES, as a Lender

		
	 By:
	 	 /s/ Werner Schmidbauer

	 Name:
	 	Werner Schmidbauer
	 Title:
	 	Senior Vice President
		
	 By:
	 	 /s/ Karla Wirth

	 Name:
	 	Karla Wirth
	 Title:
	 	Assistant Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 CIT LENDING SERVICES CORPORATION,
 as
a Lender

		
	 By:
	 	 /s/ Anthony Holland

	 Name:
	 	Anthony Holland
	 Title:
	 	Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 KEYBANK NATIONAL ASSOCIATION,
 as a
Lender

		
	 By:
	 	 /s/ Brendan A. Lawlor

	 Name:
	 	Brendan A. Lawlor
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	HSH NORDBANK AG, NEW YORK BRANCH,
	as a Lender
		
	 By:
	 	 /s/ Paul Verdi

	 Name:
	 	Paul Verdi
	 Title:
	 	Vice President
		
	 By:
	 	 /s/ David Lopez Menendez

	 Name:
	 	David Lopez Menendez
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 THE BANK OF NOVA SCOTIA,

	 as a Lender

		
	 By:
	 	 /s/ Mark Sparrow

	 Name:
	 	Mark Sparrow
	 Title:
	 	Director, Execution

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 SUMITOMO MITSUI BANKING

	 CORPORATION, as a Lender

		
	By:	 	 /s/ Shigeru Tsuru

	Name:	 	Shigeru Tsuru
	Title:	 	Joint General Manager

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	GOLDMAN SACHS CREDIT PARTNERS L.P.,
	 as a Lender

		
	 By:
	 	 /s/ Mark Walton

	 Name:
	 	Mark Walton
	 Title:
	 	Authorized Signatory

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 THE GOVERNOR AND COMPANY OF THE

	 BANK OF IRELAND, as a Lender

		
	 By:
	 	 /s/ Daniel McAneny

	 Name:
	 	Daniel McAneny
	 Title:
	 	Authorized Signatory
		
	 By:
	 	 /s/ Barry Heraty

	 Name:
	 	Barry Heraty
	 Title:
	 	Authorized Signatory

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 COMERICA BANK,

	 as a Lender

		
	 By:
	 	 /s/ Kevin T. Urban

	 Name:
	 	Kevin T. Urban
	 Title:
	 	Assistant Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 DEUTSCHE BANK TRUST COMPANY

	 AMERICAS, as a Lender

		
	 By:
	 	 /s/ Alex Johnson

	 Name:
	 	Alex Johnson
	 Title:
	 	Managing Director
		
	 By:
	 	 /s/ Linda Wang

	 Name:
	 	Linda Wang
	 Title:
	 	Director

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 TD BANKNORTH, N.A., as a Lender

		
	 By:
	 	 /s/ James R. Riley

	 Name:
	 	James R. Riley
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 ALLIED IRISH BANKS, PLC, as a Lender

		
	 By:
	 	 /s/ John F. Farrace 

	 Name:
	 	John F. Farrace
	 Title:
	 	Director of Corporate Banking N.A.
		
	 By:
	 	 /s/ Eanna P. Mulkere

	 Name:
	 	Eanna P. Mulkere
	 Title:
	 	Assistant Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 NATIONAL CITY BANK,

	 as a Lender

		
	 By:
	 	 /s/ Russell H. Liebetrau, Jr.

	 Name:
	 	Russell H. Liebetrau, Jr.
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 PEOPLE’S BANK, as a Lender

		
	 By:
	 	 /s/ George F. Paik

	 Name:
	 	George F. Paik
	 Title:
	 	Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 SOVEREIGN BANK, as a Lender

		
	By:	 	 /s/ David Hawthorne

	Name:	 	David Hawthorne
	Title:	 	Assistant Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 BANK HAPOALIM, as a Lender

		
	 By:
	 	 /s/ Shaun Breidbart

	 Name:
	 	Shaun Breidbart
	 Title:
	 	Vice President
		
	 By:
	 	 /s/ Charles McLaughlin

	 Name:
	 	Charles McLaughlin
	 Title:
	 	Senior Vice President

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page] 

			
	 NATIVE AMERICAN BANK, N.A.,

	 as a Lender

		
	 By:
	 	 /s/ Nathan Bell

	 Name:
	 	Nathan Bell
	 Title:
	 	Chief Credit Officer

  

 [Mohegan Tribal Gaming Authority Credit 
 Agreement Signature Page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]